two arm study
  5
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0003792|arm|t029
  c0205448|two (qualifier value)|t081
  c0446516|upper arm|t029
prostate
  2
  c1278980|entire prostate|t023
  c0033572|prostate|t023
pelvic lymphadenectomy
  1
  c0193883|pelvic lymphadenectomy (procedure)|t061
acceptable toxicity
  4
  c0814633|acceptability|t080
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c1272684|accepted (qualifier value)|t080
advances
  1
  c0725066|advance|t074
not contiguous parametrial tissue
  2
  c0040300|tissues|t024
  c0205283|contiguous (qualifier value)|t082
only eligible patients
  1
  c0030705|patients|t101
spleen
  2
  c1278932|entire spleen|t023
  c0037993|spleen|t023
hematologic effects
  2
  c1280500|effect (qualifier value)|t080
  c0205488|hematologic (qualifier value)|t169
gog performance scale
  4
  c0597198|performance|t055
  c0175659|weight measurement scales|t073
  c0349674|intellectual scale|t170
  c0222045|integumentary scale|t023
staging
  1
  c0332305|with staging (attribute)|t169
grade proctitis
  2
  c0441800|grade|t185
  c0033246|proctitis|t047
body
  1
  c0242821|human body|t016
prolonged neurologic toxicity
  4
  c0040539|toxicity aspects|t081
  c0439590|prolonged (qualifier value)|t079
  c0205494|neurologic (qualifier value)|t169
  c0600688|toxic effect|t037
c patients
  2
  c0007886|cesium|t196
  c0030705|patients|t101
major surgery
  1
  c0679637|major surgery|t061
same dose
  2
  c0445247|same (qualifier value)|t080
  c0178602|dosages (qualifier value)|t081
first
  1
  c0205435|first (qualifier value)|t081
two sample wilcoxon test
  2
  c0392366|tests (qualifier value)|t170
  c0205448|two (qualifier value)|t081
consistent observations
  3
  c0700325|patient observation|t061
  c0332290|consistent with (qualifier value)|t078
  c0302523|observation in research|t062
tissue
  1
  c0040300|tissues|t024
poor prognosis
  1
  c0278252|prognosis bad (finding)|t033
other factors
  1
  c0205394|other|t080
clinical congestive heart failure
  2
  c0205210|clinical (qualifier value)|t080
  c0018802|heart failure, congestive|t047
white blood cell count
  1
  c0023508|white blood cell count procedure|t059
significantly higher response rates
  5
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0235146|euphoric mood|t041
  c0750502|significant (qualifier value)|t078
  c0205250|high|t080
previous malignancy
  3
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
  c0205156|previous (qualifier value)|t082
radiosensitivity
  1
  c0034537|radiation tolerance|t032
m observed group
  5
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0441833|groups (qualifier value)|t170
  c0870992|observers|t097
  c1300322|group (social concept)|t096
treatment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
different stages
  2
  c1306673|stages (qualifier value)|t169
  c0443199|differential (qualifier value)|t080
ssd
  1
  c0723179|ssd|t109
dukes cl
  2
  c0010575|cycloleucine|t116
  c0201952|chloride measurement|t059
transient diarrhea
  3
  c0205374|transitory|t079
  c0040704|transient population group|t098
  c0011991|diarrhea|t184
indeed poor prognostic features
  1
  c0278252|prognosis bad (finding)|t033
high toxicity rate
  5
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0235146|euphoric mood|t041
  c0871208|rating|t062
  c0205250|high|t080
function
  3
  c0542341|function|t169
  c0700205|function axis|t185
  c0031843|physiological aspects|t039
pulmonary disease
  1
  c0024115|lung diseases|t047
complete blood counts
  1
  c0009555|blood count, complete|t059
maximum therapeutic effect
  4
  c1280500|effect (qualifier value)|t080
  c0039796|the science and art of healing|t061
  c0806909|maximum|t033
  c0302350|therapeutic|t169
gastrointestinal anastomosis
  4
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
  c0521362|gastrointestinal|t023
more organs
  2
  c0205172|more (qualifier value)|t081
  c0178784|organ|t023
compelling reason to
  2
  c0600104|obsessive compulsive behavior|t048
  c0684328|reasoning|t041
10th percentile
  1
  c1264641|percentile (property) (qualifier value)|t081
simultaneous therapy group
  2
  c0033971|psychotherapy, group|t061
  c0521115|simultaneous (qualifier value)|t079
pulmonary toxicity
  1
  c0919924|pulmonary toxicity|t046
mayo clinic study
  3
  c1077578|bikinia le-testui|t002
  c0454788|mayo county, republic of ireland|t083
  c0008972|clinical research|t062
residual pelvic tumor
  4
  c0030793|pelvic neoplasms|t191
  c0205347|residual (qualifier value)|t080
  c0030797|pelvis|t029
  c0543478|residual tumor|t191
clinical decisions
  2
  c0205210|clinical (qualifier value)|t080
  c0679006|decision|t170
second generation
  2
  c0079411|generations|t079
  c0205436|second (qualifier value)|t081
intestinal perforation
  1
  c0021845|intestinal perforation|t020
three way interactions
  2
  c0687133|drug interactions|t044
  c0205449|three (qualifier value)|t081
pilot data
  1
  c0473169|pilot - aircraft (occupation)|t097
l2
  1
  c1179699|l2 innervation|t029
continuing adverse effects
  2
  c0750536|continued|t078
  c0001688|adverse effects|t037
kaplan–meier estimates
  1
  c0750572|estimated|t078
similar patterns
  2
  c0871364|simile|t170
  c0449774|patterns (qualifier value)|t082
treatment group
  1
  c0036669|sensitivity training groups|t065
enhanced tumor cell kill
  3
  c0599733|cell killing|t043
  c0086222|enhancer|t114
  c0027651|neoplasms|t191
previous findings
  2
  c0243095|findings|t169
  c0205156|previous (qualifier value)|t082
preoperative tumor size
  2
  c0475440|tumor size (observable entity)|t082
  c0445204|preoperative (qualifier value)|t032
ischemia
  1
  c0022116|ischemia|t047
two treatment
  3
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0205448|two (qualifier value)|t081
latter group
  2
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
significant survival advantage
  4
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0308269|advantage|t131
  c0750502|significant (qualifier value)|t078
partially hyperfractionated radiation fractionation schedule
  6
  c0524811|dose fractionation|t061
  c0851346|radiation|t070
  c0086960|schedules|t170
  c0016640|fractionation|t059
  c0728938|partial (qualifier value)|t081
  c0796569|hyperfractionation|t061
fever
  1
  c0015967|fever|t184
liver
  3
  c0023899|liver extract|t123
  c0023884|liver|t023
  c1278929|entire liver|t023
dox arm
  5
  c0048808|5'-deoxy-5-fluorouridine|t114
  c0013090|doxycycline|t195
  c0003792|arm|t029
  c0013089|doxorubicin|t195
  c0446516|upper arm|t029
underlies
  1
  c0444455|underlay (qualifier value)|t082
more nodes
  2
  c0205172|more (qualifier value)|t081
  c0746922|node|t023
clinical research efforts
  2
  c0015264|exertion|t040
  c0008972|clinical research|t062
namely cmf
  1
  c0950521|cmf|t061
possible neurotoxicity
  2
  c0332149|possible|t080
  c0235032|neurotoxicity syndromes|t037
third stands out
  3
  c0439787|out (qualifier value)|t082
  c0596013|does stand (finding)|t201
  c0205437|third (qualifier value)|t081
primary radiotherapy
  4
  c0439631|primary operation (qualifier value)|t061
  c0034618|radiation therapy|t061
  c0205225|primary|t080
  c0034619|radiotherapeutic|t170
serum bilirubin
  3
  c0428442|serum bilirubin nos (procedure)|t059
  c1318178|serum bilirubin nos|t034
  c0863144|serum bilirubin|t059
assay
  1
  c0243073|assay|t059
two layer interrupted anastomosis
  6
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
  c0934502|layer|t023
  c0443239|interrupted (qualifier value)|t080
  c0205448|two (qualifier value)|t081
initial ps
  2
  c0036421|systemic scleroderma|t047
  c0205265|initial (qualifier value)|t079
one postoperative ureterovaginal fistula
  3
  c0238133|ureterovaginal fistula (disorder)|t190
  c0032790|postoperative period|t079
  c0205447|one (qualifier value)|t081
radiation therapy oncology group
  2
  c0033971|psychotherapy, group|t061
  c0243005|radiation oncology|t091
5-fu arm
  3
  c0016360|fluorouracil|t114
  c0003792|arm|t029
  c0446516|upper arm|t029
ib
  1
  c0444976|ib (qualifier value)|t170
treatment-related toxicities
  4
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0600688|toxic effect|t037
  c0039798|therapeutic aspects|t169
gog 92 multicenter prospective randomized study
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
sgot
  1
  c0201899|aspartate aminotransferase assay|t059
50% reduction
  2
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
primary tumor related poor prognostic factors
  3
  c0445223|related (finding)|t033
  c0677930|primary tumor|t191
  c0278252|prognosis bad (finding)|t033
reasonable balance
  3
  c0014653|equilibrium|t040
  c0684328|reasoning|t041
  c0205415|balanced - adjective|t169
followed one
  2
  c0332282|following (attribute)|t079
  c0205447|one (qualifier value)|t081
gynecologic oncology group performance status
  6
  c0278596|gynecologic oncology|t091
  c0449438|status (attribute)|t080
  c0870623|group performance|t102
  c0441833|groups (qualifier value)|t170
  c0935728|performance status|t033
  c1300322|group (social concept)|t096
fields
  1
  c0440042|field's stain|t130
relative dose intensity
  3
  c0080103|relative (related person)|t099
  c0205345|relative|t080
  c0178602|dosages (qualifier value)|t081
creatinine clearance
  1
  c0812399|creatinine clearance|t033
clinical chf
  2
  c0205210|clinical (qualifier value)|t080
  c0018802|heart failure, congestive|t047
further cancer treatment
  5
  c0998265|cancer genus|t009
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0087111|therapeutic procedure|t061
  c0006826|malignant neoplasms|t191
  c0039798|therapeutic aspects|t169
90th percentiles
  1
  c1264641|percentile (property) (qualifier value)|t081
started one
  2
  c1272689|started (qualifier value)|t080
  c0205447|one (qualifier value)|t081
further years
  1
  c0439234|year (qualifier value)|t079
model selection
  2
  c0036576|selection (genetics)|t045
  c0026336|models|t170
ast 2.5 x n
  2
  c0439225|ns (qualifier value)|t081
  c0004002|aspartate transaminase|t116
dose reduction scheme
  3
  c0301630|reduction (chemical)|t070
  c0178602|dosages (qualifier value)|t081
  c0441610|reduction - action|t061
wilcoxon test
  1
  c0392366|tests (qualifier value)|t170
21.0 weeks
  1
  c0439230|week (qualifier value)|t079
reduced overall mortality
  4
  c0282416|overall [publication type]|t170
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
  c0392756|reduced (qualifier value)|t080
first recurrence
  2
  c0034897|recurrence|t067
  c0205435|first (qualifier value)|t081
perioperative adjuvant chemotherapy
  3
  c0231379|at risk for joint contractures (finding)|t033
  c0085533|chemotherapy, adjuvant|t061
  c0231393|at risk for cognitive impairment (finding)|t033
eight radiotherapy patients
  4
  c0030705|patients|t101
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
  c0205454|eight (qualifier value)|t170
safe use
  2
  c0036043|safety|t068
  c0042153|utilization|t081
lactate dehydrogenase
  1
  c0022917|lactate dehydrogenase|t116
poorer results
  3
  c1274040|result (navigational concept)|t169
  c0542537|poor - grade value|t080
  c0699761|financially poor|t080
calcium folinate
  1
  c0731033|leucovorin calcium|t109
evaluable patients
  3
  c1261322|assessment procedure (procedure)|t058
  c0030705|patients|t101
  c0220825|evaluation|t169
initial therapy
  3
  c0087111|therapeutic procedure|t061
  c0205265|initial (qualifier value)|t079
  c0039798|therapeutic aspects|t169
rectum
  2
  c0034896|rectum|t023
  c1278926|entire rectum|t023
methotrexate
  1
  c0025677|methotrexate|t109
platelet count x l
  14
  c0442022|lumbar (qualifier value)|t082
  c0392223|lights, manufactured|t074
  c0032181|platelet count|t059
  c0078606|xanthosine|t114
  c0336769|lighter, device (physical object)|t073
  c0023693|light|t070
  c1304698|liquid (finding)|t033
  c1287267|finding of platelet count (finding)|t034
  c0205091|left (qualifier value)|t082
  c0023870|lithium|t196
  c0302908|liquid substance|t167
  c0023700|lighting|t068
  c1306462|light color|t169
  c0475211|l (qualifier value)|t081
original design
  1
  c0205313|original (qualifier value)|t078
attenuator
  1
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
pelvic examination
  1
  c0200045|manual pelvic examination (procedure)|t060
radiotherapy
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
corpus
  1
  c0227813|body of uterus|t023
five studies
  3
  c0205451|five (qualifier value)|t081
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
ii disease
  2
  c0012634|disease|t047
  c0439069|roman numeral ii|t170
elastic sleeve
  2
  c0183336|sleeves|t074
  c0681018|elastic|t169
deep stromal invasion
  2
  c0927195|stroma|t023
  c0205125|depth (qualifier value)|t082
urogenital toxicity
  3
  c0447566|urogenital structure|t023
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
rt regimen
  1
  c0677937|regimen|t061
used endomyocardial biopsy
  2
  c0042153|utilization|t081
  c0189785|endomyocardial biopsy (procedure)|t060
ct scan
  1
  c0040405|x-ray computed tomography|t060
czech republic
  1
  c0206578|czech republic|t083
main important pharmacologic factor affecting tumor response
  2
  c0871261|responses|t054
  c0205225|primary|t080
renal function
  2
  c0232804|renal function, nos|t042
  c0042031|urinary tract physiology|t042
same problem
  2
  c0445247|same (qualifier value)|t080
  c0033213|problem (finding)|t033
closure
  1
  c0185003|reparative closure (procedure)|t061
similar trial
  1
  c0871364|simile|t170
recent reports
  2
  c0332185|recent episode (qualifier value)|t079
  c0684224|report (document)|t170
iatrogenic mortality
  3
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
  c0439669|iatrogenic (qualifier value)|t080
antitumor effect
  1
  c1280500|effect (qualifier value)|t080
planned reoperation
  2
  c0035110|reoperation|t061
  c1301732|planned (qualifier value)|t169
register
  1
  c0600375|registers (pt)|t170
reasonable possibility
  1
  c0684328|reasoning|t041
curative potential
  1
  c0237399|potential|t080
median durations
  3
  c0449238|duration|t079
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
electrocardiogram
  1
  c0013798|electrocardiogram|t060
absolute neutrophil count 2.0 l
  12
  c0442022|lumbar (qualifier value)|t082
  c0392223|lights, manufactured|t074
  c0023870|lithium|t196
  c0336769|lighter, device (physical object)|t073
  c0948762|absolute neutrophil count|t059
  c0023693|light|t070
  c0302908|liquid substance|t167
  c0023700|lighting|t068
  c1304698|liquid (finding)|t033
  c0205091|left (qualifier value)|t082
  c1306462|light color|t169
  c0475211|l (qualifier value)|t081
next day to
  2
  c0439228|day (qualifier value)|t079
  c0205117|juxta-posed (qualifier value)|t082
patients then
  1
  c0030705|patients|t101
fewer positive nodes
  3
  c0205388|few (qualifier value)|t081
  c0746922|node|t023
  c0205159|positive (qualifier value)|t080
correct position
  2
  c0733755|positioning attribute|t082
  c0719517|correct|t109
small surgical adjuvant study
  3
  c0700321|small|t080
  c0278788|adjuvant study|t062
  c0038895|surgical aspects|t169
same trend
  2
  c0445247|same (qualifier value)|t080
  c0040833|trends|t079
local recurrences only
  2
  c0205276|local (qualifier value)|t082
  c0034897|recurrence|t067
minor deviations
  3
  c0012727|spatial displacement|t082
  c0205165|minor (value)|t080
  c0026193|minor|t098
effective adjuvant combination chemotherapy
  5
  c0205414|effective (qualifier value)|t080
  c0085533|chemotherapy, adjuvant|t061
  c0001551|adjuvants, immunologic|t129
  c0013218|drug therapy, combination|t061
  c0205195|combined (qualifier value)|t080
charcoal
  1
  c0007955|charcoal|t196
equal therapeutic effects
  4
  c1280500|effect (qualifier value)|t080
  c0205163|equal (qualifier value)|t080
  c0039796|the science and art of healing|t061
  c0302350|therapeutic|t169
early analysis
  3
  c0002778|analysis of substances|t059
  c0205085|early (qualifier value)|t079
  c0936012|analysis|t062
mlr stepping option
  1
  c0859325|stepping|t184
fifteen patients
  1
  c0030705|patients|t101
latter approach
  1
  c0449445|approach (attribute)|t082
reactions
  1
  c0443286|reaction (qualifier value)|t169
perioperative portal chemotherapy
  6
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0231379|at risk for joint contractures (finding)|t033
  c0013216|pharmacotherapy|t061
  c0205054|hepatic|t029
  c0231393|at risk for cognitive impairment (finding)|t033
trend
  1
  c0040833|trends|t079
stepwise logistic regression
  1
  c0206031|logistic regression|t062
two treatment-related deaths
  5
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0205448|two (qualifier value)|t081
  c0011065|cessation of life|t040
95% confidence limit
  1
  c0237530|confidence limits|t081
negative psychologic reactions
  3
  c0205486|psychologic|t169
  c0205160|negative (qualifier value)|t080
  c0443286|reaction (qualifier value)|t169
selection criteria
  1
  c0242801|selection criteria|t080
secondary analyses
  4
  c0002778|analysis of substances|t059
  c0036525|metastatic to|t169
  c0175668|secondary to|t079
  c0936012|analysis|t062
study period
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0332182|periodic (qualifier value)|t079
hazard ratios
  2
  c0598697|hazard|t080
  c0456603|ratio (property) (qualifier value)|t170
limited adverse effects
  2
  c0439801|limited (qualifier value)|t169
  c0001688|adverse effects|t037
examinations
  1
  c0579007|examination - action (qualifier value)|t169
serum bilirubin level
  2
  c0428441|serum bilirubin measurement (procedure)|t059
  c1287366|finding of serum bilirubin level (finding)|t034
technical aspects
  2
  c0025664|methodology|t170
  c0449851|techniques|t170
less time
  1
  c0040223|time|t079
5-year survival rates
  2
  c0038954|survival rate|t081
  c0439234|year (qualifier value)|t079
sgpt
  1
  c0001899|alanine transaminase|t116
late effects
  1
  c0543419|sequela (disorder)|t046
meccnu dose reductions
  4
  c0036637|semustine|t109
  c0301630|reduction (chemical)|t070
  c0178602|dosages (qualifier value)|t081
  c0441610|reduction - action|t061
post-operative chemotherapy
  4
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c0241311|surgery, past|t033
survival rate
  1
  c0038954|survival rate|t081
preferred treatment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
randomized trials
  1
  c0034656|random allocation|t062
discontinuation
  1
  c0457454|discontinuation (procedure)|t058
one dose
  2
  c0205447|one (qualifier value)|t081
  c0178602|dosages (qualifier value)|t081
patient entry criteria
  2
  c0030705|patients|t101
  c0243161|criteria|t170
factor is
  1
  c0441913|is (tumor staging)|t170
synergistic activity
  4
  c0600075|endurance of activity|t033
  c0441655|activities|t052
  c0221187|physical activity|t056
  c0812303|fyn gene|t028
moderate patients
  2
  c0030705|patients|t101
  c0205081|moderate (severity modifier) (qualifier value)|t080
control arms
  2
  c0243148|control|t169
  c0003792|arm|t029
one fatal pulmonary embolism
  3
  c1302234|fatal (qualifier value)|t080
  c0034065|pulmonary embolism|t047
  c0205447|one (qualifier value)|t081
tumor-specific biologic action
  5
  c0205460|biologic (qualifier value)|t169
  c0441472|action (qualifier value)|t169
  c0027651|neoplasms|t191
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
spine
  3
  c0037949|vertebral column|t023
  c1267072|entire vertebral column|t023
  c1280065|entire spine|t023
primary diameter cm
  4
  c0332517|diameter (qualifier value)|t032
  c0439631|primary operation (qualifier value)|t061
  c0475210|cm (qualifier value)|t081
  c0205225|primary|t080
multicenter study
  1
  c0282439|multicenter studies|t170
new york memorial study
  3
  c0027976|new york|t083
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
radiation therapy now
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
postoperative radiotherapy
  3
  c0032790|postoperative period|t079
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
cox multiple regression analysis
  5
  c0002778|analysis of substances|t059
  c0033551|prostaglandin-endoperoxide synthase|t116
  c0936012|analysis|t062
  c0681923|multiple regression|t080
  c0442996|cox microbiology subtype|t170
dose schedule
  2
  c0086960|schedules|t170
  c0178602|dosages (qualifier value)|t081
age 30–70 years
  2
  c0001779|age (qualifier value)|t079
  c0439234|year (qualifier value)|t079
cls
  2
  c0010575|cycloleucine|t116
  c0201952|chloride measurement|t059
similar differences
  2
  c0871364|simile|t170
  c0443199|differential (qualifier value)|t080
main complication
  2
  c0205225|primary|t080
  c0009566|complication|t046
internal mammary lymph nodes
  1
  c0229755|parasternal lymph node (body structure)|t023
assessable patients
  2
  c1261322|assessment procedure (procedure)|t058
  c0030705|patients|t101
secondary leukemias
  1
  c0275814|streptococcal lymphadenitis of swine|t047
im iv
  6
  c0442123|intravascular (qualifier value)|t082
  c0442122|intravaginal (qualifier value)|t082
  c0231377|at risk for impaired home maintenance management (finding)|t033
  c0348016|intravenous|t082
  c0442106|intervertebral (qualifier value)|t029
  c0205281|invasive (qualifier value)|t080
80.8 gy
  1
  c0556636|gy (qualifier value)|t081
central review
  2
  c0282443|review [publication type]|t170
  c0205099|central|t082
men
  1
  c0025266|male population group|t098
curative local therapy
  1
  c0677903|local therapy|t061
reassuring
  1
  c0557055|reassuring (procedure)|t061
leukocytopenia
  1
  c0023530|leukopenia|t047
information
  1
  c0870705|information|t078
consistency
  1
  c0332529|consistency finding (finding)|t080
squamous cell carcinoma
  1
  c0007137|carcinoma, squamous cell|t191
hemoglobin g
  1
  c1319312|hemoglobin g (substance)|t116
two sided significance level
  4
  c0814896|significance level|t062
  c0441987|side (qualifier value)|t082
  c0457012|sidedness (qualifier value)|t082
  c0205448|two (qualifier value)|t081
poor quality
  3
  c0332306|with quality (attribute)|t080
  c0542537|poor - grade value|t080
  c0699761|financially poor|t080
five year rates
  3
  c0205451|five (qualifier value)|t081
  c0439234|year (qualifier value)|t079
  c0871208|rating|t062
local failure
  3
  c0680095|personal failure|t055
  c0205276|local (qualifier value)|t082
  c0231174|failure (biologic function)|t169
patients to
  1
  c0030705|patients|t101
patients characteristics
  1
  c0815172|patient characteristics|t201
five postoperative radiation only
  3
  c0205451|five (qualifier value)|t081
  c0032790|postoperative period|t079
  c0851346|radiation|t070
pelvic radiotherapy
  3
  c0030797|pelvis|t029
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
use
  1
  c0042153|utilization|t081
two scheduled interim analyses
  3
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
  c0205448|two (qualifier value)|t081
sequence dependent synergy
  2
  c0851827|dependent (qualifier value)|t098
  c0599739|synergism|t044
figo stage advance
  2
  c0725066|advance|t074
  c0450454|figo stage (attribute)|t170
disturbing finding
  1
  c0243095|findings|t169
bowel obstruction
  1
  c0021843|intestinal obstruction|t047
excess number
  3
  c0750570|excessively|t078
  c0449788|count of entities (property) (qualifier value)|t081
  c0442802|excessive (qualifier value)|t080
four cycles
  2
  c0205450|four (qualifier value)|t081
  c0439596|cyclic (qualifier value)|t079
6.7 weeks
  1
  c0439230|week (qualifier value)|t079
myoblastoma
  1
  c0027043|myoblastoma|t191
powerful prognostic predictor
  3
  c0681842|prediction|t170
  c0220901|prognostic|t170
  c0032863|power (psychology)|t068
two multidrug combinations
  2
  c0453882|combinations (physical object)|t073
  c0205448|two (qualifier value)|t081
astler coller modification
  1
  c0205349|altered (qualifier value)|t169
relative shortterm adjuvant systemic treatment
  4
  c0080103|relative (related person)|t099
  c0087111|therapeutic procedure|t061
  c0205345|relative|t080
  c0039798|therapeutic aspects|t169
curative surgery
  3
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
eighty one
  1
  c0205447|one (qualifier value)|t081
images
  2
  c0175631|imagery|t041
  c0150627|guided imagery|t061
synergistic effect
  2
  c1280500|effect (qualifier value)|t080
  c0812303|fyn gene|t028
2-day difference
  2
  c0439228|day (qualifier value)|t079
  c0443199|differential (qualifier value)|t080
frequent vomiting
  3
  c0332183|frequent (qualifier value)|t079
  c0042963|vomiting|t184
  c0401156|vomiting nos (disorder)|t047
serum levels
  2
  c0229671|serum|t024
  c0441889|levels (qualifier value)|t170
lower midline incision
  2
  c0456276|midline incision (procedure)|t061
  c0441994|lower (qualifier value)|t169
responding patients
  2
  c0871261|responses|t054
  c0030705|patients|t101
abnormal renal function
  1
  c0151746|abnormal renal function (finding)|t046
only minimal effect
  2
  c1280500|effect (qualifier value)|t080
  c0547039|minimal (qualifier value)|t080
select patient population
  3
  c0032659|population|t081
  c0036576|selection (genetics)|t045
  c0030705|patients|t101
single layer technique
  5
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0934502|layer|t023
  c0449851|techniques|t170
  c0087136|unmarried|t098
sleep disturbance
  2
  c0037317|sleep disturbances|t047
  c0700201|dyssomnias|t047
m fluorouracil
  1
  c0016360|fluorouracil|t114
36.0 gy
  1
  c0556636|gy (qualifier value)|t081
6.5 years
  1
  c0439234|year (qualifier value)|t079
important finding to
  1
  c0243095|findings|t169
basis
  1
  c0178499|base|t120
pulmonary embolism
  1
  c0034065|pulmonary embolism|t047
survival advantage
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0308269|advantage|t131
neutron therapy
  1
  c0278623|high-let neutron therapy|t061
costal margins
  1
  c0582240|border of rib (body structure)|t029
localised radiation therapy to
  3
  c0392752|localized (qualifier value)|t082
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
cell division
  1
  c0007590|cell division|t043
technique to
  1
  c0449851|techniques|t170
negative
  1
  c0205160|negative (qualifier value)|t080
statistically significant benefit
  2
  c0237881|statistical significance|t081
  c0814225|benefits|t081
urea nitrogen
  1
  c0521881|urea nitrogen (substance)|t123
ctx
  1
  c0010583|cyclophosphamide|t115
high proportion
  3
  c0205351|proportional (qualifier value)|t080
  c0235146|euphoric mood|t041
  c0205250|high|t080
insufficient to significantly impact
  2
  c0231180|insufficient|t169
  c0726639|impact|t168
investigators
  1
  c0035173|research personnel|t097
5-fu patients
  2
  c0016360|fluorouracil|t114
  c0030705|patients|t101
eortc qlqc30 questionnaire
  1
  c0034394|questionnaires|t170
females
  1
  c0086287|females|t098
cox model multivariate analysis
  2
  c0026777|multivariate analysis|t081
  c0010234|cox models|t170
platelet count nadir
  2
  c0032181|platelet count|t059
  c1287267|finding of platelet count (finding)|t034
one patient receiving epi
  6
  c0544683|reception|t042
  c0030705|patients|t101
  c0221908|epithelial|t169
  c0014609|epithelium|t024
  c0205447|one (qualifier value)|t081
  c0014544|epilepsy|t047
central neurotoxicity
  2
  c0205099|central|t082
  c0235032|neurotoxicity syndromes|t037
x-ray
  4
  c0043299|diagnostic radiologic examination|t060
  c0043309|roentgen rays|t070
  c0034571|roentgenographic|t169
  c1306645|plain film (procedure)|t060
sublethal damage
  1
  c0010957|damage (morphologic abnormality)|t169
five year survival rate
  3
  c0205451|five (qualifier value)|t081
  c0038954|survival rate|t081
  c0439234|year (qualifier value)|t079
laboratory evidence
  1
  c0022877|laboratories|t073
disagreement
  1
  c0680238|discord|t054
one hundred four patients
  2
  c0030705|patients|t101
  c0205447|one (qualifier value)|t081
prior therapy
  3
  c0087111|therapeutic procedure|t061
  c0750516|prior|t078
  c0039798|therapeutic aspects|t169
definitive results
  2
  c1274040|result (navigational concept)|t169
  c0443196|definitive (qualifier value)|t079
stabilisation
  1
  c1293130|stabilization (procedure)|t061
apparent success
  2
  c0750489|apparent|t078
  c0597535|success|t054
treated patients
  2
  c1292734|treats (attribute)|t185
  c0030705|patients|t101
phase ii study
  1
  c0278782|phase ii study|t062
mm3
  1
  c1300558|mm3 (qualifier value)|t081
total white cell count
  2
  c0427547|total white cell count nos (procedure)|t059
  c1318024|total white cell count nos|t034
stages ib
  2
  c0457152|stage 1 lower case bee|t185
  c0456597|stage 1 upper case bee|t185
high response rates
  4
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0235146|euphoric mood|t041
  c0205250|high|t080
significant survival benefit
  4
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0814225|benefits|t081
  c0750502|significant (qualifier value)|t078
significantly more hysterectomy specimens
  4
  c0205172|more (qualifier value)|t081
  c0020699|hysterectomy|t061
  c0370003|specimen (specimen)|t167
  c0750502|significant (qualifier value)|t078
81.0 gy
  1
  c0556636|gy (qualifier value)|t081
exponential model
  1
  c0026336|models|t170
surviving patients
  2
  c0310255|survive (product)|t121
  c0030705|patients|t101
hormonal manipulations
  1
  c0586971|hormone manipulation (procedure)|t061
fewer deaths
  2
  c0205388|few (qualifier value)|t081
  c0011065|cessation of life|t040
provision
  1
  c0359589|provide (product)|t168
cervical stromal invasion
  2
  c0927195|stroma|t023
  c0205064|cervical (qualifier value)|t082
more extreme result
  3
  c0205172|more (qualifier value)|t081
  c1274040|result (navigational concept)|t169
  c0205403|extreme (qualifier value)|t080
remote control afterloading system to
  2
  c0179406|brachytherapy systems, remote afterloading|t074
  c0680582|abc monopoly system|t089
$4-cm tumor
  2
  c0027651|neoplasms|t191
  c0475210|cm (qualifier value)|t081
abdominal hernia
  1
  c0178282|hernia of abdominal cavity|t020
definitive statement
  2
  c1301808|state (environment)|t083
  c0443196|definitive (qualifier value)|t079
untreated patients
  1
  c0030705|patients|t101
adverse events
  1
  c0877248|adverse event|t033
ureters
  1
  c0041951|ureter|t023
other trials
  1
  c0205394|other|t080
requiring hospitalization
  1
  c0019993|hospitalization|t058
anthracycline
  2
  c0282564|anthracyclines|t109
  c0003234|anthracycline antibiotics|t195
intravaginal radiation therapy
  3
  c0442122|intravaginal (qualifier value)|t082
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
concomitant treatment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
additional toxic problems
  3
  c0033213|problem (finding)|t033
  c0442796|additive (qualifier value)|t080
  c0600688|toxic effect|t037
concurrent chemotherapy usually
  4
  c0205420|concurrent (qualifier value)|t079
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
subclinical clonogenic cell repopulation
  3
  c0007634|cells|t025
  c1269647|entire cell|t025
  c0205211|subclinical (qualifier value)|t080
radiological examination
  1
  c0043299|diagnostic radiologic examination|t060
adjuvant cmf
  2
  c0950521|cmf|t061
  c0001551|adjuvants, immunologic|t129
important prognostic factor
  1
  c0220901|prognostic|t170
retrospective stratification
  2
  c0205363|stratified (qualifier value)|t080
  c0035363|retrospective studies|t081
elevation
  2
  c0702240|elevation - value (qualifier value)|t082
  c0439775|elevation (procedure)|t061
secondary endpoints
  3
  c0036525|metastatic to|t169
  c0150100|endpoint|t062
  c0175668|secondary to|t079
cancer related mortality
  6
  c0998265|cancer genus|t009
  c0445223|related (finding)|t033
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
  c0006826|malignant neoplasms|t191
stage ib
  2
  c0457152|stage 1 lower case bee|t185
  c0456597|stage 1 upper case bee|t185
single colorectal cancer patient
  5
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0030705|patients|t101
  c0087136|unmarried|t098
  c0009402|colorectal cancer|t191
four field box technique
  5
  c0205450|four (qualifier value)|t081
  c0449851|techniques|t170
  c0440042|field's stain|t130
  c0179400|boxes|t073
  c0006080|boxing|t056
effects presumably
  1
  c1280500|effect (qualifier value)|t080
intracavitary radiotherapy
  3
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
  c1298613|intracavitary (qualifier value)|t082
then oral folinic acid rescue
  2
  c0442027|oral (qualifier value)|t082
  c0023413|leucovorin|t109
severe late gastrointestinal complications
  3
  c0205087|late (qualifier value)|t079
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0161819|gastrointestinal complication (disorder)|t046
intended operation
  2
  c0162425|intention|t041
  c0543467|general operative procedures|t061
large cervical lesion
  2
  c0549177|large|t080
  c0235656|lesion of cervix (finding)|t046
bony structures
  1
  c0447961|bone structure (body structure)|t017
dose intensity
  1
  c0178602|dosages (qualifier value)|t081
prescribed regimen
  2
  c0278329|prescribed|t169
  c0677937|regimen|t061
systemic recurrence
  2
  c0205373|systemic (qualifier value)|t169
  c0034897|recurrence|t067
surgical specimen
  2
  c0370003|specimen (specimen)|t167
  c0038895|surgical aspects|t169
tumor masses
  4
  c0728811|masse|t109
  c1306372|mass, a measure of quantity of matter (property) (qualifier value)|t081
  c0577559|mass of body structure (finding)|t033
  c0027651|neoplasms|t191
similar treatment regimen
  4
  c0871364|simile|t170
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0677937|regimen|t061
sufficient patients to
  2
  c0205410|sufficient (qualifier value)|t080
  c0030705|patients|t101
severe toxicity
  3
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
hazard ratio
  2
  c0598697|hazard|t080
  c0456603|ratio (property) (qualifier value)|t170
multivariate cox regression analysis to
  1
  c0034980|regression analysis|t081
preclinical studies
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
following systemic treatment
  4
  c0205373|systemic (qualifier value)|t169
  c0087111|therapeutic procedure|t061
  c0332282|following (attribute)|t079
  c0039798|therapeutic aspects|t169
95% confidence intervals
  1
  c0009667|confidence intervals|t081
considerably lower dose
  2
  c0750591|consider|t078
  c0445550|low dose (qualifier value)|t081
bleomycin u
  2
  c0041928|uranium|t196
  c0005740|bleomycin|t116
only treatment to
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
increasing serum creatinine
  1
  c0700225|serum creatinine raised (finding)|t033
x l
  12
  c0442022|lumbar (qualifier value)|t082
  c0392223|lights, manufactured|t074
  c0078606|xanthosine|t114
  c0023870|lithium|t196
  c0336769|lighter, device (physical object)|t073
  c0023693|light|t070
  c0302908|liquid substance|t167
  c0023700|lighting|t068
  c1304698|liquid (finding)|t033
  c0205091|left (qualifier value)|t082
  c1306462|light color|t169
  c0475211|l (qualifier value)|t081
grade
  1
  c0441800|grade|t185
tumour characteristics
  1
  c0027651|neoplasms|t191
radiation scheme
  1
  c0851346|radiation|t070
default conditions
  2
  c0009647|conditioning (psychology)|t041
  c0348080|condition (attribute)|t080
cr
  1
  c0008574|chromium|t123
previous meta-analysis
  2
  c0920317|meta-analysis|t170
  c0205156|previous (qualifier value)|t082
hysterectomy specimens
  2
  c0020699|hysterectomy|t061
  c0370003|specimen (specimen)|t167
liver scans
  1
  c0203758|radioisotope study of liver (procedure)|t060
study performance
  3
  c0597198|performance|t055
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
senior authors
  1
  c0221192|author (occupation)|t097
localized disease
  1
  c0277565|local disease (finding)|t047
prolonged continuous infusion
  2
  c0444889|continuous infusion (qualifier value)|t061
  c0439590|prolonged (qualifier value)|t079
radiation
  1
  c0851346|radiation|t070
exact timing
  2
  c0059927|exact|t122
  c0449243|timing (attribute)|t079
computed tomographic scans
  1
  c0040405|x-ray computed tomography|t060
local treatment
  3
  c0087111|therapeutic procedure|t061
  c0205276|local (qualifier value)|t082
  c0039798|therapeutic aspects|t169
relative frequency
  3
  c0080103|relative (related person)|t099
  c0205345|relative|t080
  c0376249|with frequency|t081
eleven patients
  3
  c0445482|serotype eleven|t032
  c0030705|patients|t101
  c0205457|number eleven|t081
two fractions
  2
  c0457426|fractions of (qualifier value)|t081
  c0205448|two (qualifier value)|t081
protocol entry criteria
  2
  c1273873|protocol entry (qualifier value)|t170
  c0243161|criteria|t170
dukes b
  7
  c0337527|brothers|t099
  c0004927|behavior|t055
  c0004587|bacillus <bacterium>|t007
  c0677505|behaviors and observations relating to behavior|t033
  c1040746|bacilli|t007
  c0150141|bathing|t061
  c0175640|baths (medical device)|t074
asia
  1
  c0003980|asia|t083
relevant prognostic factors
  1
  c0220901|prognostic|t170
unknown v negative
  7
  c0042306|vanadium|t123
  c0449468|volume (property) (qualifier value)|t081
  c0439830|velocity (property) (qualifier value)|t169
  c0598352|v (voltage)|t081
  c0205160|negative (qualifier value)|t080
  c0439673|unknown (qualifier value)|t078
  c0439502|v - volt (qualifier value)|t081
total amount
  2
  c0439810|total (qualifier value)|t080
  c0205389|quantity (attribute)|t081
presence
  1
  c0392148|providing presence (regime/therapy)|t061
earlier gynecologic oncology group trial
  4
  c0278596|gynecologic oncology|t091
  c0205085|early (qualifier value)|t079
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
whole pelvic postoperative radiation therapy
  5
  c0444667|whole (qualifier value)|t081
  c0032790|postoperative period|t079
  c0030797|pelvis|t029
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
additional effect
  2
  c1280500|effect (qualifier value)|t080
  c0442796|additive (qualifier value)|t080
central pathology review
  2
  c0807322|pathologist review|t033
  c0205099|central|t082
therapeutic effect
  3
  c1280500|effect (qualifier value)|t080
  c0039796|the science and art of healing|t061
  c0302350|therapeutic|t169
treatment methodology
  3
  c0969625|methodology aspects|t170
  c0025664|methodology|t170
  c0679607|treatment method|t061
stage iia cancer
  5
  c0998265|cancer genus|t009
  c0441768|stage 2 upper case ay|t185
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
  c0457158|stage 2 lower case ay|t185
other criteria
  2
  c0205394|other|t080
  c0243161|criteria|t170
significant difference
  2
  c0443199|differential (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
patient follow-up
  2
  c0030705|patients|t101
  c0589120|follow-up status (finding)|t169
five scales
  3
  c0205451|five (qualifier value)|t081
  c0175659|weight measurement scales|t073
  c0222045|integumentary scale|t023
21.6 gy
  1
  c0556636|gy (qualifier value)|t081
or delayed chemotherapy
  5
  c0205421|deferred (qualifier value)|t079
  c0392920|chemotherapy-oncologic procedure|t061
  c0069590|oralit|t197
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
tumor size $2 cm
  2
  c0475440|tumor size (observable entity)|t082
  c0475210|cm (qualifier value)|t081
complete blood cell count
  6
  c0007634|cells|t025
  c0005771|blood cell count|t059
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
  c1269647|entire cell|t025
  c0009555|blood count, complete|t059
kaplan–meier analysis
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
percent difference
  2
  c0443199|differential (qualifier value)|t080
  c0439165|percent (qualifier value)|t081
recurrence outcomes
  1
  c0034897|recurrence|t067
activityin cervical cancer
  1
  c0007847|malignant neoplasm of cervix uteri|t191
additional benefit
  2
  c0814225|benefits|t081
  c0442796|additive (qualifier value)|t080
lower margin
  3
  c0441994|lower (qualifier value)|t169
  c1269830|tumor margin status|t033
  c0205284|marginal (qualifier value)|t082
karnofsky scale
  1
  c0206065|karnofsky performance status|t034
gy
  1
  c0556636|gy (qualifier value)|t081
sex ratios
  1
  c0036893|sex ratio|t081
cardiac disease
  1
  c0018799|heart diseases|t047
only combined modality regimens
  3
  c0695347|modality|t078
  c0677937|regimen|t061
  c0205195|combined (qualifier value)|t080
equally likely explanation
  3
  c0205163|equal (qualifier value)|t080
  c0681841|explanation|t062
  c0750504|likely|t078
acute toxicities
  2
  c0205178|acuteness (qualifier value)|t079
  c0600688|toxic effect|t037
nine
  1
  c0205455|nine (qualifier value)|t081
recommendations
  1
  c0034866|recommendations|t078
laparotomy scar
  2
  c0023038|laparotomy|t061
  c0008767|scar|t046
cycles
  1
  c0439596|cyclic (qualifier value)|t079
frequency
  1
  c0376249|with frequency|t081
platinum based regimens
  4
  c0178499|base|t120
  c1171558|platinum metallicum, platinum, homeopathic preparation|t121
  c0032207|platinum|t196
  c0677937|regimen|t061
sample size goal
  2
  c0018017|goals|t170
  c0242618|sample size|t081
further treatment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
patients often
  2
  c0030705|patients|t101
  c0332183|frequent (qualifier value)|t079
other specific tests
  4
  c0205394|other|t080
  c0392366|tests (qualifier value)|t170
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
hemoglobin
  1
  c0019046|hemoglobin|t116
affect performance status
  2
  c0935728|performance status|t033
  c0001721|affect|t041
sufficient data
  1
  c0205410|sufficient (qualifier value)|t080
present prospective randomized study
  3
  c0033522|prospective studies|t081
  c0034656|random allocation|t062
  c0150312|present|t169
14% response rate
  2
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
more conservative approach
  3
  c0205172|more (qualifier value)|t081
  c0449445|approach (attribute)|t082
  c0009800|conservatism|t078
financial scores
  2
  c0449820|scores (qualifier value)|t081
  c0376243|financial|t081
important information
  1
  c0870705|information|t078
simon
  1
  c0443058|simon (qualifier value)|t170
common set
  2
  c0205214|common (qualifier value)|t081
  c0036849|set (psychology)|t041
cox’s proportional hazard model
  1
  c0033489|proportional hazards models|t170
envelope system
  1
  c0449913|system (attribute)|t169
treatment efficacy
  1
  c0087113|treatment effectiveness|t080
enhanced efficacy
  1
  c0086222|enhancer|t114
additional relapses
  2
  c0442796|additive (qualifier value)|t080
  c0035020|relapse|t067
close surgical margins
  3
  c0229985|surgical margins (body structure)|t023
  c0587267|closed|t169
  c0677512|closed approach|t082
best adjuvant treatment
  5
  c0205170|good (qualifier value)|t080
  c0087111|therapeutic procedure|t061
  c0332272|better (qualifier value)|t080
  c0001551|adjuvants, immunologic|t129
  c0039798|therapeutic aspects|t169
similar proportions
  2
  c0871364|simile|t170
  c0205351|proportional (qualifier value)|t080
total number
  2
  c0439810|total (qualifier value)|t080
  c0449788|count of entities (property) (qualifier value)|t081
most distressing side effects
  4
  c0700361|feeling upset (finding)|t033
  c0231303|distress (finding)|t041
  c0205393|most (qualifier value)|t081
  c0001688|adverse effects|t037
urine ph
  1
  c0042044|urine ph test (procedure)|t059
first 5-year analysis
  3
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
  c0205435|first (qualifier value)|t081
relative likelihood
  3
  c0080103|relative (related person)|t099
  c0205345|relative|t080
  c0750504|likely|t078
chronic toxicities
  1
  c1264527|chronic poisoning (disorder)|t037
accelerated repopulation
  1
  c0521110|accelerated (contextual qualifier) (qualifier value)|t169
observed reduction
  5
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0301630|reduction (chemical)|t070
  c0870992|observers|t097
  c0441610|reduction - action|t061
purine concentrations
  3
  c0034140|purines|t109
  c0086045|concentration|t041
  c0220903|purine|t109
postirradiation recurrent cancer
  1
  c0549379|recurrent cancer|t191
cervical diameter
  2
  c0332517|diameter (qualifier value)|t032
  c0205064|cervical (qualifier value)|t082
methods
  2
  c0025664|methodology|t170
  c0025663|methods|t170
two pa dissemination
  3
  c0205221|disseminated (qualifier value)|t082
  c0030125|p-aminosalicylic acid|t109
  c0205448|two (qualifier value)|t081
hydroxyl group
  1
  c0700307|hydroxyl group|t197
disease-free survival advantage
  2
  c0308269|advantage|t131
  c0242793|disease-free survival|t081
originally pro1 posed
  1
  c0205313|original (qualifier value)|t078
adequate bone marrow
  2
  c0005953|bone marrow|t024
  c0205411|adequate (qualifier value)|t080
small fraction
  2
  c0457426|fractions of (qualifier value)|t081
  c0700321|small|t080
required follow-up
  1
  c0589120|follow-up status (finding)|t169
fibrosarcoma
  1
  c0016057|fibrosarcoma|t191
high-risk cervical cancers
  2
  c1134717|high-risk cancer|t191
  c0205064|cervical (qualifier value)|t082
underwent surgery
  3
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
toxicity profile
  2
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
multimodality approach
  1
  c0449445|approach (attribute)|t082
primary reason
  3
  c0684328|reasoning|t041
  c0439631|primary operation (qualifier value)|t061
  c0205225|primary|t080
presacral nodes
  1
  c0746922|node|t023
much poorer rate
  3
  c0542537|poor - grade value|t080
  c0871208|rating|t062
  c0699761|financially poor|t080
treatment weeks
  3
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0439230|week (qualifier value)|t079
significantly fewer recurrences
  3
  c0034897|recurrence|t067
  c0205388|few (qualifier value)|t081
  c0750502|significant (qualifier value)|t078
clinical assessment
  2
  c0205210|clinical (qualifier value)|t080
  c1261322|assessment procedure (procedure)|t058
internal iliac vessels
  2
  c0729890|iliac vessel (body structure)|t023
  c0205102|intrinsic|t082
adjuvant therapy
  1
  c0677850|adjuvant therapy|t061
sudden onset
  2
  c1272517|sudden onset (contextual qualifier) (qualifier value)|t170
  c1276802|sudden onset (attribute)|t080
kruskal–wallis test
  1
  c0392366|tests (qualifier value)|t170
preoperative four preoperative radiation
  2
  c0851346|radiation|t070
  c0445204|preoperative (qualifier value)|t032
clinical data
  1
  c0205210|clinical (qualifier value)|t080
55% decrease
  1
  c0547047|decrease (qualifier value)|t081
cardiotoxicity
  1
  c0876994|cardiotoxicity|t047
mid-axilla
  1
  c0441926|level ii (tumor staging)|t170
many investigations
  2
  c0439064|numerous (qualifier value)|t081
  c0430007|clinical investigation|t058
feasible histologic examination
  2
  c0579007|examination - action (qualifier value)|t169
  c0205462|histologic|t169
blood chemistries
  1
  c0005774|blood chemical analysis|t059
cholinergic syndromes
  1
  c0274702|poisoning by parasympathomimetic drug (disorder)|t037
third patient
  2
  c0030705|patients|t101
  c0205437|third (qualifier value)|t081
survival decline
  2
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
commonly
  1
  c0205214|common (qualifier value)|t081
phase trials
  1
  c0205390|phase (qualifier value)|t079
greater effects
  2
  c0443228|greater (qualifier value)|t081
  c1280500|effect (qualifier value)|t080
intervals
  1
  c1272706|interval (qualifier value)|t079
earlier extensive phase i
  3
  c0205390|phase (qualifier value)|t079
  c0205085|early (qualifier value)|t079
  c0205231|extensive (qualifier value)|t080
magnesium sulfate
  1
  c0024480|magnesium sulfate|t197
39.0 mg
  2
  c0024467|magnesium|t123
  c0439210|milligram|t081
neoadjuvant chemotherapy
  3
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
similar survival
  3
  c0220921|survival aspects|t081
  c0871364|simile|t170
  c0038952|continuance of life|t052
certain patients
  2
  c0205423|certainty (attribute)|t080
  c0030705|patients|t101
continuous 3.0 polypropylene
  2
  c0549178|continuous (qualifier value)|t079
  c0032582|polypropylenes|t122
central telephone randomization
  3
  c0205099|central|t082
  c0034656|random allocation|t062
  c0039457|telephone|t073
planned number
  2
  c0449788|count of entities (property) (qualifier value)|t081
  c1301732|planned (qualifier value)|t169
units heparin
  2
  c0439148|unit|t081
  c0019134|heparin|t123
standard dose prescription
  4
  c0038137|standards characteristics|t170
  c0175675|standards of weights and measures|t080
  c0033080|prescriptions|t058
  c0178602|dosages (qualifier value)|t081
vincristine combination
  2
  c0042679|vincristine|t109
  c0205195|combined (qualifier value)|t080
actuarial probability
  2
  c0334965|actuary (occupation)|t097
  c0033204|probability|t081
brazil
  1
  c0006137|brazil|t083
mammography
  1
  c0024671|mammography|t060
argument
  1
  c0680226|disputes|t054
sites
  1
  c0205145|associated topography (attribute)|t082
remarkable consistency
  1
  c0332529|consistency finding (finding)|t080
suggestion
  1
  c0038659|suggestion|t061
intracavitary placement
  3
  c0441587|clinical act of insertion|t058
  c0449268|placement|t058
  c1298613|intracavitary (qualifier value)|t082
entirely human antibodies
  5
  c0086418|homo sapiens|t016
  c0439751|entire (qualifier value)|t081
  c0813154|antibodies, in vitro diagnostic|t130
  c0003241|antibodies|t116
  c0020114|human|t016
barium enema
  1
  c0203075|barium enema (procedure)|t060
condition
  1
  c0348080|condition (attribute)|t080
65% 5-year survival rate
  2
  c0038954|survival rate|t081
  c0439234|year (qualifier value)|t079
further four courses
  2
  c0205450|four (qualifier value)|t081
  c0750729|courses (qualifier value)|t079
high antitumour efficacy
  2
  c0235146|euphoric mood|t041
  c0205250|high|t080
treatment-related intestinal obstructions
  4
  c0021843|intestinal obstruction|t047
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
significant coexistent disease
  2
  c0750502|significant (qualifier value)|t078
  c0243085|coexistent disease|t046
serum creatinine concentration
  5
  c0201976|serum creatinine tests|t059
  c0600061|serum creatinine level|t034
  c0086045|concentration|t041
  c0683149|serum drug concentration|t081
  c0010294|creatinine|t123
remaining patients
  1
  c0030705|patients|t101
stage ib cervical cancer
  1
  c0278582|cervical carcinoma stage ib|t191
median dose
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0178602|dosages (qualifier value)|t081
programmed local treatment
  4
  c0087111|therapeutic procedure|t061
  c0205276|local (qualifier value)|t082
  c0376691|programs [publication type]|t170
  c0039798|therapeutic aspects|t169
17-la target
  2
  c0599894|targeting|t043
  c0023031|lanthanum|t196
regimens
  1
  c0677937|regimen|t061
al’s study
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
extended serum half-lives
  3
  c0018517|half-life|t079
  c0231449|extended (qualifier value)|t082
  c0229671|serum|t024
not eligible central nervous system metastasis
  1
  c0279130|cns metastases (tumor staging)|t191
failure patterns
  3
  c0680095|personal failure|t055
  c0449774|patterns (qualifier value)|t082
  c0231174|failure (biologic function)|t169
arm
  2
  c0003792|arm|t029
  c0446516|upper arm|t029
national surgical adjuvant breast
  5
  c0015737|federal government|t092
  c0006141|breast|t023
  c0038895|surgical aspects|t169
  c1268990|entire breast|t023
  c0001551|adjuvants, immunologic|t129
bladder
  2
  c0005682|bladder|t023
  c1281573|entire bladder|t023
s1 junction
  2
  c0205144|junctional (qualifier value)|t082
  c1179704|s1 innervation|t029
dosage schedule
  2
  c0086960|schedules|t170
  c0178602|dosages (qualifier value)|t081
31% chance
  1
  c0237506|chance|t080
source
  1
  c0449416|source (attribute)|t033
mtx
  1
  c0025677|methotrexate|t109
partially fixed tumours
  3
  c0443218|fixed (qualifier value)|t080
  c0027651|neoplasms|t191
  c0728938|partial (qualifier value)|t081
balance potential benefit to
  4
  c0014653|equilibrium|t040
  c0205415|balanced - adjective|t169
  c0814225|benefits|t081
  c0237399|potential|t080
randomized trial to
  1
  c0034656|random allocation|t062
older equipment
  4
  c0014672|equipment|t073
  c0677546|old episode|t079
  c0220824|equipment used|t073
  c0580836|old|t079
full drug doses
  2
  c0678766|drug dose (finding)|t081
  c0443225|full (qualifier value)|t080
histology
  3
  c0019638|histology|t091
  c0205462|histologic|t169
  c0344441|histology procedure|t059
end
  1
  c0444930|end (qualifier value)|t082
kinetics
  2
  c0022702|kinetics|t078
  c0220865|kinetic characteristics|t169
secondary objective
  3
  c0036525|metastatic to|t169
  c0018017|goals|t170
  c0175668|secondary to|t079
skin reactions
  1
  c0221743|skin reaction (observable entity)|t034
leukocyte count nadir
  1
  c0023508|white blood cell count procedure|t059
contrast computed tomography
  1
  c0040405|x-ray computed tomography|t060
only sampling
  2
  c0870078|sampling|t078
  c0441621|sampling - surgical action|t060
improved overall response rate
  4
  c0184511|improved (qualifier value)|t080
  c0237629|frequency of responses|t079
  c0282416|overall [publication type]|t170
  c0878525|cancer treatment response rate|t079
lower limit wasthe caudal pole
  2
  c0935623|pole|t029
  c0441994|lower (qualifier value)|t169
subsequent morbidity
  3
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0750530|subsequent|t078
cardiac failure
  1
  c0018801|heart failure nos (disorder)|t047
meccnu patients
  2
  c0030705|patients|t101
  c0036637|semustine|t109
late complications
  3
  c1171258|complication aspects|t046
  c0205087|late (qualifier value)|t079
  c0009566|complication|t046
list
  1
  c0745732|list|t077
adjuvant x-ray
  5
  c0043299|diagnostic radiologic examination|t060
  c0043309|roentgen rays|t070
  c0034571|roentgenographic|t169
  c1306645|plain film (procedure)|t060
  c0001551|adjuvants, immunologic|t129
best supportive care
  3
  c0205170|good (qualifier value)|t080
  c0344211|supportive care|t058
  c0332272|better (qualifier value)|t080
increased morbidity
  3
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0205217|increased (qualifier value)|t169
median follow-up
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0589120|follow-up status (finding)|t169
european trial
  1
  c0239307|european|t098
chemistry profile
  1
  c0545265|chemistry profile|t059
running absorbable suture
  2
  c0035953|running|t056
  c0461643|absorbable suture (physical object)|t074
finding
  1
  c0243095|findings|t169
informed consent form
  1
  c0009797|consent forms|t170
gastrointestinal series
  1
  c0849994|gi series|t060
normal blood counts
  4
  c0005767|blood|t024
  c0005768|in blood|t031
  c0205307|normal (qualifier value)|t033
  c0439157|counts (qualifier value)|t081
pathologic risk factors
  2
  c0205469|pathological aspects|t169
  c0035648|risk factors|t081
supervoltage radiation therapy
  1
  c0454064|megavoltage radiation therapy (procedure)|t061
others probably increased toxicity
  4
  c0182412|probes, other|t074
  c0040539|toxicity aspects|t081
  c0205217|increased (qualifier value)|t169
  c0600688|toxic effect|t037
depletion
  1
  c0333668|depletion (morphologic abnormality)|t169
uterine vessels
  2
  c0005847|blood vessels|t023
  c0042149|uterus|t023
median interval
  3
  c1272706|interval (qualifier value)|t079
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
major response rate
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0205164|major (qualifier value)|t080
radiotherapy group patients
  5
  c0030705|patients|t101
  c0441833|groups (qualifier value)|t170
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
  c1300322|group (social concept)|t096
measurable lesion
  3
  c0444706|measured (qualifier value)|t080
  c0221198|lesion|t033
  c0079809|measures|t081
therapeutic responses
  1
  c0521982|therapeutic response, function (observable entity)|t033
perioperative complications
  4
  c1171258|complication aspects|t046
  c0231379|at risk for joint contractures (finding)|t033
  c0231393|at risk for cognitive impairment (finding)|t033
  c0009566|complication|t046
very few patients
  3
  c0442824|very (qualifier value)|t080
  c0030705|patients|t101
  c0205388|few (qualifier value)|t081
combined postoperative chemotherapy
  2
  c0032790|postoperative period|t079
  c0013218|drug therapy, combination|t061
prophylactic radiation
  2
  c0851346|radiation|t070
  c0445202|prophylactic (qualifier value)|t169
disease-free survival rates
  2
  c0871208|rating|t062
  c0242793|disease-free survival|t081
time days
  2
  c0439228|day (qualifier value)|t079
  c0040223|time|t079
assistance
  1
  c0018896|helping behavior|t054
local relapses
  2
  c0205276|local (qualifier value)|t082
  c0035020|relapse|t067
serum creatinine 1.5 mg
  2
  c0036818|serum magnesium level observed|t034
  c0010294|creatinine|t123
opinion
  1
  c0871010|opinions|t041
other advantages
  2
  c0205394|other|t080
  c0308269|advantage|t131
student t test
  1
  c0871453|students t test|t170
time intervals
  1
  c0872291|time interval|t079
high-pressure bladder
  9
  c0392677|pressure|t201
  c0033095|pressure- physical agent|t067
  c0005682|bladder|t023
  c0460139|pressure - action|t033
  c1281573|entire bladder|t023
  c0235146|euphoric mood|t041
  c0234222|baresthesia|t042
  c0205250|high|t080
  c1306345|pressure - action (qualifier value)|t169
preferentially adriamycin containing regimen
  4
  c0085752|adriamycin|t195
  c0558295|preferences (qualifier value)|t055
  c0332256|containing (qualifier value)|t169
  c0677937|regimen|t061
colonoscopy
  1
  c0009378|colonoscopy|t060
9.3 weeks
  1
  c0439230|week (qualifier value)|t079
probably alkylating agent
  3
  c0750492|probably|t078
  c0332148|probable diagnosis|t080
  c0002073|alkylating agents|t131
acute side effects
  2
  c0001688|adverse effects|t037
  c0205178|acuteness (qualifier value)|t079
large retrospective analyses
  4
  c0549177|large|t080
  c0002778|analysis of substances|t059
  c0035363|retrospective studies|t081
  c0936012|analysis|t062
three clinical stages
  2
  c0205563|clinical staging (qualifier value)|t079
  c0205449|three (qualifier value)|t081
cumulative epi doses
  4
  c0719635|dos|t109
  c0221908|epithelial|t169
  c0014609|epithelium|t024
  c0014544|epilepsy|t047
repair
  3
  c0374711|repair - action|t169
  c0184985|surgical repair (procedure)|t061
  c0043240|wound healing|t040
adjust
  4
  c0001537|clinical adjustment|t058
  c0683269|psychological adjustment|t055
  c0376209|individual adjustment|t055
  c0456081|adjustment action|t058
two layer
  2
  c0934502|layer|t023
  c0205448|two (qualifier value)|t081
written informed consent
  3
  c0043266|writing|t090
  c0021430|informed consent|t058
  c0341628|writer (occupation)|t097
less cardiotoxic drug
  2
  c0013227|pharmaceutical preparations|t121
  c0876994|cardiotoxicity|t047
six patients
  2
  c0205452|six (qualifier value)|t081
  c0030705|patients|t101
two deaths
  2
  c0205448|two (qualifier value)|t081
  c0011065|cessation of life|t040
survival time
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0040223|time|t079
not cells
  1
  c0007634|cells|t025
twenty five patients
  2
  c0205451|five (qualifier value)|t081
  c0030705|patients|t101
lemberts method
  1
  c0025663|methods|t170
three risk factors
  2
  c0035648|risk factors|t081
  c0205449|three (qualifier value)|t081
insulin-dependent diabetic man
  4
  c0011854|diabetes mellitus, insulin-dependent|t047
  c0086418|homo sapiens|t016
  c0025266|male population group|t098
  c0024554|male gender|t032
similar pharmacokinetic behavior
  3
  c0004927|behavior|t055
  c0871364|simile|t170
  c0031328|pharmacokinetic|t169
tion therapy
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
treatment allocation
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
tumor response
  2
  c0871261|responses|t054
  c0027651|neoplasms|t191
acceptable radiation doses
  3
  c0814633|acceptability|t080
  c0034524|radiation dosage|t081
  c1272684|accepted (qualifier value)|t080
improving survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c1272745|improving (qualifier value)|t170
serum creatinine
  2
  c0201976|serum creatinine tests|t059
  c0600061|serum creatinine level|t034
surgical treatment
  1
  c0543467|general operative procedures|t061
interaction
  2
  c0037420|social interaction|t033
  c0687133|drug interactions|t044
one death
  2
  c0205447|one (qualifier value)|t081
  c0011065|cessation of life|t040
great proportion
  2
  c0549177|large|t080
  c0205351|proportional (qualifier value)|t080
bowel preparation
  1
  c0455052|preparation of bowel for procedure (procedure)|t058
qlq-c30 questionnaire
  1
  c0034394|questionnaires|t170
renewed interest
  1
  c0543488|interested (finding)|t041
associated mortality
  4
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
  c0004083|mental association|t041
  c0699792|relationship by association|t054
wrong primary tumor
  3
  c0332271|worsening (qualifier value)|t080
  c0677930|primary tumor|t191
  c1279889|deterioration of status|t080
subclinical cardiac injury
  3
  c0205041|cardio-|t082
  c0175677|injury inflicted to the body by an external force|t037
  c0205211|subclinical (qualifier value)|t080
cumulative dose to
  1
  c0178602|dosages (qualifier value)|t081
overall pelvic control
  2
  c0282416|overall [publication type]|t170
  c0561970|ability to control pelvic posture (observable entity)|t033
dukes c
  1
  c0007886|cesium|t196
three week schedule
  3
  c0086960|schedules|t170
  c0205449|three (qualifier value)|t081
  c0439230|week (qualifier value)|t079
systemic relapses
  2
  c0205373|systemic (qualifier value)|t169
  c0035020|relapse|t067
reproducibility
  2
  c0748342|reproductive|t185
  c0035150|reproduction|t040
independent additive cytotoxic effect
  5
  c1280500|effect (qualifier value)|t080
  c0010868|cytotoxin|t123
  c1299583|independently able (qualifier value)|t033
  c0442796|additive (qualifier value)|t080
  c0596402|cytotoxicity|t049
experienced recurrences
  2
  c0596545|experience|t041
  c0034897|recurrence|t067
endomyocardial biopsy
  1
  c0189785|endomyocardial biopsy (procedure)|t060
concomitant therapy
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
follow-up examinations
  1
  c0260832|[v]follow-up examination (context-dependent category)|t033
completeness
  1
  c0439812|completeness (qualifier value)|t080
median cumulative doses
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0719635|dos|t109
only high-risk patients
  3
  c0030705|patients|t101
  c0235146|euphoric mood|t041
  c0205250|high|t080
low response rates
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0205251|low (qualifier value)|t080
m treated group
  1
  c0036669|sensitivity training groups|t065
disease-free survival analyses
  3
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
  c0242793|disease-free survival|t081
iib tumors
  1
  c0027651|neoplasms|t191
evaluation
  2
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
excessive toxicity
  3
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0442802|excessive (qualifier value)|t080
other eligibility criteria
  2
  c0205394|other|t080
  c0243161|criteria|t170
subsequent mortality
  3
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
  c0750530|subsequent|t078
7.5 mg
  2
  c0024467|magnesium|t123
  c0439210|milligram|t081
only .05 probability
  1
  c0033204|probability|t081
different methods
  3
  c0025664|methodology|t170
  c0025663|methods|t170
  c0443199|differential (qualifier value)|t080
cervical neoplasms
  1
  c0007873|cervix neoplasms|t191
17-ia antibody
  4
  c0524427|intraarterial|t082
  c0022037|iowa|t083
  c0230168|abdominal cavity structure|t029
  c0003241|antibodies|t116
major symptoms
  2
  c0205164|major (qualifier value)|t080
  c0683368|symptoms|t169
median cumulative dose
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0178602|dosages (qualifier value)|t081
computed tomography scan
  1
  c0040405|x-ray computed tomography|t060
wide resection
  3
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
  c0332464|widened structure (morphologic abnormality)|t082
injections
  1
  c0021485|injections|t061
history
  5
  c0019664|recording of previous events|t090
  c0019665|history|t170
  c0262926|medical history|t033
  c1321503|history of (contextual qualifier) (qualifier value)|t033
  c0262512|history of (present illness) (contextual qualifier) (qualifier value)|t032
patient’s informed consent
  1
  c0021430|informed consent|t058
local metastases
  3
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0205276|local (qualifier value)|t082
  c0027627|neoplasm metastasis|t191
therefore high incidence
  4
  c0021149|incidence|t081
  c0220856|incidence of cases|t169
  c0235146|euphoric mood|t041
  c0205250|high|t080
epirubicin
  1
  c0014582|epirubicin|t109
initial radiation
  2
  c0851346|radiation|t070
  c0205265|initial (qualifier value)|t079
placebo
  1
  c0032042|placebos|t074
treatment protocol epi
  4
  c0040808|treatment protocols|t062
  c0221908|epithelial|t169
  c0014609|epithelium|t024
  c0014544|epilepsy|t047
anastomotic failure
  3
  c0680095|personal failure|t055
  c0332854|anastomotic|t082
  c0231174|failure (biologic function)|t169
m2 epirubicin x days
  2
  c0439228|day (qualifier value)|t079
  c0014582|epirubicin|t109
one refusal
  1
  c0205447|one (qualifier value)|t081
data forms
  1
  c0376315|manufactured form|t073
therapeutic results
  1
  c0808233|therapeutic results|t033
vascular invasion
  1
  c0005847|blood vessels|t023
six protocol violations
  2
  c0205452|six (qualifier value)|t081
  c0442711|protocols documentation|t170
cisplatin based regimens
  3
  c0178499|base|t120
  c0008838|cisplatin|t197
  c0677937|regimen|t061
pt4 tumors however
  1
  c0027651|neoplasms|t191
full protocol doses
  3
  c0442711|protocols documentation|t170
  c0719635|dos|t109
  c0443225|full (qualifier value)|t080
thomas deviations
  1
  c0012727|spatial displacement|t082
radiosensitizer
  1
  c0034541|radiation-sensitizing agents|t121
center
  1
  c0205099|central|t082
fu mg
  3
  c0016360|fluorouracil|t114
  c0024467|magnesium|t123
  c0439210|milligram|t081
two sided
  3
  c0441987|side (qualifier value)|t082
  c0457012|sidedness (qualifier value)|t082
  c0205448|two (qualifier value)|t081
haemoglobin g
  1
  c1319312|hemoglobin g (substance)|t116
calculations
  1
  c0444686|calculated (qualifier value)|t169
adverse effects
  1
  c0001688|adverse effects|t037
patients’ medical records
  1
  c0025102|medical records|t170
treatment cycle
  3
  c0087111|therapeutic procedure|t061
  c0439596|cyclic (qualifier value)|t079
  c0039798|therapeutic aspects|t169
weekly cisplatin
  2
  c0008838|cisplatin|t197
  c0332174|weekly (qualifier value)|t079
delivery
  3
  c0011209|obstetric delivery|t061
  c1135594|delivery|t061
  c0559563|delivery finding (finding)|t033
eight weeks
  2
  c0205454|eight (qualifier value)|t170
  c0439230|week (qualifier value)|t079
study end point
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0150100|endpoint|t062
ii axillary lymph nodes
  2
  c0729594|axillary lymph node group|t023
  c0439069|roman numeral ii|t170
lymphangiogram nodal findings
  3
  c0443268|nodal (qualifier value)|t082
  c0243095|findings|t169
  c0024219|lymphangiography|t060
cervical cancer results
  2
  c0007847|malignant neoplasm of cervix uteri|t191
  c1274040|result (navigational concept)|t169
inadequate irradiation dosage
  5
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0205412|inadequate (qualifier value)|t080
  c0034618|radiation therapy|t061
  c0178602|dosages (qualifier value)|t081
interval
  1
  c1272706|interval (qualifier value)|t079
participating institutions
  3
  c1272753|institution (social concept)|t078
  c0679646|participant|t098
  c0679823|participation|t055
site
  1
  c0205145|associated topography (attribute)|t082
patient population
  2
  c0032659|population|t081
  c0030705|patients|t101
iqr 4.12 days
  1
  c0439228|day (qualifier value)|t079
extrafascial hysterectomy
  1
  c0020699|hysterectomy|t061
1-year survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439234|year (qualifier value)|t079
estimated five year survival rates
  4
  c0205451|five (qualifier value)|t081
  c0750572|estimated|t078
  c0038954|survival rate|t081
  c0439234|year (qualifier value)|t079
significantly longer hazard ratio
  4
  c0205166|long (qualifier value)|t080
  c0598697|hazard|t080
  c0456603|ratio (property) (qualifier value)|t170
  c0750502|significant (qualifier value)|t078
resection
  2
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
median size
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0702146|size (attribute)|t081
20% mortality
  2
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
disease relapsed interval
  5
  c1272706|interval (qualifier value)|t079
  c0205336|relapsing course|t079
  c0580802|relapse phase|t079
  c0012634|disease|t047
  c0035020|relapse|t067
abdominal carcinomatosis
  2
  c0456438|abdominal (qualifier value)|t082
  c0205699|carcinomatosis|t191
continuous infusion
  1
  c0444889|continuous infusion (qualifier value)|t061
single agent weekly cisplatin
  6
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0008838|cisplatin|t197
  c0450442|agent (attribute)|t120
  c0332174|weekly (qualifier value)|t079
  c0087136|unmarried|t098
treatment effect
  3
  c1280500|effect (qualifier value)|t080
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
e e m
  3
  c0679138|expectations (qualifier value)|t041
  c0542479|energy, physics|t070
  c0424589|vitality|t033
protocol specific eligibility checklists
  3
  c0442711|protocols documentation|t170
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
bowel project
  4
  c0348018|spatial projection|t082
  c0016538|projections and predictions|t170
  c0021853|intestines|t023
  c0033363|projection defense mechanism|t041
recurrent tumors
  1
  c0521158|recurrent tumor (finding)|t191
pelvic lymph nodes
  1
  c0729595|pelvic lymph node group|t023
ifosfamide 5.0 g
  2
  c0020823|ifosfamide|t115
  c0162832|apc gene|t028
min.
  1
  c0439232|minute of time|t079
irradiation
  3
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
increase
  1
  c0442805|increase (qualifier value)|t169
condition requiring surgery
  4
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0348080|condition (attribute)|t080
  c0038894|surgery specialty|t091
day
  1
  c0439228|day (qualifier value)|t079
radiation responsiveness
  2
  c0851346|radiation|t070
  c0205342|responsive (qualifier value)|t169
required treatment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
intravaginal therapy
  3
  c0442122|intravaginal (qualifier value)|t082
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
30-month rate
  2
  c0871208|rating|t062
  c0439231|month (qualifier value)|t079
previous adjuvant therapy
  2
  c0677850|adjuvant therapy|t061
  c0205156|previous (qualifier value)|t082
magnesium
  1
  c0024467|magnesium|t123
preoperative treatment
  3
  c0087111|therapeutic procedure|t061
  c0445204|preoperative (qualifier value)|t032
  c0039798|therapeutic aspects|t169
conflicting results
  2
  c1274040|result (navigational concept)|t169
  c0009671|conflict (psychology)|t055
recurrence free intervals
  3
  c0016694|freedom|t078
  c1272706|interval (qualifier value)|t079
  c0034897|recurrence|t067
platelets 100,000/cu mm
  2
  c0439200|millimeter|t081
  c0005821|blood platelets|t025
local event
  2
  c0441471|events (event)|t051
  c0205276|local (qualifier value)|t082
x
  1
  c0078606|xanthosine|t114
patients considerable amount
  3
  c0750591|consider|t078
  c0030705|patients|t101
  c0205389|quantity (attribute)|t081
significant similarity
  2
  c0871364|simile|t170
  c0750502|significant (qualifier value)|t078
retroperitoneal surgical exploration
  4
  c0184899|surgical exploration (procedure)|t060
  c0038895|surgical aspects|t169
  c0035359|retroperitoneal space|t030
  c1112507|retroperitoneal exploration|t061
confirmation
  1
  c0750484|confirmed|t078
several approaches
  2
  c0449445|approach (attribute)|t082
  c0443302|several (qualifier value)|t081
only regimen
  1
  c0677937|regimen|t061
stomatitis
  1
  c0038362|stomatitis|t047
angiography
  1
  c0002978|angiography|t060
repeat measurements
  1
  c0871881|repeated measures|t062
more high70 years
  2
  c0205172|more (qualifier value)|t081
  c0439234|year (qualifier value)|t079
prognostic importance
  1
  c0220901|prognostic|t170
severity
  1
  c0449294|with severity (attribute)|t080
4 6 mo thereafter
  2
  c0026402|molybdenum|t123
  c1271041|other regular care provider|t097
two compounds
  2
  c0205198|compound (qualifier value)|t080
  c0205448|two (qualifier value)|t081
singularly discouraging
  1
  c0205171|singular|t081
survival benefit
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0814225|benefits|t081
chemotherapy group
  5
  c0392920|chemotherapy-oncologic procedure|t061
  c0441833|groups (qualifier value)|t170
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c1300322|group (social concept)|t096
to follow-up evaluation
  3
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
  c0589120|follow-up status (finding)|t169
prior irradiation
  4
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0750516|prior|t078
  c0034618|radiation therapy|t061
surface
  1
  c0205148|surface (qualifier value)|t032
colon cancer
  1
  c0007102|malignant tumor of colon|t191
occasional confusion
  1
  c0009676|confusion|t048
cell culture
  1
  c0007585|cell culture|t059
systemic chemotherapy
  4
  c0205373|systemic (qualifier value)|t169
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
leukemogenic effect
  2
  c1280500|effect (qualifier value)|t080
  c0023418|leukemia|t191
persisting bone pain
  3
  c0205322|persistent (qualifier value)|t079
  c0151825|bone pain (finding)|t184
  c0546816|persistence (finding)|t041
cisplatin therapy
  3
  c0008838|cisplatin|t197
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
patient accrual
  1
  c0030705|patients|t101
nine additional deaths
  3
  c0442796|additive (qualifier value)|t080
  c0205455|nine (qualifier value)|t081
  c0011065|cessation of life|t040
young unpublished data
  1
  c0332239|young (qualifier value)|t079
improved results
  2
  c0184511|improved (qualifier value)|t080
  c1274040|result (navigational concept)|t169
32% objective response rate
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0018017|goals|t170
40% cause specific survival rate
  6
  c0678227|causing (attribute)|t169
  c0038954|survival rate|t081
  c0015127|causality|t169
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
  c1314792|etiology|t169
10.5 months
  1
  c0439231|month (qualifier value)|t079
multiple regression analysis
  3
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
  c0681923|multiple regression|t080
mesna
  1
  c0000294|mesna|t109
median total dose
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0172161|tyramine-deoxysorbitol|t109
level
  1
  c0456079|disease classification level|t185
dose effect relationships
  1
  c0683160|dose-effect relationship|t038
surveillance committees
  3
  c0220920|surveillance aspects|t169
  c0733511|medical surveillance|t058
  c0684245|legal surveillance|t057
only group significantly
  3
  c0441833|groups (qualifier value)|t170
  c0750502|significant (qualifier value)|t078
  c1300322|group (social concept)|t096
homogeneity
  1
  c0181200|homogenizers|t074
opaque
  2
  c1261286|opaque (qualifier value)|t169
  c0029053|decreased translucency|t033
lateral surface
  2
  c0205093|lateral (qualifier value)|t082
  c0205148|surface (qualifier value)|t032
tumor size $5 cm
  2
  c0475440|tumor size (observable entity)|t082
  c0475210|cm (qualifier value)|t081
nationwide use
  1
  c0042153|utilization|t081
accurate method—a direct measurement
  2
  c0443131|accurate (qualifier value)|t080
  c0242485|measurement|t081
other topoisomerase i inhibitor
  3
  c0205394|other|t080
  c0012920|dna topoisomerase|t116
  c0243077|inhibitors|t120
visceral involvement
  2
  c0392760|not free of (attribute)|t169
  c0442045|visceral (qualifier value)|t082
vomiting
  2
  c0042963|vomiting|t184
  c0401156|vomiting nos (disorder)|t047
favoring patients
  2
  c0309049|favor (product)|t121
  c0030705|patients|t101
other eight studies
  4
  c0205394|other|t080
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205454|eight (qualifier value)|t170
wbc
  1
  c0023516|leukocytes|t025
group
  2
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
drug
  1
  c0013227|pharmaceutical preparations|t121
activity
  3
  c0600075|endurance of activity|t033
  c0441655|activities|t052
  c0221187|physical activity|t056
metaanalyses
  1
  c0920317|meta-analysis|t170
university
  1
  c0041740|universities|t073
vincristine
  1
  c0042679|vincristine|t109
treatment control group
  3
  c0087111|therapeutic procedure|t061
  c0009932|control groups|t096
  c0039798|therapeutic aspects|t169
common iliac lymph nodes
  1
  c0229807|structure of iliac lymph node (body structure)|t023
dyspnoea
  1
  c0013404|dyspnea|t184
median followirinotecan group
  4
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
10/533 patients
  1
  c0030705|patients|t101
acceptable to virtually patients
  3
  c0814633|acceptability|t080
  c0030705|patients|t101
  c1272684|accepted (qualifier value)|t080
calcium folinate only
  1
  c0731033|leucovorin calcium|t109
radical surgery
  5
  c0302912|radicals (chemistry)|t104
  c0543467|general operative procedures|t061
  c0439807|radical (qualifier value)|t080
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
received prior chemotherapy
  5
  c0544683|reception|t042
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c0750516|prior|t078
benefits
  1
  c0814225|benefits|t081
significant improvement
  4
  c0184511|improved (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
fisher exact test
  3
  c0059927|exact|t122
  c0325045|martes pennanti (organism)|t015
  c0392366|tests (qualifier value)|t170
closer analysis
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
dox cardiomyopathy
  4
  c0048808|5'-deoxy-5-fluorouridine|t114
  c0027049|cardiomyopathy|t047
  c0013090|doxycycline|t195
  c0013089|doxorubicin|t195
corticosteroids
  1
  c0001617|adrenal cortex hormones|t125
route
  1
  c0449444|route (attribute)|t082
concurrent malignant disease
  2
  c0442867|malignant disease|t047
  c0205420|concurrent (qualifier value)|t079
empiric dose limitation
  2
  c0376548|empiricism|t078
  c0935905|dose-limiting|t037
combination therapy treatment plan
  3
  c0556895|combination electrotherapy|t061
  c0599880|plan of treatment|t170
  c0009429|combined modality therapy|t061
daily fractions
  2
  c0457426|fractions of (qualifier value)|t081
  c0332173|daily (qualifier value)|t079
other drugs to
  2
  c0205394|other|t080
  c0013227|pharmaceutical preparations|t121
two other randomized trials
  3
  c0205394|other|t080
  c0034656|random allocation|t062
  c0205448|two (qualifier value)|t081
stage iib bulky
  2
  c0457160|stage 2 lower case bee|t185
  c0441769|stage 2 upper case bee|t185
colleagues pated toxicity
  2
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
possible chemotherapy infusion
  5
  c0332149|possible|t080
  c0574032|infusion (procedure)|t061
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
primary stage ib squamous adenosquamous carcinoma
  6
  c0206623|carcinoma, adenosquamous|t191
  c0457152|stage 1 lower case bee|t185
  c0456597|stage 1 upper case bee|t185
  c0439631|primary operation (qualifier value)|t061
  c1182670|squamous|t080
  c0205225|primary|t080
sensitivity
  3
  c0312418|personality sensitivity|t041
  c0427965|antimicrobial susceptibility|t033
  c0036667|statistical sensitivity|t081
regional recurrence
  2
  c0034897|recurrence|t067
  c0205147|regional (qualifier value)|t082
written consent
  2
  c0043266|writing|t090
  c0341628|writer (occupation)|t097
meccnu treatment arm
  5
  c0087111|therapeutic procedure|t061
  c0036637|semustine|t109
  c0039798|therapeutic aspects|t169
  c0003792|arm|t029
  c0446516|upper arm|t029
fractionation scheme
  2
  c0524811|dose fractionation|t061
  c0016640|fractionation|t059
concomitant chemotherapy
  3
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
following end points
  2
  c0332282|following (attribute)|t079
  c0150100|endpoint|t062
access
  1
  c0444454|access (attribute)|t082
comparative frequency
  1
  c0376249|with frequency|t081
partially hyperfractionated rt
  2
  c0728938|partial (qualifier value)|t081
  c0796569|hyperfractionation|t061
randomized study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0034656|random allocation|t062
lung toxicity
  1
  c0919924|pulmonary toxicity|t046
linear logistic model
  2
  c0205132|linear|t082
  c0023965|logistic models|t170
scan
  1
  c0441633|scanning|t060
m stage
  1
  c0456533|m category (observable entity)|t170
chicago
  1
  c0008044|chicago|t083
postoperative pelvic radiotherapy
  4
  c0032790|postoperative period|t079
  c0030797|pelvis|t029
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
sequential delivery
  3
  c0011209|obstetric delivery|t061
  c1135594|delivery|t061
  c0559563|delivery finding (finding)|t033
recurrent tumor
  1
  c0521158|recurrent tumor (finding)|t191
low dose rate intracavitary irradiation to
  7
  c0677884|dose-rate|t081
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0205251|low (qualifier value)|t080
  c0034618|radiation therapy|t061
  c0445550|low dose (qualifier value)|t081
  c1298613|intracavitary (qualifier value)|t082
life style
  1
  c0023676|life style|t054
age 18 75 years
  2
  c0001779|age (qualifier value)|t079
  c0439234|year (qualifier value)|t079
test
  1
  c0392366|tests (qualifier value)|t170
financial impact scores
  3
  c0449820|scores (qualifier value)|t081
  c0726639|impact|t168
  c0376243|financial|t081
surgery group patients
  3
  c0441833|groups (qualifier value)|t170
  c0871463|surgical patients|t101
  c1300322|group (social concept)|t096
hypoxic cell radiation sensitizers
  4
  c0007634|cells|t025
  c0034541|radiation-sensitizing agents|t121
  c1269647|entire cell|t025
  c0242184|oxygen deficiency|t046
radiographic techniques
  3
  c0444708|radiographic (qualifier value)|t070
  c0025664|methodology|t170
  c0449851|techniques|t170
patients
  1
  c0030705|patients|t101
significance level
  1
  c0814896|significance level|t062
less time to
  1
  c0040223|time|t079
significant prolongation
  2
  c0439590|prolonged (qualifier value)|t079
  c0750502|significant (qualifier value)|t078
gynecology
  1
  c0018417|gynecology|t091
statistical evaluation
  3
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
  c0220917|statistical|t170
lack
  1
  c0332268|lacking (qualifier value)|t080
cisplatin based regimen
  3
  c0178499|base|t120
  c0008838|cisplatin|t197
  c0677937|regimen|t061
c m regimen
  2
  c0007886|cesium|t196
  c0677937|regimen|t061
antineoplastic effects
  2
  c1280500|effect (qualifier value)|t080
  c0003392|antineoplastic agents|t121
unfavorable prognostic factor
  1
  c0220901|prognostic|t170
country variable
  2
  c0454664|countries (geographic location)|t083
  c0439828|variable (qualifier value)|t080
end to side
  2
  c0444930|end (qualifier value)|t082
  c0441987|side (qualifier value)|t082
timing
  1
  c0449243|timing (attribute)|t079
long-term analysis
  3
  c0002778|analysis of substances|t059
  c0443252|long-term (qualifier value)|t079
  c0936012|analysis|t062
radiotherapy group
  4
  c0441833|groups (qualifier value)|t170
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
  c1300322|group (social concept)|t096
patients previously
  2
  c0030705|patients|t101
  c0205156|previous (qualifier value)|t082
white blood cells
  1
  c0023516|leukocytes|t025
local response
  2
  c0871261|responses|t054
  c0205276|local (qualifier value)|t082
only five patients
  2
  c0205451|five (qualifier value)|t081
  c0030705|patients|t101
chemotherapy concurrently
  4
  c0205420|concurrent (qualifier value)|t079
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
log rank tests
  3
  c0699794|rank|t170
  c0392366|tests (qualifier value)|t170
  c0335467|logger (occupation)|t097
randomized radiotherapy trial
  3
  c0034618|radiation therapy|t061
  c0034656|random allocation|t062
  c0034619|radiotherapeutic|t170
method
  1
  c0025663|methods|t170
high-dose brachytherapy
  1
  c1273556|high dose brachytherapy (regime/therapy)|t061
observation
  2
  c0700325|patient observation|t061
  c0302523|observation in research|t062
above-mentioned statement
  2
  c1301808|state (environment)|t083
  c1282910|supra- (qualifier value)|t082
medical contraindications
  1
  c1301624|medical contraindication (finding)|t033
threeyear survival rates
  1
  c0038954|survival rate|t081
future cooperative group trials
  2
  c0677877|cooperative group|t093
  c0016884|future|t079
pooling
  1
  c0337051|pool (environment)|t083
single models
  4
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0026336|models|t170
  c0087136|unmarried|t098
cox model
  1
  c0010234|cox models|t170
useful predictor
  1
  c0681842|prediction|t170
cardiac toxicity
  1
  c0280951|cardiac toxicity|t037
radiographic evidence
  1
  c0444708|radiographic (qualifier value)|t070
reduced potential
  2
  c0392756|reduced (qualifier value)|t080
  c0237399|potential|t080
ability
  1
  c0085732|ability|t032
toxic manifestations
  2
  c0600688|toxic effect|t037
  c0205319|manifest (qualifier value)|t169
cooperative german group
  2
  c0337805|german population|t098
  c0677877|cooperative group|t093
regional recurrences
  2
  c0034897|recurrence|t067
  c0205147|regional (qualifier value)|t082
local recurrences
  2
  c0205276|local (qualifier value)|t082
  c0034897|recurrence|t067
dl
  1
  c0439241|dl (qualifier value)|t081
colleagues study
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
similar findings
  2
  c0871364|simile|t170
  c0243095|findings|t169
analyses
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
adjustment
  4
  c0001537|clinical adjustment|t058
  c0683269|psychological adjustment|t055
  c0376209|individual adjustment|t055
  c0456081|adjustment action|t058
adult patients
  2
  c0030705|patients|t101
  c0001675|adult|t100
to accrue patients
  2
  c0333038|accretion (morphologic abnormality)|t169
  c0030705|patients|t101
capillary lymphatic space
  5
  c1280521|entire capillary blood vessel (organ)|t023
  c0935624|capillary, unspecified|t023
  c0229889|lymphatic vessel|t023
  c0006901|blood capillaries|t023
  c0221874|spacer (physical object)|t074
optimal duration
  1
  c0449238|duration|t079
overall major response rate
  4
  c0237629|frequency of responses|t079
  c0282416|overall [publication type]|t170
  c0878525|cancer treatment response rate|t079
  c0205164|major (qualifier value)|t080
renal sonogram
  2
  c0022646|kidney|t023
  c0041618|ultrasonography|t060
patients evenly
  1
  c0030705|patients|t101
theoretical risk
  1
  c0035647|risk|t080
life-threatening episodes
  2
  c0678231|episodes (qualifier value)|t079
  c0376558|life|t078
alone group
  3
  c0441833|groups (qualifier value)|t170
  c0679994|alone|t102
  c1300322|group (social concept)|t096
combination
  1
  c0205195|combined (qualifier value)|t080
retrospective analysis
  3
  c0002778|analysis of substances|t059
  c0035363|retrospective studies|t081
  c0936012|analysis|t062
appropriate guidelines
  4
  c0814634|appropriateness|t080
  c0220845|guiding characteristics|t170
  c0680799|appropriation|t064
  c0162791|guidelines|t170
principal effect
  3
  c1280500|effect (qualifier value)|t080
  c0401925|teaching principal|t097
  c0205225|primary|t080
permuted block
  1
  c0028778|obstruction|t046
slow rise
  3
  c0995005|rose extract|t121
  c0439834|slow (qualifier value)|t080
  c0035853|rosa|t002
axillary node dissection
  4
  c1293093|dissection procedure (procedure)|t061
  c1306808|dissection - action (qualifier value)|t169
  c0012737|dissection|t059
  c0729594|axillary lymph node group|t023
intestinal obstruction
  1
  c0021843|intestinal obstruction|t047
four groups
  2
  c0205450|four (qualifier value)|t081
  c0441833|groups (qualifier value)|t170
total
  1
  c0439810|total (qualifier value)|t080
interim tests
  1
  c0392366|tests (qualifier value)|t170
prospective randomized study
  2
  c0033522|prospective studies|t081
  c0034656|random allocation|t062
primary treatment failure
  3
  c0439631|primary operation (qualifier value)|t061
  c0162643|treatment failure|t080
  c0205225|primary|t080
medical treatments
  1
  c1171203|medication treatment|t061
p120 nucleolar antigen
  2
  c0521448|nucleolar|t029
  c0003320|antigens|t129
bilirubin
  1
  c0005437|bilirubin|t123
randomly assigned treatment
  3
  c0087111|therapeutic procedure|t061
  c0814868|random assignment|t062
  c0039798|therapeutic aspects|t169
acceptable treatment deviations
  5
  c0814633|acceptability|t080
  c0012727|spatial displacement|t082
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c1272684|accepted (qualifier value)|t080
vast majorities
  2
  c0680220|majority|t054
  c0814230|veterans alcoholism screening test|t170
fluorodeoxyuridine monophosphate
  1
  c0016343|floxuridine|t114
considerable research effort
  3
  c0035168|research|t062
  c0750591|consider|t078
  c0015264|exertion|t040
middle third stromal invasion
  2
  c0927195|stroma|t023
  c0442050|middle third (qualifier value)|t082
estimating tumor diameter
  3
  c0750572|estimated|t078
  c0332517|diameter (qualifier value)|t032
  c0027651|neoplasms|t191
node dissection
  4
  c1293093|dissection procedure (procedure)|t061
  c1306808|dissection - action (qualifier value)|t169
  c0746922|node|t023
  c0012737|dissection|t059
eight patients randomly
  3
  c0439605|random (qualifier value)|t082
  c0030705|patients|t101
  c0205454|eight (qualifier value)|t170
reference values
  1
  c0034926|reference values|t081
total dose to
  1
  c0172161|tyramine-deoxysorbitol|t109
iib disease
  1
  c0012634|disease|t047
equivalent
  1
  c0439185|eq (qualifier value)|t081
agent
  1
  c0450442|agent (attribute)|t120
survival probability
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0033204|probability|t081
significant hypoxic cell populations
  5
  c0032659|population|t081
  c0007634|cells|t025
  c1269647|entire cell|t025
  c0750502|significant (qualifier value)|t078
  c0242184|oxygen deficiency|t046
pelvic radiation
  1
  c0747411|pelvis radiation|t061
os
  1
  c0262950|skeletal bone|t021
neoadjuvant bomp ct
  2
  c0053926|bomp protocol|t061
  c0040405|x-ray computed tomography|t060
hypothesis tests
  1
  c0681918|hypothesis testing|t062
percent confidence interval
  2
  c0009667|confidence intervals|t081
  c0439165|percent (qualifier value)|t081
dose reduction
  3
  c0301630|reduction (chemical)|t070
  c0178602|dosages (qualifier value)|t081
  c0441610|reduction - action|t061
greater decrease
  2
  c0443228|greater (qualifier value)|t081
  c0547047|decrease (qualifier value)|t081
longest delay
  2
  c0205166|long (qualifier value)|t080
  c0205421|deferred (qualifier value)|t079
univariate analyses to
  1
  c0683962|univariate analysis|t062
most unfavourable pathological prognostic factors
  2
  c0205393|most (qualifier value)|t081
  c0220901|prognostic|t170
malignant fibrous histiocytoma
  1
  c0334463|[m]fibroxanthosarcoma (morphologic abnormality)|t191
detection
  2
  c0442726|detected (qualifier value)|t033
  c0335385|detective (occupation)|t097
one other patient
  3
  c0205394|other|t080
  c0030705|patients|t101
  c0205447|one (qualifier value)|t081
mediastinum
  2
  c1278909|entire mediastinum|t023
  c0025066|mediastinum|t029
controversy
  1
  c0680243|controversy|t054
large number
  2
  c0549177|large|t080
  c0449788|count of entities (property) (qualifier value)|t081
descending
  1
  c0205386|descending (qualifier value)|t080
follow-up studies pretreatment evaluation
  3
  c1261322|assessment procedure (procedure)|t058
  c0016441|follow-up studies|t062
  c0220825|evaluation|t169
nominal level
  1
  c0456079|disease classification level|t185
actuarial disease-free survival
  2
  c0334965|actuary (occupation)|t097
  c0242793|disease-free survival|t081
less local progression
  2
  c0205276|local (qualifier value)|t082
  c0449258|progression (attribute)|t169
other patients
  2
  c0205394|other|t080
  c0030705|patients|t101
mean time
  2
  c0444504|mean (qualifier value)|t081
  c0040223|time|t079
5.8 years
  1
  c0439234|year (qualifier value)|t079
further studies
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
pilot study used mitolactol
  3
  c0026252|mitolactol|t118
  c0042153|utilization|t081
  c0031928|pilot projects|t062
blood loss
  2
  c0019080|hemorrhage|t046
  c0553700|actual blood loss|t201
m control group
  1
  c0009932|control groups|t096
risk
  1
  c0035647|risk|t080
persistent leukopenia
  2
  c0205322|persistent (qualifier value)|t079
  c0023530|leukopenia|t047
remaining tumors
  1
  c0027651|neoplasms|t191
statistics
  1
  c0038215|science of statistics|t090
effects
  1
  c1280500|effect (qualifier value)|t080
ulceration
  1
  c0041582|ulcer|t046
death
  1
  c0011065|cessation of life|t040
larger total cumulative dose
  2
  c0443228|greater (qualifier value)|t081
  c0178602|dosages (qualifier value)|t081
figo stage
  1
  c0450454|figo stage (attribute)|t170
leukemogenic potential
  2
  c0023418|leukemia|t191
  c0237399|potential|t080
low toxicity
  3
  c0040539|toxicity aspects|t081
  c0205251|low (qualifier value)|t080
  c0600688|toxic effect|t037
postirradiation fibrosis
  1
  c0016059|fibrosis|t046
diarrhea
  1
  c0011991|diarrhea|t184
potential selection factors
  2
  c0036576|selection (genetics)|t045
  c0237399|potential|t080
one package
  2
  c0030176|packaging|t068
  c0205447|one (qualifier value)|t081
abdominal ct scanning
  1
  c0412620|ct of abdomen (procedure)|t060
total doxorubicin doses
  3
  c0439810|total (qualifier value)|t080
  c0719635|dos|t109
  c0013089|doxorubicin|t195
toxic death
  2
  c0600688|toxic effect|t037
  c0011065|cessation of life|t040
cmf cycles
  2
  c0439596|cyclic (qualifier value)|t079
  c0950521|cmf|t061
tests
  1
  c0392366|tests (qualifier value)|t170
laterally fields
  3
  c0205093|lateral (qualifier value)|t082
  c0331809|fielding|t093
  c0440042|field's stain|t130
cross-resistance
  4
  c0917925|cancer resistance to treatment|t033
  c0683598|social resistance|t054
  c0205203|crossed (qualifier value)|t082
  c0237834|resistance (psychotherapeutic)|t041
control arm
  3
  c0243148|control|t169
  c0003792|arm|t029
  c0446516|upper arm|t029
median overall dfs
  4
  c0282416|overall [publication type]|t170
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0011145|deferoxamine|t123
demonstrated transient tumor regression
  7
  c0205374|transitory|t079
  c0040704|transient population group|t098
  c0332265|demonstrable (qualifier value)|t169
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
  c0027651|neoplasms|t191
  c0335296|demonstrator (occupation)|t097
advanced colorectal carcinoma
  2
  c0205179|advanced phase|t080
  c0009403|colorectal carcinoma|t191
meaningful advantage
  3
  c0876919|meaning|t078
  c0308269|advantage|t131
  c0870867|meaningfulness|t080
small cell carcinoma
  1
  c0149925|carcinoma, small cell|t191
leucocyte nadir
  1
  c0023516|leukocytes|t025
grade histology
  4
  c0441800|grade|t185
  c0019638|histology|t091
  c0205462|histologic|t169
  c0344441|histology procedure|t059
randomized trial
  1
  c0034656|random allocation|t062
texas
  1
  c0039711|texas|t083
administration
  2
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
alkaline phosphatase u
  3
  c0041928|uranium|t196
  c1318717|alkaline phosphatase stain|t130
  c0002059|alkaline phosphatase|t116
reported benefits
  2
  c0700287|reporting|t058
  c0814225|benefits|t081
75th percentiles
  1
  c1264641|percentile (property) (qualifier value)|t081
lowest level
  3
  c0441994|lower (qualifier value)|t169
  c0456079|disease classification level|t185
  c0205251|low (qualifier value)|t080
target sample size
  2
  c0599894|targeting|t043
  c0242618|sample size|t081
noirinotecan group
  2
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
intraabdominal abscesses
  2
  c0000833|abscess|t046
  c0230168|abdominal cavity structure|t029
disease progression
  1
  c0242656|disease progression|t046
creatinine clearance 1.0 ml
  2
  c0812399|creatinine clearance|t033
  c0439242|ml (qualifier value)|t081
immune response
  1
  c0301872|immune response|t040
escalation
  1
  c0014829|escalators|t073
disease recurrence
  1
  c0679254|disease recurrence|t033
sufficient uniformity
  2
  c0205410|sufficient (qualifier value)|t080
  c0439827|uniformities (qualifier value)|t080
members
  1
  c0680022|member of (attribute)|t098
only 4.6 months
  1
  c0439231|month (qualifier value)|t079
melphalan
  1
  c0025241|melphalan|t116
factorial analysis
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
centers
  1
  c0205099|central|t082
17-la treatment
  3
  c0087111|therapeutic procedure|t061
  c0023031|lanthanum|t196
  c0039798|therapeutic aspects|t169
nineteen patients
  1
  c0030705|patients|t101
exploratory laparotomy
  1
  c0085704|exploratory laparotomy (procedure)|t060
uncontrolled infections
  2
  c0205318|uncontrolled (qualifier value)|t080
  c0021311|infection|t047
neoadjuvant bomp chemotherapy
  4
  c0053926|bomp protocol|t061
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
complete blood count
  1
  c0009555|blood count, complete|t059
clinical prognostic factors
  2
  c0205210|clinical (qualifier value)|t080
  c0220901|prognostic|t170
two treatments
  2
  c0087111|therapeutic procedure|t061
  c0205448|two (qualifier value)|t081
also observed one additional response
  6
  c0700325|patient observation|t061
  c0871261|responses|t054
  c0302523|observation in research|t062
  c0442796|additive (qualifier value)|t080
  c0205447|one (qualifier value)|t081
  c0870992|observers|t097
cervical cancers
  1
  c0007847|malignant neoplasm of cervix uteri|t191
superior extent
  2
  c0205105|superior (qualifier value)|t082
  c0439792|extents (qualifier value)|t080
dose reduction schedule
  4
  c0086960|schedules|t170
  c0301630|reduction (chemical)|t070
  c0178602|dosages (qualifier value)|t081
  c0441610|reduction - action|t061
primary objective
  3
  c0439631|primary operation (qualifier value)|t061
  c0018017|goals|t170
  c0205225|primary|t080
5-fu activity
  4
  c0600075|endurance of activity|t033
  c0441655|activities|t052
  c0221187|physical activity|t056
  c0016360|fluorouracil|t114
prognosis
  1
  c0033325|forecast of outcome|t058
gastrointestinal tumor study group
  7
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0441833|groups (qualifier value)|t170
  c0027651|neoplasms|t191
  c0430681|gastrointestinal investigation (procedure)|t060
  c0017185|gastrointestinal neoplasms|t191
  c1300322|group (social concept)|t096
portal catheter
  2
  c0205054|hepatic|t029
  c0085590|catheter|t074
advantages
  1
  c0308269|advantage|t131
tumour status
  1
  c0475752|tumor status (attribute)|t080
treatment duration
  1
  c0444921|duration of treatment (qualifier value)|t079
significantly fewer distant recurrences
  4
  c0443203|distant (qualifier value)|t082
  c0034897|recurrence|t067
  c0205388|few (qualifier value)|t081
  c0750502|significant (qualifier value)|t078
specimen
  1
  c0370003|specimen (specimen)|t167
observed complication rate
  5
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0871208|rating|t062
  c0870992|observers|t097
  c0009566|complication|t046
thoracic spine
  2
  c0581269|thoracic spine structure|t023
  c1269870|entire thoracic spine|t023
total proteins
  2
  c1261360|total protein|t034
  c0555903|total protein measurement (procedure)|t059
upfront ct
  1
  c0040405|x-ray computed tomography|t060
overall operative mortality
  5
  c0282416|overall [publication type]|t170
  c0543467|general operative procedures|t061
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
  c0038895|surgical aspects|t169
intestinal anastomosis
  1
  c0192711|anastomosis of intestine nos (procedure)|t061
studies
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
greater stromal invasion
  2
  c0443228|greater (qualifier value)|t081
  c0927195|stroma|t023
false pelvis
  1
  c0230276|major pelvis structure (body structure)|t023
treatment assignments
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
pt3 tumors
  1
  c0027651|neoplasms|t191
major role
  2
  c0205164|major (qualifier value)|t080
  c0035820|role|t054
wide acceptance
  2
  c0332464|widened structure (morphologic abnormality)|t082
  c1272684|accepted (qualifier value)|t080
limiting toxic effect
  2
  c0439801|limited (qualifier value)|t169
  c0600688|toxic effect|t037
performance status deterioration
  2
  c0868945|deterioration|t067
  c0935728|performance status|t033
extraperitoneal surgical staging
  3
  c0332305|with staging (attribute)|t169
  c0442090|extraperitoneal (qualifier value)|t082
  c0038895|surgical aspects|t169
clearly defined perfusion defect
  2
  c0205305|clear (qualifier value)|t080
  c0243067|defects|t169
main finding
  2
  c0243095|findings|t169
  c0205225|primary|t080
percent decrease
  2
  c0547047|decrease (qualifier value)|t081
  c0439165|percent (qualifier value)|t081
enhanced activity
  4
  c0600075|endurance of activity|t033
  c0441655|activities|t052
  c0221187|physical activity|t056
  c0086222|enhancer|t114
3.0 polypropylene suture
  1
  c0491217|polypropylene suture (physical object)|t074
normal serum bilirubin levels
  3
  c0428441|serum bilirubin measurement (procedure)|t059
  c1287366|finding of serum bilirubin level (finding)|t034
  c0205307|normal (qualifier value)|t033
leukocyte depression
  6
  c0023516|leukocytes|t025
  c0011570|mental depression|t048
  c0011581|depressive disorder|t048
  c0349217|depressive episode, unspecified|t048
  c0344315|depressed mood|t033
  c0460137|depression motion|t169
sigmoid colon
  1
  c0227391|sigmoid colon|t023
completion
  1
  c0205197|complete (qualifier value)|t080
minimal residual disease
  1
  c0242596|neoplasm, residual|t191
most important prognostic factor
  2
  c0205393|most (qualifier value)|t081
  c0220901|prognostic|t170
cell synchronization
  3
  c0007634|cells|t025
  c0183760|synchronizers|t074
  c1269647|entire cell|t025
five randomized trials
  2
  c0205451|five (qualifier value)|t081
  c0034656|random allocation|t062
eight patients
  2
  c0030705|patients|t101
  c0205454|eight (qualifier value)|t170
bleomycin dose
  2
  c0178602|dosages (qualifier value)|t081
  c0005740|bleomycin|t116
external pelvic irradiation
  5
  c1282930|irradiation (physical force)|t070
  c0205101|external (qualifier value)|t082
  c0030797|pelvis|t029
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
long delay
  2
  c0205166|long (qualifier value)|t080
  c0205421|deferred (qualifier value)|t079
significant interobserver variability
  2
  c0021713|interobserver variation|t081
  c0750502|significant (qualifier value)|t078
further follow-up
  1
  c0589120|follow-up status (finding)|t169
dose limits
  1
  c0935905|dose-limiting|t037
intergroup rectal adjuvant protocol
  2
  c0278788|adjuvant study|t062
  c0205052|rectal (qualifier value)|t082
range 4–81 months
  1
  c0439231|month (qualifier value)|t079
dose attenuation percent
  3
  c0599946|attenuation|t045
  c0178602|dosages (qualifier value)|t081
  c0439165|percent (qualifier value)|t081
radiotherapy related complications
  5
  c1171258|complication aspects|t046
  c0445223|related (finding)|t033
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
  c0009566|complication|t046
now matured study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205286|mature (qualifier value)|t079
fm
  1
  c0015853|fermium|t196
brachytherapy
  1
  c0006098|brachytherapy|t061
point b
  8
  c0337527|brothers|t099
  c0004927|behavior|t055
  c0324413|pointer (organism)|t015
  c0004587|bacillus <bacterium>|t007
  c0677505|behaviors and observations relating to behavior|t033
  c1040746|bacilli|t007
  c0150141|bathing|t061
  c0175640|baths (medical device)|t074
ct
  1
  c0040405|x-ray computed tomography|t060
primary outcome measures
  3
  c0439631|primary operation (qualifier value)|t061
  c0086749|outcome measures|t081
  c0205225|primary|t080
informed written consent
  3
  c0043266|writing|t090
  c0021430|informed consent|t058
  c0341628|writer (occupation)|t097
most common toxic effects
  3
  c0205393|most (qualifier value)|t081
  c0600688|toxic effect|t037
  c0205214|common (qualifier value)|t081
further analysis
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
major toxicity
  3
  c0205164|major (qualifier value)|t080
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
epi less cardiotoxic anthracycline
  5
  c0282564|anthracyclines|t109
  c0003234|anthracycline antibiotics|t195
  c0221908|epithelial|t169
  c0014609|epithelium|t024
  c0014544|epilepsy|t047
unnecessary side effects
  1
  c0001688|adverse effects|t037
standard therapy
  1
  c0879531|standard therapy|t047
dose reductions
  3
  c0301630|reduction (chemical)|t070
  c0178602|dosages (qualifier value)|t081
  c0441610|reduction - action|t061
treatment assignment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
low-dose brachytherapy
  2
  c0006098|brachytherapy|t061
  c0445550|low dose (qualifier value)|t081
data analysis
  1
  c0010992|data analysis|t057
estimated cumulative incidence function
  4
  c0750572|estimated|t078
  c0542341|function|t169
  c0700205|function axis|t185
  c0031843|physiological aspects|t039
active infection
  2
  c0205177|active|t169
  c0021311|infection|t047
opcs death certificate
  1
  c0011066|death certificates|t073
nominal significance level
  1
  c0814896|significance level|t062
additive effects
  2
  c1280500|effect (qualifier value)|t080
  c0442796|additive (qualifier value)|t080
subsequently
  1
  c0750530|subsequent|t078
respiratory death
  2
  c0521346|respiratory|t169
  c0011065|cessation of life|t040
interim analysis
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
single layer anastomoses
  5
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0332853|anastomosis|t020
  c0934502|layer|t023
  c0087136|unmarried|t098
one rectovaginal fistula
  2
  c0205447|one (qualifier value)|t081
  c0034895|rectovaginal fistula|t190
histologic grade
  1
  c0919553|histopathologic grade|t185
pathologic predictors
  2
  c0681842|prediction|t170
  c0205469|pathological aspects|t169
myocardial infarctions
  1
  c0027051|myocardial infarction|t047
14% incidence
  2
  c0021149|incidence|t081
  c0220856|incidence of cases|t169
cause specific survival analysis
  6
  c0038953|survival analysis|t081
  c0678227|causing (attribute)|t169
  c0015127|causality|t169
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
  c1314792|etiology|t169
29% cr rate
  2
  c0008574|chromium|t123
  c0871208|rating|t062
more recurrences
  2
  c0205172|more (qualifier value)|t081
  c0034897|recurrence|t067
11.9 months
  1
  c0439231|month (qualifier value)|t079
90th percentile
  1
  c1264641|percentile (property) (qualifier value)|t081
megavoltage radiotherapy
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
cervix
  1
  c0007874|uterine cervix-anatomy|t023
protocol methodology
  3
  c0969625|methodology aspects|t170
  c0442711|protocols documentation|t170
  c0025664|methodology|t170
local recurrence rate
  3
  c0205276|local (qualifier value)|t082
  c0034897|recurrence|t067
  c0871208|rating|t062
revised sample size goal
  6
  c1293090|revision (procedure)|t061
  c0018017|goals|t170
  c0439616|revisions (qualifier value)|t079
  c0439617|revision - value (qualifier value)|t079
  c0558347|revision procedure (qualifier value)|t061
  c0242618|sample size|t081
direction
  1
  c0449738|direction|t082
randomization
  1
  c0034656|random allocation|t062
impact
  1
  c0726639|impact|t168
median disease-free survival
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0242793|disease-free survival|t081
subsequent treatment course
  4
  c0449922|course (attribute)|t079
  c0087111|therapeutic procedure|t061
  c0750530|subsequent|t078
  c0039798|therapeutic aspects|t169
twenty four percent
  2
  c0205450|four (qualifier value)|t081
  c0439165|percent (qualifier value)|t081
permanent interruption
  2
  c0443239|interrupted (qualifier value)|t080
  c0205355|permanent (qualifier value)|t079
rt interruptions
  1
  c0443239|interrupted (qualifier value)|t080
substantial difference
  1
  c0443199|differential (qualifier value)|t080
most extreme case
  3
  c0205403|extreme (qualifier value)|t080
  c0868928|case (qualifier value)|t169
  c0205393|most (qualifier value)|t081
permanent indiana pouch urinary conduit
  4
  c0021206|indiana|t083
  c0770824|pouch urinary|t074
  c0441247|conduit implant|t074
  c0205355|permanent (qualifier value)|t079
c m arm
  3
  c0007886|cesium|t196
  c0003792|arm|t029
  c0446516|upper arm|t029
4% experienced grade thrombocytopenia
  3
  c0040034|thrombocytopenia|t047
  c0441800|grade|t185
  c0596545|experience|t041
months
  1
  c0439231|month (qualifier value)|t079
volume
  1
  c0449468|volume (property) (qualifier value)|t081
average age
  3
  c0001779|age (qualifier value)|t079
  c0043778|nicaraven|t109
  c0752050|anteroventral thalamic nucleus|t023
drug levels
  2
  c1261153|drug measurement (procedure)|t059
  c0428212|finding of drug level (finding)|t034
kaplan meier method
  1
  c0025663|methods|t170
assessment
  1
  c1261322|assessment procedure (procedure)|t058
most significant prognostic factor
  2
  c0220901|prognostic|t170
  c1299394|most significant (qualifier value)|t080
less toxic compound
  2
  c0205198|compound (qualifier value)|t080
  c0600688|toxic effect|t037
other conditions
  3
  c0205394|other|t080
  c0009647|conditioning (psychology)|t041
  c0348080|condition (attribute)|t080
other symptomatic therapy
  2
  c0231220|symptomatic (qualifier value)|t169
  c0418967|other therapy nos (regime/therapy)|t061
four centers
  3
  c0205450|four (qualifier value)|t081
  c0205099|central|t082
  c0935444|centering|t041
unacceptable toxic effects
  1
  c0600688|toxic effect|t037
equal number
  2
  c0205163|equal (qualifier value)|t080
  c0449788|count of entities (property) (qualifier value)|t081
study design
  1
  c0035171|research design|t062
transfusions
  1
  c0199960|transfusion - action (qualifier value)|t061
consistent improvement
  4
  c0184511|improved (qualifier value)|t080
  c0332290|consistent with (qualifier value)|t078
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
promising improvement
  3
  c0184511|improved (qualifier value)|t080
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
few reports
  2
  c0205388|few (qualifier value)|t081
  c0684224|report (document)|t170
prospective randomized clinical trial
  1
  c0206034|clinical trials, randomized|t170
more detailed description
  2
  c0205172|more (qualifier value)|t081
  c0678257|description|t062
imbalance clearly
  1
  c0205305|clear (qualifier value)|t080
poor performance status
  3
  c0542537|poor - grade value|t080
  c0699761|financially poor|t080
  c0935728|performance status|t033
survival prognosis
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0033325|forecast of outcome|t058
ii trials
  1
  c0439069|roman numeral ii|t170
levamisole
  1
  c0023556|levamisole|t109
significantly higher 5-year disease-free survival
  2
  c0750502|significant (qualifier value)|t078
  c0242793|disease-free survival|t081
subcutaneous soft tissue
  4
  c0225317|soft tissues (body structure)|t024
  c0278403|subcutaneous tissue|t024
  c0443315|subcutaneous (qualifier value)|t082
  c0205358|soft (qualifier value)|t080
major protocol viola patients
  4
  c0205164|major (qualifier value)|t080
  c0330463|viola|t002
  c0442711|protocols documentation|t170
  c0030705|patients|t101
im
  1
  c0231377|at risk for impaired home maintenance management (finding)|t033
levamisole treated patients
  3
  c1292734|treats (attribute)|t185
  c0023556|levamisole|t109
  c0030705|patients|t101
haematology
  2
  c0018943|hematology|t091
  c0200627|hematology procedure|t059
chemotherapy
  3
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
recruitment
  1
  c0271510|recruitment (finding)|t039
50% increase
  1
  c0442805|increase (qualifier value)|t169
two layer anastomoses
  3
  c0332853|anastomosis|t020
  c0934502|layer|t023
  c0205448|two (qualifier value)|t081
swiss group
  3
  c0241315|swiss (ethnic group)|t098
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
cisplatin treatment day
  4
  c0439228|day (qualifier value)|t079
  c0008838|cisplatin|t197
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
likely
  1
  c0750504|likely|t078
indices
  1
  c0918012|indexes|t170
stereoisomer
  1
  c0376211|stereoisomers|t104
shrinkage
  1
  c0332513|shrinkage (finding)|t169
produced impressive response rates
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0033268|production|t057
width
  1
  c0487742|width (qualifier value)|t081
recurrent squamous cell carcinoma
  2
  c0205335|recurrent (qualifier value)|t079
  c0007137|carcinoma, squamous cell|t191
serum carcinoembryonic antigen measurement
  2
  c0201933|carcinoembryonic antigen measurement|t059
  c0229671|serum|t024
recent introduction
  2
  c0332185|recent episode (qualifier value)|t079
  c1293116|introduction (procedure)|t058
iproplatin
  1
  c0057856|iproplatin|t109
different adjuvant treatments
  3
  c0087111|therapeutic procedure|t061
  c0443199|differential (qualifier value)|t080
  c0001551|adjuvants, immunologic|t129
pr
  1
  c0279766|progesterone receptor negative|t034
provided data
  1
  c0359589|provide (product)|t168
scheduled treatment
  3
  c0205539|scheduled (qualifier value)|t169
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
one event
  2
  c0441471|events (event)|t051
  c0205447|one (qualifier value)|t081
measurements
  1
  c0242485|measurement|t081
myocardial infarction
  1
  c0027051|myocardial infarction|t047
m2 x days
  2
  c0439228|day (qualifier value)|t079
  c0078606|xanthosine|t114
normal tissues
  1
  c0332441|normal tissue (finding)|t033
more evidence
  1
  c0205172|more (qualifier value)|t081
cox’s proportional hazards model
  1
  c0033489|proportional hazards models|t170
number
  1
  c0449788|count of entities (property) (qualifier value)|t081
ischiorectal abscess
  1
  c0149816|ischiorectal abscess (disorder)|t020
receiving three doses
  3
  c0544683|reception|t042
  c0719635|dos|t109
  c0205449|three (qualifier value)|t081
fifty one patients
  2
  c0030705|patients|t101
  c0205447|one (qualifier value)|t081
austria
  1
  c0004348|austria|t083
limited future
  2
  c0439801|limited (qualifier value)|t169
  c0016884|future|t079
bipedal lymphangiogram
  1
  c0024219|lymphangiography|t060
six months
  2
  c0205452|six (qualifier value)|t081
  c0439231|month (qualifier value)|t079
calcium folinate weekly
  2
  c0332174|weekly (qualifier value)|t079
  c0731033|leucovorin calcium|t109
significant number
  2
  c0449788|count of entities (property) (qualifier value)|t081
  c0750502|significant (qualifier value)|t078
f
  3
  c0441722|force|t067
  c0016330|fluorine|t123
  c0015895|fertility|t032
1.4 years
  1
  c0439234|year (qualifier value)|t079
5-year data
  1
  c0439234|year (qualifier value)|t079
pattern
  1
  c0449774|patterns (qualifier value)|t082
kaplan meier estimates
  1
  c0750572|estimated|t078
irradiated patients
  4
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0030705|patients|t101
  c0034618|radiation therapy|t061
steady progressive decline
  2
  c0205361|steady (qualifier value)|t080
  c0205329|progressive (qualifier value)|t169
logrank tests
  1
  c0392366|tests (qualifier value)|t170
association
  2
  c0004083|mental association|t041
  c0699792|relationship by association|t054
prearranged time
  1
  c0040223|time|t079
preoperative investigations
  2
  c0445204|preoperative (qualifier value)|t032
  c0430007|clinical investigation|t058
two series
  2
  c0205549|series (qualifier value)|t081
  c0205448|two (qualifier value)|t081
hematology
  2
  c0018943|hematology|t091
  c0200627|hematology procedure|t059
study protocol
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0442711|protocols documentation|t170
peritoneal carcinomatosis
  2
  c0442034|peritoneal (qualifier value)|t023
  c0205699|carcinomatosis|t191
concurrent chemotherapy truly adds
  5
  c0205420|concurrent (qualifier value)|t079
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0442796|additive (qualifier value)|t080
  c0013216|pharmacotherapy|t061
series
  1
  c0205549|series (qualifier value)|t081
40 patients
  1
  c0030705|patients|t101
provincial cancer institute
  4
  c0998265|cancer genus|t009
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
  c0021622|institutes|t092
immunohistochemical staining
  1
  c0038129|staining|t059
tumour progresses
  1
  c0178874|neoplasm progression|t191
endometrial carcinoma
  1
  c0476089|endometrial carcinoma|t191
cytopenias
  1
  c0010828|cytopenia (finding)|t046
55.0 gy
  1
  c0556636|gy (qualifier value)|t081
areas
  1
  c0205146|area (qualifier value)|t082
median total duration
  4
  c0449238|duration|t079
  c0439810|total (qualifier value)|t080
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
mortality
  2
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
brain
  2
  c0006104|brain|t023
  c1269537|entire brain|t023
cardiac impairment
  3
  c0684336|impaired health|t033
  c0231171|physical impairment|t046
  c0205041|cardio-|t082
overall crude survival
  3
  c0282416|overall [publication type]|t170
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
flow
  1
  c0806140|flow|t032
authors
  1
  c0221192|author (occupation)|t097
­ days
  1
  c0439228|day (qualifier value)|t079
postoperative irradiation
  4
  c0032790|postoperative period|t079
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
neck region
  1
  c0920882|region of neck (body structure)|t029
cisplatin combinations
  2
  c0008838|cisplatin|t197
  c0453882|combinations (physical object)|t073
procedure
  1
  c0184661|procedures|t058
gog performance score
  2
  c0449820|scores (qualifier value)|t081
  c0597198|performance|t055
weeks
  1
  c0439230|week (qualifier value)|t079
present results
  2
  c1274040|result (navigational concept)|t169
  c0150312|present|t169
thirty nine
  1
  c0205455|nine (qualifier value)|t081
wash-out
  1
  c0392674|exhaustion (finding)|t184
short-term interval
  2
  c0443303|short-term (qualifier value)|t079
  c1272706|interval (qualifier value)|t079
significant morbidity
  3
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0750502|significant (qualifier value)|t078
added efficacy
  1
  c0442796|additive (qualifier value)|t080
direct internal mammary field
  5
  c0929301|mammary gland|t023
  c0205102|intrinsic|t082
  c0700157|direct type of resin cement|t122
  c0439851|direct type of relationship|t080
  c0440042|field's stain|t130
absolute benefit
  2
  c0205344|absolute (qualifier value)|t080
  c0814225|benefits|t081
peritoneal seeding
  2
  c0036563|seeds|t002
  c0442034|peritoneal (qualifier value)|t023
slightly higher percentage
  3
  c0235146|euphoric mood|t041
  c0205250|high|t080
  c0750482|slightly|t078
abdominoperineal excision
  3
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
  c0442411|abdominoperineal approach (qualifier value)|t082
relative mortality rate
  3
  c0080103|relative (related person)|t099
  c0026565|mortality vital statistics|t081
  c0205345|relative|t080
seventh years
  2
  c0205441|seventh (qualifier value)|t081
  c0439234|year (qualifier value)|t079
grade gastrointestinal toxicity
  2
  c0441800|grade|t185
  c1142499|gastrointestinal toxicity|t033
en bloc resection
  6
  c0014245|endoscopy|t060
  c0014268|administration of enema|t061
  c0028778|obstruction|t046
  c0993595|enema solution|t122
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
additional entry criteria
  2
  c0442796|additive (qualifier value)|t080
  c0243161|criteria|t170
complete data
  2
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
treatment regimen
  3
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0677937|regimen|t061
enrollment goal
  1
  c0018017|goals|t170
relatively even distribution
  3
  c0587117|evening (qualifier value)|t079
  c0520511|distributing|t078
  c0037775|spatial distribution|t082
elisa
  1
  c0014441|enzyme-linked immunosorbent assay|t059
combining radiotherapy
  1
  c0436241|combined radiotherapy nos (procedure)|t061
more courses
  2
  c0205172|more (qualifier value)|t081
  c0750729|courses (qualifier value)|t079
natural history
  1
  c0175860|natural history|t090
premature discontinuation
  2
  c0205252|immature (qualifier value)|t079
  c0457454|discontinuation (procedure)|t058
baseline prognostic factors
  2
  c0168634|baseline|t122
  c0220901|prognostic|t170
cisplatin containing chemotherapy
  5
  c0008838|cisplatin|t197
  c0332256|containing (qualifier value)|t169
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
alkaline phosphatase
  2
  c1318717|alkaline phosphatase stain|t130
  c0002059|alkaline phosphatase|t116
treatments
  1
  c0087111|therapeutic procedure|t061
obstetrics
  2
  c0700061|obstetric patient|t101
  c0028773|discipline of obstetrics|t091
disease status
  2
  c0449438|status (attribute)|t080
  c0012634|disease|t047
disease characteristics
  1
  c0599878|disease characteristic|t046
visible disease
  2
  c0012634|disease|t047
  c0205379|visible (qualifier value)|t080
tumor cell type
  2
  c0431085|[m]unspecified tumor cell nos (morphologic abnormality)|t191
  c0332307|with type (attribute)|t169
optimal time delay
  2
  c0205421|deferred (qualifier value)|t079
  c0040223|time|t079
neck
  2
  c0027530|neck|t017
  c1281592|entire neck|t023
prior treatment
  3
  c0087111|therapeutic procedure|t061
  c0750516|prior|t078
  c0039798|therapeutic aspects|t169
second tumors
  2
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0027627|neoplasm metastasis|t191
d sc
  4
  c0439228|day (qualifier value)|t079
  c0332517|diameter (qualifier value)|t032
  c0036274|scandium|t196
  c0011530|deoxyribose|t123
deep third stromal invasion
  3
  c0927195|stroma|t023
  c0205125|depth (qualifier value)|t082
  c0205437|third (qualifier value)|t081
cytologic documentation
  3
  c0175636|act of documentation|t058
  c0920316|documentation|t170
  c0205471|cytologic (qualifier value)|t169
cumulative dose
  1
  c0178602|dosages (qualifier value)|t081
escalating 5-fu treatment results
  2
  c1274040|result (navigational concept)|t169
  c0014829|escalators|t073
recurrence rate
  2
  c0034897|recurrence|t067
  c0871208|rating|t062
concurrent chemotherapy
  4
  c0205420|concurrent (qualifier value)|t079
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
ifo 1.8 g
  1
  c0162832|apc gene|t028
lymph node involvement
  1
  c0806692|lymph node involvement|t032
additional patient
  2
  c0030705|patients|t101
  c0442796|additive (qualifier value)|t080
transvaginal parametrial needle biopsy
  4
  c0175672|transvaginal approach|t082
  c0227822|parametrium|t023
  c1281249|entire parametrium|t023
  c0005560|needle biopsy procedure|t060
cardiopulmonary functions
  3
  c1261339|heart and lung|t023
  c0553534|cardiopulmonary|t042
  c0422812|functions (observable entity)|t169
platelet count
  2
  c0032181|platelet count|t059
  c1287267|finding of platelet count (finding)|t034
supportive care
  1
  c0344211|supportive care|t058
host
  1
  c1167395|host|t032
most common complications
  4
  c1171258|complication aspects|t046
  c0205393|most (qualifier value)|t081
  c0205214|common (qualifier value)|t081
  c0009566|complication|t046
moderately high response rate
  5
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0205081|moderate (severity modifier) (qualifier value)|t080
  c0235146|euphoric mood|t041
  c0205250|high|t080
chance observation
  3
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0237506|chance|t080
post-operative rt
  2
  c0032790|postoperative period|t079
  c0241311|surgery, past|t033
treatment delays
  3
  c0205421|deferred (qualifier value)|t079
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
to follow-up
  1
  c0589120|follow-up status (finding)|t169
most active nonhormonal drug
  2
  c0205393|most (qualifier value)|t081
  c0013227|pharmaceutical preparations|t121
difference
  1
  c0443199|differential (qualifier value)|t080
safety
  1
  c0036043|safety|t068
later curves
  2
  c0205087|late (qualifier value)|t079
  c0205134|curved (qualifier value)|t082
bilateral removal
  4
  c0281267|bilateral breast cancer|t191
  c0728940|surgical removal - action|t169
  c0238767|bilateral|t082
  c0015252|excision|t061
median 64.7 years
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0439234|year (qualifier value)|t079
disease recurrences
  1
  c0679254|disease recurrence|t033
irinotecan combination
  2
  c0123931|irinotecan|t109
  c0205195|combined (qualifier value)|t080
too few patients
  2
  c0030705|patients|t101
  c0205388|few (qualifier value)|t081
stage iva
  2
  c0441773|stage 4 lower case ay|t185
  c0456600|stage 4 upper case ay|t185
exact test
  2
  c0059927|exact|t122
  c0392366|tests (qualifier value)|t170
differ debate
  1
  c0870392|debates|t052
five field radiotherapy
  4
  c0205451|five (qualifier value)|t081
  c0034618|radiation therapy|t061
  c0440042|field's stain|t130
  c0034619|radiotherapeutic|t170
significant superiority
  2
  c0680218|superiority|t054
  c0750502|significant (qualifier value)|t078
severe leukopenia
  2
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0023530|leukopenia|t047
step
  1
  c1261552|step (qualifier value)|t169
7-year analysis
  3
  c0002778|analysis of substances|t059
  c0439234|year (qualifier value)|t079
  c0936012|analysis|t062
95% confidence limits
  1
  c0237530|confidence limits|t081
continuous single layer suture
  8
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0038969|surgical sutures|t074
  c0549178|continuous (qualifier value)|t079
  c0934502|layer|t023
  c0502420|suture joint|t030
  c0009068|closure by suture|t061
  c0087136|unmarried|t098
low-risk group
  4
  c0441833|groups (qualifier value)|t170
  c0205251|low (qualifier value)|t080
  c0035647|risk|t080
  c1300322|group (social concept)|t096
greater reduction
  3
  c0443228|greater (qualifier value)|t081
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
cut edge
  2
  c0205154|along edge (qualifier value)|t082
  c0000925|incised wound - morphology (morphologic abnormality)|t037
suggested survival advantage
  4
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0308269|advantage|t131
  c0424012|suggestible (finding)|t033
cardiac monitoring
  1
  c0150496|cardiac monitoring (regime/therapy)|t060
slight excess
  3
  c0750570|excessively|t078
  c0547040|slight (qualifier value)|t080
  c0442802|excessive (qualifier value)|t080
subsequent patients
  2
  c0750530|subsequent|t078
  c0030705|patients|t101
lung
  2
  c0024109|lung|t023
  c1278908|entire lung|t023
measurable parameters
  3
  c0444706|measured (qualifier value)|t080
  c0449381|observation parameter (observable entity)|t033
  c0079809|measures|t081
adequacy
  1
  c0205411|adequate (qualifier value)|t080
3.0 silk lembert sutures
  1
  c0183745|silk suture, device (physical object)|t074
monoclonal antibody
  1
  c0003250|antibodies, monoclonal|t129
substantial shift
  1
  c0333051|shift (morphologic abnormality)|t169
fixed limitation
  2
  c0443218|fixed (qualifier value)|t080
  c0449295|limitation (attribute)|t169
especially pain
  2
  c0205555|special (qualifier value)|t080
  c0030193|pain|t184
undergone specific type
  3
  c0332307|with type (attribute)|t169
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
para-aortic radiation
  2
  c0442134|para-aortic (qualifier value)|t082
  c0851346|radiation|t070
m v dox
  8
  c0042306|vanadium|t123
  c0048808|5'-deoxy-5-fluorouridine|t114
  c0449468|volume (property) (qualifier value)|t081
  c0439830|velocity (property) (qualifier value)|t169
  c0598352|v (voltage)|t081
  c0439502|v - volt (qualifier value)|t081
  c0013090|doxycycline|t195
  c0013089|doxorubicin|t195
inclusion
  1
  c0332257|including (qualifier value)|t169
antineoplastic therapy
  3
  c0087111|therapeutic procedure|t061
  c0003392|antineoplastic agents|t121
  c0039798|therapeutic aspects|t169
synergy
  1
  c0599739|synergism|t044
alt
  2
  c0001899|alanine transaminase|t116
  c1140170|alternative billing concepts|t170
clinical examination
  1
  c0031809|clinical examination|t058
follow-up visits
  1
  c0589121|follow-up visit (procedure)|t058
similar regimen
  2
  c0871364|simile|t170
  c0677937|regimen|t061
cox proportional hazard
  4
  c0598697|hazard|t080
  c0205351|proportional (qualifier value)|t080
  c0033551|prostaglandin-endoperoxide synthase|t116
  c0442996|cox microbiology subtype|t170
minimum time
  2
  c0439232|minute of time|t079
  c0040223|time|t079
potential source
  2
  c0449416|source (attribute)|t033
  c0237399|potential|t080
main reason
  2
  c0684328|reasoning|t041
  c0205225|primary|t080
three prospective randomized comparison
  2
  c0034656|random allocation|t062
  c0205449|three (qualifier value)|t081
toxicity sometimes troublesome
  2
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
preoperative carcinoembryonic antigen concentration
  3
  c0007082|carcinoembryonic antigen|t116
  c0086045|concentration|t041
  c0445204|preoperative (qualifier value)|t032
treatment effects
  3
  c1280500|effect (qualifier value)|t080
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
pearson chi-square test
  1
  c0008041|chi-square test|t081
combined chemotherapy hormonal therapy
  2
  c0278784|hormone therapy (procedure)|t061
  c0013218|drug therapy, combination|t061
26% patients
  1
  c0030705|patients|t101
patient years old
  4
  c0677546|old episode|t079
  c0030705|patients|t101
  c0580836|old|t079
  c0439234|year (qualifier value)|t079
abnormal liver function
  1
  c0232742|abnormal liver function (finding)|t046
creatinine 1.25 x n
  2
  c0860945|creatinine normal|t033
  c0078606|xanthosine|t114
17-percentage-point improvement
  4
  c0184511|improved (qualifier value)|t080
  c0324413|pointer (organism)|t015
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
phase iii clinical trial
  1
  c1096780|clinical trial, phase iii [publication type]|t062
first generation trials
  2
  c0079411|generations|t079
  c0205435|first (qualifier value)|t081
superior border
  2
  c0205105|superior (qualifier value)|t082
  c0205284|marginal (qualifier value)|t082
alkaline phosphatase level two
  2
  c0428332|finding of alkaline phosphatase level (finding)|t034
  c0205448|two (qualifier value)|t081
upper third
  1
  c0442049|upper third (qualifier value)|t082
adjunctive radiotherapy
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
hematologic toxicity
  3
  c0205488|hematologic (qualifier value)|t169
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
hemoglobin level
  2
  c0019029|hemoglobin level|t034
  c1314664|dipstick assessment of hemoglobin concentration (procedure)|t059
local regional s
  4
  c0205276|local (qualifier value)|t082
  c0457385|seconds|t079
  c0205147|regional (qualifier value)|t082
  c0205436|second (qualifier value)|t081
mitomycin
  2
  c0026254|mitomycins|t109
  c0002475|mitomycin|t195
only external beam treatment
  3
  c0205101|external (qualifier value)|t082
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
radiological lymph node status
  4
  c0043299|diagnostic radiologic examination|t060
  c0034599|radiology specialty|t091
  c0807679|radiology studies|t059
  c0449927|lymph nodal status (attribute)|t080
ii study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0439069|roman numeral ii|t170
recent studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0332185|recent episode (qualifier value)|t079
median observation time
  5
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0040223|time|t079
important role
  1
  c0035820|role|t054
six weeks
  2
  c0205452|six (qualifier value)|t081
  c0439230|week (qualifier value)|t079
exploration
  2
  c1280903|exploration procedure (procedure)|t061
  c0581690|exploration - action (qualifier value)|t058
planned adjuvant
  2
  c1301732|planned (qualifier value)|t169
  c0001551|adjuvants, immunologic|t129
various drugs
  2
  c0013227|pharmaceutical preparations|t121
  c0440102|various (substance)|t130
common toxicity criteria
  4
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0205214|common (qualifier value)|t081
  c0243161|criteria|t170
grade 3.4 neutropenia
  2
  c0441800|grade|t185
  c0027947|neutropenia|t047
lymph node metastases
  1
  c0686619|secondary malignant neoplasm of lymph node (disorder)|t191
equal
  1
  c0205163|equal (qualifier value)|t080
various other reasons
  3
  c0205394|other|t080
  c0684328|reasoning|t041
  c0440102|various (substance)|t130
contour
  2
  c0876954|contour form|t082
  c0302821|contour alloy|t197
primarily headache
  3
  c0439631|primary operation (qualifier value)|t061
  c0018681|headache|t184
  c0205225|primary|t080
higher rates
  3
  c0235146|euphoric mood|t041
  c0871208|rating|t062
  c0205250|high|t080
anterior border
  2
  c0205094|anterior|t082
  c0205284|marginal (qualifier value)|t082
6.2 1 8 months
  1
  c0439231|month (qualifier value)|t079
probabilities
  1
  c0033204|probability|t081
para-aortic radiotherapy
  3
  c0442134|para-aortic (qualifier value)|t082
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
regressions
  2
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
external iliac nodes
  1
  c0229815|external iliac lymph node group|t023
vein
  3
  c1278960|entire vein|t023
  c0042449|veins|t023
  c0923878|vein|t023
intravenous 5-fu mg
  3
  c0024467|magnesium|t123
  c0348016|intravenous|t082
  c0439210|milligram|t081
statistical methods comparison
  3
  c0025664|methodology|t170
  c0025663|methods|t170
  c0220917|statistical|t170
cisplatinbased chemotherapy
  3
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
present trial
  1
  c0150312|present|t169
calculated response rates
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0444686|calculated (qualifier value)|t169
interrupted radiotherapy
  3
  c0443239|interrupted (qualifier value)|t080
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
onset
  1
  c0332162|onset of (contextual qualifier) (qualifier value)|t080
intracavitary irradiation
  4
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
  c1298613|intracavitary (qualifier value)|t082
possibly detrimental effect
  2
  c1280500|effect (qualifier value)|t080
  c0332149|possible|t080
superior definitive therapy
  4
  c0205105|superior (qualifier value)|t082
  c0087111|therapeutic procedure|t061
  c0443196|definitive (qualifier value)|t079
  c0039798|therapeutic aspects|t169
estrogen receptor positive
  1
  c0279754|estrogen receptor positive|t034
thrombocytopenia
  1
  c0040034|thrombocytopenia|t047
myocardium
  1
  c0027061|myocardium|t024
46.8 months
  1
  c0439231|month (qualifier value)|t079
seven patients
  2
  c0030705|patients|t101
  c0205453|seven (qualifier value)|t081
gonadal function
  1
  c0678878|gonad function|t042
two patients
  2
  c0030705|patients|t101
  c0205448|two (qualifier value)|t081
prospective randomised trial
  1
  c0034656|random allocation|t062
previous radio
  3
  c0034546|radio|t170
  c1304639|radio (physical object)|t073
  c0205156|previous (qualifier value)|t082
portal
  1
  c0205054|hepatic|t029
locoregional recurrences
  1
  c0034897|recurrence|t067
chemotherapy records
  1
  c0552366|chemotherapy records|t201
less times
  3
  c0392761|timed (qualifier value)|t169
  c0040223|time|t079
  c0449243|timing (attribute)|t079
delayed diarrhoea
  2
  c0011991|diarrhea|t184
  c0205421|deferred (qualifier value)|t079
tumor control
  2
  c0243148|control|t169
  c0027651|neoplasms|t191
women
  2
  c0043209|human females|t098
  c0043210|human adult females|t098
pilot study
  1
  c0031928|pilot projects|t062
recent national institutes of health consensus conference
  4
  c0086047|conferences|t068
  c0332185|recent episode (qualifier value)|t079
  c0027468|national institutes of health (u.s.)|t093
  c0376298|consensus|t054
concomitant use
  1
  c0042153|utilization|t081
ab3 antibodies
  2
  c0813154|antibodies, in vitro diagnostic|t130
  c0003241|antibodies|t116
lymphography
  1
  c0024290|lymphography|t060
primary cervical cancers
  3
  c0439631|primary operation (qualifier value)|t061
  c0007847|malignant neoplasm of cervix uteri|t191
  c0205225|primary|t080
population
  1
  c0032659|population|t081
performed several prospective randomized studies
  4
  c0884358|performed (qualifier value)|t169
  c0443302|several (qualifier value)|t081
  c0033522|prospective studies|t081
  c0034656|random allocation|t062
second rnca study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205436|second (qualifier value)|t081
multigated radionuclide cineangiocardiography
  2
  c0202855|cineradiography of cardiovascular system (procedure)|t060
  c0034595|radioisotopes|t196
recurrence free survival
  4
  c0016694|freedom|t078
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0034897|recurrence|t067
randomized studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0034656|random allocation|t062
alternative approach
  3
  c0332270|alternating (qualifier value)|t169
  c0449445|approach (attribute)|t082
  c0919661|heart alternation|t046
cervical site
  2
  c0205145|associated topography (attribute)|t082
  c0205064|cervical (qualifier value)|t082
parametrial failure
  4
  c0680095|personal failure|t055
  c0227822|parametrium|t023
  c0231174|failure (biologic function)|t169
  c1281249|entire parametrium|t023
neurologic adverse effects
  1
  c0027852|neurological effects|t039
histopathology
  2
  c0677043|histopathology|t046
  c0243140|histopathological aspects|t169
median randomization time
  4
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0034656|random allocation|t062
  c0040223|time|t079
significant renal toxicity
  2
  c0595916|toxic nephropathy (disorder)|t047
  c0750502|significant (qualifier value)|t078
nerves
  2
  c0027740|nerve|t024
  c0027769|nervousness|t184
preplanned limitation
  1
  c0449295|limitation (attribute)|t169
immediate surgery
  4
  c0543467|general operative procedures|t061
  c0205253|immediate (qualifier value)|t079
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
histologically positive axillary nodes
  3
  c0205462|histologic|t169
  c0729594|axillary lymph node group|t023
  c0205159|positive (qualifier value)|t080
remainder clear cell
  1
  c0229473|cell of claudius (cell)|t025
one more
  2
  c0205172|more (qualifier value)|t081
  c0205447|one (qualifier value)|t081
biopsy proved metastasis
  5
  c0456369|proven findings|t080
  c0220797|biopsy characteristics|t169
  c0700164|proven venom|t123
  c0005558|biopsy|t060
  c0027627|neoplasm metastasis|t191
antagonistic interactions
  4
  c0687133|drug interactions|t044
  c0680242|antagonism|t054
  c0231491|antagonist muscle action|t042
  c0243076|antagonists|t120
kaplanmeier survival curves
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0205134|curved (qualifier value)|t082
time gap to
  2
  c0061928|gtpase-activating proteins|t116
  c0040223|time|t079
95.5 mg
  2
  c0024467|magnesium|t123
  c0439210|milligram|t081
cardiac complications
  1
  c0161816|cardiac complication of care nos (disorder)|t046
hyperfractionated rt
  1
  c0796569|hyperfractionation|t061
sections
  1
  c1293097|division (procedure)|t061
additional external beam therapy
  4
  c0205101|external (qualifier value)|t082
  c0087111|therapeutic procedure|t061
  c0442796|additive (qualifier value)|t080
  c0039798|therapeutic aspects|t169
serious late complication rate
  4
  c0205087|late (qualifier value)|t079
  c0205404|serious (qualifier value)|t080
  c0871208|rating|t062
  c0009566|complication|t046
radiation dose violations
  1
  c0034524|radiation dosage|t081
posterior ports
  4
  c0205095|dorsal|t082
  c0452253|port - alcoholic beverage|t168
  c0475311|harbor|t073
  c0935727|port-a-cath|t074
anastomosis related complications
  2
  c1141928|anastomotic complication|t046
  c0445223|related (finding)|t033
minimum
  1
  c0439232|minute of time|t079
parametrial extension
  3
  c0227822|parametrium|t023
  c0231448|extension (qualifier value)|t042
  c1281249|entire parametrium|t023
chisquare test
  1
  c0392366|tests (qualifier value)|t170
more weeks
  2
  c0205172|more (qualifier value)|t081
  c0439230|week (qualifier value)|t079
meager effectiveness
  2
  c0205414|effective (qualifier value)|t080
  c1280519|effectiveness (qualifier value)|t170
occasional severe diarrhea
  2
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0011991|diarrhea|t184
1.5 cm
  1
  c0475210|cm (qualifier value)|t081
one tail
  2
  c0039259|tail|t023
  c0205447|one (qualifier value)|t081
groups
  1
  c0441833|groups (qualifier value)|t170
actuarial survival curves
  4
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0205134|curved (qualifier value)|t082
  c0334965|actuary (occupation)|t097
7.4,and 6.8 months
  1
  c0439231|month (qualifier value)|t079
irinotecan group
  3
  c0123931|irinotecan|t109
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
fig
  1
  c0349966|figs - dietary|t168
two layer anastomosis
  5
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
  c0934502|layer|t023
  c0205448|two (qualifier value)|t081
p value
  1
  c0879541|p-value|t081
forty five patients
  2
  c0205451|five (qualifier value)|t081
  c0030705|patients|t101
statistically significant greater cumulative dose
  3
  c0443228|greater (qualifier value)|t081
  c0237881|statistical significance|t081
  c0178602|dosages (qualifier value)|t081
side-effects
  1
  c0001688|adverse effects|t037
patients tolerance
  3
  c0231197|physiologic tolerance|t039
  c0030705|patients|t101
  c0220929|mental tolerance|t041
antiemetic treatment
  3
  c0087111|therapeutic procedure|t061
  c0003297|antiemetics|t121
  c0039798|therapeutic aspects|t169
adjusted relative risk
  5
  c0001537|clinical adjustment|t058
  c0683269|psychological adjustment|t055
  c0376209|individual adjustment|t055
  c0242492|relative risk|t080
  c0456081|adjustment action|t058
longterm remissions
  2
  c0687702|cancer remission|t191
  c0544452|disease remission|t033
white blood cell counts
  2
  c0023508|white blood cell count procedure|t059
  c0427512|white blood cell count laboratory result|t034
only long-term analysis
  3
  c0002778|analysis of substances|t059
  c0443252|long-term (qualifier value)|t079
  c0936012|analysis|t062
antigen expression
  2
  c0185117|expression - action (qualifier value)|t061
  c0003320|antigens|t129
sixty first events
  2
  c0441471|events (event)|t051
  c0205435|first (qualifier value)|t081
hope frequently
  2
  c0392347|hope|t041
  c0332183|frequent (qualifier value)|t079
grade iv
  1
  c0547054|grade four rank|t081
age yr
  2
  c0001779|age (qualifier value)|t079
  c0439234|year (qualifier value)|t079
granulocyte count
  1
  c0857490|granulocyte count (procedure)|t059
continuous anastomosis
  4
  c0549178|continuous (qualifier value)|t079
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
date patient
  2
  c0011008|dates|t079
  c0030705|patients|t101
local radiation
  2
  c0851346|radiation|t070
  c0205276|local (qualifier value)|t082
second countries
  2
  c0454664|countries (geographic location)|t083
  c0205436|second (qualifier value)|t081
5-year analysis
  3
  c0002778|analysis of substances|t059
  c0439234|year (qualifier value)|t079
  c0936012|analysis|t062
negative cls
  3
  c0010575|cycloleucine|t116
  c0205160|negative (qualifier value)|t080
  c0201952|chloride measurement|t059
baseline
  1
  c0168634|baseline|t122
higher numbers
  3
  c0237753|numbers (qualifier value)|t170
  c0235146|euphoric mood|t041
  c0205250|high|t080
tumor grade
  2
  c0441800|grade|t185
  c0027651|neoplasms|t191
5-yr rfs
  2
  c0748398|rf|t033
  c0439234|year (qualifier value)|t079
overall 5-year survival rates
  2
  c0282416|overall [publication type]|t170
  c0038954|survival rate|t081
single doses
  4
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0719635|dos|t109
  c0087136|unmarried|t098
south africa
  1
  c0037712|south africa|t083
better estimate
  2
  c0750572|estimated|t078
  c0332272|better (qualifier value)|t080
relatively favorable prognosis
  2
  c0309049|favor (product)|t121
  c0033325|forecast of outcome|t058
day via continuous 24-hr infusion
  2
  c0439228|day (qualifier value)|t079
  c0574032|infusion (procedure)|t061
superior results
  2
  c0205105|superior (qualifier value)|t082
  c1274040|result (navigational concept)|t169
then months
  1
  c0439231|month (qualifier value)|t079
underwent preoperative radiation therapy
  3
  c0034618|radiation therapy|t061
  c0445204|preoperative (qualifier value)|t032
  c0034619|radiotherapeutic|t170
biochemical profiles
  1
  c0205474|biochemical (qualifier value)|t169
pilot trial
  1
  c0473169|pilot - aircraft (occupation)|t097
gastric cancer
  1
  c0024623|malignant neoplasm of stomach|t191
therefore patients
  1
  c0030705|patients|t101
g
  1
  c0162832|apc gene|t028
cea
  1
  c0007082|carcinoembryonic antigen|t116
enteric fistula
  2
  c0016169|fistula|t190
  c0021852|intestines, small|t023
weakness
  3
  c0030552|paresis|t184
  c0086525|lassitude|t184
  c0004093|asthenia|t184
performance states
  2
  c0597198|performance|t055
  c1301808|state (environment)|t083
event
  1
  c0441471|events (event)|t051
disappointing
  1
  c0870427|disappointment|t041
fisher
  1
  c0325045|martes pennanti (organism)|t015
improvement
  3
  c0184511|improved (qualifier value)|t080
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
treatment schedule
  3
  c0087111|therapeutic procedure|t061
  c0086960|schedules|t170
  c0039798|therapeutic aspects|t169
full thickness
  1
  c0439809|full thickness (qualifier value)|t081
significant effect
  2
  c1280500|effect (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
power
  1
  c0032863|power (psychology)|t068
m intravenously
  1
  c0348016|intravenous|t082
bones
  2
  c1266909|entire bony skeleton|t022
  c0262950|skeletal bone|t021
male
  1
  c0024554|male gender|t032
minor response
  3
  c0205165|minor (value)|t080
  c0871261|responses|t054
  c0026193|minor|t098
six additional patients
  3
  c0205452|six (qualifier value)|t081
  c0030705|patients|t101
  c0442796|additive (qualifier value)|t080
paraaortic radiation
  1
  c0851346|radiation|t070
percent confidence intervals
  2
  c0009667|confidence intervals|t081
  c0439165|percent (qualifier value)|t081
bone marrow function
  7
  c0376152|marrow|t023
  c0542341|function|t169
  c0231542|bone function (observable entity)|t042
  c0005953|bone marrow|t024
  c0086590|vegetable marrow|t168
  c0700205|function axis|t185
  c0031843|physiological aspects|t039
again trend
  1
  c0040833|trends|t079
unexpectedly high proportion
  3
  c0205351|proportional (qualifier value)|t080
  c0235146|euphoric mood|t041
  c0205250|high|t080
rectum cancer patients
  2
  c0030705|patients|t101
  c0007113|cancer of rectum|t191
comparing patients
  1
  c0030705|patients|t101
treatment strategies
  3
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0679199|strategy|t041
potential candidates
  1
  c0237399|potential|t080
actuarial survival rates
  2
  c0038954|survival rate|t081
  c0334965|actuary (occupation)|t097
occult parametrial involvement
  4
  c0392760|not free of (attribute)|t169
  c0205262|occult (qualifier value)|t169
  c0227822|parametrium|t023
  c1281249|entire parametrium|t023
safety profile
  1
  c0036043|safety|t068
categorical data
  1
  c0683312|categories|t170
alternative hypothesis
  2
  c0332270|alternating (qualifier value)|t169
  c0919661|heart alternation|t046
second diagnosis
  1
  c0332138|secondary diagnosis|t080
m2 body surface area intravenously infusion
  5
  c1261466|body surface area (body structure)|t032
  c0005902|body surface area|t060
  c0574032|infusion (procedure)|t061
  c0021440|infusions, intravenous|t061
  c1272892|intravenous infusion (product)|t073
two vulvar
  2
  c0042993|vulva|t023
  c0205448|two (qualifier value)|t081
therapeutic efficacy
  2
  c0039796|the science and art of healing|t061
  c0302350|therapeutic|t169
normal liver
  4
  c0205307|normal (qualifier value)|t033
  c0023899|liver extract|t123
  c0023884|liver|t023
  c1278929|entire liver|t023
adjuvant radiotherapy
  1
  c0242939|radiotherapy, adjuvant|t061
cardiotoxic effects
  2
  c1280500|effect (qualifier value)|t080
  c0876994|cardiotoxicity|t047
reducing chemotherapeutic regimen
  2
  c0392920|chemotherapy-oncologic procedure|t061
  c0392756|reduced (qualifier value)|t080
one fraction
  2
  c0457426|fractions of (qualifier value)|t081
  c0205447|one (qualifier value)|t081
daily infusions
  2
  c0574032|infusion (procedure)|t061
  c0332173|daily (qualifier value)|t079
prognostic variables
  2
  c0220901|prognostic|t170
  c0439828|variable (qualifier value)|t080
time point
  2
  c0324413|pointer (organism)|t015
  c0040223|time|t079
majority
  1
  c0680220|majority|t054
toxic effects
  1
  c0600688|toxic effect|t037
distinct hama response
  1
  c0871261|responses|t054
pathology documents
  4
  c0677042|pathology processes|t046
  c0205469|pathological aspects|t169
  c1301746|documents (qualifier value)|t170
  c0030664|pathology|t091
ny chemotherapy
  3
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
univariate analyses
  1
  c0683962|univariate analysis|t062
41% reduction
  2
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
paraaortic lymph nodes
  1
  c0229789|aortic lymph node (body structure)|t023
true differences
  2
  c0205238|true (qualifier value)|t080
  c0443199|differential (qualifier value)|t080
deep invasion
  1
  c0205125|depth (qualifier value)|t082
other sites
  2
  c0205394|other|t080
  c0205145|associated topography (attribute)|t082
positive result
  2
  c1274040|result (navigational concept)|t169
  c0205159|positive (qualifier value)|t080
selection bias
  1
  c0036577|selection bias|t081
perineal pain
  1
  c0240717|perineal pain (finding)|t184
figs
  1
  c0349966|figs - dietary|t168
borderline values
  2
  c0042295|valuing|t080
  c0205189|borderline (qualifier value)|t080
difficulties
  1
  c1299586|has difficulty doing (qualifier value)|t033
failure to
  2
  c0680095|personal failure|t055
  c0231174|failure (biologic function)|t169
infusion treatment
  3
  c0574032|infusion (procedure)|t061
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
rather mild toxicity
  3
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0205080|mild (qualifier value)|t080
pathological findings
  1
  c1317598|pathologic findings|t033
mucosal toxicity
  3
  c0040539|toxicity aspects|t081
  c0026724|mucous membrane|t024
  c0600688|toxic effect|t037
further five patients
  2
  c0205451|five (qualifier value)|t081
  c0030705|patients|t101
ii trial
  1
  c0439069|roman numeral ii|t170
more risk factors
  2
  c0205172|more (qualifier value)|t081
  c0035648|risk factors|t081
again significant treatment advantage
  4
  c0087111|therapeutic procedure|t061
  c0308269|advantage|t131
  c0750502|significant (qualifier value)|t078
  c0039798|therapeutic aspects|t169
severe events
  2
  c0441471|events (event)|t051
  c0205082|severe (severity modifier) (qualifier value)|t080
fluorouracil
  1
  c0016360|fluorouracil|t114
negative pretreatment
  1
  c0205160|negative (qualifier value)|t080
neoplastic cells
  1
  c0597032|neoplastic cell|t025
one-sided significance level
  2
  c0814896|significance level|t062
  c0205092|unilateral (qualifier value)|t082
clinical cardiac dysfunction
  4
  c0205210|clinical (qualifier value)|t080
  c0031847|physiopathological|t169
  c0205041|cardio-|t082
  c0277785|functional disorder|t046
hours
  1
  c0439227|hour|t079
only single risk factor
  4
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0087136|unmarried|t098
  c0035648|risk factors|t081
radiation proctitis re
  2
  c0400827|radiation proctitis (disorder)|t047
  c0035419|rhenium|t196
arm ii post-operative rt
  3
  c0241311|surgery, past|t033
  c0003792|arm|t029
  c0446516|upper arm|t029
hence survival
  2
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
leukocyte count
  1
  c0023508|white blood cell count procedure|t059
first stopping rule
  4
  c0450446|stops (attribute)|t073
  c0870077|rules|t170
  c0723457|stop|t109
  c0205435|first (qualifier value)|t081
positive paraaortic lymph node biopsy
  4
  c0220797|biopsy characteristics|t169
  c0229789|aortic lymph node (body structure)|t023
  c0005558|biopsy|t060
  c0205159|positive (qualifier value)|t080
adverse effect
  1
  c0879626|adverse effect|t037
significance levels
  2
  c0814896|significance level|t062
  c0441889|levels (qualifier value)|t170
positive impact
  2
  c0726639|impact|t168
  c0205159|positive (qualifier value)|t080
biochemistries
  1
  c0005477|biochemistry|t090
radical hysterectomy
  1
  c0677962|total hysterectomy (procedure)|t061
inherently superior prognosis
  2
  c0205105|superior (qualifier value)|t082
  c0033325|forecast of outcome|t058
highest combined frequency
  2
  c0205212|high frequency (qualifier value)|t079
  c0205195|combined (qualifier value)|t080
pain control
  1
  c1304888|pain control (procedure)|t061
increasing 5-fu incorporation
  2
  c0442808|increasing (qualifier value)|t169
  c0243126|incorporation|t169
or death
  2
  c0069590|oralit|t197
  c0011065|cessation of life|t040
overall survival curve
  4
  c0282416|overall [publication type]|t170
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0205134|curved (qualifier value)|t082
prospective study
  1
  c0033522|prospective studies|t081
irinotecan mg
  3
  c0123931|irinotecan|t109
  c0024467|magnesium|t123
  c0439210|milligram|t081
external beam
  1
  c0205101|external (qualifier value)|t082
overall survival improvement
  6
  c0184511|improved (qualifier value)|t080
  c0282416|overall [publication type]|t170
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
angiosarcoma
  1
  c0018923|hemangiosarcoma|t191
international federation
  1
  c1138414|internationality|t078
further infection
  1
  c0021311|infection|t047
higher rate
  3
  c0235146|euphoric mood|t041
  c0871208|rating|t062
  c0205250|high|t080
well recognized prognostic factors
  2
  c0205170|good (qualifier value)|t080
  c0220901|prognostic|t170
screening
  3
  c1305399|screening - procedure intent (qualifier value)|t169
  c0220908|screening procedure|t060
  c0220909|aspects of disease screening|t169
several prospective randomised comparisons
  2
  c0443302|several (qualifier value)|t081
  c0034656|random allocation|t062
intravenous pyelography
  1
  c0203108|intravenous pyelogram|t060
paraaortic nodal disease
  2
  c0443268|nodal (qualifier value)|t082
  c0012634|disease|t047
leukopenia
  1
  c0023530|leukopenia|t047
pelvic disease volume
  3
  c0030797|pelvis|t029
  c0449468|volume (property) (qualifier value)|t081
  c0012634|disease|t047
complications
  2
  c1171258|complication aspects|t046
  c0009566|complication|t046
pelvic wall
  1
  c0230284|pelvic wall structure (body structure)|t023
factorial design
  1
  c0681865|factorial design|t062
dextrose
  1
  c0017725|glucose|t123
made use
  2
  c0554244|maker nos (occupation)|t097
  c0042153|utilization|t081
lesion
  1
  c0221198|lesion|t033
questions
  1
  c0750481|questionable|t078
continued interest
  2
  c0543488|interested (finding)|t041
  c0750536|continued|t078
agents
  1
  c0450442|agent (attribute)|t120
first generation
  2
  c0079411|generations|t079
  c0205435|first (qualifier value)|t081
participating clinic
  3
  c0679646|participant|t098
  c0442592|clinic (environment)|t093
  c0679823|participation|t055
local tumor control
  3
  c0243148|control|t169
  c0205276|local (qualifier value)|t082
  c0027651|neoplasms|t191
response category
  2
  c0871261|responses|t054
  c0683312|categories|t170
imprecise method
  1
  c0025663|methods|t170
chemotherapeutic regimens
  1
  c0392920|chemotherapy-oncologic procedure|t061
double needle suture
  5
  c0038969|surgical sutures|t074
  c0205173|duplicate|t040
  c0502420|suture joint|t030
  c0009068|closure by suture|t061
  c0027551|needles|t074
reduced incidence
  3
  c0021149|incidence|t081
  c0220856|incidence of cases|t169
  c0392756|reduced (qualifier value)|t080
same prognosis
  2
  c0033325|forecast of outcome|t058
  c0445247|same (qualifier value)|t080
regional lymph node metastases
  1
  c0332397|pn1 category (finding)|t185
interim analyses
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
other findings
  2
  c0205394|other|t080
  c0243095|findings|t169
total doses
  1
  c0172161|tyramine-deoxysorbitol|t109
81/4 months
  1
  c0439231|month (qualifier value)|t079
advanced disease patients
  2
  c0030705|patients|t101
  c0679246|advanced disease|t033
significant sequence dependent differences
  2
  c0443199|differential (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
6.5 cm
  1
  c0475210|cm (qualifier value)|t081
hepatic function
  1
  c0232741|liver function (observable entity)|t042
rare histologic subtype
  3
  c0205462|histologic|t169
  c0332184|rare (qualifier value)|t079
  c0449560|subtype (attribute)|t170
local sites
  2
  c0205276|local (qualifier value)|t082
  c0205145|associated topography (attribute)|t082
only first
  1
  c0205435|first (qualifier value)|t081
negative impact
  2
  c0205160|negative (qualifier value)|t080
  c0726639|impact|t168
duration
  1
  c0449238|duration|t079
and mesna
  1
  c0000294|mesna|t109
response rates
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0871208|rating|t062
iia cervical cancer
  1
  c0007847|malignant neoplasm of cervix uteri|t191
first intracavitary treatment
  4
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0205435|first (qualifier value)|t081
  c1298613|intracavitary (qualifier value)|t082
safe regimen
  2
  c0036043|safety|t068
  c0677937|regimen|t061
17-1a treatment again
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
hemoglobin level g
  2
  c0456079|disease classification level|t185
  c1319312|hemoglobin g (substance)|t116
only small proportion
  2
  c0700321|small|t080
  c0205351|proportional (qualifier value)|t080
surgical procedure
  1
  c0543467|general operative procedures|t061
gynaecologist
  1
  c0237419|gynecologist (occupation)|t097
intent adjuvant
  2
  c0679197|has intent (attribute)|t041
  c0001551|adjuvants, immunologic|t129
pathologic factors
  1
  c0205469|pathological aspects|t169
marked modulation
  2
  c0443264|modulated (qualifier value)|t082
  c0522501|massive (qualifier value)|t080
pelvic recurrence
  2
  c0030797|pelvis|t029
  c0034897|recurrence|t067
physiologic level
  2
  c0205463|physiologic (qualifier value)|t169
  c0456079|disease classification level|t185
locoregional radiotherapy
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
urothelial cancer
  4
  c0998265|cancer genus|t009
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
  c0227598|urothelium|t024
cmf
  1
  c0950521|cmf|t061
end points
  1
  c0150100|endpoint|t062
radiation oncology
  1
  c0243005|radiation oncology|t091
late toxicities
  2
  c0205087|late (qualifier value)|t079
  c0600688|toxic effect|t037
nine other drugs
  3
  c0205394|other|t080
  c0013227|pharmaceutical preparations|t121
  c0205455|nine (qualifier value)|t081
ascending
  1
  c0205385|ascending (qualifier value)|t080
physicians
  1
  c0031831|physicians|t097
preoperative findings
  2
  c0243095|findings|t169
  c0445204|preoperative (qualifier value)|t032
continuous data
  1
  c0549178|continuous (qualifier value)|t079
fixation
  2
  c0185023|fixation - action|t061
  c0728733|psychological fixation|t170
isocentric technique
  1
  c0449851|techniques|t170
two refills
  2
  c0807726|refills|t033
  c0205448|two (qualifier value)|t081
two courses
  2
  c0750729|courses (qualifier value)|t079
  c0205448|two (qualifier value)|t081
3.5 percent
  1
  c0439165|percent (qualifier value)|t081
prior chemotherapy
  4
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c0750516|prior|t078
first results
  2
  c1274040|result (navigational concept)|t169
  c0205435|first (qualifier value)|t081
postoperative radiation “prevented local recurrences
  2
  c0032790|postoperative period|t079
  c0034897|recurrence|t067
neutrophils l
  12
  c0442022|lumbar (qualifier value)|t082
  c0392223|lights, manufactured|t074
  c0023870|lithium|t196
  c0336769|lighter, device (physical object)|t073
  c0023693|light|t070
  c0302908|liquid substance|t167
  c0023700|lighting|t068
  c1304698|liquid (finding)|t033
  c0205091|left (qualifier value)|t082
  c0027950|neutrophils|t025
  c1306462|light color|t169
  c0475211|l (qualifier value)|t081
powerful prognostic determinant
  4
  c0680730|adjudication|t064
  c0220901|prognostic|t170
  c1148554|determination aspects|t059
  c0032863|power (psychology)|t068
less protracted exposure
  4
  c0274281|effects of exposure to external causes|t037
  c0391838|exposure condition|t169
  c0728853|accident due to exposure to weather conditions|t037
  c0491912|protractor|t074
localisation
  1
  c0475264|localization - action (qualifier value)|t169
confidence limits
  1
  c0237530|confidence limits|t081
intention to
  1
  c0162425|intention|t041
s3 posteriorly
  2
  c0205095|dorsal|t082
  c1179706|s3|t029
radiation oncologist
  1
  c0278603|radiation oncologist|t097
compliance
  2
  c0009563|biomechanical compliance|t081
  c0030680|patient compliance|t055
recurrences
  1
  c0034897|recurrence|t067
median 17.4 4 irinotecan group
  4
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
significance
  1
  c0750502|significant (qualifier value)|t078
flexible granulocyte colony-stimulating factor
  2
  c0443220|flexible (qualifier value)|t080
  c0079459|granulocyte colony-stimulating factor|t116
d
  3
  c0439228|day (qualifier value)|t079
  c0332517|diameter (qualifier value)|t032
  c0011530|deoxyribose|t123
major site
  2
  c0205164|major (qualifier value)|t080
  c0205145|associated topography (attribute)|t082
gpt
  1
  c0001899|alanine transaminase|t116
amputation
  1
  c0002688|amputation|t061
full treatment
  3
  c0087111|therapeutic procedure|t061
  c0443225|full (qualifier value)|t080
  c0039798|therapeutic aspects|t169
histological evidence
  1
  c0205462|histologic|t169
10.30 patients
  1
  c0030705|patients|t101
only one cycle
  2
  c0439596|cyclic (qualifier value)|t079
  c0205447|one (qualifier value)|t081
pump
  1
  c0182537|pump, device (physical object)|t074
one report
  3
  c0700287|reporting|t058
  c0205447|one (qualifier value)|t081
  c0684224|report (document)|t170
small bowel
  1
  c0021852|intestines, small|t023
gastrointestinal bleeding
  1
  c0017181|gastrointestinal hemorrhage|t033
distribution
  2
  c0520511|distributing|t078
  c0037775|spatial distribution|t082
improvements
  3
  c0184511|improved (qualifier value)|t080
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
cumulative doses
  1
  c0719635|dos|t109
important prognostic variables
  2
  c0220901|prognostic|t170
  c0439828|variable (qualifier value)|t080
success
  1
  c0597535|success|t054
cancer progression
  1
  c0178874|neoplasm progression|t191
one global health status scale
  6
  c0018759|health status|t080
  c0205246|generalized (qualifier value)|t082
  c0175659|weight measurement scales|t073
  c0349674|intellectual scale|t170
  c0222045|integumentary scale|t023
  c0205447|one (qualifier value)|t081
pre-operative radiation therapy
  3
  c0034618|radiation therapy|t061
  c0445204|preoperative (qualifier value)|t032
  c0034619|radiotherapeutic|t170
large tumor diameter
  2
  c0475278|large tumor (finding)|t080
  c0332517|diameter (qualifier value)|t032
adjuvant chemotherapy
  1
  c0085533|chemotherapy, adjuvant|t061
platelets
  1
  c0005821|blood platelets|t025
metoclopramide
  1
  c0025853|metoclopramide|t109
distal margin
  3
  c0205108|distal (qualifier value)|t082
  c1269830|tumor margin status|t033
  c0205284|marginal (qualifier value)|t082
reversible alopecia
  2
  c0205343|reversible (qualifier value)|t169
  c0002170|alopecia|t184
dox
  3
  c0048808|5'-deoxy-5-fluorouridine|t114
  c0013090|doxycycline|t195
  c0013089|doxorubicin|t195
breast irradiation
  5
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0006141|breast|t023
  c1268990|entire breast|t023
  c0034618|radiation therapy|t061
then effect
  1
  c1280500|effect (qualifier value)|t080
consistent trend
  2
  c0332290|consistent with (qualifier value)|t078
  c0040833|trends|t079
maintaining reasonable state
  4
  c1314677|maintained (qualifier value)|t169
  c0684328|reasoning|t041
  c1301808|state (environment)|t083
  c0721534|maintain|t109
occult local satellites
  3
  c0036238|satellite viruses|t005
  c0205262|occult (qualifier value)|t169
  c0205276|local (qualifier value)|t082
definitive deterioration
  2
  c0443196|definitive (qualifier value)|t079
  c0868945|deterioration|t067
cyclophosphamide
  1
  c0010583|cyclophosphamide|t115
primary end-point
  3
  c0439631|primary operation (qualifier value)|t061
  c0150100|endpoint|t062
  c0205225|primary|t080
linear accelerator
  2
  c1318457|linear accelerator electrons (procedure)|t061
  c0023730|linear accelerators|t073
second line cytotoxic chemotherapy
  4
  c0205132|linear|t082
  c0677881|cytotoxic drug therapy nos (procedure)|t061
  c0700221|intravascular line|t074
  c0205436|second (qualifier value)|t081
deep tumor invasion
  2
  c1269955|status of invasion by tumor (observable entity)|t201
  c0205125|depth (qualifier value)|t082
filgrastim
  1
  c0210630|filgrastim|t116
only small number
  2
  c0700321|small|t080
  c0449788|count of entities (property) (qualifier value)|t081
one progression
  2
  c0449258|progression (attribute)|t169
  c0205447|one (qualifier value)|t081
institutional upper normal limit
  3
  c1272753|institution (social concept)|t078
  c0442816|normal limits (qualifier value)|t081
  c0547042|upper (qualifier value)|t082
modifications
  1
  c0205349|altered (qualifier value)|t169
bypass surgery
  4
  c0741847|bypass|t061
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
m2 patients
  1
  c0030705|patients|t101
skeleton
  3
  c1283922|entire skeleton|t022
  c0037253|skeletal system|t022
  c0816871|skeleton|t022
other grade toxicities
  3
  c0205394|other|t080
  c0441800|grade|t185
  c0600688|toxic effect|t037
actuarial survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0334965|actuary (occupation)|t097
stable patients
  2
  c0205360|stable (qualifier value)|t080
  c0030705|patients|t101
multivariate analyses
  1
  c0026777|multivariate analysis|t081
dextran-coated charcoal assay
  2
  c0079414|genes, dcc|t028
  c0243073|assay|t059
appropriate therapy
  4
  c0814634|appropriateness|t080
  c0680799|appropriation|t064
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
unfavorable effects
  1
  c1280500|effect (qualifier value)|t080
stage ivb patients
  3
  c0456601|stage 4 upper case bee|t185
  c0030705|patients|t101
  c0441775|stage 4 lower case bee|t185
exclusion criteria
  2
  c0680251|exclusion|t169
  c0243161|criteria|t170
preexisting malignancy
  2
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
indeterminate
  1
  c0205258|indeterminate|t078
a1
  1
  c0933653|trunk of apical segmental artery|t023
progressive metastatic disease
  4
  c0036525|metastatic to|t169
  c0677932|progressive disease|t191
  c0205329|progressive (qualifier value)|t169
  c0027627|neoplasm metastasis|t191
more effective treatment
  4
  c0205414|effective (qualifier value)|t080
  c0205172|more (qualifier value)|t081
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
renal failure afterone course
  2
  c0449922|course (attribute)|t079
  c0035078|kidney failure|t047
fibrosis
  1
  c0016059|fibrosis|t046
dose response curve
  1
  c0683162|dose-response curve|t081
gastric adenocarcinoma
  2
  c0038351|stomach|t023
  c0001418|adenocarcinoma|t191
equivalent degrees
  3
  c0439185|eq (qualifier value)|t081
  c0542560|academic degree|t170
  c0449286|degree or extent|t080
same staging criteria
  3
  c0332305|with staging (attribute)|t169
  c0445247|same (qualifier value)|t080
  c0243161|criteria|t170
treatment-related toxicity
  5
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0039798|therapeutic aspects|t169
erroneous staging
  1
  c0332305|with staging (attribute)|t169
somewhat more frequent diarrhea
  3
  c0205172|more (qualifier value)|t081
  c0011991|diarrhea|t184
  c0332183|frequent (qualifier value)|t079
median tumor size
  3
  c0475440|tumor size (observable entity)|t082
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
requiring medication
  1
  c0013227|pharmaceutical preparations|t121
p values to
  1
  c0879541|p-value|t081
roche
  1
  c0331965|roche|t093
four arm study
  5
  c0205450|four (qualifier value)|t081
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0003792|arm|t029
  c0446516|upper arm|t029
demolitive surgery now
  3
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
three patients
  2
  c0030705|patients|t101
  c0205449|three (qualifier value)|t081
first course
  2
  c0449922|course (attribute)|t079
  c0205435|first (qualifier value)|t081
d orally
  4
  c0439228|day (qualifier value)|t079
  c0332517|diameter (qualifier value)|t032
  c0011530|deoxyribose|t123
  c0442027|oral (qualifier value)|t082
ci
  1
  c0162854|commonwealth of independent states|t083
linear source
  2
  c0205132|linear|t082
  c0449416|source (attribute)|t033
umbilicus
  3
  c1280744|entire umbilicus|t023
  c1040830|umbilicus genus|t002
  c0041638|umbilicus (anatomy)|t023
one caesium-137 ldr insertion
  3
  c0021107|implantation procedure|t061
  c0441587|clinical act of insertion|t058
  c0205447|one (qualifier value)|t081
because most responding patients
  2
  c0205393|most (qualifier value)|t081
  c0030705|patients|t101
previous trials
  1
  c0205156|previous (qualifier value)|t082
recovery
  1
  c0237820|recovery from disease|t040
sound clinical reasons to
  4
  c0205210|clinical (qualifier value)|t080
  c0684328|reasoning|t041
  c0037709|sound - physical agent|t070
  c0175663|sounds device|t074
therapy forms
  3
  c0087111|therapeutic procedure|t061
  c0376315|manufactured form|t073
  c0039798|therapeutic aspects|t169
only small subgroup
  1
  c0700321|small|t080
5-year follow-up evaluation
  4
  c1261322|assessment procedure (procedure)|t058
  c0439234|year (qualifier value)|t079
  c0220825|evaluation|t169
  c0589120|follow-up status (finding)|t169
haemorrhage
  1
  c0019080|hemorrhage|t046
crude estimate
  1
  c0750572|estimated|t078
previous study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205156|previous (qualifier value)|t082
overall toxicity
  3
  c0282416|overall [publication type]|t170
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
chest x-ray
  1
  c0202783|radiographic procedure on chest (procedure)|t060
radiodermatitis
  1
  c0034561|radiodermatitis|t037
possible patients
  2
  c0332149|possible|t080
  c0030705|patients|t101
concurrent administration
  3
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
  c0205420|concurrent (qualifier value)|t079
bias
  1
  c0242568|biases|t078
bilateral hydronephrosis
  1
  c0521622|bilateral hydronephrosis (disorder)|t047
intensive radiation
  1
  c0851346|radiation|t070
confirming evidence
  1
  c0750484|confirmed|t078
planned program
  2
  c0376691|programs [publication type]|t170
  c1301732|planned (qualifier value)|t169
infection
  1
  c0021311|infection|t047
infusion
  1
  c0574032|infusion (procedure)|t061
prediction
  1
  c0681842|prediction|t170
randomization procedures
  3
  c0025664|methodology|t170
  c0184661|procedures|t058
  c0034656|random allocation|t062
cut
  1
  c0000925|incised wound - morphology (morphologic abnormality)|t037
onthe cifx arm
  2
  c0003792|arm|t029
  c0446516|upper arm|t029
nadir sepsis days
  3
  c0439228|day (qualifier value)|t079
  c1090821|sepsis (invertebrate)|t009
  c0243026|systemic infection|t047
calibration
  1
  c0006751|calibration|t081
further month
  1
  c0439231|month (qualifier value)|t079
chambers
  1
  c0179874|chambers|t074
estimation
  1
  c0680844|estimation|t041
c2 equivalent
  3
  c0439185|eq (qualifier value)|t081
  c0009505|complement 2|t116
  c1305857|c2 innervation|t029
severe morbidity
  3
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0205082|severe (severity modifier) (qualifier value)|t080
better pelvic control
  2
  c0561970|ability to control pelvic posture (observable entity)|t033
  c0332272|better (qualifier value)|t080
seven relapses
  2
  c0035020|relapse|t067
  c0205453|seven (qualifier value)|t081
preliminary data
  1
  c0439611|preliminary (qualifier value)|t079
federal regulations
  2
  c0851285|regulation|t064
  c0220905|regulatory|t089
leakage rate
  2
  c0015376|extravasation (morphologic abnormality)|t046
  c0871208|rating|t062
methods patient eligibility study
  4
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0025664|methodology|t170
  c0025663|methods|t170
multiple data sets
  2
  c0439064|numerous (qualifier value)|t081
  c0150098|data set|t170
bleeding requiring transfusion
  2
  c0019080|hemorrhage|t046
  c0199960|transfusion - action (qualifier value)|t061
institution’s equipment
  2
  c0014672|equipment|t073
  c0220824|equipment used|t073
france
  1
  c0016674|france|t083
apparent lack
  2
  c0332268|lacking (qualifier value)|t080
  c0750489|apparent|t078
chest x ray
  1
  c0202783|radiographic procedure on chest (procedure)|t060
potassium chloride
  1
  c0032825|potassium chloride|t197
highest proportion
  3
  c0205351|proportional (qualifier value)|t080
  c0235146|euphoric mood|t041
  c0205250|high|t080
significant reductions
  3
  c0301630|reduction (chemical)|t070
  c0750502|significant (qualifier value)|t078
  c0441610|reduction - action|t061
log rank statistic
  3
  c0038215|science of statistics|t090
  c0699794|rank|t170
  c0335467|logger (occupation)|t097
overall survival
  3
  c0282416|overall [publication type]|t170
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
m treatment group
  1
  c0036669|sensitivity training groups|t065
suggested maximal doses
  3
  c0205289|maximal (qualifier value)|t080
  c0424012|suggestible (finding)|t033
  c0719635|dos|t109
bilateral pelvic lymphadenectomy
  3
  c0281267|bilateral breast cancer|t191
  c0193883|pelvic lymphadenectomy (procedure)|t061
  c0238767|bilateral|t082
10-fold increase
  2
  c0442805|increase (qualifier value)|t169
  c0332462|folded structure (morphologic abnormality)|t082
slides
  1
  c0444330|slide (specimen)|t075
mf
  3
  c0025979|microfilaments|t026
  c0026987|myelofibrosis|t047
  c0752265|microfibrils|t031
nonhematologic toxicities
  1
  c0600688|toxic effect|t037
initial response rate
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0205265|initial (qualifier value)|t079
type i error
  1
  c0871555|type i errors|t033
four additional patients
  3
  c0205450|four (qualifier value)|t081
  c0030705|patients|t101
  c0442796|additive (qualifier value)|t080
urogenital tract
  2
  c0447566|urogenital structure|t023
  c1185740|tract|t023
leukemic potential
  2
  c0023418|leukemia|t191
  c0237399|potential|t080
intracavitary radiation
  2
  c0851346|radiation|t070
  c1298613|intracavitary (qualifier value)|t082
residual disease
  1
  c0543478|residual tumor|t191
upper quarter
  1
  c0547042|upper (qualifier value)|t082
adjuvant portal chemotherapy
  2
  c0205054|hepatic|t029
  c0085533|chemotherapy, adjuvant|t061
median duration
  3
  c0449238|duration|t079
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
yield tumor response rates
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0027651|neoplasms|t191
hazards ratio
  2
  c0598697|hazard|t080
  c0456603|ratio (property) (qualifier value)|t170
risks
  1
  c0035647|risk|t080
median diameter
  3
  c0332517|diameter (qualifier value)|t032
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
radiation techniques
  3
  c0025664|methodology|t170
  c0851346|radiation|t070
  c0449851|techniques|t170
statistical significance
  1
  c0237881|statistical significance|t081
total treatment time
  4
  c0439810|total (qualifier value)|t080
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0040223|time|t079
partial response
  1
  c0677924|partial response|t080
transient leucopenia
  3
  c0205374|transitory|t079
  c0040704|transient population group|t098
  c0023530|leukopenia|t047
paraortic region
  1
  c0205147|regional (qualifier value)|t082
three received surgery
  5
  c0544683|reception|t042
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
  c0205449|three (qualifier value)|t081
80% power to
  1
  c0032863|power (psychology)|t068
postoperative complications
  1
  c0032787|postoperative complications|t046
remaining nine patients
  2
  c0030705|patients|t101
  c0205455|nine (qualifier value)|t081
curative resection
  2
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
inferior margin
  4
  c1269830|tumor margin status|t033
  c0542339|inferior|t082
  c0205284|marginal (qualifier value)|t082
  c0678975|inferiority|t054
missing chart
  1
  c0684240|chart|t170
one arm
  3
  c0205447|one (qualifier value)|t081
  c0003792|arm|t029
  c0446516|upper arm|t029
primary objectives
  3
  c0439631|primary operation (qualifier value)|t061
  c0018017|goals|t170
  c0205225|primary|t080
significantly lower rate
  3
  c0441994|lower (qualifier value)|t169
  c0750502|significant (qualifier value)|t078
  c0871208|rating|t062
logrank test
  1
  c0392366|tests (qualifier value)|t170
carcinoembryonic antigen
  1
  c0007082|carcinoembryonic antigen|t116
institutional pathologists
  2
  c1272753|institution (social concept)|t078
  c0334866|medical pathologist (occupation)|t097
concurrent use
  2
  c0042153|utilization|t081
  c0205420|concurrent (qualifier value)|t079
minor responses
  3
  c0205165|minor (value)|t080
  c0871261|responses|t054
  c0026193|minor|t098
five surviving patients
  3
  c0205451|five (qualifier value)|t081
  c0310255|survive (product)|t121
  c0030705|patients|t101
short course
  2
  c0449922|course (attribute)|t079
  c0205167|short (qualifier value)|t079
lateral fields
  3
  c0205093|lateral (qualifier value)|t082
  c0331809|fielding|t093
  c0440042|field's stain|t130
second application
  2
  c0185125|application (procedure)|t058
  c0205436|second (qualifier value)|t081
italy
  1
  c0022277|italy|t083
peripheral blood
  1
  c0229664|peripheral blood (substance)|t031
participants
  1
  c0679646|participant|t098
adriamycin containing regimen
  3
  c0085752|adriamycin|t195
  c0332256|containing (qualifier value)|t169
  c0677937|regimen|t061
complete blood analysis
  6
  c0005767|blood|t024
  c0005768|in blood|t031
  c0002778|analysis of substances|t059
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
  c0936012|analysis|t062
radiation trials
  1
  c0851346|radiation|t070
complete responses
  1
  c0008574|chromium|t123
stroke
  1
  c0038454|cerebrovascular accident|t047
other five cycles
  3
  c0205394|other|t080
  c0205451|five (qualifier value)|t081
  c0439596|cyclic (qualifier value)|t079
lymph node biopsy to
  1
  c0193842|biopsy of lymph node (procedure)|t060
recognition
  1
  c0524637|recognition (psychology)|t041
overt liver metastases
  1
  c0494165|secondary malignant neoplasm of liver (disorder)|t191
diarrhoea
  1
  c0011991|diarrhea|t184
pelvic radiography
  3
  c0043299|diagnostic radiologic examination|t060
  c0030797|pelvis|t029
  c0034571|roentgenographic|t169
sixth courses
  2
  c0205440|sixth (qualifier value)|t081
  c0750729|courses (qualifier value)|t079
hematuria requiring transfusion
  3
  c0238157|benign hematuria|t047
  c0018965|hematuria|t033
  c0199960|transfusion - action (qualifier value)|t061
quality
  1
  c0332306|with quality (attribute)|t080
controlled comparison
  1
  c0702113|controlled (qualifier value)|t169
response categories
  2
  c0871261|responses|t054
  c0683312|categories|t170
metastasis free survival
  4
  c0016694|freedom|t078
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0027627|neoplasm metastasis|t191
potential
  1
  c0237399|potential|t080
ecog
  1
  c0430797|electrocorticogram (procedure)|t060
predetermined schedule
  1
  c0086960|schedules|t170
insertion
  2
  c0021107|implantation procedure|t061
  c0441587|clinical act of insertion|t058
steep transvascular concentration gradient
  2
  c0812409|gradient|t081
  c0086045|concentration|t041
prospective randomized controlled trial
  1
  c0282440|randomized controlled trials|t170
significantly better
  2
  c0332272|better (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
applicator flange
  1
  c0179108|applicator (physical object)|t074
major lifethreatening adverse effects
  2
  c0205164|major (qualifier value)|t080
  c0001688|adverse effects|t037
surgeons
  1
  c0582175|surgeon (occupation)|t097
one vascular lesion
  3
  c0005847|blood vessels|t023
  c0205447|one (qualifier value)|t081
  c0221198|lesion|t033
compartmental resection
  3
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
  c1185625|set of compartments|t030
complete computerised plane
  4
  c0444660|plane (attribute)|t082
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
  c0009622|computers|t073
most dependent variable
  2
  c0871711|dependent variables|t169
  c0205393|most (qualifier value)|t081
two parallel opposed fields cm
  2
  c0475210|cm (qualifier value)|t081
  c0205448|two (qualifier value)|t081
aspiration cytology
  9
  c0700198|pulmonary aspiration|t046
  c1305671|cytology procedure|t059
  c0010820|cellular aspects of|t033
  c0184931|aspiration (procedure)|t061
  c0220787|endotracheal aspiration|t046
  c0849088|test, cytology, digestive|t059
  c0349707|aspiration-action|t058
  c1306321|endotracheal aspiration (qualifier value)|t169
  c0010819|cytology|t091
ct guided percutaneous needle aspiration
  3
  c0882992|ct guide|t060
  c1293115|percutaneous aspiration (procedure)|t061
  c0027551|needles|t074
antigenic heterogeneity
  2
  c0019409|heterogeneity|t102
  c0003320|antigens|t129
9.0 weeks
  1
  c0439230|week (qualifier value)|t079
radiotherapy significantly
  3
  c0034618|radiation therapy|t061
  c0750502|significant (qualifier value)|t078
  c0034619|radiotherapeutic|t170
perineal wounds
  3
  c0021501|injuries|t037
  c0031066|anogenital region|t029
  c0043250|injury wounds|t037
side effects
  1
  c0001688|adverse effects|t037
multivariate methods
  2
  c0025664|methodology|t170
  c0025663|methods|t170
depth
  2
  c0205125|depth (qualifier value)|t082
  c0449292|depth (attribute)|t082
most effective doses
  3
  c0205414|effective (qualifier value)|t080
  c0205393|most (qualifier value)|t081
  c0719635|dos|t109
apparently superior results
  3
  c0205105|superior (qualifier value)|t082
  c1274040|result (navigational concept)|t169
  c0750541|apparently|t078
reports
  1
  c0684224|report (document)|t170
established distant micrometastases
  2
  c0443203|distant (qualifier value)|t082
  c0443211|established (qualifier value)|t080
accurately type
  2
  c0332307|with type (attribute)|t169
  c0443131|accurate (qualifier value)|t080
particularly tamoxifen
  1
  c0039286|tamoxifen|t109
distant disease
  2
  c0443203|distant (qualifier value)|t082
  c0012634|disease|t047
pathological assessment
  1
  c1294089|pathologist evaluation (procedure)|t060
saw
  1
  c0183089|saws|t074
present
  1
  c0150312|present|t169
s3
  1
  c1179706|s3|t029
only technique
  1
  c0449851|techniques|t170
intensive postoperative course
  2
  c0449922|course (attribute)|t079
  c0032790|postoperative period|t079
similar type
  2
  c0871364|simile|t170
  c0332307|with type (attribute)|t169
choice
  1
  c0008300|choice behavior|t055
wrong cell type
  3
  c0332271|worsening (qualifier value)|t080
  c1279889|deterioration of status|t080
  c0449475|type of cell (qualifier value)|t170
tumor sizes
  1
  c0475440|tumor size (observable entity)|t082
substantially more frequent mucocutaneous reactions
  2
  c0205172|more (qualifier value)|t081
  c0443286|reaction (qualifier value)|t169
median
  2
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
radiation effect
  1
  c0034525|effects of radiation|t067
survival difference
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0443199|differential (qualifier value)|t080
israel
  1
  c0022271|israel|t083
worsening
  1
  c0332271|worsening (qualifier value)|t080
severe nausea
  2
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0027497|nausea|t033
tumour burden
  1
  c0027651|neoplasms|t191
immune suppression
  1
  c0021079|therapeutic immunosuppression|t061
severe anorexia
  2
  c0003123|anorexia|t184
  c0205082|severe (severity modifier) (qualifier value)|t080
surgeon
  1
  c0582175|surgeon (occupation)|t097
toxic treatment program
  2
  c0600688|toxic effect|t037
  c0679841|treatment program|t058
dukes classification
  3
  c0008903|taxonomic|t185
  c0008902|classification|t185
  c0678229|classification of information|t057
5-fu doses
  1
  c0366485|fluorouracil:mass:point in time:dose med or substance:quantitative|t201
equal therapeutic potency
  4
  c0205163|equal (qualifier value)|t080
  c0039796|the science and art of healing|t061
  c0302350|therapeutic|t169
  c0237399|potential|t080
4.9 percent
  1
  c0439165|percent (qualifier value)|t081
murine 17-1a antibody
  2
  c0591833|murine|t109
  c0003241|antibodies|t116
developed leukemia
  4
  c0020119|human development|t039
  c0180397|developers|t130
  c0023418|leukemia|t191
  c0243107|development aspects|t039
morbidity
  2
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
biopsy samples
  2
  c0677862|biopsy sample (specimen)|t024
  c0441625|biopsy sampling (qualifier value)|t060
international federation of gynecology and obstetrics
  3
  c1138414|internationality|t078
  c0700061|obstetric patient|t101
  c0028773|discipline of obstetrics|t091
likelihood
  1
  c0750504|likely|t078
critical structures
  3
  c0335034|critic (occupation)|t097
  c0678594|structure|t170
  c0231224|crisis (finding)|t033
weekly concomitant treatment
  3
  c0087111|therapeutic procedure|t061
  c0332174|weekly (qualifier value)|t079
  c0039798|therapeutic aspects|t169
early termination
  2
  c0205085|early (qualifier value)|t079
  c0231800|expiration, function (observable entity)|t040
highest regression rate
  5
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
  c0235146|euphoric mood|t041
  c0871208|rating|t062
  c0205250|high|t080
same time
  2
  c0445247|same (qualifier value)|t080
  c0040223|time|t079
suggested low serum albumin level
  4
  c0424012|suggestible (finding)|t033
  c0205251|low (qualifier value)|t080
  c0728877|serum albumin level|t034
  c0523465|serum albumin measurement|t059
systemic relapse
  4
  c0205373|systemic (qualifier value)|t169
  c0205336|relapsing course|t079
  c0580802|relapse phase|t079
  c0035020|relapse|t067
protocol adherence
  2
  c0334154|adherent|t169
  c0442711|protocols documentation|t170
acute decrease
  2
  c0547047|decrease (qualifier value)|t081
  c0205178|acuteness (qualifier value)|t079
disease extension
  2
  c0231448|extension (qualifier value)|t042
  c0012634|disease|t047
major contributor
  1
  c0205164|major (qualifier value)|t080
distal edge
  2
  c0205108|distal (qualifier value)|t082
  c0205154|along edge (qualifier value)|t082
hypercoagulability
  1
  c0398623|thrombophilia|t047
decreased fraction size
  2
  c0457426|fractions of (qualifier value)|t081
  c0332511|decreased size (finding)|t080
second line therapy
  5
  c0205132|linear|t082
  c0087111|therapeutic procedure|t061
  c0700221|intravascular line|t074
  c0039798|therapeutic aspects|t169
  c0205436|second (qualifier value)|t081
patient refusal
  1
  c0030705|patients|t101
cells
  1
  c0007634|cells|t025
delay failures
  3
  c0680095|personal failure|t055
  c0205421|deferred (qualifier value)|t079
  c0231174|failure (biologic function)|t169
intracavitary brachytherapy
  1
  c0021864|radiotherapy, intracavity|t061
none
  1
  c0549184|none (qualifier value)|t081
clearly defined liver edge
  2
  c0205305|clear (qualifier value)|t080
  c0426689|liver edge (finding)|t033
synovial sarcoma
  1
  c0039101|sarcoma, synovial|t191
cervical carcinoma
  1
  c0302592|carcinoma of cervix (disorder)|t191
postoperative radiochemotherapy
  2
  c0032790|postoperative period|t079
  c0436307|radiochemotherapy nos (procedure)|t061
pyelogram
  1
  c0203108|intravenous pyelogram|t060
first group included countries
  5
  c0454664|countries (geographic location)|t083
  c0332257|including (qualifier value)|t169
  c0441833|groups (qualifier value)|t170
  c0205435|first (qualifier value)|t081
  c1300322|group (social concept)|t096
treatment field
  3
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0440042|field's stain|t130
serum albumin level
  2
  c0728877|serum albumin level|t034
  c0523465|serum albumin measurement|t059
cisplatin administration
  3
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
  c0008838|cisplatin|t197
first survival analysis
  2
  c0038953|survival analysis|t081
  c0205435|first (qualifier value)|t081
two major trials
  2
  c0205164|major (qualifier value)|t080
  c0205448|two (qualifier value)|t081
tumor regression
  3
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
  c0027651|neoplasms|t191
routine bone scans
  2
  c0205547|routine (qualifier value)|t080
  c0203668|radioisotope scan of bone (procedure)|t060
bilateral pelvic wall involvement
  4
  c0392760|not free of (attribute)|t169
  c0281267|bilateral breast cancer|t191
  c0238767|bilateral|t082
  c0230284|pelvic wall structure (body structure)|t023
observation time
  3
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0040223|time|t079
min
  1
  c0439232|minute of time|t079
biopsy only
  1
  c0439796|biopsy only (qualifier value)|t169
chest radiography
  1
  c0202783|radiographic procedure on chest (procedure)|t060
dacarbazine
  1
  c0010927|dacarbazine|t109
cardiac injury
  2
  c0205041|cardio-|t082
  c0175677|injury inflicted to the body by an external force|t037
blood counts
  3
  c0005767|blood|t024
  c0005768|in blood|t031
  c0439157|counts (qualifier value)|t081
performance
  1
  c0597198|performance|t055
major symptomatic improvement
  5
  c0184511|improved (qualifier value)|t080
  c0205164|major (qualifier value)|t080
  c0231220|symptomatic (qualifier value)|t169
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
abdominopelvic computerized tomography
  1
  c0040405|x-ray computed tomography|t060
seski’s study
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
institutional state
  2
  c1272753|institution (social concept)|t078
  c1301808|state (environment)|t083
initial evaluation also included chest radiography
  2
  c0202783|radiographic procedure on chest (procedure)|t060
  c0205265|initial (qualifier value)|t079
extensiveness
  1
  c0439795|extensiveness (qualifier value)|t080
preestablished randomization table
  3
  c1168570|table - visual aid|t170
  c0039224|table - furniture|t073
  c0034656|random allocation|t062
laboratory data
  1
  c0745590|lab data|t077
obstetricians
  1
  c0334897|obstetrician (occupation)|t097
subsequent courses
  2
  c0750530|subsequent|t078
  c0750729|courses (qualifier value)|t079
laspartic acid
  1
  c0001128|acids|t103
locoregional disease
  1
  c0012634|disease|t047
positive role
  2
  c0035820|role|t054
  c0205159|positive (qualifier value)|t080
concurrent radiation
  2
  c0851346|radiation|t070
  c0205420|concurrent (qualifier value)|t079
more indolent course
  3
  c0234227|indolent|t169
  c0449922|course (attribute)|t079
  c0205172|more (qualifier value)|t081
fraction
  1
  c0457426|fractions of (qualifier value)|t081
question
  1
  c0750481|questionable|t078
separate criteria
  2
  c0443299|separate (qualifier value)|t082
  c0243161|criteria|t170
leukocyte nadirs
  1
  c0023516|leukocytes|t025
only two isolated vault failures
  3
  c0680095|personal failure|t055
  c0231174|failure (biologic function)|t169
  c0205448|two (qualifier value)|t081
less toxic analogue
  2
  c0243071|analog|t104
  c0600688|toxic effect|t037
planned treatment
  3
  c0087111|therapeutic procedure|t061
  c1301732|planned (qualifier value)|t169
  c0039798|therapeutic aspects|t169
paraortic metastases
  2
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0027627|neoplasm metastasis|t191
hysterectomy
  1
  c0020699|hysterectomy|t061
repetition
  1
  c0205341|repeat (qualifier value)|t169
primary lesion
  3
  c0439631|primary operation (qualifier value)|t061
  c0205225|primary|t080
  c0221198|lesion|t033
others
  1
  c0205394|other|t080
liver scan
  1
  c0203758|radioisotope study of liver (procedure)|t060
gram-negative septicaemia
  1
  c0036685|gram-negative septicemia nos (disorder)|t047
lateral boundaries
  1
  c0205093|lateral (qualifier value)|t082
size
  1
  c0702146|size (attribute)|t081
overall risk
  2
  c0282416|overall [publication type]|t170
  c0035647|risk|t080
only three patients
  2
  c0030705|patients|t101
  c0205449|three (qualifier value)|t081
lower third
  1
  c0442051|lower third (qualifier value)|t082
cooperative study group
  6
  c0596382|cooperative study|t062
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0677877|cooperative group|t093
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
only humoral antiidiotype response
  2
  c0871261|responses|t054
  c0020168|humor|t078
overall time savings
  3
  c0282416|overall [publication type]|t170
  c0040223|time|t079
  c0036245|savings|t081
primary treatment modality
  5
  c0695347|modality|t078
  c0439631|primary operation (qualifier value)|t061
  c0087111|therapeutic procedure|t061
  c0205225|primary|t080
  c0039798|therapeutic aspects|t169
magnetic resonance imaging
  1
  c0024485|magnetic resonance imaging|t060
coworkers
  1
  c0681088|coworker|t098
pyrimidine synthesis
  3
  c0034284|pyrimidine|t109
  c0034289|pyrimidines|t109
  c0869032|synthesis|t067
liver failure
  1
  c0085605|liver failure|t047
supportive care group
  3
  c0344211|supportive care|t058
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
clear superiority
  2
  c0680218|superiority|t054
  c0205305|clear (qualifier value)|t080
acute toxicity
  3
  c0040539|toxicity aspects|t081
  c0205178|acuteness (qualifier value)|t079
  c0600688|toxic effect|t037
box technique
  3
  c0449851|techniques|t170
  c0179400|boxes|t073
  c0006080|boxing|t056
lymphangiography
  1
  c0024219|lymphangiography|t060
subgroup analyses
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
e
  3
  c0679138|expectations (qualifier value)|t041
  c0542479|energy, physics|t070
  c0424589|vitality|t033
only cases
  1
  c0868928|case (qualifier value)|t169
response criteria
  2
  c0871261|responses|t054
  c0243161|criteria|t170
death rate
  2
  c1108678|death rate aspects|t081
  c0205848|death rate|t081
potent inhibitor
  2
  c0243077|inhibitors|t120
  c0237399|potential|t080
portal adjuvant therapy
  2
  c0677850|adjuvant therapy|t061
  c0205054|hepatic|t029
endocrine therapy
  1
  c0279025|endocrine therapy (procedure)|t061
more bladder toxicity
  5
  c0205172|more (qualifier value)|t081
  c0040539|toxicity aspects|t081
  c0005682|bladder|t023
  c0600688|toxic effect|t037
  c1281573|entire bladder|t023
j m.b.
  9
  c0162443|journals|t170
  c0337527|brothers|t099
  c0004927|behavior|t055
  c0439256|joule, unit of energy|t081
  c0004587|bacillus <bacterium>|t007
  c0677505|behaviors and observations relating to behavior|t033
  c1040746|bacilli|t007
  c0150141|bathing|t061
  c0175640|baths (medical device)|t074
need
  1
  c0027552|needs|t080
most severe complications
  4
  c1171258|complication aspects|t046
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0205393|most (qualifier value)|t081
  c0009566|complication|t046
multiple drug regimens
  3
  c0439064|numerous (qualifier value)|t081
  c0013227|pharmaceutical preparations|t121
  c0677937|regimen|t061
weekend break
  1
  c0680190|weekend|t079
surveys
  1
  c0038951|surveys|t062
median survivals
  4
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
alternative explanation
  3
  c0332270|alternating (qualifier value)|t169
  c0681841|explanation|t062
  c0919661|heart alternation|t046
new agent closely
  4
  c0450442|agent (attribute)|t120
  c0205314|new (qualifier value)|t079
  c0587267|closed|t169
  c0677512|closed approach|t082
steroids
  1
  c0038317|steroids|t110
shortness
  1
  c0205167|short (qualifier value)|t079
preliminary results
  2
  c1274040|result (navigational concept)|t169
  c0439611|preliminary (qualifier value)|t079
two packets
  1
  c0205448|two (qualifier value)|t081
single low-dose rate intracavitary application
  7
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0677884|dose-rate|t081
  c0185125|application (procedure)|t058
  c0205251|low (qualifier value)|t080
  c0087136|unmarried|t098
  c1298613|intracavitary (qualifier value)|t082
prior radiation exposure
  2
  c0015333|[x]exposure to unspecified type of radiation, occurrence at unspecified place (finding)|t037
  c0750516|prior|t078
intravenous pyelogram
  1
  c0203108|intravenous pyelogram|t060
cycles chemotherapy alone
  5
  c0439596|cyclic (qualifier value)|t079
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c0679994|alone|t102
wilcoxon statistical test
  1
  c0237913|statistical tests|t170
myelosuppression
  1
  c0854467|myelosuppression (finding)|t047
severe illness—major contraindications
  2
  c0079164|contraindications|t080
  c0205082|severe (severity modifier) (qualifier value)|t080
histologic confirmation
  2
  c0205462|histologic|t169
  c0750484|confirmed|t078
shortening
  1
  c0441636|surgical shortening - action (qualifier value)|t061
eliminating bulky disease
  3
  c0518891|elimination outcomes|t170
  c0221102|excretory function|t039
  c0012634|disease|t047
favorable results
  2
  c1274040|result (navigational concept)|t169
  c0309049|favor (product)|t121
monk
  1
  c0682252|monk|t097
disease
  1
  c0012634|disease|t047
two treatment arms
  4
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0003792|arm|t029
  c0205448|two (qualifier value)|t081
small decrease
  2
  c0547047|decrease (qualifier value)|t081
  c0700321|small|t080
alive six patients
  2
  c0205452|six (qualifier value)|t081
  c0030705|patients|t101
allergic bleomycin reaction
  2
  c0020517|hypersensitivity|t046
  c0005740|bleomycin|t116
standardized utilization
  2
  c0038136|standardization|t062
  c0042153|utilization|t081
u
  1
  c0041928|uranium|t196
synchronous local relapse
  5
  c0205336|relapsing course|t079
  c0439580|synchronous (qualifier value)|t079
  c0580802|relapse phase|t079
  c0205276|local (qualifier value)|t082
  c0035020|relapse|t067
cisplatin ­ bleomycin ­ vincristine
  2
  c0042679|vincristine|t109
  c0008838|cisplatin|t197
other common toxicities
  3
  c0205394|other|t080
  c0600688|toxic effect|t037
  c0205214|common (qualifier value)|t081
material costs
  2
  c0010186|financial cost|t081
  c0520510|materials|t167
inevaluable patient
  1
  c0030705|patients|t101
selected patient characteristics
  2
  c0036576|selection (genetics)|t045
  c0815172|patient characteristics|t201
serum aspartate aminotransferase level
  2
  c0201899|aspartate aminotransferase assay|t059
  c0456079|disease classification level|t185
postradiation chemotherapy
  3
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
equal fraction
  2
  c0457426|fractions of (qualifier value)|t081
  c0205163|equal (qualifier value)|t080
received radiotherapy
  3
  c0544683|reception|t042
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
combined evidence
  1
  c0205195|combined (qualifier value)|t080
rapid repopulation
  1
  c0439831|rapid (qualifier value)|t080
colorectal cancer
  1
  c0009402|colorectal cancer|t191
discernable impact
  2
  c0205396|identified (qualifier value)|t169
  c0726639|impact|t168
serial hematologic evaluations
  3
  c0205488|hematologic (qualifier value)|t169
  c0031082|periodicals|t170
  c0220825|evaluation|t169
achieved prs
  2
  c0279766|progesterone receptor negative|t034
  c0001072|achievement|t055
adverse urologic effects
  2
  c0205479|urologic (qualifier value)|t091
  c0001688|adverse effects|t037
optimal dosing schedule
  2
  c0086960|schedules|t170
  c0178602|dosages (qualifier value)|t081
films
  1
  c0086296|films|t073
superior limit
  2
  c0205105|superior (qualifier value)|t082
  c0449205|lim (body structure)|t029
consecutive episodes
  1
  c0678231|episodes (qualifier value)|t079
laboratory abnormalities
  1
  c0745587|lab abnormality|t033
mg
  2
  c0024467|magnesium|t123
  c0439210|milligram|t081
merit comment
  2
  c0947611|comment|t170
  c0282411|published comment|t170
criteria
  1
  c0243161|criteria|t170
white cell count
  5
  c0007584|cell count|t059
  c0007457|caucasoid race|t098
  c1306888|white color (finding)|t033
  c0220938|white color|t080
  c0043157|caucasians|t098
causes
  2
  c0015127|causality|t169
  c1314792|etiology|t169
local dfs
  2
  c0205276|local (qualifier value)|t082
  c0011145|deferoxamine|t123
also nine patients
  2
  c0030705|patients|t101
  c0205455|nine (qualifier value)|t081
nft group
  3
  c0085400|neurofibrillary tangles|t020
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
diameter
  1
  c0332517|diameter (qualifier value)|t032
regression
  2
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
random permuted blocks
  4
  c0439605|random (qualifier value)|t082
  c0332206|blocking|t169
  c0028778|obstruction|t046
  c0233660|mental blocking|t048
5-year kaplan–meier survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439234|year (qualifier value)|t079
present article
  1
  c0150312|present|t169
bulky tumors
  1
  c0027651|neoplasms|t191
current study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0521116|current (qualifier value)|t079
patients predominantly
  2
  c0332251|predominate (qualifier value)|t080
  c0030705|patients|t101
princess margaret hospital
  1
  c0019994|hospitals|t093
mof strept regimen
  2
  c0026766|multiple organ failure|t033
  c0677937|regimen|t061
chemotherapy–radiotherapy group
  2
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
tolerable dose schedule
  4
  c0231198|tolerant|t169
  c0086960|schedules|t170
  c0178602|dosages (qualifier value)|t081
  c0680282|implicit permission|t054
survival rates
  1
  c0038954|survival rate|t081
mg total dose
  3
  c0024467|magnesium|t123
  c0439210|milligram|t081
  c0172161|tyramine-deoxysorbitol|t109
rt days
  1
  c0439228|day (qualifier value)|t079
three months
  2
  c0439231|month (qualifier value)|t079
  c0205449|three (qualifier value)|t081
randomized study treatment
  5
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0087111|therapeutic procedure|t061
  c0034656|random allocation|t062
  c0039798|therapeutic aspects|t169
lower frequency
  1
  c0205213|low frequency (qualifier value)|t079
4.6 months
  1
  c0439231|month (qualifier value)|t079
5-hydroxytryptamine-3 antagonists
  2
  c0162466|hydroxytryptamine|t124
  c0243076|antagonists|t120
late toxicity
  3
  c0205087|late (qualifier value)|t079
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
optimum treatment strategies
  3
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0679199|strategy|t041
original statistical design
  2
  c0205313|original (qualifier value)|t078
  c0220917|statistical|t170
further exploration
  2
  c1280903|exploration procedure (procedure)|t061
  c0581690|exploration - action (qualifier value)|t058
twelve days after treatment initiation
  5
  c0439228|day (qualifier value)|t079
  c0001758|aftercare|t058
  c0678321|aod use initiation|t079
  c0205458|twelve (qualifier value)|t081
  c0589507|cognitive function: initiation|t041
cardiac function
  1
  c0232164|cardiac function (observable entity)|t042
early reporting
  2
  c0700287|reporting|t058
  c0205085|early (qualifier value)|t079
received treatment
  3
  c0544683|reception|t042
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
total length
  2
  c0439537|lengths (qualifier value)|t081
  c0439810|total (qualifier value)|t080
8.9 weeks
  1
  c0439230|week (qualifier value)|t079
modification
  1
  c0205349|altered (qualifier value)|t169
second most frequent cancer
  3
  c0205393|most (qualifier value)|t081
  c0332183|frequent (qualifier value)|t079
  c0751623|second cancer|t191
ineligible stage
  2
  c0684248|stage of surgical procedure|t079
  c0027646|diagnostic neoplasm staging|t060
median actual dose
  4
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0237400|actual|t080
  c0178602|dosages (qualifier value)|t081
new interest
  2
  c0543488|interested (finding)|t041
  c0205314|new (qualifier value)|t079
sixteen daily treatments
  2
  c0087111|therapeutic procedure|t061
  c0332173|daily (qualifier value)|t079
radiologic diagnosis
  3
  c0011900|diagnosis|t060
  c0205483|radiologic (qualifier value)|t169
  c0348026|diagnostic|t169
clinical stage
  1
  c0205563|clinical staging (qualifier value)|t079
part
  1
  c0449719|part (attribute)|t082
radiation remains
  1
  c0851346|radiation|t070
development
  2
  c0020119|human development|t039
  c0243107|development aspects|t039
primary site
  1
  c0449695|site of primary lesion (attribute)|t082
17-1a antigen
  1
  c0003320|antigens|t129
high incidence
  4
  c0021149|incidence|t081
  c0220856|incidence of cases|t169
  c0235146|euphoric mood|t041
  c0205250|high|t080
m increments course
  1
  c0449922|course (attribute)|t079
combined therapy regimen
  2
  c0033972|psychotherapy, multiple|t061
  c0677937|regimen|t061
prolongation
  1
  c0439590|prolonged (qualifier value)|t079
involvement
  1
  c0392760|not free of (attribute)|t169
formation
  1
  c0439634|formations (qualifier value)|t082
toxicity
  2
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
transperitoneal staging procedure
  2
  c0205501|transperitoneal approach (qualifier value)|t082
  c1276306|staging - procedure intent (qualifier value)|t169
disease-free interval
  2
  c1272706|interval (qualifier value)|t079
  c0012634|disease|t047
histologic evaluation
  3
  c0205462|histologic|t169
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
positive lymphangiography
  2
  c0205159|positive (qualifier value)|t080
  c0024219|lymphangiography|t060
significantly longer progression free survival
  3
  c0205166|long (qualifier value)|t080
  c0242792|progression-free survival|t081
  c0750502|significant (qualifier value)|t078
collected series
  2
  c0205549|series (qualifier value)|t081
  c0180011|collectors|t074
full course radiotherapy
  4
  c0449922|course (attribute)|t079
  c0443225|full (qualifier value)|t080
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
capillary lymphatic space tumor involvement
  6
  c1280521|entire capillary blood vessel (organ)|t023
  c0935624|capillary, unspecified|t023
  c0746333|lymphatic involvement|t033
  c0027651|neoplasms|t191
  c0006901|blood capillaries|t023
  c0221874|spacer (physical object)|t074
toxicity grades
  3
  c0441800|grade|t185
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
uncertain margins
  3
  c0205424|uncertain (qualifier value)|t080
  c1269830|tumor margin status|t033
  c0205284|marginal (qualifier value)|t082
event free times
  5
  c0392761|timed (qualifier value)|t169
  c0441471|events (event)|t051
  c0040223|time|t079
  c0683585|free time|t056
  c0449243|timing (attribute)|t079
ifosfamide 1.8 g
  2
  c0020823|ifosfamide|t115
  c0162832|apc gene|t028
doxorubicin
  1
  c0013089|doxorubicin|t195
transaminases
  2
  c0919834|transaminase assay|t059
  c0002594|transaminases|t116
dibromodulcitol
  1
  c0026252|mitolactol|t118
few second generation trials
  3
  c0079411|generations|t079
  c0205388|few (qualifier value)|t081
  c0205436|second (qualifier value)|t081
pelvic control rate
  2
  c0561970|ability to control pelvic posture (observable entity)|t033
  c0871208|rating|t062
positive
  1
  c0205159|positive (qualifier value)|t080
sensitize tumor cells
  1
  c0431085|[m]unspecified tumor cell nos (morphologic abnormality)|t191
serious complications
  3
  c1171258|complication aspects|t046
  c0205404|serious (qualifier value)|t080
  c0009566|complication|t046
one hundred twenty five patients
  2
  c0030705|patients|t101
  c0205447|one (qualifier value)|t081
medical
  1
  c0205476|medical (qualifier value)|t169
malignant schwannoma
  2
  c0751690|malignant peripheral nerve sheath tumors|t191
  c0701838|malignant neurilemmoma|t191
four patients
  2
  c0205450|four (qualifier value)|t081
  c0030705|patients|t101
additional women
  3
  c0043209|human females|t098
  c0043210|human adult females|t098
  c0442796|additive (qualifier value)|t080
wk
  1
  c0439230|week (qualifier value)|t079
acceptable safety profile
  3
  c0814633|acceptability|t080
  c0036043|safety|t068
  c1272684|accepted (qualifier value)|t080
radiotherapy actually developed chf
  7
  c0020119|human development|t039
  c0018802|heart failure, congestive|t047
  c0180397|developers|t130
  c0237400|actual|t080
  c0243107|development aspects|t039
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
m mitolactol daily
  2
  c0026252|mitolactol|t118
  c0332173|daily (qualifier value)|t079
sepsis
  2
  c1090821|sepsis (invertebrate)|t009
  c0243026|systemic infection|t047
er tumors
  2
  c0279756|estrogen receptor negative|t034
  c0027651|neoplasms|t191
overall prognosis
  2
  c0282416|overall [publication type]|t170
  c0033325|forecast of outcome|t058
fluorouracil regimen
  2
  c0016360|fluorouracil|t114
  c0677937|regimen|t061
abdominal mass cm
  2
  c0000734|[d]abdominal mass (context-dependent category)|t184
  c0475210|cm (qualifier value)|t081
grade nausea
  2
  c0441800|grade|t185
  c0027497|nausea|t033
c m
  1
  c0007886|cesium|t196
cox model analysis
  3
  c0002778|analysis of substances|t059
  c0010234|cox models|t170
  c0936012|analysis|t062
study treatments
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0087111|therapeutic procedure|t061
declined radiotherapy
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
cervical tumours
  1
  c0027533|neck neoplasms|t191
not prior 5-fu failure
  3
  c0680095|personal failure|t055
  c0231174|failure (biologic function)|t169
  c0750516|prior|t078
wrong stage
  4
  c0332271|worsening (qualifier value)|t080
  c0684248|stage of surgical procedure|t079
  c0027646|diagnostic neoplasm staging|t060
  c1279889|deterioration of status|t080
fit
  2
  c0036572|seizures|t184
  c0424576|fit and well|t033
planned radiotherapy
  3
  c1301732|planned (qualifier value)|t169
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
sutures
  1
  c0038969|surgical sutures|t074
irinotecan groups
  2
  c0123931|irinotecan|t109
  c0441833|groups (qualifier value)|t170
metachronous relapse
  3
  c0205336|relapsing course|t079
  c0580802|relapse phase|t079
  c0035020|relapse|t067
immunomodulatory effects
  2
  c1280500|effect (qualifier value)|t080
  c0001551|adjuvants, immunologic|t129
capillary lymphatic space involvement
  5
  c1280521|entire capillary blood vessel (organ)|t023
  c0935624|capillary, unspecified|t023
  c0746333|lymphatic involvement|t033
  c0006901|blood capillaries|t023
  c0221874|spacer (physical object)|t074
radiation effects
  2
  c0034526|aspects of radiation effects|t170
  c0034525|effects of radiation|t067
time
  1
  c0040223|time|t079
repetitive dose treatments
  2
  c0178602|dosages (qualifier value)|t081
  c0420265|repeat treatment nos (context-dependent category)|t033
mo
  1
  c0026402|molybdenum|t123
results
  1
  c1274040|result (navigational concept)|t169
mean administered doses
  4
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
  c0444504|mean (qualifier value)|t081
  c0719635|dos|t109
higher frequency
  1
  c0205212|high frequency (qualifier value)|t079
30-day postoperative mortality rate
  2
  c0439228|day (qualifier value)|t079
  c0026565|mortality vital statistics|t081
immediate postoperative intraportal infusion
  2
  c0574032|infusion (procedure)|t061
  c0205253|immediate (qualifier value)|t079
interstitial pneumonitis requiring corticosteroids
  2
  c0001617|adrenal cortex hormones|t125
  c0206061|pneumonitis, interstitial|t047
uncontrolled infectious process
  2
  c0745283|infectious process|t047
  c0205318|uncontrolled (qualifier value)|t080
only substantial improvement
  3
  c0184511|improved (qualifier value)|t080
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
humanized antibodies
  2
  c0813154|antibodies, in vitro diagnostic|t130
  c0003241|antibodies|t116
sufficient number
  2
  c0205410|sufficient (qualifier value)|t080
  c0449788|count of entities (property) (qualifier value)|t081
three courses
  2
  c0750729|courses (qualifier value)|t079
  c0205449|three (qualifier value)|t081
m2 iv
  5
  c0442123|intravascular (qualifier value)|t082
  c0442122|intravaginal (qualifier value)|t082
  c0348016|intravenous|t082
  c0442106|intervertebral (qualifier value)|t029
  c0205281|invasive (qualifier value)|t080
location
  1
  c0450429|location (attribute)|t082
biologically similar dose
  3
  c0205460|biologic (qualifier value)|t169
  c0871364|simile|t170
  c0178602|dosages (qualifier value)|t081
poor medical condition
  4
  c0205476|medical (qualifier value)|t169
  c0542537|poor - grade value|t080
  c0348080|condition (attribute)|t080
  c0699761|financially poor|t080
most unique toxicity
  3
  c0205393|most (qualifier value)|t081
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
secondary analysis
  4
  c0002778|analysis of substances|t059
  c0036525|metastatic to|t169
  c0175668|secondary to|t079
  c0936012|analysis|t062
general health
  1
  c0552464|general health|t032
study
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
suspicious radiographic findings
  3
  c0750493|suspicious|t078
  c0444708|radiographic (qualifier value)|t070
  c0243095|findings|t169
cox proportional hazards model
  1
  c0010235|cox proportional hazards models|t170
risk ratio
  1
  c0028873|odds ratio|t081
figo stage iib disease
  4
  c0457160|stage 2 lower case bee|t185
  c0441769|stage 2 upper case bee|t185
  c0450454|figo stage (attribute)|t170
  c0012634|disease|t047
histologically proven adenocarcinoma
  4
  c0205462|histologic|t169
  c0456369|proven findings|t080
  c0700164|proven venom|t123
  c0001418|adenocarcinoma|t191
admission
  1
  c0809949|admission|t058
result
  1
  c1274040|result (navigational concept)|t169
fixed tumours
  2
  c0443218|fixed (qualifier value)|t080
  c0027651|neoplasms|t191
clinical evaluation
  3
  c0205210|clinical (qualifier value)|t080
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
tumor diameter to
  2
  c0332517|diameter (qualifier value)|t032
  c0027651|neoplasms|t191
possible underdosing
  2
  c0332149|possible|t080
  c1112363|underdose|t037
accounts
  1
  c0000937|accountant nos (occupation)|t097
gastrointestinal effects
  2
  c1280500|effect (qualifier value)|t080
  c0521362|gastrointestinal|t023
fluorouracil significantly
  2
  c0016360|fluorouracil|t114
  c0750502|significant (qualifier value)|t078
tumour progression
  1
  c0178874|neoplasm progression|t191
dose limitation
  1
  c0935905|dose-limiting|t037
present italian co-operative study closed patient accrual
  6
  c0596382|cooperative study|t062
  c0022275|italian language (qualifier value)|t171
  c0030705|patients|t101
  c0587267|closed|t169
  c0677512|closed approach|t082
  c0150312|present|t169
third bleomycin cycle
  3
  c0439596|cyclic (qualifier value)|t079
  c0205437|third (qualifier value)|t081
  c0005740|bleomycin|t116
opposed fields
  5
  c1253942|opposition|t169
  c0331809|fielding|t093
  c0231519|gegenhalten|t184
  c0680238|discord|t054
  c0440042|field's stain|t130
arms
  1
  c0003792|arm|t029
creatinine 1.3 mg
  3
  c0010294|creatinine|t123
  c0024467|magnesium|t123
  c0439210|milligram|t081
age
  1
  c0001779|age (qualifier value)|t079
surgery allowing
  4
  c0683607|allowing|t054
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
obstruction
  1
  c0028778|obstruction|t046
average median relative dose intensity
  7
  c0080103|relative (related person)|t099
  c0205345|relative|t080
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0178602|dosages (qualifier value)|t081
  c0043778|nicaraven|t109
  c0752050|anteroventral thalamic nucleus|t023
hydration
  1
  c0517526|hydration|t033
effect
  1
  c1280500|effect (qualifier value)|t080
ultimate test
  1
  c0392366|tests (qualifier value)|t170
cns toxicity
  3
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0927232|neuraxis|t023
cls involvement
  3
  c0392760|not free of (attribute)|t169
  c0010575|cycloleucine|t116
  c0201952|chloride measurement|t059
activation
  1
  c0879526|activate|t169
clinical characteristics
  1
  c0683325|clinical aspects|t201
introduction
  1
  c1293116|introduction (procedure)|t058
striking difference
  3
  c0038452|strikes, employee|t057
  c0443199|differential (qualifier value)|t080
  c0275626|struck (disorder)|t047
statistical methods
  3
  c0025664|methodology|t170
  c0025663|methods|t170
  c0220917|statistical|t170
peripheral hemogram
  2
  c0200631|complete blood count without differential (procedure)|t059
  c0205100|peripheral (qualifier value)|t082
negative lymph nodes
  2
  c0205160|negative (qualifier value)|t080
  c0024204|lymph nodes|t023
first intestinal anastomosis
  2
  c0192711|anastomosis of intestine nos (procedure)|t061
  c0205435|first (qualifier value)|t081
basic law
  5
  c0178499|base|t120
  c0023150|rules of conduct|t089
  c0597742|basicity|t081
  c0728724|legal system|t089
  c0220866|aspects of laws|t089
schedule
  1
  c0086960|schedules|t170
third
  1
  c0205437|third (qualifier value)|t081
distal recurrences
  2
  c0205108|distal (qualifier value)|t082
  c0034897|recurrence|t067
bleomycin
  1
  c0005740|bleomycin|t116
recurrent disease
  1
  c0277556|recurrent disease (finding)|t047
folic acid
  1
  c0016410|folic acid|t109
chemotherapy only treatment arm
  5
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c0003792|arm|t029
  c0446516|upper arm|t029
probable explanation
  2
  c0332148|probable diagnosis|t080
  c0681841|explanation|t062
kaplan meier survival curves
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0205134|curved (qualifier value)|t082
mean survival time
  1
  c0086595|mean survival time|t081
5-yr results
  2
  c1274040|result (navigational concept)|t169
  c0439234|year (qualifier value)|t079
age group
  2
  c0027362|human age group|t100
  c0596048|age group unspecified|t100
fishers exact test
  3
  c0059927|exact|t122
  c0325045|martes pennanti (organism)|t015
  c0392366|tests (qualifier value)|t170
similar results
  2
  c0871364|simile|t170
  c1274040|result (navigational concept)|t169
meccnu treatment
  3
  c0087111|therapeutic procedure|t061
  c0036637|semustine|t109
  c0039798|therapeutic aspects|t169
20% cr rate
  2
  c0008574|chromium|t123
  c0871208|rating|t062
various vesical complications
  4
  c0205058|vesical|t082
  c1171258|complication aspects|t046
  c0440102|various (substance)|t130
  c0009566|complication|t046
cox model analyses
  3
  c0002778|analysis of substances|t059
  c0010234|cox models|t170
  c0936012|analysis|t062
similar complication
  2
  c0871364|simile|t170
  c0009566|complication|t046
arm edema
  4
  c0013604|edema|t046
  c0333239|edematous|t033
  c0003792|arm|t029
  c0446516|upper arm|t029
percutaneous nephrostomies
  1
  c0027724|nephrostomy, percutaneous|t061
apparent difference
  2
  c0750489|apparent|t078
  c0443199|differential (qualifier value)|t080
apparent increase
  2
  c0442805|increase (qualifier value)|t169
  c0750489|apparent|t078
mechanisms
  1
  c0441712|mechanisms (qualifier value)|t067
resection type
  3
  c0332307|with type (attribute)|t169
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
only patients
  1
  c0030705|patients|t101
reported p values
  2
  c0700287|reporting|t058
  c0879541|p-value|t081
extensive parametrial invasion
  3
  c0227822|parametrium|t023
  c0205231|extensive (qualifier value)|t080
  c1281249|entire parametrium|t023
complete medical history
  3
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
  c0262926|medical history|t033
patient selection
  1
  c0242802|patient selection|t058
slow growing disease
  2
  c0012634|disease|t047
  c0445266|slow grower (qualifier value)|t080
significant advantage
  2
  c0308269|advantage|t131
  c0750502|significant (qualifier value)|t078
arm i post-operative rt
  3
  c0241311|surgery, past|t033
  c0003792|arm|t029
  c0446516|upper arm|t029
pelvic area
  2
  c0030797|pelvis|t029
  c0205146|area (qualifier value)|t082
b
  7
  c0337527|brothers|t099
  c0004927|behavior|t055
  c0004587|bacillus <bacterium>|t007
  c0677505|behaviors and observations relating to behavior|t033
  c1040746|bacilli|t007
  c0150141|bathing|t061
  c0175640|baths (medical device)|t074
performance status score
  2
  c0449820|scores (qualifier value)|t081
  c0935728|performance status|t033
median survival durations
  5
  c0220921|survival aspects|t081
  c0449238|duration|t079
  c0038952|continuance of life|t052
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
distant relapses
  2
  c0443203|distant (qualifier value)|t082
  c0035020|relapse|t067
results also
  1
  c1274040|result (navigational concept)|t169
other considerations
  2
  c0205394|other|t080
  c0518609|consideration|t033
mitolactol
  1
  c0026252|mitolactol|t118
antibody
  1
  c0003241|antibodies|t116
strategies to
  1
  c0679199|strategy|t041
poor end point
  3
  c0542537|poor - grade value|t080
  c0150100|endpoint|t062
  c0699761|financially poor|t080
patient safety
  1
  c1113679|patient safety|t061
well recognised prognostic factor
  2
  c0205170|good (qualifier value)|t080
  c0220901|prognostic|t170
additional three patients
  3
  c0030705|patients|t101
  c0442796|additive (qualifier value)|t080
  c0205449|three (qualifier value)|t081
pelvic failure
  3
  c0680095|personal failure|t055
  c0030797|pelvis|t029
  c0231174|failure (biologic function)|t169
disease-free actuarial 5-year survival
  2
  c0439234|year (qualifier value)|t079
  c0242793|disease-free survival|t081
cardiotoxic potencies
  2
  c0876994|cardiotoxicity|t047
  c0237399|potential|t080
goal
  1
  c0018017|goals|t170
three weeks
  2
  c0205449|three (qualifier value)|t081
  c0439230|week (qualifier value)|t079
dose
  1
  c0178602|dosages (qualifier value)|t081
principal cause
  5
  c0678227|causing (attribute)|t169
  c0015127|causality|t169
  c0401925|teaching principal|t097
  c1314792|etiology|t169
  c0205225|primary|t080
allowance
  1
  c0556660|allowance (administrative concept)|t081
5-fu dose to
  1
  c0366485|fluorouracil:mass:point in time:dose med or substance:quantitative|t201
distinct antitumor effect
  1
  c1280500|effect (qualifier value)|t080
not only marker
  1
  c0005516|biological markers|t080
bleomycin related pulmonary toxicity
  3
  c0445223|related (finding)|t033
  c0919924|pulmonary toxicity|t046
  c0005740|bleomycin|t116
proven high efficacy
  4
  c0456369|proven findings|t080
  c0700164|proven venom|t123
  c0235146|euphoric mood|t041
  c0205250|high|t080
3.8 months
  1
  c0439231|month (qualifier value)|t079
observation times
  5
  c0700325|patient observation|t061
  c0392761|timed (qualifier value)|t169
  c0302523|observation in research|t062
  c0040223|time|t079
  c0449243|timing (attribute)|t079
5-year actuarial survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439234|year (qualifier value)|t079
intermediate dose level
  3
  c0456079|disease classification level|t185
  c0205103|intermediate (qualifier value)|t082
  c0178602|dosages (qualifier value)|t081
histology slides
  5
  c0332246|sliding|t169
  c0019638|histology|t091
  c0205462|histologic|t169
  c0444330|slide (specimen)|t075
  c0344441|histology procedure|t059
confirmed responses
  2
  c0871261|responses|t054
  c0750484|confirmed|t078
year
  1
  c0439234|year (qualifier value)|t079
forty nine
  1
  c0205455|nine (qualifier value)|t081
the netherlands
  1
  c0027778|netherlands|t083
survival analysis methods
  3
  c0038953|survival analysis|t081
  c0025664|methodology|t170
  c0025663|methods|t170
fulminant septicemia
  1
  c0036690|septicemia|t047
figo state
  1
  c1301808|state (environment)|t083
one layer
  2
  c0934502|layer|t023
  c0205447|one (qualifier value)|t081
statistically significant difference
  2
  c0237881|statistical significance|t081
  c0443199|differential (qualifier value)|t080
fifth years
  2
  c0205439|fifth (qualifier value)|t081
  c0439234|year (qualifier value)|t079
glimelius reported evidence
  1
  c0700287|reporting|t058
focus
  1
  c0205234|focal (qualifier value)|t082
additional pretreatment evaluations
  2
  c0442796|additive (qualifier value)|t080
  c0220825|evaluation|t169
median follow-up duration
  4
  c0449238|duration|t079
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0589120|follow-up status (finding)|t169
likely consequence
  1
  c0750504|likely|t078
scarring
  1
  c0036287|scarring|t042
radiotherapy groups
  3
  c0441833|groups (qualifier value)|t170
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
recurrence
  1
  c0034897|recurrence|t067
same postradiation regimen
  2
  c0445247|same (qualifier value)|t080
  c0677937|regimen|t061
continued efforts to
  2
  c0750536|continued|t078
  c0015264|exertion|t040
methodological problems
  3
  c0969625|methodology aspects|t170
  c0025664|methodology|t170
  c0033213|problem (finding)|t033
clinical staging system to
  4
  c0205563|clinical staging (qualifier value)|t079
  c0205210|clinical (qualifier value)|t080
  c0449913|system (attribute)|t169
  c0449394|staging system (attribute)|t170
fistula
  1
  c0016169|fistula|t190
performance status 0.2
  1
  c0935728|performance status|t033
standard pretreatment evaluation
  4
  c1261322|assessment procedure (procedure)|t058
  c0038137|standards characteristics|t170
  c0220825|evaluation|t169
  c0175675|standards of weights and measures|t080
other tests
  2
  c0205394|other|t080
  c0392366|tests (qualifier value)|t170
decrease
  1
  c0547047|decrease (qualifier value)|t081
grade ? neutrophil count
  2
  c0441800|grade|t185
  c0200633|neutrophil count nos (procedure)|t059
median follow-up time
  4
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0589120|follow-up status (finding)|t169
  c0040223|time|t079
fourth treatment
  3
  c0087111|therapeutic procedure|t061
  c0205438|fourth (qualifier value)|t081
  c0039798|therapeutic aspects|t169
locoregional radiation
  1
  c0851346|radiation|t070
also antiidlotype specific t cells
  3
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
  c0039194|t-lymphocytes|t025
vulnerable phase
  4
  c0205390|phase (qualifier value)|t079
  c0021501|injuries|t037
  c0332797|wounded|t169
  c0043250|injury wounds|t037
al
  1
  c0002367|aluminum|t196
predefined dose reduction scheme
  3
  c0301630|reduction (chemical)|t070
  c0178602|dosages (qualifier value)|t081
  c0441610|reduction - action|t061
increased cell proliferation
  2
  c0205217|increased (qualifier value)|t169
  c0596290|cell proliferation|t043
1 2 wk to
  1
  c0439230|week (qualifier value)|t079
other pelvic tissues
  3
  c0205394|other|t080
  c0030797|pelvis|t029
  c0040300|tissues|t024
high-grade spindle cell
  4
  c0007634|cells|t025
  c0205082|severe (severity modifier) (qualifier value)|t080
  c1166795|spindle|t026
  c1269647|entire cell|t025
fractions
  1
  c0457426|fractions of (qualifier value)|t081
chemotherapeutic effect
  4
  c1280500|effect (qualifier value)|t080
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
meta-analysis
  1
  c0920317|meta-analysis|t170
high-risk group
  1
  c0684030|high-risk group|t098
principal toxicity
  4
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0401925|teaching principal|t097
  c0205225|primary|t080
radioactive liver scan
  2
  c0003873|rheumatoid arthritis|t047
  c0203758|radioisotope study of liver (procedure)|t060
concurrent weekly treatment
  4
  c0087111|therapeutic procedure|t061
  c0205420|concurrent (qualifier value)|t079
  c0332174|weekly (qualifier value)|t079
  c0039798|therapeutic aspects|t169
prolonged exposure
  4
  c0274281|effects of exposure to external causes|t037
  c0391838|exposure condition|t169
  c0728853|accident due to exposure to weather conditions|t037
  c0439590|prolonged (qualifier value)|t079
1.2 years
  1
  c0439234|year (qualifier value)|t079
overall incidence
  3
  c0021149|incidence|t081
  c0282416|overall [publication type]|t170
  c0220856|incidence of cases|t169
computed tomography
  1
  c0040405|x-ray computed tomography|t060
previous adjuvant chemotherapy
  2
  c0085533|chemotherapy, adjuvant|t061
  c0205156|previous (qualifier value)|t082
randomised patients
  2
  c0030705|patients|t101
  c0034656|random allocation|t062
additional risk factors
  2
  c0442796|additive (qualifier value)|t080
  c0035648|risk factors|t081
study also
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
removal
  2
  c0728940|surgical removal - action|t169
  c0015252|excision|t061
increased frequency
  2
  c0376249|with frequency|t081
  c0205217|increased (qualifier value)|t169
probability values
  2
  c0042295|valuing|t080
  c0033204|probability|t081
four block stratification
  3
  c0205450|four (qualifier value)|t081
  c0205363|stratified (qualifier value)|t080
  c0028778|obstruction|t046
primary end point
  3
  c0439631|primary operation (qualifier value)|t061
  c0150100|endpoint|t062
  c0205225|primary|t080
high risk factors
  3
  c0235146|euphoric mood|t041
  c0205250|high|t080
  c0035648|risk factors|t081
performance status less
  1
  c0935728|performance status|t033
only one response
  2
  c0871261|responses|t054
  c0205447|one (qualifier value)|t081
renal collecting system
  3
  c0449913|system (attribute)|t169
  c0022646|kidney|t023
  c0180011|collectors|t074
arizona group
  5
  c0036112|salmonella arizonae|t007
  c0003787|arizona|t083
  c0441833|groups (qualifier value)|t170
  c1275677|salmonella enterica subsp. arizonae|t007
  c1300322|group (social concept)|t096
tissue damage
  1
  c0010957|damage (morphologic abnormality)|t169
intracavitary insertions
  3
  c0021107|implantation procedure|t061
  c0441587|clinical act of insertion|t058
  c1298613|intracavitary (qualifier value)|t082
longer gold standards
  2
  c0205166|long (qualifier value)|t080
  c0150110|gold standard|t080
nonprescribed doses
  1
  c0719635|dos|t109
not one new study
  4
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205314|new (qualifier value)|t079
  c0205447|one (qualifier value)|t081
surgery induced impairment
  6
  c0543467|general operative procedures|t061
  c0684336|impaired health|t033
  c0231171|physical impairment|t046
  c0205263|induced (qualifier value)|t169
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
study parameters
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0449381|observation parameter (observable entity)|t033
responses
  1
  c0871261|responses|t054
sufficient numbers to
  2
  c0205410|sufficient (qualifier value)|t080
  c0237753|numbers (qualifier value)|t170
end result reporting
  3
  c0444930|end (qualifier value)|t082
  c0700287|reporting|t058
  c1274040|result (navigational concept)|t169
cause
  2
  c0015127|causality|t169
  c1314792|etiology|t169
stratification
  1
  c0205363|stratified (qualifier value)|t080
follow-up observation
  3
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0589120|follow-up status (finding)|t169
antigen s
  3
  c0457385|seconds|t079
  c0003320|antigens|t129
  c0205436|second (qualifier value)|t081
m mitomycin
  2
  c0026254|mitomycins|t109
  c0002475|mitomycin|t195
iva disease
  2
  c0012634|disease|t047
  c1054142|iva|t002
hyperfractionated irradiation
  4
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
  c0796569|hyperfractionation|t061
standard definitions
  2
  c0038137|standards characteristics|t170
  c0175675|standards of weights and measures|t080
two tail
  2
  c0039259|tail|t023
  c0205448|two (qualifier value)|t081
left ventricular function
  1
  c0080310|ventricular function, left|t042
obtaining written informed consent
  4
  c0043266|writing|t090
  c0021430|informed consent|t058
  c1301820|obtained (attribute)|t169
  c0341628|writer (occupation)|t097
other studies
  3
  c0205394|other|t080
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
percent
  1
  c0439165|percent (qualifier value)|t081
nausea
  1
  c0027497|nausea|t033
mev
  1
  c0556642|mev (qualifier value)|t081
concomitant medications
  1
  c0013227|pharmaceutical preparations|t121
nature
  2
  c0349590|nature|t078
  c1262865|natures|t169
alanine aminotransferase
  1
  c0001899|alanine transaminase|t116
expected survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0679138|expectations (qualifier value)|t041
perirectal fat
  2
  c0424612|obese build|t032
  c0015677|fatty acid glycerol esters|t119
locoregional control
  1
  c0243148|control|t169
less favorable results
  2
  c1274040|result (navigational concept)|t169
  c0309049|favor (product)|t121
higher local tissue concentration
  5
  c0086045|concentration|t041
  c0040300|tissues|t024
  c0205276|local (qualifier value)|t082
  c0235146|euphoric mood|t041
  c0205250|high|t080
survival analysis
  1
  c0038953|survival analysis|t081
progression free survival
  1
  c0242792|progression-free survival|t081
deeply invasive lesions
  2
  c0221198|lesion|t033
  c0205281|invasive (qualifier value)|t080
sufficiently
  1
  c0205410|sufficient (qualifier value)|t080
bun 8.9 mmol
  1
  c0439190|mmol (qualifier value)|t081
similar risk
  2
  c0871364|simile|t170
  c0035647|risk|t080
progress
  1
  c0205329|progressive (qualifier value)|t169
dose limiting toxicity to
  3
  c0040539|toxicity aspects|t081
  c0935905|dose-limiting|t037
  c0600688|toxic effect|t037
5-year survival rate
  2
  c0038954|survival rate|t081
  c0439234|year (qualifier value)|t079
residual tumor
  1
  c0543478|residual tumor|t191
response rate
  2
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
standard formulas
  3
  c0038137|standards characteristics|t170
  c0175675|standards of weights and measures|t080
  c0489829|mathematical formula|t170
confirmatory arm
  3
  c0750568|confirmatory|t078
  c0003792|arm|t029
  c0446516|upper arm|t029
prior surgery
  4
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0750516|prior|t078
  c0038894|surgery specialty|t091
significant delay
  2
  c0205421|deferred (qualifier value)|t079
  c0750502|significant (qualifier value)|t078
actuarial 5-yr rfs
  2
  c0748398|rf|t033
  c0334965|actuary (occupation)|t097
beneficial effect
  1
  c1280500|effect (qualifier value)|t080
about percent
  1
  c0439165|percent (qualifier value)|t081
view
  1
  c0449911|view (attribute)|t032
in vitro data
  1
  c0021135|in vitro|t080
different regimen
  2
  c0443199|differential (qualifier value)|t080
  c0677937|regimen|t061
er
  1
  c0279756|estrogen receptor negative|t034
more rigorous staging
  4
  c0026837|muscle rigidity|t184
  c0332305|with staging (attribute)|t169
  c0205172|more (qualifier value)|t081
  c0424790|rigor - temperature-associated observation|t184
cytologic confirmation
  2
  c0750484|confirmed|t078
  c0205471|cytologic (qualifier value)|t169
1.5 mg
  2
  c0024467|magnesium|t123
  c0439210|milligram|t081
11.3 months v 7.5 months
  6
  c0042306|vanadium|t123
  c0449468|volume (property) (qualifier value)|t081
  c0439830|velocity (property) (qualifier value)|t169
  c0598352|v (voltage)|t081
  c0439502|v - volt (qualifier value)|t081
  c0439231|month (qualifier value)|t079
planning
  1
  c0032074|cognitive function: planning (observable entity)|t041
one hour apart
  2
  c0439227|hour|t079
  c0205447|one (qualifier value)|t081
semustine
  1
  c0036637|semustine|t109
contiguous parametrial tissue
  4
  c0227822|parametrium|t023
  c0040300|tissues|t024
  c0205283|contiguous (qualifier value)|t082
  c1281249|entire parametrium|t023
first event
  2
  c0441471|events (event)|t051
  c0205435|first (qualifier value)|t081
significant improvements
  4
  c0184511|improved (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
escalating 5-fu arm
  3
  c0014829|escalators|t073
  c0003792|arm|t029
  c0446516|upper arm|t029
scheduling
  2
  c0205539|scheduled (qualifier value)|t169
  c0086960|schedules|t170
medical history taking
  1
  c0025084|medical history taking|t060
objective regression rates
  4
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
  c0018017|goals|t170
  c0871208|rating|t062
years v years
  6
  c0042306|vanadium|t123
  c0449468|volume (property) (qualifier value)|t081
  c0439830|velocity (property) (qualifier value)|t169
  c0598352|v (voltage)|t081
  c0439502|v - volt (qualifier value)|t081
  c0439234|year (qualifier value)|t079
radiographic test
  2
  c0444708|radiographic (qualifier value)|t070
  c0392366|tests (qualifier value)|t170
forty eight patients
  2
  c0030705|patients|t101
  c0205454|eight (qualifier value)|t170
estrogen receptor
  1
  c0034804|estrogen receptors|t116
often first site
  3
  c0332183|frequent (qualifier value)|t079
  c0205145|associated topography (attribute)|t082
  c0205435|first (qualifier value)|t081
strategy
  1
  c0679199|strategy|t041
statistically significant differences
  2
  c0237881|statistical significance|t081
  c0443199|differential (qualifier value)|t080
most likely explanation
  2
  c0681841|explanation|t062
  c0750501|most likely|t078
comparative rfs
  1
  c0748398|rf|t033
study groups
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0441833|groups (qualifier value)|t170
supine bicycle exercise
  2
  c0999587|sus|t015
  c0392218|exercisers, bicycle|t074
comparable rfs
  1
  c0748398|rf|t033
objective antitumour activity
  4
  c0600075|endurance of activity|t033
  c0441655|activities|t052
  c0221187|physical activity|t056
  c0018017|goals|t170
estimated reduction
  3
  c0750572|estimated|t078
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
radioisotopes
  1
  c0034595|radioisotopes|t196
42.resected tissue
  2
  c0040300|tissues|t024
  c0015252|excision|t061
figo stage ib
  4
  c0457152|stage 1 lower case bee|t185
  c0456597|stage 1 upper case bee|t185
  c0444976|ib (qualifier value)|t170
  c0450454|figo stage (attribute)|t170
univariate cox model
  1
  c0010234|cox models|t170
beneficial impact
  1
  c0726639|impact|t168
special comment
  3
  c0205555|special (qualifier value)|t080
  c0947611|comment|t170
  c0282411|published comment|t170
good candidates
  1
  c0205170|good (qualifier value)|t080
other chemotherapeutic regiments
  1
  c0478584|[x]other chemotherapy (context-dependent category)|t061
c rectal cancer
  2
  c0007886|cesium|t196
  c0007113|cancer of rectum|t191
ecog performance score
  3
  c0449820|scores (qualifier value)|t081
  c0430797|electrocorticogram (procedure)|t060
  c0597198|performance|t055
foundation bergonie trials,19 used similar patient selection criteria
  2
  c0242801|selection criteria|t080
  c0016617|foundations|t092
worse toxicity
  4
  c0332271|worsening (qualifier value)|t080
  c0040539|toxicity aspects|t081
  c1279889|deterioration of status|t080
  c0600688|toxic effect|t037
patient cohort
  2
  c0599755|cohort|t098
  c0030705|patients|t101
7.1 months
  1
  c0439231|month (qualifier value)|t079
second
  1
  c0205436|second (qualifier value)|t081
anticipated 5% loss
  2
  c0679106|anticipation|t041
  c0745777|lost|t033
continuing
  1
  c0750536|continued|t078
­ 25% response rate
  2
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
anastomosis watertight
  3
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
primary colorectal carcinoma
  3
  c0439631|primary operation (qualifier value)|t061
  c0205225|primary|t080
  c0009403|colorectal carcinoma|t191
loco regional recurrence
  3
  c0275191|astragalus species poisoning (disorder)|t037
  c0034897|recurrence|t067
  c0205147|regional (qualifier value)|t082
persisting more
  3
  c0205322|persistent (qualifier value)|t079
  c0205172|more (qualifier value)|t081
  c0546816|persistence (finding)|t041
munne monoclonal mmunoglobulin igg2a antibody
  2
  c0003250|antibodies, monoclonal|t129
  c0020857|igg2a|t116
not received antibodies
  3
  c0544683|reception|t042
  c0813154|antibodies, in vitro diagnostic|t130
  c0003241|antibodies|t116
first line treatment
  5
  c0205132|linear|t082
  c0087111|therapeutic procedure|t061
  c0700221|intravascular line|t074
  c0039798|therapeutic aspects|t169
  c0205435|first (qualifier value)|t081
eligible patients
  1
  c0030705|patients|t101
case
  1
  c0868928|case (qualifier value)|t169
iia disease
  1
  c0012634|disease|t047
one tail test
  3
  c0392366|tests (qualifier value)|t170
  c0039259|tail|t023
  c0205447|one (qualifier value)|t081
severe diarrhoea
  2
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0011991|diarrhea|t184
detailed gog clinical pathologic study
  2
  c0205469|pathological aspects|t169
  c0008972|clinical research|t062
common result
  2
  c1274040|result (navigational concept)|t169
  c0205214|common (qualifier value)|t081
logistic regression model
  5
  c0026336|models|t170
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
  c0206031|logistic regression|t062
  c0023965|logistic models|t170
median weekly dose
  4
  c0332174|weekly (qualifier value)|t079
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0178602|dosages (qualifier value)|t081
overall stage ib mortality
  5
  c0282416|overall [publication type]|t170
  c0457152|stage 1 lower case bee|t185
  c0456597|stage 1 upper case bee|t185
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
dose level
  2
  c0456079|disease classification level|t185
  c0178602|dosages (qualifier value)|t081
one meta-analysis
  2
  c0920317|meta-analysis|t170
  c0205447|one (qualifier value)|t081
kidney function
  1
  c0232804|renal function, nos|t042
histologically proven metastatic colorectal cancer
  4
  c0205462|histologic|t169
  c0456369|proven findings|t080
  c0700164|proven venom|t123
  c0948380|colorectal cancer metastatic|t191
previous malignant disease
  2
  c0442867|malignant disease|t047
  c0205156|previous (qualifier value)|t082
morphologic cardiac abnormalities
  2
  c0332447|morphologically abnormal structure (morphologic abnormality)|t190
  c0205041|cardio-|t082
altered regimen
  2
  c0205349|altered (qualifier value)|t169
  c0677937|regimen|t061
permanent decrease
  2
  c0547047|decrease (qualifier value)|t081
  c0205355|permanent (qualifier value)|t079
yr
  1
  c0439234|year (qualifier value)|t079
now sufficient evidence to
  1
  c0205410|sufficient (qualifier value)|t080
liquid diet
  1
  c0301571|liquid diet (finding)|t033
abscess
  1
  c0000833|abscess|t046
tumor characteristics
  1
  c0027651|neoplasms|t191
relatively good cardiac tolerance
  4
  c0205170|good (qualifier value)|t080
  c0231197|physiologic tolerance|t039
  c0220929|mental tolerance|t041
  c0205041|cardio-|t082
patient also
  1
  c0030705|patients|t101
drugs three weeks
  3
  c0013227|pharmaceutical preparations|t121
  c0205449|three (qualifier value)|t081
  c0439230|week (qualifier value)|t079
platelet count less
  2
  c0032181|platelet count|t059
  c1287267|finding of platelet count (finding)|t034
treatment more
  3
  c0205172|more (qualifier value)|t081
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
three controlled trials
  2
  c0702113|controlled (qualifier value)|t169
  c0205449|three (qualifier value)|t081
topoisomerase i inhibitor
  1
  c0598317|topoisomerase inhibitor (substance)|t121
extraperitoneal staging laparotomy
  2
  c0442090|extraperitoneal (qualifier value)|t082
  c0843591|staging laparotomy|t060
eligible patient
  1
  c0030705|patients|t101
local therapy
  1
  c0677903|local therapy|t061
cervical cancer
  1
  c0007847|malignant neoplasm of cervix uteri|t191
standard
  2
  c0038137|standards characteristics|t170
  c0175675|standards of weights and measures|t080
high-dose fluorouracil
  2
  c0016360|fluorouracil|t114
  c0444956|high dose (qualifier value)|t081
tumor recurrence rate
  3
  c0027651|neoplasms|t191
  c0034897|recurrence|t067
  c0871208|rating|t062
excess
  2
  c0750570|excessively|t078
  c0442802|excessive (qualifier value)|t080
start
  1
  c0452588|start (substance)|t168
more positive nodes
  3
  c0205172|more (qualifier value)|t081
  c0746922|node|t023
  c0205159|positive (qualifier value)|t080
20% protraction
  1
  c0491912|protractor|t074
response
  1
  c0871261|responses|t054
slightly higher doses
  2
  c0444956|high dose (qualifier value)|t081
  c0750482|slightly|t078
ribonucleotide reductase
  1
  c0035547|ribonucleotide reductase|t116
p 0.13),a nonsignificant trend
  5
  c0518611|poise|t033
  c0031603|inorganic phosphate|t197
  c0947648|phosphorus preparation|t121
  c0031705|phosphorus|t196
  c0040833|trends|t079
observed major therapeutic response rate
  8
  c0237629|frequency of responses|t079
  c0700325|patient observation|t061
  c0878525|cancer treatment response rate|t079
  c0205164|major (qualifier value)|t080
  c0302523|observation in research|t062
  c0039796|the science and art of healing|t061
  c0302350|therapeutic|t169
  c0870992|observers|t097
variables
  1
  c0439828|variable (qualifier value)|t080
curative operations
  1
  c0038895|surgical aspects|t169
15% difference
  1
  c0443199|differential (qualifier value)|t080
merely less potent anthracycline
  3
  c0282564|anthracyclines|t109
  c0003234|anthracycline antibiotics|t195
  c0237399|potential|t080
deaths
  1
  c0011065|cessation of life|t040
precise mucosal approximation
  2
  c0332232|approximate (qualifier value)|t169
  c0026724|mucous membrane|t024
increased survival times
  6
  c0220921|survival aspects|t081
  c0392761|timed (qualifier value)|t169
  c0038952|continuance of life|t052
  c0205217|increased (qualifier value)|t169
  c0040223|time|t079
  c0449243|timing (attribute)|t079
bone scan
  1
  c0203668|radioisotope scan of bone (procedure)|t060
stable lvef
  1
  c0205360|stable (qualifier value)|t080
third cycle
  2
  c0439596|cyclic (qualifier value)|t079
  c0205437|third (qualifier value)|t081
lymph node metastasis
  1
  c0686619|secondary malignant neoplasm of lymph node (disorder)|t191
single agent
  4
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0450442|agent (attribute)|t120
  c0087136|unmarried|t098
topoisomerase i
  1
  c0012920|dna topoisomerase|t116
alternating delivery
  4
  c0332270|alternating (qualifier value)|t169
  c0011209|obstetric delivery|t061
  c1135594|delivery|t061
  c0559563|delivery finding (finding)|t033
required modifications
  1
  c0205349|altered (qualifier value)|t169
four nonevaluable patients
  2
  c0205450|four (qualifier value)|t081
  c0030705|patients|t101
metastatic lesion
  2
  c0036525|metastatic to|t169
  c0221198|lesion|t033
radiation sensitization
  1
  c0034541|radiation-sensitizing agents|t121
insufficient power to
  2
  c0231180|insufficient|t169
  c0032863|power (psychology)|t068
dosimetry calculations
  2
  c0444686|calculated (qualifier value)|t169
  c0599911|dosimetry|t081
classes
  1
  c0441884|classes (qualifier value)|t170
supportive care included antibiotics
  3
  c0344211|supportive care|t058
  c0332257|including (qualifier value)|t169
  c0003232|antibiotics|t195
poor prognostic factors
  1
  c0278252|prognosis bad (finding)|t033
calcium folinate significantly increased response rates
  5
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0205217|increased (qualifier value)|t169
  c0731033|leucovorin calcium|t109
  c0750502|significant (qualifier value)|t078
combination regimen
  2
  c0677937|regimen|t061
  c0205195|combined (qualifier value)|t080
c
  1
  c0007886|cesium|t196
conservative surgery
  4
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0009800|conservatism|t078
  c0038894|surgery specialty|t091
day administration
  3
  c0439228|day (qualifier value)|t079
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
ten patients
  2
  c0030705|patients|t101
  c0205456|ten (qualifier value)|t081
pretreatment gynecologic examination
  1
  c0200044|gynecological examination|t060
cancellation
  1
  c0205544|cancelled (qualifier value)|t080
shorter costs
  2
  c0010186|financial cost|t081
  c0205167|short (qualifier value)|t079
nine patients
  2
  c0030705|patients|t101
  c0205455|nine (qualifier value)|t081
single distant events
  2
  c0585347|single event (qualifier value)|t079
  c0443203|distant (qualifier value)|t082
radiation protocol
  2
  c0442711|protocols documentation|t170
  c0851346|radiation|t070
other reasons
  2
  c0205394|other|t080
  c0684328|reasoning|t041
stomach
  2
  c1278920|entire stomach|t017
  c0038351|stomach|t023
risk factor
  1
  c0035648|risk factors|t081
previously described pattern
  2
  c0449774|patterns (qualifier value)|t082
  c0205156|previous (qualifier value)|t082
endpoints
  1
  c0150100|endpoint|t062
patient age
  2
  c0001779|age (qualifier value)|t079
  c0030705|patients|t101
drugs
  1
  c0013227|pharmaceutical preparations|t121
diffuse peritonitis
  2
  c0205219|diffuse (qualifier value)|t080
  c0031154|peritonitis|t047
only isolated vaginal vault recurrences
  5
  c0227794|vaginal fornix|t029
  c0549115|structure of vaginal vault|t023
  c0205409|isolated (qualifier value)|t169
  c0034897|recurrence|t067
  c1280346|entire vaginal vault|t023
6% increase
  1
  c0442805|increase (qualifier value)|t169
median total treatment time
  6
  c0439810|total (qualifier value)|t080
  c0087111|therapeutic procedure|t061
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0039798|therapeutic aspects|t169
  c0040223|time|t079
failures
  2
  c0680095|personal failure|t055
  c0231174|failure (biologic function)|t169
colorectal carcinoma
  1
  c0009403|colorectal carcinoma|t191
life table estimates
  1
  c0023680|life table estimates|t170
posterior midline attenuator
  3
  c0205095|dorsal|t082
  c0549183|median (qualifier value)|t082
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
optimal treatment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
five treatments
  2
  c0205451|five (qualifier value)|t081
  c0087111|therapeutic procedure|t061
highest dose intensity ever
  1
  c0444956|high dose (qualifier value)|t081
paraortic nodes
  1
  c0746922|node|t023
consistent reduction
  3
  c0332290|consistent with (qualifier value)|t078
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
19% reduction
  2
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
tumor markers
  2
  c1139415|reagents, tumor markers|t130
  c0041365|tumor markers|t123
more severe nausea
  3
  c0205172|more (qualifier value)|t081
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0027497|nausea|t033
ischemic continuous anastomosis
  5
  c0549178|continuous (qualifier value)|t079
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
  c0475224|ischemic|t169
surgical stress
  3
  c0723460|stress bismuth subsalicylate|t109
  c0038895|surgical aspects|t169
  c0038435|stress|t033
concomitant administration
  2
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
significantly longer survival
  4
  c0205166|long (qualifier value)|t080
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0750502|significant (qualifier value)|t078
treatment results
  3
  c1274040|result (navigational concept)|t169
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
south america
  1
  c0037713|south america|t083
one irinotecan
  2
  c0123931|irinotecan|t109
  c0205447|one (qualifier value)|t081
support
  3
  c0344211|supportive care|t058
  c1317973|support|t032
  c0183683|support, device|t074
pathologists
  1
  c0334866|medical pathologist (occupation)|t097
original hypothesis
  1
  c0205313|original (qualifier value)|t078
adriamycin
  1
  c0085752|adriamycin|t195
mean age
  2
  c0001779|age (qualifier value)|t079
  c0444504|mean (qualifier value)|t081
further gy
  1
  c0556636|gy (qualifier value)|t081
informed consents
  1
  c0021430|informed consent|t058
exclusion
  1
  c0680251|exclusion|t169
own findings
  1
  c0243095|findings|t169
10 12 months
  1
  c0439231|month (qualifier value)|t079
first uk medical research council
  2
  c0079816|medical research|t062
  c0205435|first (qualifier value)|t081
transient paraplegia
  3
  c0205374|transitory|t079
  c0040704|transient population group|t098
  c0030486|paraplegia|t047
25% increase
  1
  c0442805|increase (qualifier value)|t169
multivariate cox regression
  4
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
  c0033551|prostaglandin-endoperoxide synthase|t116
  c0442996|cox microbiology subtype|t170
extensive parametrial extension
  4
  c0227822|parametrium|t023
  c0231448|extension (qualifier value)|t042
  c0205231|extensive (qualifier value)|t080
  c1281249|entire parametrium|t023
anastomosis
  3
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
pelvic irradiation
  4
  c1282930|irradiation (physical force)|t070
  c0030797|pelvis|t029
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
yearly clinical examinations
  2
  c0332181|annual (qualifier value)|t079
  c0031809|clinical examination|t058
drug administration
  1
  c0150270|procedure related to management of drug administration (procedure)|t061
retrospective study
  1
  c0035363|retrospective studies|t081
symptoms
  1
  c0683368|symptoms|t169
56.2 years
  1
  c0439234|year (qualifier value)|t079
extended field radiation
  3
  c0851346|radiation|t070
  c0231449|extended (qualifier value)|t082
  c0440042|field's stain|t130
patient’s health
  1
  c0018684|health|t078
stable disease
  1
  c0677946|stable disease|t191
hydroureteronephrosis
  1
  c0268804|hydroureteronephrosis (disorder)|t047
patients selection
  1
  c0242802|patient selection|t058
cox partial likelihood score statistic
  6
  c0038215|science of statistics|t090
  c0449820|scores (qualifier value)|t081
  c0033551|prostaglandin-endoperoxide synthase|t116
  c0750504|likely|t078
  c0728938|partial (qualifier value)|t081
  c0442996|cox microbiology subtype|t170
4.4 group
  2
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
acceptably low morbidity
  4
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0205251|low (qualifier value)|t080
  c1272684|accepted (qualifier value)|t080
also assessed quality
  2
  c1261322|assessment procedure (procedure)|t058
  c0332306|with quality (attribute)|t080
apparently curative resections
  3
  c0750541|apparently|t078
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
first evidence
  1
  c0205435|first (qualifier value)|t081
valid statistical analyses
  1
  c0871424|statistical analysis|t062
interim testing
  1
  c0039593|testing|t062
rfs
  1
  c0748398|rf|t033
other randomized phase ii trials
  2
  c0205394|other|t080
  c0205390|phase (qualifier value)|t079
al also
  1
  c0002367|aluminum|t196
events
  1
  c0441471|events (event)|t051
custom shielding
  2
  c0162343|customs|t078
  c0183251|shield, device (physical object)|t074
c w.
  4
  c0007886|cesium|t196
  c0332797|wounded|t169
  c0004093|asthenia|t184
  c0206275|widowhood|t099
pain
  1
  c0030193|pain|t184
omentum
  1
  c0028977|omentum|t023
several other comparisons
  2
  c0205394|other|t080
  c0443302|several (qualifier value)|t081
combined sometimes
  1
  c0205195|combined (qualifier value)|t080
grade mucositis
  2
  c0441800|grade|t185
  c0236177|inflammatory disease of mucous membrane (disorder)|t046
multivanate analyses
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
certain antineoplastic agents
  2
  c0205423|certainty (attribute)|t080
  c0003392|antineoplastic agents|t121
otherwise operable rectal cancer
  2
  c0205188|operable (qualifier value)|t080
  c0007113|cancer of rectum|t191
tumor related prognostic factors
  3
  c0445223|related (finding)|t033
  c0220901|prognostic|t170
  c0027651|neoplasms|t191
s
  2
  c0457385|seconds|t079
  c0205436|second (qualifier value)|t081
vagina
  2
  c1278985|entire vagina|t023
  c0042232|vagina|t023
fluorouracil mg
  3
  c0016360|fluorouracil|t114
  c0024467|magnesium|t123
  c0439210|milligram|t081
significant prognostic factors
  2
  c0220901|prognostic|t170
  c0750502|significant (qualifier value)|t078
pelvic node dissection
  5
  c1293093|dissection procedure (procedure)|t061
  c1306808|dissection - action (qualifier value)|t169
  c0030797|pelvis|t029
  c0746922|node|t023
  c0012737|dissection|t059
intensified adjuvant chemotherapy
  1
  c0085533|chemotherapy, adjuvant|t061
chest x-rays
  1
  c0202783|radiographic procedure on chest (procedure)|t060
pilot
  1
  c0473169|pilot - aircraft (occupation)|t097
high dose
  1
  c0444956|high dose (qualifier value)|t081
weight loss
  1
  c0043096|weight loss|t184
salvage surgery
  5
  c0864553|salvage|t061
  c0543467|general operative procedures|t061
  c0442967|salvage procedure (qualifier value)|t169
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
two groups
  2
  c0441833|groups (qualifier value)|t170
  c0205448|two (qualifier value)|t081
cumulative cardiotoxicity data
  1
  c0876994|cardiotoxicity|t047
two
  1
  c0205448|two (qualifier value)|t081
prolonged administration unnecessary
  3
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
  c0439590|prolonged (qualifier value)|t079
lymph-vascular space involvement
  2
  c0392760|not free of (attribute)|t169
  c0024202|lymph|t031
pn
  1
  c0206417|peripheral nervous system|t022
question soon
  1
  c0876928|questioning|t041
early cholinergic syndrome
  2
  c0205085|early (qualifier value)|t079
  c0274702|poisoning by parasympathomimetic drug (disorder)|t037
second cycle
  2
  c0439596|cyclic (qualifier value)|t079
  c0205436|second (qualifier value)|t081
recurrent cervical cancer
  1
  c0278579|cervix carcinoma recurrent|t191
ct rt
  1
  c0040405|x-ray computed tomography|t060
significant survival improvement
  6
  c0184511|improved (qualifier value)|t080
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0750502|significant (qualifier value)|t078
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
differential effect
  2
  c1280500|effect (qualifier value)|t080
  c0443199|differential (qualifier value)|t080
substantial survival improvement
  5
  c0184511|improved (qualifier value)|t080
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
urological complications
  3
  c1171258|complication aspects|t046
  c0042077|urology|t091
  c0009566|complication|t046
expected 5-year survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0679138|expectations (qualifier value)|t041
premenopausal women
  3
  c0043209|human females|t098
  c0043210|human adult females|t098
  c0279752|premenopausal|t079
vulnerability
  3
  c0021501|injuries|t037
  c0332797|wounded|t169
  c0043250|injury wounds|t037
further analyses
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
transient hypotension
  3
  c0205374|transitory|t079
  c0020649|hypotension|t033
  c0040704|transient population group|t098
prognostic factors
  1
  c0220901|prognostic|t170
present study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0150312|present|t169
best response
  3
  c0205170|good (qualifier value)|t080
  c0871261|responses|t054
  c0332272|better (qualifier value)|t080
paraaortic areas
  1
  c0205146|area (qualifier value)|t082
asthenia
  1
  c0004093|asthenia|t184
delayed week
  2
  c0205421|deferred (qualifier value)|t079
  c0439230|week (qualifier value)|t079
years
  1
  c0439234|year (qualifier value)|t079
radiation therapy
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
ct rt groups
  2
  c0441833|groups (qualifier value)|t170
  c0040405|x-ray computed tomography|t060
control groups
  1
  c0009932|control groups|t096
tumor cells
  1
  c0431085|[m]unspecified tumor cell nos (morphologic abnormality)|t191
blood supply
  3
  c0005839|blood supply aspects|t042
  c0920762|vascular blood supply|t042
  c0678861|arterial blood supply|t039
ast
  1
  c0004002|aspartate transaminase|t116
study’s target sample size
  2
  c0599894|targeting|t043
  c0242618|sample size|t081
many combinations
  2
  c0439064|numerous (qualifier value)|t081
  c0453882|combinations (physical object)|t073
broad spectrum
  1
  c0332464|widened structure (morphologic abnormality)|t082
treatment comparisons
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
sensitive enzyme linked mmunoadsorbent assay
  2
  c0243073|assay|t059
  c0332324|sensitive (qualifier value)|t169
creatinine
  1
  c0010294|creatinine|t123
follow-up visit
  1
  c0589121|follow-up visit (procedure)|t058
pelvic control
  1
  c0561970|ability to control pelvic posture (observable entity)|t033
more level i
  2
  c0441925|level i (tumor staging)|t170
  c0205172|more (qualifier value)|t081
most important clinical risk factors
  2
  c0205393|most (qualifier value)|t081
  c0035648|risk factors|t081
nutritional status to
  1
  c0392209|nutritional status|t032
literature
  1
  c0023866|literature|t170
adjuvant trials
  1
  c0278788|adjuvant study|t062
obesity
  1
  c0028754|obesity|t047
meaningful response duration
  3
  c0237585|response duration|t079
  c0876919|meaning|t078
  c0870867|meaningfulness|t080
progressive disease
  1
  c0677932|progressive disease|t191
renal function tests
  1
  c0022662|kidney function tests|t059
improved progression free survival
  2
  c0184511|improved (qualifier value)|t080
  c0242792|progression-free survival|t081
distant s
  3
  c0443203|distant (qualifier value)|t082
  c0457385|seconds|t079
  c0205436|second (qualifier value)|t081
intraportal injection
  2
  c0021485|injections|t061
  c1272883|injection (product)|t073
randomised treatment allocation
  3
  c0087111|therapeutic procedure|t061
  c0034656|random allocation|t062
  c0039798|therapeutic aspects|t169
survival outcome
  2
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
late treatment-related fatalities
  5
  c0205087|late (qualifier value)|t079
  c1302234|fatal (qualifier value)|t080
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
pelvic relapses
  2
  c0030797|pelvis|t029
  c0035020|relapse|t067
daily
  1
  c0332173|daily (qualifier value)|t079
greece
  1
  c0018226|greece|t083
mean platelet count
  3
  c0444504|mean (qualifier value)|t081
  c0032181|platelet count|t059
  c1287267|finding of platelet count (finding)|t034
chest radiogram
  1
  c0202783|radiographic procedure on chest (procedure)|t060
investigating
  1
  c1292732|investigates (attribute)|t169
principal adverse effect
  3
  c0879626|adverse effect|t037
  c0401925|teaching principal|t097
  c0205225|primary|t080
three week epi
  5
  c0221908|epithelial|t169
  c0014609|epithelium|t024
  c0014544|epilepsy|t047
  c0205449|three (qualifier value)|t081
  c0439230|week (qualifier value)|t079
preoperative neoadjuvant chemotherapy
  4
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c0445204|preoperative (qualifier value)|t032
haemoglobin
  1
  c0019046|hemoglobin|t116
diameter cm v cm
  7
  c0332517|diameter (qualifier value)|t032
  c0042306|vanadium|t123
  c0449468|volume (property) (qualifier value)|t081
  c0439830|velocity (property) (qualifier value)|t169
  c0598352|v (voltage)|t081
  c0439502|v - volt (qualifier value)|t081
  c0475210|cm (qualifier value)|t081
follow-up
  1
  c0589120|follow-up status (finding)|t169
patient related factors
  2
  c0445223|related (finding)|t033
  c0030705|patients|t101
63,and years
  1
  c0439234|year (qualifier value)|t079
major goal
  2
  c0205164|major (qualifier value)|t080
  c0018017|goals|t170
rnca abnormalities
  2
  c0000769|teratologic|t169
  c0000768|congenital abnormality|t019
guidelines
  2
  c0220845|guiding characteristics|t170
  c0162791|guidelines|t170
selected patients
  2
  c0036576|selection (genetics)|t045
  c0030705|patients|t101
5-fu infusion
  2
  c0574032|infusion (procedure)|t061
  c0016360|fluorouracil|t114
surgery alone group
  6
  c0543467|general operative procedures|t061
  c0441833|groups (qualifier value)|t170
  c0038895|surgical aspects|t169
  c0679994|alone|t102
  c0038894|surgery specialty|t091
  c1300322|group (social concept)|t096
noncompliant patients
  2
  c0030705|patients|t101
  c0376405|patient noncompliance|t055
aserum creatinine concentration
  2
  c0086045|concentration|t041
  c0010294|creatinine|t123
angina pectoris
  1
  c0002962|angina pectoris|t047
pelvic field
  2
  c0030797|pelvis|t029
  c0440042|field's stain|t130
weekly intravenous infusions
  2
  c0332174|weekly (qualifier value)|t079
  c0021440|infusions, intravenous|t061
25% planned level
  1
  c0441890|planned level (qualifier value)|t080
follow-up evaluations
  2
  c0220825|evaluation|t169
  c0589120|follow-up status (finding)|t169
recent major surgery
  2
  c0679637|major surgery|t061
  c0332185|recent episode (qualifier value)|t079
serum creatinine levels
  1
  c0600061|serum creatinine level|t034
quality control
  1
  c0034378|quality control|t057
escalating single agent 5-fu regimen
  2
  c0014829|escalators|t073
  c0677937|regimen|t061
6 24 days
  2
  c0439228|day (qualifier value)|t079
  c1271041|other regular care provider|t097
recurrence free interval
  3
  c0016694|freedom|t078
  c1272706|interval (qualifier value)|t079
  c0034897|recurrence|t067
combined treatment
  1
  c0009429|combined modality therapy|t061
initiation
  2
  c0678321|aod use initiation|t079
  c0589507|cognitive function: initiation|t041
quantitative data
  1
  c0392762|quantitative (qualifier value)|t081
radiosensitization
  1
  c0279024|radiosensitization|t061
stage
  2
  c0684248|stage of surgical procedure|t079
  c0027646|diagnostic neoplasm staging|t060
surgery
  3
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
sometimes larger numbers
  2
  c0443228|greater (qualifier value)|t081
  c0237753|numbers (qualifier value)|t170
external beam fields
  3
  c0205101|external (qualifier value)|t082
  c0331809|fielding|t093
  c0440042|field's stain|t130
new york
  1
  c0027976|new york|t083
significant differences
  2
  c0443199|differential (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
dna replication step
  2
  c0012902|dna replication|t045
  c1261552|step (qualifier value)|t169
liver metastases
  1
  c0494165|secondary malignant neoplasm of liver (disorder)|t191
month to
  1
  c0439231|month (qualifier value)|t079
two doses
  2
  c0719635|dos|t109
  c0205448|two (qualifier value)|t081
necropsy
  1
  c0004398|autopsy|t060
relapses
  1
  c0035020|relapse|t067
disease-free survival results
  2
  c1274040|result (navigational concept)|t169
  c0242793|disease-free survival|t081
urinalysis
  1
  c0042014|urinalysis|t059
chosen threshold
  2
  c0449864|threshold (property) (qualifier value)|t169
  c0812351|choosing|t041
5-year survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439234|year (qualifier value)|t079
simulation films
  2
  c0679083|simulation|t062
  c0086296|films|t073
cox proportional hazards
  4
  c0598697|hazard|t080
  c0205351|proportional (qualifier value)|t080
  c0033551|prostaglandin-endoperoxide synthase|t116
  c0442996|cox microbiology subtype|t170
first mention
  1
  c0205435|first (qualifier value)|t081
proportional hazards procedures
  4
  c0598697|hazard|t080
  c0025664|methodology|t170
  c0205351|proportional (qualifier value)|t080
  c0184661|procedures|t058
also regimen
  1
  c0677937|regimen|t061
tumoricidal effects
  1
  c1280500|effect (qualifier value)|t080
little change
  3
  c0392747|changing|t169
  c0700321|small|t080
  c0443172|changed status|t081
adequate performance
  2
  c0597198|performance|t055
  c0205411|adequate (qualifier value)|t080
major response rates
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0205164|major (qualifier value)|t080
plt
  1
  c0201617|primed lymphocyte test (procedure)|t059
sd
  1
  c0332147|suspected diagnosis (contextual qualifier) (qualifier value)|t080
increased late toxicity particularly
  4
  c0205087|late (qualifier value)|t079
  c0040539|toxicity aspects|t081
  c0205217|increased (qualifier value)|t169
  c0600688|toxic effect|t037
other traditional risk factors
  3
  c0443324|traditional (qualifier value)|t169
  c0205394|other|t080
  c0035648|risk factors|t081
cisplatin based chemotherapy
  5
  c0178499|base|t120
  c0008838|cisplatin|t197
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
4 cm
  1
  c0475210|cm (qualifier value)|t081
fatigue
  1
  c0015672|fatigue|t184
advantage
  1
  c0308269|advantage|t131
institutions
  1
  c1272753|institution (social concept)|t078
interrupted anastomosis
  4
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
  c0443239|interrupted (qualifier value)|t080
ninety nine patients
  2
  c0030705|patients|t101
  c0205455|nine (qualifier value)|t081
treatment induced parametrial fibrosis
  4
  c0087111|therapeutic procedure|t061
  c0404483|parametrial fibrosis (disorder)|t047
  c0205263|induced (qualifier value)|t169
  c0039798|therapeutic aspects|t169
hydroxyurea
  1
  c0020402|hydroxyurea|t109
not eligible previous treatment
  3
  c0087111|therapeutic procedure|t061
  c0205156|previous (qualifier value)|t082
  c0039798|therapeutic aspects|t169
estimated power
  2
  c0750572|estimated|t078
  c0032863|power (psychology)|t068
stress incontinence
  1
  c0042025|urinary incontinence, stress|t047
most frequent cancer
  5
  c0998265|cancer genus|t009
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0205393|most (qualifier value)|t081
  c0006826|malignant neoplasms|t191
  c0332183|frequent (qualifier value)|t079
disease-free survival time
  2
  c0040223|time|t079
  c0242793|disease-free survival|t081
progress reports
  1
  c0242586|progress report|t170
pneumonia days after treatment initiation
  5
  c0439228|day (qualifier value)|t079
  c0001758|aftercare|t058
  c0032285|pneumonia|t047
  c0678321|aod use initiation|t079
  c0589507|cognitive function: initiation|t041
crude incidence
  2
  c0021149|incidence|t081
  c0220856|incidence of cases|t169
five year disease-free survival rates
  4
  c0205451|five (qualifier value)|t081
  c0439234|year (qualifier value)|t079
  c0871208|rating|t062
  c0242793|disease-free survival|t081
positioning
  2
  c0150305|positioning - therapy|t061
  c0733755|positioning attribute|t082
biochemical tests
  1
  c0430027|biochemical test (procedure)|t059
five function scales
  6
  c0205451|five (qualifier value)|t081
  c0542341|function|t169
  c0175659|weight measurement scales|t073
  c0222045|integumentary scale|t023
  c0700205|function axis|t185
  c0031843|physiological aspects|t039
apparent effect
  2
  c1280500|effect (qualifier value)|t080
  c0750489|apparent|t078
major weakness
  4
  c0205164|major (qualifier value)|t080
  c0030552|paresis|t184
  c0086525|lassitude|t184
  c0004093|asthenia|t184
portal fields
  3
  c0331809|fielding|t093
  c0205054|hepatic|t029
  c0440042|field's stain|t130
fluctuating
  1
  c0231241|fluctuating (qualifier value)|t079
entire rectum
  1
  c1278926|entire rectum|t023
first application
  2
  c0185125|application (procedure)|t058
  c0205435|first (qualifier value)|t081
60.0 gy
  1
  c0556636|gy (qualifier value)|t081
constant decrease
  1
  c0547047|decrease (qualifier value)|t081
stage wise comparison
  2
  c0684248|stage of surgical procedure|t079
  c0027646|diagnostic neoplasm staging|t060
significant increase
  2
  c0442805|increase (qualifier value)|t169
  c0750502|significant (qualifier value)|t078
treatment crossover
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
nonlethal toxicity
  2
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
maximum tolerated dose
  1
  c0752079|maximum tolerated dose|t081
patients doses
  2
  c0030705|patients|t101
  c0719635|dos|t109
lethargy
  1
  c0023380|lethargy|t033
cbc
  1
  c0009555|blood count, complete|t059
to better outcomes
  1
  c0332272|better (qualifier value)|t080
overall therapeutic results
  2
  c0282416|overall [publication type]|t170
  c0808233|therapeutic results|t033
total cumulative dose to
  2
  c0439810|total (qualifier value)|t080
  c0178602|dosages (qualifier value)|t081
patient then
  1
  c0030705|patients|t101
cardiorespiratory arrest
  1
  c0600228|cardiopulmonary arrest|t046
liver recurrences
  4
  c0023899|liver extract|t123
  c0023884|liver|t023
  c1278929|entire liver|t023
  c0034897|recurrence|t067
empiric dose restriction
  3
  c0376548|empiricism|t078
  c0178602|dosages (qualifier value)|t081
  c0443288|restricted (qualifier value)|t169
experienceddrug induced pulmonary toxicity
  2
  c0919924|pulmonary toxicity|t046
  c0205263|induced (qualifier value)|t169
previously untreated patients
  2
  c0030705|patients|t101
  c0205156|previous (qualifier value)|t082
90% power to
  1
  c0032863|power (psychology)|t068
somewhat more aggressive regimen
  5
  c0580822|aggressive course (qualifier value)|t079
  c1262472|aggressive cancer|t191
  c0205172|more (qualifier value)|t081
  c0001807|aggression|t055
  c0677937|regimen|t061
positive cls
  3
  c0010575|cycloleucine|t116
  c0201952|chloride measurement|t059
  c0205159|positive (qualifier value)|t080
proper histopathologic classification
  5
  c0008903|taxonomic|t185
  c0008902|classification|t185
  c0677043|histopathology|t046
  c0678229|classification of information|t057
  c0243140|histopathological aspects|t169
39% response rate
  2
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
mechanism
  1
  c0457274|mechanism (attribute)|t169
eaceful end
  1
  c0444930|end (qualifier value)|t082
compound competes
  2
  c0719453|compete|t109
  c0205198|compound (qualifier value)|t080
log rank
  2
  c0699794|rank|t170
  c0335467|logger (occupation)|t097
two others
  2
  c0205394|other|t080
  c0205448|two (qualifier value)|t081
cancers
  1
  c0006826|malignant neoplasms|t191
interest
  1
  c0543488|interested (finding)|t041
cytotoxicity
  1
  c0596402|cytotoxicity|t049
å 0.05 level
  1
  c0456079|disease classification level|t185
adria laboratories
  2
  c0022877|laboratories|t073
  c0331763|adria pharmaceuticals|t093
premenopausal patients
  2
  c0030705|patients|t101
  c0279752|premenopausal|t079
neck clinic
  3
  c0027530|neck|t017
  c0442592|clinic (environment)|t093
  c1281592|entire neck|t023
hypertension
  3
  c0340274|hypertension induced by pregnancy|t047
  c0020538|hypertension|t047
  c0235220|hypertensive disorder, systemic arterial (disorder)|t047
mitomycin mg
  4
  c0026254|mitomycins|t109
  c0002475|mitomycin|t195
  c0024467|magnesium|t123
  c0439210|milligram|t081
drug injections
  1
  c0556025|injecting drug user (finding)|t033
chi square
  1
  c0205120|square (qualifier value)|t082
platelets l
  12
  c0442022|lumbar (qualifier value)|t082
  c0392223|lights, manufactured|t074
  c0023870|lithium|t196
  c0336769|lighter, device (physical object)|t073
  c0023693|light|t070
  c0302908|liquid substance|t167
  c0023700|lighting|t068
  c1304698|liquid (finding)|t033
  c0005821|blood platelets|t025
  c0205091|left (qualifier value)|t082
  c1306462|light color|t169
  c0475211|l (qualifier value)|t081
several individual trials
  2
  c0443302|several (qualifier value)|t081
  c0237401|individual (person)|t016
known contraindications
  2
  c0079164|contraindications|t080
  c0205309|known (qualifier value)|t080
abdominal perineal resections
  4
  c0031066|anogenital region|t029
  c0456438|abdominal (qualifier value)|t082
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
posterior border
  2
  c0205095|dorsal|t082
  c0205284|marginal (qualifier value)|t082
distant areas
  2
  c0443203|distant (qualifier value)|t082
  c0205146|area (qualifier value)|t082
significantly higher rate
  4
  c0235146|euphoric mood|t041
  c0750502|significant (qualifier value)|t078
  c0871208|rating|t062
  c0205250|high|t080
survival times
  5
  c0220921|survival aspects|t081
  c0392761|timed (qualifier value)|t169
  c0038952|continuance of life|t052
  c0040223|time|t079
  c0449243|timing (attribute)|t079
throughout follow-up
  1
  c0589120|follow-up status (finding)|t169
survival outcomes
  2
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
main differences
  2
  c0443199|differential (qualifier value)|t080
  c0205225|primary|t080
cmf regimen
  1
  c0055982|cmf regimen|t061
therapeutic index
  1
  c0678793|therapeutic index|t081
temporary dose reduction only
  3
  c0205374|transitory|t079
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
formula
  1
  c0489829|mathematical formula|t170
bilirubin 1.5 x n
  2
  c0078606|xanthosine|t114
  c0858307|bilirubin normal|t033
judicious selection
  1
  c0036576|selection (genetics)|t045
only prospective randomized clinical trials yet
  1
  c0206034|clinical trials, randomized|t170
combined rt
  1
  c0205195|combined (qualifier value)|t080
overall rfs difference
  3
  c0282416|overall [publication type]|t170
  c0748398|rf|t033
  c0443199|differential (qualifier value)|t080
heart rate
  1
  c0018810|heart rate|t032
further therapy group
  1
  c0033971|psychotherapy, group|t061
required evaluation
  2
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
better survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0332272|better (qualifier value)|t080
­ years
  1
  c0439234|year (qualifier value)|t079
concomitant malignancy
  2
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
pelvic recurrences
  2
  c0030797|pelvis|t029
  c0034897|recurrence|t067
metastatic tumor
  1
  c0027627|neoplasm metastasis|t191
two-drug regimen
  3
  c0013227|pharmaceutical preparations|t121
  c0677937|regimen|t061
  c0205448|two (qualifier value)|t081
drawbacks still
  1
  c0424228|stillness (finding)|t033
months thereafter
  1
  c0439231|month (qualifier value)|t079
alive four months
  2
  c0205450|four (qualifier value)|t081
  c0439231|month (qualifier value)|t079
‘‘toxicity’’ independence
  1
  c0085862|independence|t078
1.8 g
  1
  c0162832|apc gene|t028
other points to
  2
  c0205394|other|t080
  c0324413|pointer (organism)|t015
vinblastine
  1
  c0042670|vinblastine|t123
5-year kaplan–meier disease-free survival
  2
  c0439234|year (qualifier value)|t079
  c0242793|disease-free survival|t081
recent retrospective studies
  2
  c0332185|recent episode (qualifier value)|t079
  c0035363|retrospective studies|t081
adequate blood supply
  4
  c0005839|blood supply aspects|t042
  c0920762|vascular blood supply|t042
  c0205411|adequate (qualifier value)|t080
  c0678861|arterial blood supply|t039
estimated duration
  2
  c0750572|estimated|t078
  c0449238|duration|t079
doses less
  1
  c0719635|dos|t109
significant overall benefit
  3
  c0282416|overall [publication type]|t170
  c0814225|benefits|t081
  c0750502|significant (qualifier value)|t078
pt
  6
  c0452253|port - alcoholic beverage|t168
  c0449719|part (attribute)|t082
  c0475311|harbor|t073
  c0935727|port-a-cath|t074
  c0560012|pint|t081
  c0680264|payment|t081
excluded patients
  2
  c0030705|patients|t101
  c0332196|exclude (qualifier value)|t169
obstruction requiring hospitalization
  2
  c0019993|hospitalization|t058
  c0028778|obstruction|t046
pelvic radiation concomitantly
  1
  c0747411|pelvis radiation|t061
two recent studies
  4
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0332185|recent episode (qualifier value)|t079
  c0205448|two (qualifier value)|t081
substantial protection
  1
  c0084201|protect|t109
creatinine level 1.5 mg
  3
  c0024467|magnesium|t123
  c0428279|finding of creatinine level (finding)|t034
  c0439210|milligram|t081
period
  1
  c0332182|periodic (qualifier value)|t079
possible risk
  2
  c0332149|possible|t080
  c0035647|risk|t080
category
  1
  c0683312|categories|t170
approach
  1
  c0449445|approach (attribute)|t082
kaplan–meier method
  1
  c0025663|methods|t170
reduction
  2
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
cm
  1
  c0475210|cm (qualifier value)|t081
status
  1
  c0449438|status (attribute)|t080
grade 3.4 adverse events
  2
  c0441800|grade|t185
  c0877248|adverse event|t033
periaortic lymph node sampling
  1
  c0398417|sampling of lymph nodes nos (procedure)|t060
temporary interruption
  2
  c0205374|transitory|t079
  c0443239|interrupted (qualifier value)|t080
different results
  2
  c1274040|result (navigational concept)|t169
  c0443199|differential (qualifier value)|t080
first two cycles
  3
  c0439596|cyclic (qualifier value)|t079
  c0205435|first (qualifier value)|t081
  c0205448|two (qualifier value)|t081
numerous studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0439064|numerous (qualifier value)|t081
chi-square test
  1
  c0008041|chi-square test|t081
perineal breakdown
  1
  c0031066|anogenital region|t029
similar patients
  2
  c0871364|simile|t170
  c0030705|patients|t101
overall survival rates
  2
  c0282416|overall [publication type]|t170
  c0038954|survival rate|t081
fourth cycle
  2
  c0439596|cyclic (qualifier value)|t079
  c0205438|fourth (qualifier value)|t081
new prospective study
  2
  c0205314|new (qualifier value)|t079
  c0033522|prospective studies|t081
postmenopausal patients
  2
  c0030705|patients|t101
  c0232970|postmenopausal state (finding)|t079
lost to follow-up
  2
  c0745777|lost|t033
  c0589120|follow-up status (finding)|t169
dose adjustments
  3
  c0001537|clinical adjustment|t058
  c0376209|individual adjustment|t055
  c0178602|dosages (qualifier value)|t081
drug dosages
  1
  c0870450|drug dosages|t081
median gy
  3
  c0556636|gy (qualifier value)|t081
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
greater survival advantage
  4
  c0443228|greater (qualifier value)|t081
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0308269|advantage|t131
tumor dose
  1
  c0172161|tyramine-deoxysorbitol|t109
three underwent surgical reexploration
  2
  c1293095|reexploration procedure (procedure)|t060
  c0205449|three (qualifier value)|t081
skin hyperpigmentation
  1
  c0162834|hyperpigmentation|t046
survival months
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439231|month (qualifier value)|t079
increased tumor cell kill results
  4
  c1274040|result (navigational concept)|t169
  c0599733|cell killing|t043
  c0205217|increased (qualifier value)|t169
  c0027651|neoplasms|t191
post-operative radiation therapy
  3
  c0032790|postoperative period|t079
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
neoplastic recurrence
  1
  c0521158|recurrent tumor (finding)|t191
multiple morbidity
  3
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0439064|numerous (qualifier value)|t081
prior cancer
  4
  c0998265|cancer genus|t009
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
  c0750516|prior|t078
normal limits
  1
  c0442816|normal limits (qualifier value)|t081
worst morbidity
  6
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0332271|worsening (qualifier value)|t080
  c1279889|deterioration of status|t080
  c0205169|bad (qualifier value)|t080
  c0231218|malaise|t184
high rate
  3
  c0235146|euphoric mood|t041
  c0871208|rating|t062
  c0205250|high|t080
tumour size
  1
  c0475440|tumor size (observable entity)|t082
less significant umvariate analyses
  3
  c0002778|analysis of substances|t059
  c0750502|significant (qualifier value)|t078
  c0936012|analysis|t062
gastrointestinal function
  1
  c0516983|gastrointestinal function|t042
relative risks
  1
  c0242492|relative risk|t080
higher response rate
  4
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0235146|euphoric mood|t041
  c0205250|high|t080
theoretical disadvantages
  1
  c0012613|disadvantaged|t098
other serious adverse effects
  3
  c0205394|other|t080
  c0205404|serious (qualifier value)|t080
  c0001688|adverse effects|t037
several phase studies
  4
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205390|phase (qualifier value)|t079
  c0443302|several (qualifier value)|t081
standard errors
  3
  c0038137|standards characteristics|t170
  c0743559|error|t080
  c0175675|standards of weights and measures|t080
more side-effects
  2
  c0205172|more (qualifier value)|t081
  c0001688|adverse effects|t037
three drugs
  2
  c0013227|pharmaceutical preparations|t121
  c0205449|three (qualifier value)|t081
para-aortic lymph nodes
  1
  c0229789|aortic lymph node (body structure)|t023
loperamide
  1
  c0023992|loperamide|t109
response status
  2
  c0871261|responses|t054
  c0449438|status (attribute)|t080
monofilament plastic suture
  4
  c0038969|surgical sutures|t074
  c0032167|plastics|t167
  c0502420|suture joint|t030
  c0009068|closure by suture|t061
complementary data
  1
  c0009498|complement|t116
new generation
  2
  c0079411|generations|t079
  c0205314|new (qualifier value)|t079
first two infusions
  3
  c0574032|infusion (procedure)|t061
  c0205435|first (qualifier value)|t081
  c0205448|two (qualifier value)|t081
survival duration
  3
  c0220921|survival aspects|t081
  c0449238|duration|t079
  c0038952|continuance of life|t052
theoretical explanations
  1
  c0681841|explanation|t062
cohort
  1
  c0599755|cohort|t098
several reports
  2
  c0443302|several (qualifier value)|t081
  c0684224|report (document)|t170
moderately high dose
  2
  c0444956|high dose (qualifier value)|t081
  c0205081|moderate (severity modifier) (qualifier value)|t080
effector mechanisms
  2
  c0441712|mechanisms (qualifier value)|t067
  c1280500|effect (qualifier value)|t080
phase iii multicentre randomised trial
  4
  c0205390|phase (qualifier value)|t079
  c0439070|iii (qualifier value)|t170
  c0206012|multicenter trials|t062
  c0034656|random allocation|t062
minimum follow-up
  2
  c0439232|minute of time|t079
  c0589120|follow-up status (finding)|t169
median time
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0040223|time|t079
then mo
  1
  c0026402|molybdenum|t123
positive surgical margins
  2
  c0229985|surgical margins (body structure)|t023
  c0205159|positive (qualifier value)|t080
after treatment
  1
  c0001758|aftercare|t058
treatment arm
  4
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0003792|arm|t029
  c0446516|upper arm|t029
common side-effects
  2
  c0001688|adverse effects|t037
  c0205214|common (qualifier value)|t081
non-opioids
  1
  c0242402|opioids|t131
fist successful anastomosis
  5
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c1272703|successful (qualifier value)|t080
  c0336667|fist, device (physical object)|t023
  c0500470|anatomical anastomosis|t030
positive nodes
  2
  c0746922|node|t023
  c0205159|positive (qualifier value)|t080
survival curves
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0205134|curved (qualifier value)|t082
prior radiotherapy
  3
  c0750516|prior|t078
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
potential mechanism
  2
  c0457274|mechanism (attribute)|t169
  c0237399|potential|t080
planned patients
  2
  c0030705|patients|t101
  c1301732|planned (qualifier value)|t169
other vesical complications
  2
  c0205058|vesical|t082
  c0009566|complication|t046
study population
  3
  c0032659|population|t081
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
entry criteria
  1
  c0243161|criteria|t170
bicycle exercise
  1
  c0392218|exercisers, bicycle|t074
further progression
  1
  c0449258|progression (attribute)|t169
p
  4
  c0518611|poise|t033
  c0031603|inorganic phosphate|t197
  c0947648|phosphorus preparation|t121
  c0031705|phosphorus|t196
menopausal status
  2
  c0449438|status (attribute)|t080
  c0232967|menopausal|t169
large scale clinical trials
  5
  c0549177|large|t080
  c0175659|weight measurement scales|t073
  c0349674|intellectual scale|t170
  c0222045|integumentary scale|t023
  c0008976|clinical trials|t062
received prior radiotherapy
  4
  c0544683|reception|t042
  c0750516|prior|t078
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
large tumors
  1
  c0475278|large tumor (finding)|t080
.90 probability
  1
  c0033204|probability|t081
office
  1
  c0442603|office|t073
ineligible patients
  1
  c0030705|patients|t101
results patient characteristics total
  3
  c0439810|total (qualifier value)|t080
  c1274040|result (navigational concept)|t169
  c0815172|patient characteristics|t201
considerable difference
  2
  c0750591|consider|t078
  c0443199|differential (qualifier value)|t080
life-threatening complications
  3
  c1171258|complication aspects|t046
  c0376558|life|t078
  c0009566|complication|t046
fig b
  8
  c0337527|brothers|t099
  c0004927|behavior|t055
  c0004587|bacillus <bacterium>|t007
  c0677505|behaviors and observations relating to behavior|t033
  c1040746|bacilli|t007
  c0150141|bathing|t061
  c0349966|figs - dietary|t168
  c0175640|baths (medical device)|t074
combined modality treatment arm
  4
  c0695347|modality|t078
  c0009429|combined modality therapy|t061
  c0003792|arm|t029
  c0446516|upper arm|t029
compound
  1
  c0205198|compound (qualifier value)|t080
pre
  1
  c0740175|before values (qualifier value)|t079
multiagent chemotherapy
  3
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
nodal involvement
  2
  c0392760|not free of (attribute)|t169
  c0443268|nodal (qualifier value)|t082
radiotherapy fractionation
  4
  c0524811|dose fractionation|t061
  c0016640|fractionation|t059
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
analysis
  2
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
relatively small sample size
  2
  c0700321|small|t080
  c0242618|sample size|t081
minimum detectable difference
  3
  c0442726|detected (qualifier value)|t033
  c0439232|minute of time|t079
  c0443199|differential (qualifier value)|t080
suspicious nodes
  2
  c0750493|suspicious|t078
  c0746922|node|t023
protein
  2
  c0033684|proteins|t116
  c0202202|protein measurement|t059
distant metastases
  1
  c1269798|pm category (observable entity)|t201
increased significance
  2
  c0205217|increased (qualifier value)|t169
  c0750502|significant (qualifier value)|t078
poorer prognosis
  1
  c0278252|prognosis bad (finding)|t033
follow-up program
  2
  c0376691|programs [publication type]|t170
  c0589120|follow-up status (finding)|t169
visible disruption
  2
  c0332453|disruption (morphologic abnormality)|t169
  c0205379|visible (qualifier value)|t080
consequently adequacy
  1
  c0205411|adequate (qualifier value)|t080
first site
  2
  c0205145|associated topography (attribute)|t082
  c0205435|first (qualifier value)|t081
untreated groups
  1
  c0441833|groups (qualifier value)|t170
o brien fleming group sequential boundary
  2
  c0331812|fleming|t093
  c0812406|o group|t185
overall reduction
  3
  c0282416|overall [publication type]|t170
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
statistical analysis system
  2
  c0449913|system (attribute)|t169
  c0871424|statistical analysis|t062
therapeutic effectiveness
  4
  c0205414|effective (qualifier value)|t080
  c0039796|the science and art of healing|t061
  c1280519|effectiveness (qualifier value)|t170
  c0302350|therapeutic|t169
since only five patients
  2
  c0205451|five (qualifier value)|t081
  c0030705|patients|t101
diarrhoea score
  2
  c0449820|scores (qualifier value)|t081
  c0011991|diarrhea|t184
radical radiotherapy
  4
  c0302912|radicals (chemistry)|t104
  c0439807|radical (qualifier value)|t080
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
second most frequent nonhaematological toxic effect
  2
  c0600688|toxic effect|t037
  c0205436|second (qualifier value)|t081
randomized controlled comparison
  2
  c0702113|controlled (qualifier value)|t169
  c0034656|random allocation|t062
only small fraction
  2
  c0457426|fractions of (qualifier value)|t081
  c0700321|small|t080
lactation
  1
  c0022925|lactation|t042
adjuvant irradiation
  4
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0001551|adjuvants, immunologic|t129
  c0034618|radiation therapy|t061
increased pelvic control rates
  3
  c0205217|increased (qualifier value)|t169
  c0561970|ability to control pelvic posture (observable entity)|t033
  c0871208|rating|t062
assigned treatment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
severe symptoms
  2
  c0683368|symptoms|t169
  c0205082|severe (severity modifier) (qualifier value)|t080
three arm
  3
  c0003792|arm|t029
  c0205449|three (qualifier value)|t081
  c0446516|upper arm|t029
abdomen
  2
  c0000726|abdomen|t029
  c1281594|entire abdomen|t023
life expectancy
  1
  c0023671|life expectancy|t102
usually fluorouracil
  1
  c0016360|fluorouracil|t114
fifty two patients
  2
  c0030705|patients|t101
  c0205448|two (qualifier value)|t081
exploratory analyses
  4
  c0002778|analysis of substances|t059
  c1280903|exploration procedure (procedure)|t061
  c0581690|exploration - action (qualifier value)|t058
  c0936012|analysis|t062
only first site
  2
  c0205145|associated topography (attribute)|t082
  c0205435|first (qualifier value)|t081
two other studies
  4
  c0205394|other|t080
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205448|two (qualifier value)|t081
rapid infusion
  2
  c0439831|rapid (qualifier value)|t080
  c0574032|infusion (procedure)|t061
abdominal ultrasound
  1
  c0203464|ultrasonography of abdomen (procedure)|t060
demographic characteristics
  1
  c0683970|demographic characteristics|t102
everted anastomosis
  4
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0015211|eversion (morphologic abnormality)|t169
  c0500470|anatomical anastomosis|t030
one ovary
  3
  c1278992|entire ovary|t023
  c0029939|ovary|t023
  c0205447|one (qualifier value)|t081
combinations
  1
  c0453882|combinations (physical object)|t073
randomly allocated irinotecan
  2
  c0123931|irinotecan|t109
  c0034656|random allocation|t062
discomforting complications
  2
  c1171258|complication aspects|t046
  c0009566|complication|t046
58.7 years
  1
  c0439234|year (qualifier value)|t079
neurologic toxicity
  3
  c0040539|toxicity aspects|t081
  c0205494|neurologic (qualifier value)|t169
  c0600688|toxic effect|t037
29% response rate
  2
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
pain score
  1
  c0582148|pain score (observable entity)|t033
radiation therapy oncology group study
  4
  c0033971|psychotherapy, group|t061
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0243005|radiation oncology|t091
size recurrent tumor
  2
  c0521158|recurrent tumor (finding)|t191
  c0702146|size (attribute)|t081
signs
  3
  c0220912|aspects of signs|t169
  c0220913|manufactured sign|t073
  c0311392|physical findings|t184
total dose
  1
  c0172161|tyramine-deoxysorbitol|t109
more complete responses
  2
  c0205172|more (qualifier value)|t081
  c0677874|in complete remission (qualifier value)|t033
dose dependent effect
  3
  c1280500|effect (qualifier value)|t080
  c0851827|dependent (qualifier value)|t098
  c0178602|dosages (qualifier value)|t081
real difference
  2
  c0443199|differential (qualifier value)|t080
  c0871222|reality|t078
balanced blocks
  4
  c0205415|balanced - adjective|t169
  c0332206|blocking|t169
  c0028778|obstruction|t046
  c0233660|mental blocking|t048
whitney cw
  1
  c0332290|consistent with (qualifier value)|t078
optimal regimen
  1
  c0677937|regimen|t061
refused treatment
  3
  c0087111|therapeutic procedure|t061
  c0017095|garbage|t072
  c0039798|therapeutic aspects|t169
negative v positive
  7
  c0042306|vanadium|t123
  c0449468|volume (property) (qualifier value)|t081
  c0439830|velocity (property) (qualifier value)|t169
  c0598352|v (voltage)|t081
  c0205160|negative (qualifier value)|t080
  c0439502|v - volt (qualifier value)|t081
  c0205159|positive (qualifier value)|t080
thirteen percent
  1
  c0439165|percent (qualifier value)|t081
6-cycle group
  3
  c0439596|cyclic (qualifier value)|t079
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
induration
  1
  c0332534|induration (morphologic abnormality)|t169
multicentre trials
  1
  c0206012|multicenter trials|t062
negative margins
  3
  c1269830|tumor margin status|t033
  c0205160|negative (qualifier value)|t080
  c0205284|marginal (qualifier value)|t082
m2 body surface area intravenously
  2
  c0005902|body surface area|t060
  c0348016|intravenous|t082
other clinical variables
  3
  c0205394|other|t080
  c0205210|clinical (qualifier value)|t080
  c0439828|variable (qualifier value)|t080
patient characteristics
  1
  c0815172|patient characteristics|t201
disease-free survival
  1
  c0242793|disease-free survival|t081
randomisation
  1
  c0034656|random allocation|t062
appropriate laboratory
  3
  c0814634|appropriateness|t080
  c0680799|appropriation|t064
  c0022877|laboratories|t073
standard practice
  3
  c0038137|standards characteristics|t170
  c0175675|standards of weights and measures|t080
  c0237607|experience (practice)|t041
recent data
  1
  c0332185|recent episode (qualifier value)|t079
antiarrhythmics
  1
  c0003195|anti-arrhythmia agents|t121
twice daily treatments
  2
  c0585361|twice a day|t079
  c0087111|therapeutic procedure|t061
other more favorable groups
  4
  c0205394|other|t080
  c0205172|more (qualifier value)|t081
  c0309049|favor (product)|t121
  c0441833|groups (qualifier value)|t170
incomplete resection
  4
  c0205257|incomplete|t081
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
  c0728938|partial (qualifier value)|t081
pretreatment evaluation
  2
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
difference predominantly
  2
  c0332251|predominate (qualifier value)|t080
  c0443199|differential (qualifier value)|t080
draining
  1
  c0180499|drain, device (physical object)|t074
disposable staple gun
  3
  c0524724|surgical staples|t074
  c0725865|disposable|t074
  c0018397|guns|t073
ii breast cancer
  2
  c0006142|malignant neoplasm of breast|t191
  c0439069|roman numeral ii|t170
cycle
  1
  c0439596|cyclic (qualifier value)|t079
anastomotic method
  2
  c0025663|methods|t170
  c0332854|anastomotic|t082
woman
  2
  c0043209|human females|t098
  c0043210|human adult females|t098
dukes stage
  1
  c1272820|dukes stage (observable entity)|t201
main findings
  2
  c0243095|findings|t169
  c0205225|primary|t080
determining eligibility
  2
  c0680730|adjudication|t064
  c1148554|determination aspects|t059
grading
  2
  c0441800|grade|t185
  c0796573|cancer cells grading system|t185
radiotherapy committee
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
promising results
  1
  c1274040|result (navigational concept)|t169
normal dlco pulmonary function test
  2
  c0024119|pulmonary function tests|t060
  c0205307|normal (qualifier value)|t033
magnitude
  1
  c0439535|magnitudes (qualifier value)|t081
conversion to
  1
  c0439836|conversions (qualifier value)|t082
secondary dissemination
  3
  c0205221|disseminated (qualifier value)|t082
  c0036525|metastatic to|t169
  c0175668|secondary to|t079
m d
  3
  c0439228|day (qualifier value)|t079
  c0332517|diameter (qualifier value)|t032
  c0011530|deoxyribose|t123
days week
  2
  c0439228|day (qualifier value)|t079
  c0439230|week (qualifier value)|t079
40.8 gy
  1
  c0556636|gy (qualifier value)|t081
9.9 13¡¤6 months
  1
  c0439231|month (qualifier value)|t079
tumor related factors
  2
  c0445223|related (finding)|t033
  c0027651|neoplasms|t191
metastatic colorectal cancer
  1
  c0948380|colorectal cancer metastatic|t191
nodal status
  2
  c0443268|nodal (qualifier value)|t082
  c0449438|status (attribute)|t080
leucopenia
  1
  c0023530|leukopenia|t047
median months
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0439231|month (qualifier value)|t079
ps
  1
  c0036421|systemic scleroderma|t047
fu
  1
  c0016360|fluorouracil|t114
peritonitis
  1
  c0031154|peritonitis|t047
presented 7-year follow-up data
  2
  c0589120|follow-up status (finding)|t169
  c0150312|present|t169
postcisplatin hydration
  1
  c0517526|hydration|t033
measurable disease
  1
  c0677909|measurable disease|t047
lower morbidity
  3
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0441994|lower (qualifier value)|t169
progression
  1
  c0449258|progression (attribute)|t169
parallel pair
  1
  c0233174|synclitism (finding)|t033
same two drugs
  3
  c0445247|same (qualifier value)|t080
  c0013227|pharmaceutical preparations|t121
  c0205448|two (qualifier value)|t081
interventions
  1
  c0886296|interventions|t061
significantly
  1
  c0750502|significant (qualifier value)|t078
excellent results
  1
  c1274040|result (navigational concept)|t169
pelvic lymphocyst
  2
  c0333147|lymphocyst (morphologic abnormality)|t046
  c0030797|pelvis|t029
most important practical aspect
  2
  c0205393|most (qualifier value)|t081
  c0237607|experience (practice)|t041
types
  1
  c0449470|types (qualifier value)|t170
sgot 2.5 x normal value
  2
  c0201899|aspartate aminotransferase assay|t059
  c0086715|normal range|t081
total cumulative dose
  2
  c0439810|total (qualifier value)|t080
  c0178602|dosages (qualifier value)|t081
surgery also
  3
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
complete history
  7
  c0019664|recording of previous events|t090
  c0019665|history|t170
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
  c0262926|medical history|t033
  c1321503|history of (contextual qualifier) (qualifier value)|t033
  c0262512|history of (present illness) (contextual qualifier) (qualifier value)|t032
tension
  1
  c0233494|tension (finding)|t048
leiomyosarcoma
  1
  c0023269|leiomyosarcoma|t191
competing neoplasm
  2
  c0719453|compete|t109
  c0027651|neoplasms|t191
histologic proof
  3
  c0205462|histologic|t169
  c0456369|proven findings|t080
  c0700164|proven venom|t123
tolerability
  2
  c0231198|tolerant|t169
  c0680282|implicit permission|t054
philadelphia
  1
  c0031525|philadelphia|t083
concurrent radiotherapy
  3
  c0205420|concurrent (qualifier value)|t079
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
psychiatric illness
  1
  c0004936|mental disorders|t048
evaluations
  1
  c0220825|evaluation|t169
colon
  2
  c0009368|colon|t023
  c1281569|entire colon|t023
highly significant difference
  2
  c0443199|differential (qualifier value)|t080
  c1299395|highly significant (qualifier value)|t080
specification
  1
  c0205369|specific (qualifier value)|t080
important one
  1
  c0205447|one (qualifier value)|t081
normal liver function tests
  2
  c0205307|normal (qualifier value)|t033
  c0023901|liver function tests|t059
human
  2
  c0086418|homo sapiens|t016
  c0020114|human|t016
differences
  1
  c0443199|differential (qualifier value)|t080
estrogen receptor negative tumors
  2
  c0279756|estrogen receptor negative|t034
  c0027651|neoplasms|t191
cases
  1
  c0868928|case (qualifier value)|t169
laboratory cardiotoxicity data
  2
  c0745590|lab data|t077
  c0876994|cardiotoxicity|t047
restricting therapy
  3
  c0087111|therapeutic procedure|t061
  c0443288|restricted (qualifier value)|t169
  c0039798|therapeutic aspects|t169
grade leukopenia
  2
  c0441800|grade|t185
  c0023530|leukopenia|t047
life
  1
  c0376558|life|t078
fatal complications
  3
  c1171258|complication aspects|t046
  c1302234|fatal (qualifier value)|t080
  c0009566|complication|t046
paracervical tissue involvement
  2
  c0392760|not free of (attribute)|t169
  c0040300|tissues|t024
acute treatment-related toxicity
  6
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0040539|toxicity aspects|t081
  c0205178|acuteness (qualifier value)|t079
  c0600688|toxic effect|t037
  c0039798|therapeutic aspects|t169
endometrial carcinoma in situ
  2
  c0007099|carcinoma in situ|t191
  c0227843|endometrio-|t082
external beam irradiation
  4
  c1282930|irradiation (physical force)|t070
  c0205101|external (qualifier value)|t082
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
two intracavitary applications
  3
  c0185125|application (procedure)|t058
  c0205448|two (qualifier value)|t081
  c1298613|intracavitary (qualifier value)|t082
screening chest x-ray
  1
  c0420046|screening chest x-ray (procedure)|t060
high dose intensities
  1
  c0444956|high dose (qualifier value)|t081
statistical considerations
  2
  c0518609|consideration|t033
  c0220917|statistical|t170
indication
  1
  c0237000|indications|t078
bomp ct
  2
  c0053926|bomp protocol|t061
  c0040405|x-ray computed tomography|t060
control regimen
  2
  c0243148|control|t169
  c0677937|regimen|t061
median age
  3
  c0001779|age (qualifier value)|t079
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
higher doses
  1
  c0444956|high dose (qualifier value)|t081
polymorphous rhabdomyosarcoma
  2
  c0035412|rhabdomyosarcoma|t191
  c0027950|neutrophils|t025
karnofsky performance status index
  2
  c0206065|karnofsky performance status|t034
  c0918012|indexes|t170
behaviour
  1
  c0004927|behavior|t055
cr rate
  2
  c0008574|chromium|t123
  c0871208|rating|t062
radiographs
  1
  c1306645|plain film (procedure)|t060
clinical heart failure
  2
  c0205210|clinical (qualifier value)|t080
  c0018801|heart failure nos (disorder)|t047
intravenously days
  2
  c0439228|day (qualifier value)|t079
  c0348016|intravenous|t082
fifty five percent
  2
  c0205451|five (qualifier value)|t081
  c0439165|percent (qualifier value)|t081
nonsquamous histology
  3
  c0019638|histology|t091
  c0205462|histologic|t169
  c0344441|histology procedure|t059
risk factors
  1
  c0035648|risk factors|t081
rare mortality
  3
  c0332184|rare (qualifier value)|t079
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
informed consent
  1
  c0021430|informed consent|t058
mucocutaneous effects
  1
  c1280500|effect (qualifier value)|t080
belgium
  1
  c0004950|belgium|t083
theoretical maximum tolerated dose
  1
  c0752079|maximum tolerated dose|t081
dose limiting factor
  1
  c0935905|dose-limiting|t037
here final status
  2
  c0205088|end-stage (qualifier value)|t079
  c0449438|status (attribute)|t080
meccnu regimen
  2
  c0036637|semustine|t109
  c0677937|regimen|t061
future studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0016884|future|t079
44.8 gy
  1
  c0556636|gy (qualifier value)|t081
to enroll women
  2
  c0043209|human females|t098
  c0043210|human adult females|t098
purpose
  1
  c0449256|purpose (attribute)|t033
treatment arms
  3
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0003792|arm|t029
continuous anastomoses
  2
  c0549178|continuous (qualifier value)|t079
  c0332853|anastomosis|t020
sternum
  2
  c0038293|sternum|t023
  c1279580|entire sternum|t023
postmastectomy chest wall
  2
  c0205076|chest wall structure|t023
  c1279035|entire chest wall|t023
drugs to
  1
  c0013227|pharmaceutical preparations|t121
ureter
  2
  c0041951|ureter|t023
  c1281572|entire ureter|t023
multiple studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0439064|numerous (qualifier value)|t081
isodose curves
  1
  c0205134|curved (qualifier value)|t082
episodes
  1
  c0678231|episodes (qualifier value)|t079
antitumor activity
  3
  c0600075|endurance of activity|t033
  c0441655|activities|t052
  c0221187|physical activity|t056
gynecologic oncology group
  3
  c0278596|gynecologic oncology|t091
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
refused dialysis
  4
  c0011945|physical dialysis|t070
  c1059964|genus dialysis|t009
  c0017095|garbage|t072
  c0011946|dialysis procedure|t061
radiation enhancing potential
  3
  c0851346|radiation|t070
  c0086222|enhancer|t114
  c0237399|potential|t080
not essential component
  2
  c0449432|component (attribute)|t073
  c0205224|essential (qualifier value)|t080
last cycle
  2
  c0439596|cyclic (qualifier value)|t079
  c0335882|laster (occupation)|t097
pl
  1
  c0031676|phospholipids|t119
comparable degree
  2
  c0542560|academic degree|t170
  c0449286|degree or extent|t080
adding radiation
  2
  c0851346|radiation|t070
  c0442796|additive (qualifier value)|t080
radical tumor resection
  5
  c0302912|radicals (chemistry)|t104
  c0439807|radical (qualifier value)|t080
  c0027651|neoplasms|t191
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
aortic lymph node sampling
  5
  c0398417|sampling of lymph nodes nos (procedure)|t060
  c0870078|sampling|t078
  c0229789|aortic lymph node (body structure)|t023
  c0441621|sampling - surgical action|t060
  c0003483|aorta|t023
severe dyspnea
  2
  c0013404|dyspnea|t184
  c0205082|severe (severity modifier) (qualifier value)|t080
eligibility criteria
  1
  c0243161|criteria|t170
significant frequency
  2
  c0376249|with frequency|t081
  c0750502|significant (qualifier value)|t078
prognostic features
  1
  c0220901|prognostic|t170
oxford colorectal cancer cooperative group
  2
  c0677877|cooperative group|t093
  c0009402|colorectal cancer|t191
extent
  1
  c0439792|extents (qualifier value)|t080
prs
  1
  c0279766|progesterone receptor negative|t034
techniques
  2
  c0025664|methodology|t170
  c0449851|techniques|t170
technique
  1
  c0449851|techniques|t170
less mortality
  2
  c0026565|mortality vital statistics|t081
  c0026566|aspects of mortality statistics|t170
investigator
  1
  c0035173|research personnel|t097
poor technique
  3
  c0449851|techniques|t170
  c0542537|poor - grade value|t080
  c0699761|financially poor|t080
important method
  1
  c0025663|methods|t170
dox arms
  4
  c0048808|5'-deoxy-5-fluorouridine|t114
  c0013090|doxycycline|t195
  c0003792|arm|t029
  c0013089|doxorubicin|t195
second primary tumor
  2
  c0677930|primary tumor|t191
  c0205436|second (qualifier value)|t081
relapse
  3
  c0205336|relapsing course|t079
  c0580802|relapse phase|t079
  c0035020|relapse|t067
23% planned level
  1
  c0441890|planned level (qualifier value)|t080
disease-free survival probabilities
  2
  c0033204|probability|t081
  c0242793|disease-free survival|t081
standard error
  3
  c0038137|standards characteristics|t170
  c0743559|error|t080
  c0175675|standards of weights and measures|t080
significantly more patients
  3
  c0205172|more (qualifier value)|t081
  c0030705|patients|t101
  c0750502|significant (qualifier value)|t078
compromising
  1
  c0518613|compromise|t033
cytotoxic agents
  1
  c0304497|cytotoxic agent (substance)|t121
antildiotype antibodies
  2
  c0813154|antibodies, in vitro diagnostic|t130
  c0003241|antibodies|t116
mg postoperatively
  3
  c0445193|postop|t079
  c0024467|magnesium|t123
  c0439210|milligram|t081
antibody treatment
  3
  c0087111|therapeutic procedure|t061
  c0003241|antibodies|t116
  c0039798|therapeutic aspects|t169
lowest proportion
  3
  c0441994|lower (qualifier value)|t169
  c0205351|proportional (qualifier value)|t080
  c0205251|low (qualifier value)|t080
complete recovery
  3
  c0237820|recovery from disease|t040
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
n acetylcysteine
  1
  c0001047|acetylcysteine|t116
stage ib cervical cancers
  1
  c0278582|cervical carcinoma stage ib|t191
tumor size
  1
  c0475440|tumor size (observable entity)|t082
values
  1
  c0042295|valuing|t080
rarity
  1
  c0332184|rare (qualifier value)|t079
treatment regimens
  3
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0677937|regimen|t061
tumour related symptoms
  3
  c0683368|symptoms|t169
  c0445223|related (finding)|t033
  c0027651|neoplasms|t191
withers
  1
  c0230107|withers (body structure)|t023
rectal mucosa
  1
  c0227395|rectal mucous membrane structure (body structure)|t023
sex
  2
  c0009253|coitus|t055
  c0079399|gender|t022
indicated mitolactol therapy
  6
  c0026252|mitolactol|t118
  c1235732|indicator|t012
  c0237000|indications|t078
  c0087111|therapeutic procedure|t061
  c0021212|indicators|t130
  c0039798|therapeutic aspects|t169
chemistry panel
  1
  c1254572|chemistry panels|t059
oral mucositis
  2
  c0236177|inflammatory disease of mucous membrane (disorder)|t046
  c0442027|oral (qualifier value)|t082
postmenopausal women
  3
  c0043209|human females|t098
  c0043210|human adult females|t098
  c0232970|postmenopausal state (finding)|t079
superficial squamous cell carcinomas
  2
  c0205124|superficial (qualifier value)|t082
  c0007137|carcinoma, squamous cell|t191
ongoing randomized studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0034656|random allocation|t062
progression free interval
  3
  c0016694|freedom|t078
  c1272706|interval (qualifier value)|t079
  c0449258|progression (attribute)|t169
days thereafter
  1
  c0439228|day (qualifier value)|t079
human 17-1a autoantibody
  4
  c0086418|homo sapiens|t016
  c0004358|autoantibodies|t116
  c0919704|autoantibody nos|t034
  c0020114|human|t016
balanced distribution
  3
  c0205415|balanced - adjective|t169
  c0520511|distributing|t078
  c0037775|spatial distribution|t082
biopsy
  2
  c0220797|biopsy characteristics|t169
  c0005558|biopsy|t060
haemato biochemical parameters
  2
  c0205474|biochemical (qualifier value)|t169
  c0449381|observation parameter (observable entity)|t033
appreciable difference
  1
  c0443199|differential (qualifier value)|t080
hospital
  1
  c0019994|hospitals|t093
nodal radiation
  2
  c0443268|nodal (qualifier value)|t082
  c0851346|radiation|t070
anastomotic leaks
  1
  c0919691|anastomotic leak|t046
mv x-rays
  4
  c0025275|mendelevium|t196
  c0043309|roentgen rays|t070
  c0885876|x-rays, homeopathic preparations|t121
  c0456691|millivolt|t081
acute toxic reactions
  2
  c0205178|acuteness (qualifier value)|t079
  c0542243|toxic reaction (nos)|t033
more well established performance status
  4
  c0205170|good (qualifier value)|t080
  c0205172|more (qualifier value)|t081
  c0443211|established (qualifier value)|t080
  c0935728|performance status|t033
streptozotocin
  1
  c0038432|streptozocin|t195
protocol
  1
  c0442711|protocols documentation|t170
2-weekly regimens
  2
  c0332174|weekly (qualifier value)|t079
  c0677937|regimen|t061
lower risk
  2
  c0441994|lower (qualifier value)|t169
  c0035647|risk|t080
not purpose
  1
  c0449256|purpose (attribute)|t033
computerized tomography
  1
  c0040405|x-ray computed tomography|t060
testifies
  1
  c0680706|testimony|t064
metastases
  2
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0027627|neoplasm metastasis|t191
statistical power
  1
  c0814897|statistical power|t062
not realistic end point
  2
  c0150100|endpoint|t062
  c0237815|realism|t078
staging evaluation
  3
  c0332305|with staging (attribute)|t169
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
clinical impact
  2
  c0205210|clinical (qualifier value)|t080
  c0726639|impact|t168
prior cardiac irradiation
  5
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0205041|cardio-|t082
  c0750516|prior|t078
  c0034618|radiation therapy|t061
distal presentation
  2
  c0205108|distal (qualifier value)|t082
  c0449450|presentation (attribute)|t078
node status
  2
  c0449438|status (attribute)|t080
  c0746922|node|t023
pretreatment serum albumin level 3.0 g
  3
  c0162832|apc gene|t028
  c0728877|serum albumin level|t034
  c0523465|serum albumin measurement|t059
posteroanterior parallel ports
  4
  c0452253|port - alcoholic beverage|t168
  c0233174|synclitism (finding)|t033
  c0475311|harbor|t073
  c0935727|port-a-cath|t074
different proportionate representation
  2
  c0205351|proportional (qualifier value)|t080
  c0443199|differential (qualifier value)|t080
systemic activity
  4
  c0600075|endurance of activity|t033
  c0205373|systemic (qualifier value)|t169
  c0441655|activities|t052
  c0221187|physical activity|t056
atropine
  2
  c0004259|atropine|t109
  c1161352|atropinum, atropine|t121
antagonism
  1
  c0680242|antagonism|t054
ecg
  2
  c0013798|electrocardiogram|t060
  c0180580|electrocardiographic monitoring (regime/therapy)|t061
cancer recurrence
  1
  c0920420|cancer recurrence|t191
because radiotherapy techniques
  4
  c0025664|methodology|t170
  c0449851|techniques|t170
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
antibody titers
  2
  c1287242|finding of antibody titer (finding)|t034
  c0474643|antibody titer measurement (procedure)|t059
follow-up data
  1
  c0589120|follow-up status (finding)|t169
pain-free survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0908489|pain-free|t109
extremely important clinical observation
  3
  c0700325|patient observation|t061
  c0205403|extreme (qualifier value)|t080
  c0302523|observation in research|t062
external beam x-ray treatment
  2
  c0043308|x-ray therapy|t061
  c0205101|external (qualifier value)|t082
patients data
  1
  c0030705|patients|t101
objectively verifiable dates
  2
  c0011008|dates|t079
  c0018017|goals|t170
efficacy risk
  1
  c0035647|risk|t080
51.0 gy
  1
  c0556636|gy (qualifier value)|t081
25% reduction
  2
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
fewer local recurrences
  3
  c0205276|local (qualifier value)|t082
  c0034897|recurrence|t067
  c0205388|few (qualifier value)|t081
procedures
  2
  c0025664|methodology|t170
  c0184661|procedures|t058
rio de janeiro
  2
  c0012203|diethylstilbestrol|t131
  c0445581|rio (qualifier value)|t170
overall dfs
  2
  c0282416|overall [publication type]|t170
  c0011145|deferoxamine|t123
pleura
  2
  c1279036|entire pleura|t023
  c0032225|pleura|t017
recurrent cancer
  1
  c0549379|recurrent cancer|t191
problem
  1
  c0033213|problem (finding)|t033
improved disease-free survival
  2
  c0184511|improved (qualifier value)|t080
  c0242793|disease-free survival|t081
tumor diameter
  2
  c0332517|diameter (qualifier value)|t032
  c0027651|neoplasms|t191
carboplatin
  1
  c0079083|carboplatin|t109
wbc count
  1
  c0023508|white blood cell count procedure|t059
limited overall treatment times
  4
  c0282416|overall [publication type]|t170
  c0332186|definite time (qualifier value)|t079
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
less circumferential clearing
  2
  c0205305|clear (qualifier value)|t080
  c0205113|circumferential (qualifier value)|t082
various combinations
  2
  c0440102|various (substance)|t130
  c0453882|combinations (physical object)|t073
further chemotherapy
  3
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
running 3.0 polyglycolic acid suture
  2
  c0183741|sutures, polyglycolic acid|t074
  c0035953|running|t056
sq m
  3
  c0205120|square (qualifier value)|t082
  c1182670|squamous|t080
  c0038071|squalene|t123
mild stomatitis
  2
  c0205080|mild (qualifier value)|t080
  c0038362|stomatitis|t047
limb sparing procedures
  4
  c0015385|limb structure|t023
  c0025664|methodology|t170
  c0184661|procedures|t058
  c1280090|entire limb|t023
four courses
  2
  c0205450|four (qualifier value)|t081
  c0750729|courses (qualifier value)|t079
interrupted anastomoses
  2
  c0332853|anastomosis|t020
  c0443239|interrupted (qualifier value)|t080
rectal cancer
  1
  c0007113|cancer of rectum|t191
intracellular concentration
  3
  c0086045|concentration|t041
  c0175996|protoplasm|t026
  c0178719|intracellular|t082
five needled sutures
  6
  c0205451|five (qualifier value)|t081
  c0038969|surgical sutures|t074
  c0398296|cannulation of vascular fistula, graft or prosthetic device|t061
  c0398266|venous cannula insertion|t061
  c0007431|arterial catheterization|t061
  c0027551|needles|t074
preoperative radiotherapy
  3
  c0034618|radiation therapy|t061
  c0445204|preoperative (qualifier value)|t032
  c0034619|radiotherapeutic|t170
other technical problems
  4
  c0205394|other|t080
  c0025664|methodology|t170
  c0449851|techniques|t170
  c0033213|problem (finding)|t033
altered fractionation schedules
  4
  c0205349|altered (qualifier value)|t169
  c0524811|dose fractionation|t061
  c0086960|schedules|t170
  c0016640|fractionation|t059
homogeneous group
  3
  c0181200|homogenizers|t074
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
relative risk
  1
  c0242492|relative risk|t080
platelets less
  1
  c0005821|blood platelets|t025
distant micrometastases
  1
  c0443203|distant (qualifier value)|t082
end to end
  1
  c0444930|end (qualifier value)|t082
modified radical mastectomy
  2
  c0024883|mastectomy, modified radical|t061
  c1320277|modified radical mastectomy (procedure)|t061
27% recurrence rate
  2
  c0034897|recurrence|t067
  c0871208|rating|t062
leakage rates
  2
  c0015376|extravasation (morphologic abnormality)|t046
  c0871208|rating|t062
proctoscopy
  1
  c0033251|proctoscopy|t060
cisplatin mg
  3
  c0008838|cisplatin|t197
  c0024467|magnesium|t123
  c0439210|milligram|t081
hlstopathologic confirmation
  1
  c0750484|confirmed|t078
chance
  1
  c0237506|chance|t080
objectives
  1
  c0018017|goals|t170
regarding patients
  1
  c0030705|patients|t101
phase i dose escalation studies
  3
  c0278783|phase i study|t062
  c0178602|dosages (qualifier value)|t081
  c0014829|escalators|t073
full biochemical modulating effect
  4
  c1280500|effect (qualifier value)|t080
  c0443264|modulated (qualifier value)|t082
  c0205474|biochemical (qualifier value)|t169
  c0443225|full (qualifier value)|t080
comparable results
  1
  c1274040|result (navigational concept)|t169
severe proctites severe oedema
  1
  c0032954|severe pre-eclampsia nos (disorder)|t047
ap pa
  1
  c0030125|p-aminosalicylic acid|t109
prospective randomized trial
  1
  c0034656|random allocation|t062
ileal obstruction
  2
  c0028778|obstruction|t046
  c0020885|ileum|t023
laboratory investigations
  2
  c0022877|laboratories|t073
  c0430007|clinical investigation|t058
chemotherapy schedules
  4
  c0086960|schedules|t170
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
treatment groups
  1
  c0036669|sensitivity training groups|t065
review
  1
  c0282443|review [publication type]|t170
additional patients
  2
  c0030705|patients|t101
  c0442796|additive (qualifier value)|t080
packed red cell transfusions
  3
  c0184967|insertion of pack (procedure)|t061
  c0014792|erythrocytes|t025
  c0199960|transfusion - action (qualifier value)|t061
treatment outcome
  2
  c0085415|treatment outcome|t080
  c0599860|non-human treatment outcome|t080
complete physical examination
  1
  c0436120|physical examination, complete (procedure)|t058
analysis also invalidated objections
  3
  c0002778|analysis of substances|t059
  c0347997|physical object (physical object)|t073
  c0936012|analysis|t062
insufficient compensatory increase
  3
  c0231180|insufficient|t169
  c0442805|increase (qualifier value)|t169
  c0231186|compensatory|t169
gross changes
  3
  c0392747|changing|t169
  c0439806|gross (qualifier value)|t081
  c0443172|changed status|t081
local recurrence
  2
  c0205276|local (qualifier value)|t082
  c0034897|recurrence|t067
bowel morbidity
  3
  c0220880|morbidity aspects|t170
  c0026538|morbidity - disease rate|t102
  c0021853|intestines|t023
exact tests
  2
  c0059927|exact|t122
  c0392366|tests (qualifier value)|t170
uneven distribution
  2
  c0520511|distributing|t078
  c0037775|spatial distribution|t082
radiation fraction size
  3
  c0457426|fractions of (qualifier value)|t081
  c0851346|radiation|t070
  c0702146|size (attribute)|t081
pathologist
  1
  c0334866|medical pathologist (occupation)|t097
treatment related factors
  2
  c0445223|related (finding)|t033
  c0679853|treatment factors|t170
diseases
  1
  c0012634|disease|t047
distant recurrences
  2
  c0443203|distant (qualifier value)|t082
  c0034897|recurrence|t067
tumour invaded bladder
  3
  c1269955|status of invasion by tumor (observable entity)|t201
  c0005682|bladder|t023
  c1281573|entire bladder|t023
extended field radiotherapy
  4
  c0231449|extended (qualifier value)|t082
  c0034618|radiation therapy|t061
  c0440042|field's stain|t130
  c0034619|radiotherapeutic|t170
durations twenty four patients
  2
  c0449238|duration|t079
  c0030705|patients|t101
distant recurrence
  2
  c0443203|distant (qualifier value)|t082
  c0034897|recurrence|t067
left ventricular ejection fraction
  1
  c0428772|left ventricular ejection fraction (observable entity)|t034
grade predominantly granulocytopenia
  3
  c0332251|predominate (qualifier value)|t080
  c0441800|grade|t185
  c1261272|granulocytopenia|t046
two additional cycles
  3
  c0439596|cyclic (qualifier value)|t079
  c0442796|additive (qualifier value)|t080
  c0205448|two (qualifier value)|t081
severe bladder symptoms
  2
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0741548|bladder symptoms|t184
suspicious appearing lymph nodes
  4
  c0750493|suspicious|t078
  c0700364|appearance|t080
  c0233426|personal appearance|t032
  c0024204|lymph nodes|t023
conservative radical surgery
  6
  c0302912|radicals (chemistry)|t104
  c0543467|general operative procedures|t061
  c0439807|radical (qualifier value)|t080
  c0038895|surgical aspects|t169
  c0009800|conservatism|t078
  c0038894|surgery specialty|t091
sequential exposure
  3
  c0274281|effects of exposure to external causes|t037
  c0391838|exposure condition|t169
  c0728853|accident due to exposure to weather conditions|t037
two lateral fields
  4
  c0205093|lateral (qualifier value)|t082
  c0331809|fielding|t093
  c0440042|field's stain|t130
  c0205448|two (qualifier value)|t081
three different dose levels
  2
  c0441889|levels (qualifier value)|t170
  c0205449|three (qualifier value)|t081
additional histopathologic features
  3
  c0677043|histopathology|t046
  c0442796|additive (qualifier value)|t080
  c0243140|histopathological aspects|t169
increased acute toxicity
  4
  c0040539|toxicity aspects|t081
  c0205217|increased (qualifier value)|t169
  c0205178|acuteness (qualifier value)|t079
  c0600688|toxic effect|t037
pharmacokinetic studies
  1
  c0201734|pharmacokinetic study (procedure)|t059
other ancillary treatment
  3
  c0205394|other|t080
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
median survival times
  1
  c0591830|mst|t109
lateral margins
  3
  c0205093|lateral (qualifier value)|t082
  c1269830|tumor margin status|t033
  c0205284|marginal (qualifier value)|t082
non cross-resistant drugs often
  4
  c0013227|pharmaceutical preparations|t121
  c0205203|crossed (qualifier value)|t082
  c0332183|frequent (qualifier value)|t079
  c0332325|resistant (qualifier value)|t169
lymph nodes
  1
  c0024204|lymph nodes|t023
statement
  1
  c1301808|state (environment)|t083
assuming first five patients
  3
  c0205451|five (qualifier value)|t081
  c0030705|patients|t101
  c0205435|first (qualifier value)|t081
investigator chose one
  3
  c0812351|choosing|t041
  c0035173|research personnel|t097
  c0205447|one (qualifier value)|t081
schedules
  1
  c0086960|schedules|t170
cell type
  1
  c0449475|type of cell (qualifier value)|t170
great majority
  2
  c0549177|large|t080
  c0680220|majority|t054
worse survival
  4
  c0220921|survival aspects|t081
  c0332271|worsening (qualifier value)|t080
  c0038952|continuance of life|t052
  c1279889|deterioration of status|t080
pelvic rt
  1
  c0030797|pelvis|t029
percent reduction
  3
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
  c0439165|percent (qualifier value)|t081
standard treatment
  4
  c0038137|standards characteristics|t170
  c0087111|therapeutic procedure|t061
  c0175675|standards of weights and measures|t080
  c0039798|therapeutic aspects|t169
henschke applicators
  1
  c0179108|applicator (physical object)|t074
nonmeasurable disease
  1
  c0012634|disease|t047
noncardiac toxicity hematologic toxicity
  3
  c0205488|hematologic (qualifier value)|t169
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
initial accrual goal
  2
  c0018017|goals|t170
  c0205265|initial (qualifier value)|t079
adjuvant treatment
  3
  c0087111|therapeutic procedure|t061
  c0001551|adjuvants, immunologic|t129
  c0039798|therapeutic aspects|t169
bowel perforation
  1
  c0021845|intestinal perforation|t020
informed consent to
  1
  c0021430|informed consent|t058
mucocutaneous toxicity
  2
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
manifestation
  1
  c0205319|manifest (qualifier value)|t169
toxic reactions
  1
  c0542243|toxic reaction (nos)|t033
breast
  2
  c0006141|breast|t023
  c1268990|entire breast|t023
crude 5-year survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439234|year (qualifier value)|t079
total cumulative doses
  2
  c0439810|total (qualifier value)|t080
  c0719635|dos|t109
forty seven deaths
  2
  c0205453|seven (qualifier value)|t081
  c0011065|cessation of life|t040
materials
  1
  c0520510|materials|t167
antimetabolites methotrexate
  2
  c0003376|antimetabolites|t121
  c0025677|methotrexate|t109
incomplete pretreatment testing
  3
  c0205257|incomplete|t081
  c0039593|testing|t062
  c0728938|partial (qualifier value)|t081
excluding patients
  2
  c0030705|patients|t101
  c0332196|exclude (qualifier value)|t169
metastatic cancer
  2
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0346957|widespread metastatic malignant neoplastic disease (disorder)|t191
physiotherapy
  1
  c0949766|physical therapy techniques|t058
­ months
  1
  c0439231|month (qualifier value)|t079
various doses
  2
  c0719635|dos|t109
  c0440102|various (substance)|t130
five patients
  2
  c0205451|five (qualifier value)|t081
  c0030705|patients|t101
diagrams
  1
  c0681494|diagram|t170
late radiation morbidity scoring scheme
  5
  c0220880|morbidity aspects|t170
  c0449820|scores (qualifier value)|t081
  c0205087|late (qualifier value)|t079
  c0026538|morbidity - disease rate|t102
  c0851346|radiation|t070
other imbalances
  1
  c0205394|other|t080
baseline rnca scan
  2
  c0168634|baseline|t122
  c0441633|scanning|t060
total treatment
  3
  c0439810|total (qualifier value)|t080
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
cytotoxic infusion
  3
  c0574032|infusion (procedure)|t061
  c0010868|cytotoxin|t123
  c0596402|cytotoxicity|t049
probably definitive measure
  4
  c0750492|probably|t078
  c0332148|probable diagnosis|t080
  c0443196|definitive (qualifier value)|t079
  c0079809|measures|t081
four months
  2
  c0205450|four (qualifier value)|t081
  c0439231|month (qualifier value)|t079
therapeutic advantage
  3
  c0308269|advantage|t131
  c0039796|the science and art of healing|t061
  c0302350|therapeutic|t169
locoregional disease remaining
  1
  c0012634|disease|t047
tumours
  1
  c0027651|neoplasms|t191
large proportion
  2
  c0549177|large|t080
  c0205351|proportional (qualifier value)|t080
essentially adjustment
  5
  c0001537|clinical adjustment|t058
  c0683269|psychological adjustment|t055
  c0376209|individual adjustment|t055
  c0456081|adjustment action|t058
  c0205224|essential (qualifier value)|t080
two regimens
  2
  c0677937|regimen|t061
  c0205448|two (qualifier value)|t081
sample size
  1
  c0242618|sample size|t081
aspiration pneumonia
  1
  c0032290|pneumonia, aspiration|t047
alanine aminotransferases
  1
  c0001899|alanine transaminase|t116
grade hematologic toxicity
  4
  c0441800|grade|t185
  c0205488|hematologic (qualifier value)|t169
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
liposomal encapsulation
  2
  c0677902|liposomal|t169
  c0205223|encapsulated (qualifier value)|t080
long-term survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0443252|long-term (qualifier value)|t079
95% ci
  1
  c0162854|commonwealth of independent states|t083
other treatment variables
  4
  c0205394|other|t080
  c0087111|therapeutic procedure|t061
  c0439828|variable (qualifier value)|t080
  c0039798|therapeutic aspects|t169
normally cm
  2
  c0205307|normal (qualifier value)|t033
  c0475210|cm (qualifier value)|t081
computer based procedure
  3
  c0178499|base|t120
  c0184661|procedures|t058
  c0009622|computers|t073
previous gog study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205156|previous (qualifier value)|t082
metastasis
  1
  c0027627|neoplasm metastasis|t191
primary radical surgery
  7
  c0302912|radicals (chemistry)|t104
  c0439631|primary operation (qualifier value)|t061
  c0543467|general operative procedures|t061
  c0439807|radical (qualifier value)|t080
  c0038895|surgical aspects|t169
  c0205225|primary|t080
  c0038894|surgery specialty|t091
final dose
  2
  c0205088|end-stage (qualifier value)|t079
  c0178602|dosages (qualifier value)|t081
compared irinotecan
  1
  c0123931|irinotecan|t109
not problem
  1
  c0033213|problem (finding)|t033
unfavorable local behaviour
  2
  c0004927|behavior|t055
  c0205276|local (qualifier value)|t082
most frequently diagnosed malignancy
  5
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0205393|most (qualifier value)|t081
  c0006826|malignant neoplasms|t191
  c0332183|frequent (qualifier value)|t079
  c0011900|diagnosis|t060
fifth year
  2
  c0205439|fifth (qualifier value)|t081
  c0439234|year (qualifier value)|t079
dfs
  1
  c0011145|deferoxamine|t123
nutritional factors
  1
  c0331877|nutritionals|t093
cure rates
  1
  c0871208|rating|t062
southwest oncology group study
  5
  c0278627|oncology|t091
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
15% increase
  1
  c0442805|increase (qualifier value)|t169
17-1a antibody
  1
  c0003241|antibodies|t116
14.1 5 months
  1
  c0439231|month (qualifier value)|t079
hazards ratios
  2
  c0598697|hazard|t080
  c0456603|ratio (property) (qualifier value)|t170
radical external beam
  3
  c0302912|radicals (chemistry)|t104
  c0205101|external (qualifier value)|t082
  c0439807|radical (qualifier value)|t080
secondary objectives
  3
  c0036525|metastatic to|t169
  c0018017|goals|t170
  c0175668|secondary to|t079
two treatment groups
  2
  c0036669|sensitivity training groups|t065
  c0205448|two (qualifier value)|t081
randomly assigned patients irinotecan
  3
  c0123931|irinotecan|t109
  c0814868|random assignment|t062
  c0030705|patients|t101
pelvis
  2
  c0030797|pelvis|t029
  c1279864|entire pelvis|t023
written consensus
  3
  c0043266|writing|t090
  c0376298|consensus|t054
  c0341628|writer (occupation)|t097
manuscript
  1
  c0600659|manuscripts|t170
co workers
  2
  c0454802|cos (geographic location)|t083
  c0024752|workforce|t169
reduced fraction size
  3
  c0457426|fractions of (qualifier value)|t081
  c0392756|reduced (qualifier value)|t080
  c0702146|size (attribute)|t081
pelvic local failure rate
  5
  c0680095|personal failure|t055
  c0030797|pelvis|t029
  c0205276|local (qualifier value)|t082
  c0231174|failure (biologic function)|t169
  c0871208|rating|t062
pelvic sidewall lymph nodes
  1
  c0729595|pelvic lymph node group|t023
d iv bolus
  9
  c0439228|day (qualifier value)|t079
  c0332517|diameter (qualifier value)|t032
  c0677863|bolus|t061
  c0442123|intravascular (qualifier value)|t082
  c0442122|intravaginal (qualifier value)|t082
  c0011530|deoxyribose|t123
  c0348016|intravenous|t082
  c0442106|intervertebral (qualifier value)|t029
  c0205281|invasive (qualifier value)|t080
fractionation
  2
  c0524811|dose fractionation|t061
  c0016640|fractionation|t059
validated qlqc30 questionnaire
  1
  c0034394|questionnaires|t170
poor survival rates
  3
  c0542537|poor - grade value|t080
  c0038954|survival rate|t081
  c0699761|financially poor|t080
disease free 5-year survival
  2
  c0439234|year (qualifier value)|t079
  c0242793|disease-free survival|t081
portal phlebography
  2
  c0031545|phlebography|t060
  c0205054|hepatic|t029
global quality
  2
  c0205246|generalized (qualifier value)|t082
  c0332306|with quality (attribute)|t080
local relapse
  4
  c0205336|relapsing course|t079
  c0580802|relapse phase|t079
  c0205276|local (qualifier value)|t082
  c0035020|relapse|t067
dag
  1
  c0043791|1,2-diacylglycerol|t123
superficial stromal invasion
  2
  c0927195|stroma|t023
  c0205124|superficial (qualifier value)|t082
x10 white blood cells
  1
  c0023516|leukocytes|t025
diminished performance status
  2
  c0205216|decreased (qualifier value)|t080
  c0935728|performance status|t033
5-year overall survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439234|year (qualifier value)|t079
primary endpoint
  3
  c0439631|primary operation (qualifier value)|t061
  c0150100|endpoint|t062
  c0205225|primary|t080
added chemotherapy
  4
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0442796|additive (qualifier value)|t080
  c0013216|pharmacotherapy|t061
thyroid cancer
  2
  c1318516|malignant tumor of thyroid gland (disorder)|t191
  c0007115|thyroid cancer|t191
higher percentage
  2
  c0235146|euphoric mood|t041
  c0205250|high|t080
intraperitoneal disease
  2
  c0442120|intraperitoneal (qualifier value)|t082
  c0012634|disease|t047
fewer local relapses
  3
  c0205276|local (qualifier value)|t082
  c0205388|few (qualifier value)|t081
  c0035020|relapse|t067
hypogastric artery
  1
  c0226364|structure of internal iliac artery|t023
ohio
  1
  c0028905|ohio|t083
beta
  2
  c0439096|beta greek letter|t170
  c0330390|beta plant|t002
used doxorubicin
  2
  c0042153|utilization|t081
  c0013089|doxorubicin|t195
short duration
  1
  c0439593|short duration (qualifier value)|t080
combined irinotecan
  2
  c0123931|irinotecan|t109
  c0205195|combined (qualifier value)|t080
domestic animals
  1
  c0003063|animals, domestic|t008
breast cancer
  1
  c0006142|malignant neoplasm of breast|t191
meccnu arm
  3
  c0036637|semustine|t109
  c0003792|arm|t029
  c0446516|upper arm|t029
esophagus
  2
  c0014876|esophagus|t023
  c1278919|entire esophagus|t023
23% overall local relapse
  4
  c0282416|overall [publication type]|t170
  c0205336|relapsing course|t079
  c0580802|relapse phase|t079
  c0035020|relapse|t067
different times
  4
  c0392761|timed (qualifier value)|t169
  c0443199|differential (qualifier value)|t080
  c0040223|time|t079
  c0449243|timing (attribute)|t079
symptomatic chf
  2
  c0231220|symptomatic (qualifier value)|t169
  c0018802|heart failure, congestive|t047
other histological predictors
  3
  c0205394|other|t080
  c0681842|prediction|t170
  c0205462|histologic|t169
distant sites
  2
  c0443203|distant (qualifier value)|t082
  c0205145|associated topography (attribute)|t082
epi
  2
  c0014609|epithelium|t024
  c0014544|epilepsy|t047
medical oncologists
  1
  c0278631|medical oncologist (occupation)|t097
ileal spontaneous perforation
  4
  c0333324|spontaneous perforation (morphologic abnormality)|t020
  c0559938|perforation of ileum (disorder)|t037
  c0020885|ileum|t023
  c0205359|spontaneous (qualifier value)|t169
3/v2 months
  1
  c0439231|month (qualifier value)|t079
rtog study
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
similarity
  1
  c0871364|simile|t170
hemogram
  1
  c0200631|complete blood count without differential (procedure)|t059
patient
  1
  c0030705|patients|t101
questionnaire
  1
  c0034394|questionnaires|t170
palpation
  1
  c0030247|palpation|t060
alopecia
  1
  c0002170|alopecia|t184
reviews
  1
  c0282443|review [publication type]|t170
used radiotherapy concurrently
  4
  c0042153|utilization|t081
  c0205420|concurrent (qualifier value)|t079
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
correct written informed consent
  4
  c0043266|writing|t090
  c0021430|informed consent|t058
  c0719517|correct|t109
  c0341628|writer (occupation)|t097
log–rank test
  1
  c0392366|tests (qualifier value)|t170
two drugs
  2
  c0013227|pharmaceutical preparations|t121
  c0205448|two (qualifier value)|t081
surgical margins
  1
  c0229985|surgical margins (body structure)|t023
12.9 months
  1
  c0439231|month (qualifier value)|t079
seizures
  1
  c0036572|seizures|t184
poorer survival
  4
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0542537|poor - grade value|t080
  c0699761|financially poor|t080
rizzoli institute
  1
  c0021622|institutes|t092
5-year cure rate
  2
  c0439234|year (qualifier value)|t079
  c0871208|rating|t062
one
  1
  c0205447|one (qualifier value)|t081
objective response rates
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0018017|goals|t170
blometncal center
  1
  c0205099|central|t082
interrupted silk sutures
  2
  c0183745|silk suture, device (physical object)|t074
  c0443239|interrupted (qualifier value)|t080
received previous treatment
  4
  c0544683|reception|t042
  c0087111|therapeutic procedure|t061
  c0205156|previous (qualifier value)|t082
  c0039798|therapeutic aspects|t169
38.1 months
  1
  c0439231|month (qualifier value)|t079
ml
  1
  c0439242|ml (qualifier value)|t081
also difference
  1
  c0443199|differential (qualifier value)|t080
radiation also improved outcome
  2
  c0184511|improved (qualifier value)|t080
  c0851346|radiation|t070
other alkylating agent
  2
  c0205394|other|t080
  c0002073|alkylating agents|t131
other combination therapy
  5
  c0205394|other|t080
  c0556895|combination electrotherapy|t061
  c0009429|combined modality therapy|t061
  c0418967|other therapy nos (regime/therapy)|t061
  c0205195|combined (qualifier value)|t080
treatment administration
  4
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
major obstacle
  1
  c0205164|major (qualifier value)|t080
accurate continuing data
  2
  c0750536|continued|t078
  c0443131|accurate (qualifier value)|t080
grade 3.4 vomiting
  3
  c0441800|grade|t185
  c0042963|vomiting|t184
  c0401156|vomiting nos (disorder)|t047
possibly overall survival
  4
  c0282416|overall [publication type]|t170
  c0220921|survival aspects|t081
  c0332149|possible|t080
  c0038952|continuance of life|t052
possible therapeutic role
  4
  c0332149|possible|t080
  c0035820|role|t054
  c0039796|the science and art of healing|t061
  c0302350|therapeutic|t169
protocol mandated radiotherapy dose
  2
  c0034620|radiotherapy dosage|t081
  c0442711|protocols documentation|t170
fatal cns toxicity
  4
  c1302234|fatal (qualifier value)|t080
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0927232|neuraxis|t023
lymphoma
  1
  c0024299|lymphoma|t191
cox model trying to
  1
  c0010234|cox models|t170
patient eligibility
  1
  c0030705|patients|t101
same method
  2
  c0025663|methods|t170
  c0445247|same (qualifier value)|t080
proliferation
  1
  c0334094|proliferation (morphologic abnormality)|t169
1.9 percent
  1
  c0439165|percent (qualifier value)|t081
received prior radiation sensitizer treatment
  5
  c0544683|reception|t042
  c0087111|therapeutic procedure|t061
  c0750516|prior|t078
  c0034541|radiation-sensitizing agents|t121
  c0039798|therapeutic aspects|t169
histological type
  1
  c0449574|histological type (attribute)|t170
anaesthetics
  2
  c0002932|anesthetics|t121
  c0002930|anesthesiology|t091
previous studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205156|previous (qualifier value)|t082
colon cancer subgroups
  1
  c0007102|malignant tumor of colon|t191
cervical carcinomas
  1
  c0302592|carcinoma of cervix (disorder)|t191
surgery only
  3
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0038894|surgery specialty|t091
3.9 months
  1
  c0439231|month (qualifier value)|t079
neutropenic fever
  1
  c0948631|neutropenic fever|t047
comparison group
  2
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
febrile neutropenia
  1
  c0746883|febrile neutropenia|t047
planned dose
  2
  c1301732|planned (qualifier value)|t169
  c0178602|dosages (qualifier value)|t081
observations
  2
  c0700325|patient observation|t061
  c0302523|observation in research|t062
significantly greater frequency
  3
  c0443228|greater (qualifier value)|t081
  c0376249|with frequency|t081
  c0750502|significant (qualifier value)|t078
similar regimens
  2
  c0871364|simile|t170
  c0677937|regimen|t061
lowest granulocyte
  3
  c0018183|granulocytes|t025
  c0441994|lower (qualifier value)|t169
  c0205251|low (qualifier value)|t080
radiation therapy treatment arm
  5
  c1292734|treats (attribute)|t185
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
  c0003792|arm|t029
  c0446516|upper arm|t029
patient survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0030705|patients|t101
radiotherapy records
  3
  c0034869|records|t170
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
estimating disease-free survival
  2
  c0750572|estimated|t078
  c0242793|disease-free survival|t081
40-yr-old mutation theory
  2
  c0871935|theories|t078
  c0439234|year (qualifier value)|t079
third countries
  2
  c0454664|countries (geographic location)|t083
  c0205437|third (qualifier value)|t081
nodal metastases
  3
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0443268|nodal (qualifier value)|t082
  c0027627|neoplasm metastasis|t191
same degree
  3
  c0542560|academic degree|t170
  c0449286|degree or extent|t080
  c0445247|same (qualifier value)|t080
mannitol mg
  3
  c0024467|magnesium|t123
  c0439210|milligram|t081
  c0024730|mannitol|t118
disease stages
  2
  c0449385|staging of disease (attribute)|t170
  c0699749|disease stage|t060
subsequent treatment
  3
  c0087111|therapeutic procedure|t061
  c0750530|subsequent|t078
  c0039798|therapeutic aspects|t169
obvious explanation
  1
  c0681841|explanation|t062
enhancement
  1
  c0086222|enhancer|t114
major drug
  2
  c0205164|major (qualifier value)|t080
  c0013227|pharmaceutical preparations|t121
perforation
  1
  c0549099|perforation (morphologic abnormality)|t020
n
  1
  c0439225|ns (qualifier value)|t081
microscopically negative resection margins
  6
  c1269830|tumor margin status|t033
  c0205160|negative (qualifier value)|t080
  c0205288|microscopic (qualifier value)|t080
  c0205284|marginal (qualifier value)|t082
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
d x days
  2
  c0439228|day (qualifier value)|t079
  c0078606|xanthosine|t114
essentially identical estimates
  3
  c0750572|estimated|t078
  c0205280|identical (qualifier value)|t080
  c0205224|essential (qualifier value)|t080
two sided p values
  4
  c0879541|p-value|t081
  c0441987|side (qualifier value)|t082
  c0457012|sidedness (qualifier value)|t082
  c0205448|two (qualifier value)|t081
clinical reason to
  2
  c0205210|clinical (qualifier value)|t080
  c0684328|reasoning|t041
strategies
  1
  c0679199|strategy|t041
retrospectively hama positive sera
  3
  c0035363|retrospective studies|t081
  c0229671|serum|t024
  c0205159|positive (qualifier value)|t080
controlled studies
  1
  c0681867|controlled study|t062
nuclear proliferation markers
  2
  c0521447|nuclear|t082
  c0812274|proliferation markers|t123
interstitial brachytherapy
  1
  c0203580|interstitial brachytherapy (regime/therapy)|t061
80% power
  1
  c0032863|power (psychology)|t068
ii lymph nodes
  2
  c0024204|lymph nodes|t023
  c0439069|roman numeral ii|t170
iia carcinoma
  1
  c0007097|carcinoma|t191
patient related prognostic factor
  3
  c0445223|related (finding)|t033
  c0220901|prognostic|t170
  c0030705|patients|t101
surgical intervention
  1
  c0549433|surgical intervention|t033
hospitals
  1
  c0019994|hospitals|t093
large randomized trial
  2
  c0549177|large|t080
  c0034656|random allocation|t062
one scale
  4
  c0175659|weight measurement scales|t073
  c0349674|intellectual scale|t170
  c0222045|integumentary scale|t023
  c0205447|one (qualifier value)|t081
substantial improvements
  3
  c0184511|improved (qualifier value)|t080
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
4–5 years
  1
  c0439234|year (qualifier value)|t079
levels
  1
  c0441889|levels (qualifier value)|t170
twenty two patients
  2
  c0030705|patients|t101
  c0205448|two (qualifier value)|t081
hypothetical mechanisms
  1
  c0441712|mechanisms (qualifier value)|t067
liver function tests
  1
  c0023901|liver function tests|t059
other combinations
  2
  c0205394|other|t080
  c0453882|combinations (physical object)|t073
normal epithelial cells
  2
  c0014597|epithelial cells|t025
  c0205307|normal (qualifier value)|t033
five prs
  2
  c0205451|five (qualifier value)|t081
  c0279766|progesterone receptor negative|t034
significantly different prognoses
  3
  c0033325|forecast of outcome|t058
  c0443199|differential (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
selection
  1
  c0036576|selection (genetics)|t045
clinical deviations
  2
  c0012727|spatial displacement|t082
  c0205210|clinical (qualifier value)|t080
important increase
  1
  c0442805|increase (qualifier value)|t169
perioperative period
  3
  c0332182|periodic (qualifier value)|t079
  c0231379|at risk for joint contractures (finding)|t033
  c0231393|at risk for cognitive impairment (finding)|t033
bilirubin 1.2 mg
  3
  c0005437|bilirubin|t123
  c0024467|magnesium|t123
  c0439210|milligram|t081
further patient
  1
  c0030705|patients|t101
medical illness
  2
  c0205476|medical (qualifier value)|t169
  c0221423|illness (finding)|t046
circular coiled spring
  2
  c1282913|circular (qualifier value)|t082
  c0009249|coiled spring|t074
large hypoxic cell component
  3
  c0549177|large|t080
  c0243092|cellular structures|t026
  c0242184|oxygen deficiency|t046
concurrent multiagent chemoradiotherapy
  1
  c0205420|concurrent (qualifier value)|t079
high-risk features
  3
  c0235146|euphoric mood|t041
  c0205250|high|t080
  c0035647|risk|t080
only randomized trial
  1
  c0034656|random allocation|t062
pelvic disease
  2
  c0030797|pelvis|t029
  c0012634|disease|t047
previous trial
  1
  c0205156|previous (qualifier value)|t082
single drug combination
  4
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0013162|drug combinations|t121
  c0087136|unmarried|t098
fourth portion
  1
  c0205438|fourth (qualifier value)|t081
there skin reaction
  1
  c0221743|skin reaction (observable entity)|t034
additional dose
  2
  c0442796|additive (qualifier value)|t080
  c0178602|dosages (qualifier value)|t081
biochemical modulation approaches
  3
  c0449445|approach (attribute)|t082
  c0443264|modulated (qualifier value)|t082
  c0205474|biochemical (qualifier value)|t169
lung metastases
  1
  c0153676|secondary malignant neoplasm of lung (disorder)|t191
blood transfusions
  1
  c0005841|blood transfusion|t061
optimal method
  1
  c0025663|methods|t170
compensatory boost
  2
  c0857515|booster|t061
  c0231186|compensatory|t169
current practice
  2
  c0521116|current (qualifier value)|t079
  c0237607|experience (practice)|t041
granulocyte colony-stimulating factor
  1
  c0079459|granulocyte colony-stimulating factor|t116
stricture
  1
  c0333187|stricture (morphologic abnormality)|t190
exact time
  2
  c0059927|exact|t122
  c0040223|time|t079
6.5 months
  1
  c0439231|month (qualifier value)|t079
preoperative radiation therapy
  3
  c0034618|radiation therapy|t061
  c0445204|preoperative (qualifier value)|t032
  c0034619|radiotherapeutic|t170
course
  1
  c0449922|course (attribute)|t079
chances
  1
  c0237506|chance|t080
para-aortic recurrence
  2
  c0442134|para-aortic (qualifier value)|t082
  c0034897|recurrence|t067
cervical diameters
  2
  c0332517|diameter (qualifier value)|t032
  c0205064|cervical (qualifier value)|t082
nursing women
  4
  c0043209|human females|t098
  c0043210|human adult females|t098
  c0028677|discipline of nursing|t091
  c0028678|nursing therapy|t061
approximately percent
  2
  c0332232|approximate (qualifier value)|t169
  c0439165|percent (qualifier value)|t081
axis
  4
  c0728839|electrocardiographic axis|t201
  c1321509|entire axis vertebra|t023
  c0004457|axis vertebra|t017
  c0999597|genus axis|t015
excess mortality
  1
  c0079320|mortality, excess|t081
cystitis
  1
  c0010692|cystitis|t047
chest roentgenogram
  2
  c1306645|plain film (procedure)|t060
  c0817096|chest|t029
substantially increased incidence
  1
  c0220888|increasing incidence|t169
receiving adjuvant chemotherapy
  2
  c0544683|reception|t042
  c0085533|chemotherapy, adjuvant|t061
ethical considerations
  2
  c0086267|ethicists|t097
  c0518609|consideration|t033
statistical analysis
  1
  c0871424|statistical analysis|t062
univariate analyses of variance
  1
  c0002780|analysis of variance|t081
calcium folinate mg
  3
  c0731033|leucovorin calcium|t109
  c0024467|magnesium|t123
  c0439210|milligram|t081
peak level
  2
  c0444505|peak (qualifier value)|t081
  c0456079|disease classification level|t185
disease free survival
  1
  c0242793|disease-free survival|t081
significantly better quality
  3
  c0332306|with quality (attribute)|t080
  c0332272|better (qualifier value)|t080
  c0750502|significant (qualifier value)|t078
vast majority
  2
  c0680220|majority|t054
  c0814230|veterans alcoholism screening test|t170
high risk
  3
  c0235146|euphoric mood|t041
  c0205250|high|t080
  c0035647|risk|t080
eplthehal cell adhesion molecule
  1
  c0007578|cell adhesion molecules|t116
20% improvement
  3
  c0184511|improved (qualifier value)|t080
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
reduced motility
  2
  c0392756|reduced (qualifier value)|t080
  c0678835|motility (finding)|t040
presented results still
  3
  c0424228|stillness (finding)|t033
  c1274040|result (navigational concept)|t169
  c0150312|present|t169
g csf
  1
  c0079459|granulocyte colony-stimulating factor|t116
three drug regimen
  3
  c0013227|pharmaceutical preparations|t121
  c0677937|regimen|t061
  c0205449|three (qualifier value)|t081
distant metastasis
  1
  c1269798|pm category (observable entity)|t201
eighty six percent
  2
  c0205452|six (qualifier value)|t081
  c0439165|percent (qualifier value)|t081
complete staging
  3
  c0332305|with staging (attribute)|t169
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
percent improvement
  4
  c0184511|improved (qualifier value)|t080
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
  c0439165|percent (qualifier value)|t081
criterion
  1
  c0243161|criteria|t170
so far patient
  1
  c0030705|patients|t101
following criteria
  2
  c0332282|following (attribute)|t079
  c0243161|criteria|t170
fifty nine patients
  2
  c0030705|patients|t101
  c0205455|nine (qualifier value)|t081
significant treatment effects
  4
  c1280500|effect (qualifier value)|t080
  c0087111|therapeutic procedure|t061
  c0750502|significant (qualifier value)|t078
  c0039798|therapeutic aspects|t169
stage group
  4
  c0684248|stage of surgical procedure|t079
  c0027646|diagnostic neoplasm staging|t060
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
pelvic lymph node metastases
  6
  c0729595|pelvic lymph node group|t023
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0030797|pelvis|t029
  c1280315|entire pelvic lymph node|t023
  c0027627|neoplasm metastasis|t191
  c0686619|secondary malignant neoplasm of lymph node (disorder)|t191
same results
  2
  c1274040|result (navigational concept)|t169
  c0445247|same (qualifier value)|t080
measurement
  1
  c0242485|measurement|t081
conclusion
  1
  c0917903|conclude|t122
bite
  1
  c0005658|bites|t037
histopathologic confirmation
  3
  c0677043|histopathology|t046
  c0243140|histopathological aspects|t169
  c0750484|confirmed|t078
less hematologic toxicity
  3
  c0205488|hematologic (qualifier value)|t169
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
invasive procedures
  1
  c0038895|surgical aspects|t169
only assessable patients
  2
  c1261322|assessment procedure (procedure)|t058
  c0030705|patients|t101
current pessimistic view
  3
  c0424134|pessimistic (finding)|t041
  c0449911|view (attribute)|t032
  c0521116|current (qualifier value)|t079
primary outcome variable
  3
  c0439631|primary operation (qualifier value)|t061
  c0439828|variable (qualifier value)|t080
  c0205225|primary|t080
postsurgical complications
  1
  c0742723|complication postsurgical|t033
or mg
  3
  c0069590|oralit|t197
  c0024467|magnesium|t123
  c0439210|milligram|t081
fm sequence
  1
  c0015853|fermium|t196
5.1 months
  1
  c0439231|month (qualifier value)|t079
34-kd glycoprotein
  1
  c0017968|glycoproteins|t116
specific strata
  2
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
radiologic findings
  1
  c1290916|radiologic finding (finding)|t034
3-year survival rates
  2
  c0038954|survival rate|t081
  c0439234|year (qualifier value)|t079
table i
  2
  c1168570|table - visual aid|t170
  c0039224|table - furniture|t073
randomized clinical trial to
  1
  c0206034|clinical trials, randomized|t170
more granulocytopenia
  2
  c0205172|more (qualifier value)|t081
  c1261272|granulocytopenia|t046
supportive care groups
  2
  c0344211|supportive care|t058
  c0441833|groups (qualifier value)|t170
adequate renal function
  3
  c0205411|adequate (qualifier value)|t080
  c0232804|renal function, nos|t042
  c0042031|urinary tract physiology|t042
several authors
  2
  c0221192|author (occupation)|t097
  c0443302|several (qualifier value)|t081
ifosfamide
  1
  c0020823|ifosfamide|t115
diameter cm
  2
  c0332517|diameter (qualifier value)|t032
  c0475210|cm (qualifier value)|t081
response durations
  1
  c0237585|response duration|t079
infectious complications
  1
  c0940933|complication, infection|t047
survival benefits
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0814225|benefits|t081
overall disease burden
  2
  c0282416|overall [publication type]|t170
  c0012634|disease|t047
minutes
  3
  c0700321|small|t080
  c0439232|minute of time|t079
  c1282918|minute (qualifier value)|t080
maximum
  1
  c0806909|maximum|t033
13.1 g
  1
  c0162832|apc gene|t028
median survival
  4
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
intensified treatment
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
disease stage
  1
  c0699749|disease stage|t060
0.05 level
  1
  c0456079|disease classification level|t185
randomized patients
  2
  c0030705|patients|t101
  c0034656|random allocation|t062
even cr
  2
  c0587117|evening (qualifier value)|t079
  c0008574|chromium|t123
equal lengths
  2
  c0439537|lengths (qualifier value)|t081
  c0205163|equal (qualifier value)|t080
survival
  2
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
third years
  2
  c0439234|year (qualifier value)|t079
  c0205437|third (qualifier value)|t081
paclitaxel
  1
  c0144576|paclitaxel|t109
prior hysterectomy
  2
  c0020699|hysterectomy|t061
  c0750516|prior|t078
69% response rate
  2
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
observed differences
  4
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0443199|differential (qualifier value)|t080
  c0870992|observers|t097
origins
  2
  c0079946|national origin|t082
  c0439659|beginning|t079
years follow-up
  2
  c0439234|year (qualifier value)|t079
  c0589120|follow-up status (finding)|t169
indeed important advance
  1
  c0725066|advance|t074
first time
  2
  c0205435|first (qualifier value)|t081
  c0040223|time|t079
m orally
  1
  c0442027|oral (qualifier value)|t082
antigen
  1
  c0003320|antigens|t129
excellent early tumor response
  3
  c0871261|responses|t054
  c0205085|early (qualifier value)|t079
  c0027651|neoplasms|t191
more patients
  2
  c0205172|more (qualifier value)|t081
  c0030705|patients|t101
treatment sequences
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
treatment-related death
  4
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0011065|cessation of life|t040
germany
  1
  c0017480|germany|t083
effective treatment
  3
  c0205414|effective (qualifier value)|t080
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
5-year findings
  2
  c0243095|findings|t169
  c0439234|year (qualifier value)|t079
final analysis
  3
  c0205088|end-stage (qualifier value)|t079
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
bleeding
  1
  c0019080|hemorrhage|t046
anemia
  2
  c0002871|anemia|t047
  c1000483|genus anemia|t002
proportions
  1
  c0205351|proportional (qualifier value)|t080
recurrence status
  2
  c0449438|status (attribute)|t080
  c0034897|recurrence|t067
null hypothesis
  1
  c0456148|null (qualifier value)|t033
transfusion
  1
  c0199960|transfusion - action (qualifier value)|t061
larger benefit
  2
  c0443228|greater (qualifier value)|t081
  c0814225|benefits|t081
metastatic disease
  1
  c0027627|neoplasm metastasis|t191
only supportive palliative treatment
  1
  c0030231|palliative care|t058
fluorouracil combination
  2
  c0016360|fluorouracil|t114
  c0205195|combined (qualifier value)|t080
additional concern
  1
  c0442796|additive (qualifier value)|t080
superiority
  1
  c0680218|superiority|t054
tumour
  1
  c0027651|neoplasms|t191
modulation
  1
  c0443264|modulated (qualifier value)|t082
clinical findings
  1
  c0586173|clinical finding (finding)|t033
median 2.6 yr
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0439234|year (qualifier value)|t079
vincristine mg
  3
  c0042679|vincristine|t109
  c0024467|magnesium|t123
  c0439210|milligram|t081
creatinine clearance 1.17 ml
  2
  c0812399|creatinine clearance|t033
  c0439242|ml (qualifier value)|t081
significant factors
  1
  c0750502|significant (qualifier value)|t078
local ethics committee approval
  2
  c0205276|local (qualifier value)|t082
  c0085546|ethics committees|t097
partial response rates
  5
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0677924|partial response|t080
  c0871208|rating|t062
  c0728938|partial (qualifier value)|t081
preliminary findings
  2
  c0243095|findings|t169
  c0439611|preliminary (qualifier value)|t079
examined treatment group
  2
  c0036669|sensitivity training groups|t065
  c0579007|examination - action (qualifier value)|t169
thymidine regimen
  2
  c0040077|thymidine|t123
  c0677937|regimen|t061
elimination
  2
  c0518891|elimination outcomes|t170
  c0221102|excretory function|t039
chf
  1
  c0018802|heart failure, congestive|t047
one observed patient
  5
  c0700325|patient observation|t061
  c0302523|observation in research|t062
  c0030705|patients|t101
  c0205447|one (qualifier value)|t081
  c0870992|observers|t097
single layer technique exclusively
  5
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0934502|layer|t023
  c0449851|techniques|t170
  c0087136|unmarried|t098
stage i cervical cancer
  1
  c0278575|cervix carcinoma stage i|t191
treatment to
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
iv bicarbonate to
  6
  c0442123|intravascular (qualifier value)|t082
  c0442122|intravaginal (qualifier value)|t082
  c0005367|bicarbonates|t197
  c0348016|intravenous|t082
  c0442106|intervertebral (qualifier value)|t029
  c0205281|invasive (qualifier value)|t080
only significant factor predicting
  2
  c0681842|prediction|t170
  c0750502|significant (qualifier value)|t078
antiemetics
  1
  c0003297|antiemetics|t121
ratio
  1
  c0456603|ratio (property) (qualifier value)|t170
somewhat contrasting results
  1
  c1274040|result (navigational concept)|t169
baseline value
  2
  c0168634|baseline|t122
  c0042295|valuing|t080
three treatment-related deaths
  5
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0011065|cessation of life|t040
  c0205449|three (qualifier value)|t081
negative nodes
  2
  c0205160|negative (qualifier value)|t080
  c0746922|node|t023
girdles
  1
  c0453903|girdle (physical object)|t073
first metastasis
  2
  c0027627|neoplasm metastasis|t191
  c0205435|first (qualifier value)|t081
treatment volume
  3
  c0449468|volume (property) (qualifier value)|t081
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
and whitney cw
  1
  c0332290|consistent with (qualifier value)|t078
liver only
  3
  c0023899|liver extract|t123
  c0023884|liver|t023
  c1278929|entire liver|t023
three cycles
  2
  c0439596|cyclic (qualifier value)|t079
  c0205449|three (qualifier value)|t081
cgy
  1
  c0556645|cgy (qualifier value)|t081
liver involvement
  1
  c0441932|hepatic involvement|t185
italian prospective randomised trial
  2
  c0022275|italian language (qualifier value)|t171
  c0034656|random allocation|t062
uterus
  2
  c1269032|entire uterus|t023
  c0042149|uterus|t023
single layer anastomosis always
  7
  c0205171|singular|t081
  c0037179|unmarried person|t098
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
  c0934502|layer|t023
  c0087136|unmarried|t098
effectiveness
  2
  c0205414|effective (qualifier value)|t080
  c1280519|effectiveness (qualifier value)|t170
41.5 months
  1
  c0439231|month (qualifier value)|t079
skull
  1
  c0037303|bone structure of cranium|t023
occult local metastases
  4
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0205262|occult (qualifier value)|t169
  c0205276|local (qualifier value)|t082
  c0027627|neoplasm metastasis|t191
radiation dose
  1
  c0034524|radiation dosage|t081
most important hematologic side effect
  2
  c0205393|most (qualifier value)|t081
  c0001688|adverse effects|t037
lymph node status
  1
  c0449927|lymph nodal status (attribute)|t080
anterior resection
  3
  c0205094|anterior|t082
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
other groups
  2
  c0205394|other|t080
  c0441833|groups (qualifier value)|t170
rectal surgical group
  4
  c0441833|groups (qualifier value)|t170
  c0038895|surgical aspects|t169
  c0205052|rectal (qualifier value)|t082
  c1300322|group (social concept)|t096
superior response rates
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0205105|superior (qualifier value)|t082
methyl ccnu
  1
  c0036637|semustine|t109
higher cumulative doses
  1
  c0444956|high dose (qualifier value)|t081
suspected cases
  2
  c0868928|case (qualifier value)|t169
  c0332147|suspected diagnosis (contextual qualifier) (qualifier value)|t080
adequate medullary reserve
  3
  c0376152|marrow|t023
  c0205411|adequate (qualifier value)|t080
  c0086590|vegetable marrow|t168
current protocols
  2
  c0442711|protocols documentation|t170
  c0521116|current (qualifier value)|t079
bmdp statistical software to
  2
  c0037585|computer software|t170
  c0220917|statistical|t170
long-term complications
  3
  c1171258|complication aspects|t046
  c0443252|long-term (qualifier value)|t079
  c0009566|complication|t046
appearance
  2
  c0700364|appearance|t080
  c0233426|personal appearance|t032
date
  1
  c0011008|dates|t079
first published report
  4
  c0700287|reporting|t058
  c0034037|publishing|t057
  c0205435|first (qualifier value)|t081
  c0684224|report (document)|t170
abnormalities
  2
  c0000769|teratologic|t169
  c0000768|congenital abnormality|t019
ecog performance status
  2
  c0430797|electrocorticogram (procedure)|t060
  c0935728|performance status|t033
bone x-rays
  1
  c0848406|x-ray, bones|t060
m bolus
  1
  c0677863|bolus|t061
rats
  2
  c0034693|rattus norvegicus|t015
  c0034721|rattus|t015
mplr stepping option
  1
  c0859325|stepping|t184
layers
  1
  c0934502|layer|t023
adjuvant combination chemotherapy
  4
  c0085533|chemotherapy, adjuvant|t061
  c0001551|adjuvants, immunologic|t129
  c0013218|drug therapy, combination|t061
  c0205195|combined (qualifier value)|t080
tumor response definitions
  2
  c0871261|responses|t054
  c0027651|neoplasms|t191
one patient
  2
  c0030705|patients|t101
  c0205447|one (qualifier value)|t081
end point
  1
  c0150100|endpoint|t062
alpha
  1
  c0439095|alpha (qualifier value)|t170
life-threatening toxicities
  2
  c0600688|toxic effect|t037
  c0376558|life|t078
discussion
  1
  c0557061|discussion (procedure)|t061
tumor-specific antigen
  5
  c0041361|tumor antigens|t129
  c0456981|specific antigen (substance)|t129
  c0027651|neoplasms|t191
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
prolonged myelosuppression
  2
  c0854467|myelosuppression (finding)|t047
  c0439590|prolonged (qualifier value)|t079
early recurrence
  2
  c0205085|early (qualifier value)|t079
  c0034897|recurrence|t067
confidence
  1
  c0237529|self-confidence (observable entity)|t041
two intracavitary implants
  3
  c0021102|implants|t074
  c0205448|two (qualifier value)|t081
  c1298613|intracavitary (qualifier value)|t082
infusion group
  3
  c0574032|infusion (procedure)|t061
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
different scheduling
  3
  c0205539|scheduled (qualifier value)|t169
  c0086960|schedules|t170
  c0443199|differential (qualifier value)|t080
fewer recurrences
  2
  c0034897|recurrence|t067
  c0205388|few (qualifier value)|t081
postoperative course
  2
  c0449922|course (attribute)|t079
  c0032790|postoperative period|t079
late treatment-related toxicity
  6
  c0205087|late (qualifier value)|t079
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0039798|therapeutic aspects|t169
radiological physics
  1
  c0018725|health physics|t091
initial resting lvef
  2
  c0035253|rest|t056
  c0205265|initial (qualifier value)|t079
reported two deaths
  3
  c0700287|reporting|t058
  c0205448|two (qualifier value)|t081
  c0011065|cessation of life|t040
days
  1
  c0439228|day (qualifier value)|t079
pretreatment surgical evaluation
  3
  c1261322|assessment procedure (procedure)|t058
  c0038895|surgical aspects|t169
  c0220825|evaluation|t169
unknown risk
  2
  c0439673|unknown (qualifier value)|t078
  c0035647|risk|t080
yet patient
  1
  c0030705|patients|t101
one adjuvant
  2
  c0001551|adjuvants, immunologic|t129
  c0205447|one (qualifier value)|t081
therapeutic activity
  5
  c0600075|endurance of activity|t033
  c0441655|activities|t052
  c0221187|physical activity|t056
  c0039796|the science and art of healing|t061
  c0302350|therapeutic|t169
convincing reason to
  1
  c0684328|reasoning|t041
several trials
  1
  c0443302|several (qualifier value)|t081
bowel
  1
  c0021853|intestines|t023
encouragement
  1
  c0870494|encouragement|t054
adenosquamous carcinoma
  1
  c0206623|carcinoma, adenosquamous|t191
paraortic lymph nodes
  1
  c0229789|aortic lymph node (body structure)|t023
same regimen
  2
  c0445247|same (qualifier value)|t080
  c0677937|regimen|t061
theoretically tumor
  1
  c0027651|neoplasms|t191
weekly treatment
  3
  c0087111|therapeutic procedure|t061
  c0332174|weekly (qualifier value)|t079
  c0039798|therapeutic aspects|t169
low-dose cmf
  2
  c0950521|cmf|t061
  c0445550|low dose (qualifier value)|t081
malignant hepatomegaly
  3
  c0019209|hepatomegaly|t184
  c0006826|malignant neoplasms|t191
  c0205282|malignant - descriptor|t080
pregnancy
  1
  c0032961|pregnancy|t040
component
  1
  c0449432|component (attribute)|t073
chronic neurological bladder
  4
  c0005682|bladder|t023
  c0205494|neurologic (qualifier value)|t169
  c1281573|entire bladder|t023
  c0205191|chronic (qualifier value)|t079
persistent squamous cell carcinoma
  2
  c0205322|persistent (qualifier value)|t079
  c0007137|carcinoma, squamous cell|t191
systemic treatment
  3
  c0205373|systemic (qualifier value)|t169
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
postmortem study
  1
  c0683946|postmortem study|t062
cost
  2
  c0010186|financial cost|t081
  c0220812|cost aspects|t081
metastatic tumor cells
  4
  c0007634|cells|t025
  c0431085|[m]unspecified tumor cell nos (morphologic abnormality)|t191
  c0036525|metastatic to|t169
  c0027627|neoplasm metastasis|t191
abdominal perineal resection
  4
  c0031066|anogenital region|t029
  c0456438|abdominal (qualifier value)|t082
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
median delay
  3
  c0205421|deferred (qualifier value)|t079
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
thymidine
  1
  c0040077|thymidine|t123
dose reduction criteria
  4
  c0301630|reduction (chemical)|t070
  c0178602|dosages (qualifier value)|t081
  c0243161|criteria|t170
  c0441610|reduction - action|t061
bulky disease
  1
  c0012634|disease|t047
chronic organ damage
  3
  c0178784|organ|t023
  c0010957|damage (morphologic abnormality)|t169
  c0205191|chronic (qualifier value)|t079
stage ib cervical cancer risk factors
  2
  c0278582|cervical carcinoma stage ib|t191
  c0035648|risk factors|t081
top
  1
  c0000811|termination of pregnancy|t061
kg
  1
  c0439209|kg (qualifier value)|t081
radiotherapy also
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
treatment planning
  1
  c0599880|plan of treatment|t170
eastern cooperative oncology group
  1
  c0430797|electrocorticogram (procedure)|t060
substantial decrease
  1
  c0547047|decrease (qualifier value)|t081
treatment-related deaths
  4
  c0445223|related (finding)|t033
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
  c0011065|cessation of life|t040
operation
  1
  c0543467|general operative procedures|t061
higher treatmentrelated toxicity
  4
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0235146|euphoric mood|t041
  c0205250|high|t080
mastectomy
  1
  c0024881|mastectomy|t061
findings
  1
  c0243095|findings|t169
two further patients
  2
  c0030705|patients|t101
  c0205448|two (qualifier value)|t081
numbers
  1
  c0237753|numbers (qualifier value)|t170
middle
  1
  c0549183|median (qualifier value)|t082
five minute
  4
  c0205451|five (qualifier value)|t081
  c0700321|small|t080
  c0439232|minute of time|t079
  c1282918|minute (qualifier value)|t080
ulceration present
  2
  c0041582|ulcer|t046
  c0150312|present|t169
tumor
  1
  c0027651|neoplasms|t191
blood pressure
  2
  c0428878|arterial pressure|t033
  c0005823|blood pressure|t033
tumor cell burden
  1
  c0431085|[m]unspecified tumor cell nos (morphologic abnormality)|t191
cumulative incidence function estimates
  6
  c0021149|incidence|t081
  c0750572|estimated|t078
  c0542341|function|t169
  c0220856|incidence of cases|t169
  c0700205|function axis|t185
  c0031843|physiological aspects|t039
second study
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0205436|second (qualifier value)|t081
extension
  1
  c0231448|extension (qualifier value)|t042
undergone radical hysterectomy
  1
  c0677962|total hysterectomy (procedure)|t061
12-channel biochemical profile
  2
  c0439799|channel (qualifier value)|t082
  c0205474|biochemical (qualifier value)|t169
one advantage
  2
  c0308269|advantage|t131
  c0205447|one (qualifier value)|t081
dose to
  1
  c0178602|dosages (qualifier value)|t081
final status
  2
  c0205088|end-stage (qualifier value)|t079
  c0449438|status (attribute)|t080
vaginal stenosis
  1
  c0269207|stenosis of vagina (disorder)|t190
possible explanatory mechanism
  3
  c0332149|possible|t080
  c0681841|explanation|t062
  c0457274|mechanism (attribute)|t169
because radiation therapy
  2
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
two hours
  2
  c0439227|hour|t079
  c0205448|two (qualifier value)|t081
log rank test
  3
  c0699794|rank|t170
  c0392366|tests (qualifier value)|t170
  c0335467|logger (occupation)|t097
same drugs
  2
  c0445247|same (qualifier value)|t080
  c0013227|pharmaceutical preparations|t121
l hypoxanthine
  12
  c0020684|hypoxanthine|t123
  c0442022|lumbar (qualifier value)|t082
  c0392223|lights, manufactured|t074
  c0023870|lithium|t196
  c0336769|lighter, device (physical object)|t073
  c0023693|light|t070
  c0302908|liquid substance|t167
  c0023700|lighting|t068
  c1304698|liquid (finding)|t033
  c0205091|left (qualifier value)|t082
  c1306462|light color|t169
  c0475211|l (qualifier value)|t081
limited value
  2
  c0439801|limited (qualifier value)|t169
  c0042295|valuing|t080
r0 resection
  2
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
other complications
  1
  c0009566|complication|t046
platelet counts
  1
  c0032181|platelet count|t059
secondary colorectal cancer
  6
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0036525|metastatic to|t169
  c0555952|colorectal (qualifier value)|t082
  c0027627|neoplasm metastasis|t191
  c0175668|secondary to|t079
  c0009402|colorectal cancer|t191
frequencies
  1
  c0439603|frequencies (time pattern)|t079
evaluable populations
  3
  c0032659|population|t081
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
treatment centre
  3
  c0205099|central|t082
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
leukocyte
  1
  c0023516|leukocytes|t025
two local relapse
  5
  c0205336|relapsing course|t079
  c0580802|relapse phase|t079
  c0205276|local (qualifier value)|t082
  c0035020|relapse|t067
  c0205448|two (qualifier value)|t081
week
  1
  c0439230|week (qualifier value)|t079
primarily metallic taste
  3
  c0439631|primary operation (qualifier value)|t061
  c0240327|taste, metallic|t184
  c0205225|primary|t080
only few fractions
  2
  c0457426|fractions of (qualifier value)|t081
  c0205388|few (qualifier value)|t081
p values
  1
  c0879541|p-value|t081
di
  1
  c0451119|diagnostic interview schedule (assessment scale)|t170
insufficient access
  2
  c0231180|insufficient|t169
  c0444454|access (attribute)|t082
degree
  2
  c0542560|academic degree|t170
  c0449286|degree or extent|t080
role
  1
  c0035820|role|t054
proportion
  1
  c0205351|proportional (qualifier value)|t080
clinical benefit
  2
  c0205210|clinical (qualifier value)|t080
  c0814225|benefits|t081
failure
  2
  c0680095|personal failure|t055
  c0231174|failure (biologic function)|t169
synchronous metastases
  3
  c1290850|secondary malignant neoplastic disease (disorder)|t191
  c0439580|synchronous (qualifier value)|t079
  c0027627|neoplasm metastasis|t191
advanced carcinoma
  2
  c0007097|carcinoma|t191
  c0205179|advanced phase|t080
current results
  2
  c1274040|result (navigational concept)|t169
  c0521116|current (qualifier value)|t079
dosimetry deviations
  2
  c0012727|spatial displacement|t082
  c0599911|dosimetry|t081
hepatic ultrasonography
  4
  c0412555|ultrasound scan - obstetric|t060
  c0175676|use of ultrasonography|t060
  c0205054|hepatic|t029
  c0041618|ultrasonography|t060
log rank comparison
  2
  c0699794|rank|t170
  c0335467|logger (occupation)|t097
multiple transfusions
  2
  c0439064|numerous (qualifier value)|t081
  c0199960|transfusion - action (qualifier value)|t061
two sided test
  4
  c0392366|tests (qualifier value)|t170
  c0441987|side (qualifier value)|t082
  c0457012|sidedness (qualifier value)|t082
  c0205448|two (qualifier value)|t081
l
  10
  c0392223|lights, manufactured|t074
  c0023870|lithium|t196
  c0336769|lighter, device (physical object)|t073
  c0023693|light|t070
  c0302908|liquid substance|t167
  c0023700|lighting|t068
  c1304698|liquid (finding)|t033
  c0205091|left (qualifier value)|t082
  c1306462|light color|t169
  c0475211|l (qualifier value)|t081
partial response rate
  3
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
  c0728938|partial (qualifier value)|t081
low incidence
  3
  c0021149|incidence|t081
  c0220856|incidence of cases|t169
  c0205251|low (qualifier value)|t080
research nurses
  1
  c0687693|research nurse (occupation)|t097
vaginal cuff
  2
  c0180207|cuffs|t074
  c0042232|vagina|t023
following eligibility criteria
  2
  c0332282|following (attribute)|t079
  c0243161|criteria|t170
large cervical tumor
  2
  c0475278|large tumor (finding)|t080
  c0205064|cervical (qualifier value)|t082
two-thirds
  1
  c0205448|two (qualifier value)|t081
contralateral breast cancer
  1
  c1096616|contralateral breast cancer|t191
switzerland
  1
  c0039021|switzerland|t083
toxicologic effects
  2
  c1280500|effect (qualifier value)|t080
  c0205472|toxicologic (qualifier value)|t169
other two groups
  3
  c0205394|other|t080
  c0441833|groups (qualifier value)|t170
  c0205448|two (qualifier value)|t081
neurological symptoms
  1
  c0235031|neurologic symptoms|t184
suture
  3
  c0038969|surgical sutures|t074
  c0502420|suture joint|t030
  c0009068|closure by suture|t061
efficiency
  1
  c0013682|efficiency|t081
locoregional recurrence
  1
  c0034897|recurrence|t067
platelet count depression
  7
  c0032181|platelet count|t059
  c0011570|mental depression|t048
  c1287267|finding of platelet count (finding)|t034
  c0011581|depressive disorder|t048
  c0349217|depressive episode, unspecified|t048
  c0344315|depressed mood|t033
  c0460137|depression motion|t169
several studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0443302|several (qualifier value)|t081
l5-s1 junction
  2
  c0205144|junctional (qualifier value)|t082
  c1179704|s1 innervation|t029
one approach
  2
  c0449445|approach (attribute)|t082
  c0205447|one (qualifier value)|t081
subjective evaluation
  3
  c1261322|assessment procedure (procedure)|t058
  c0220825|evaluation|t169
  c0439655|subjective observation (qualifier value)|t080
concurrent malignant tumors
  3
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0205420|concurrent (qualifier value)|t079
  c0006826|malignant neoplasms|t191
efforts to
  1
  c0015264|exertion|t040
patients also
  1
  c0030705|patients|t101
previous investigations
  2
  c0205156|previous (qualifier value)|t082
  c0430007|clinical investigation|t058
determination
  2
  c0680730|adjudication|t064
  c1148554|determination aspects|t059
physical examinations
  1
  c0031809|clinical examination|t058
chronic bowel symptoms
  3
  c0683368|symptoms|t169
  c0021853|intestines|t023
  c0205191|chronic (qualifier value)|t079
full explanation
  2
  c0681841|explanation|t062
  c0443225|full (qualifier value)|t080
physical examination
  1
  c0031809|clinical examination|t058
therapeutic decision
  3
  c0039796|the science and art of healing|t061
  c0679006|decision|t170
  c0302350|therapeutic|t169
intestines
  1
  c0021853|intestines|t023
benefit
  1
  c0814225|benefits|t081
new therapies
  2
  c0087111|therapeutic procedure|t061
  c0205314|new (qualifier value)|t079
report
  2
  c0700287|reporting|t058
  c0684224|report (document)|t170
soft tissue sarcomas
  1
  c0677603|sarcoma, soft tissue|t191
major violation
  1
  c0205164|major (qualifier value)|t080
portugal
  1
  c0032729|portugal|t083
disseminated intravascular coagulation
  1
  c0012739|disseminated intravascular coagulation|t047
5-year disease-free survival
  2
  c0439234|year (qualifier value)|t079
  c0242793|disease-free survival|t081
much lower potential
  2
  c0441994|lower (qualifier value)|t169
  c0237399|potential|t080
long-term side effects
  2
  c0441987|side (qualifier value)|t082
  c0023983|longterm effects|t067
95% confidence
  1
  c0237529|self-confidence (observable entity)|t041
therapy
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
patterns
  1
  c0449774|patterns (qualifier value)|t082
biologic activity
  1
  c0678666|biological activation|t040
retrospective evaluation
  3
  c1261322|assessment procedure (procedure)|t058
  c0035363|retrospective studies|t081
  c0220825|evaluation|t169
heparin
  1
  c0019134|heparin|t123
contract
  1
  c0332522|contracts|t170
secondary outcome measure
  3
  c0036525|metastatic to|t169
  c0086749|outcome measures|t081
  c0175668|secondary to|t079
muscle
  1
  c0026845|muscle|t024
only date
  1
  c0011008|dates|t079
international federation of gynecology and obstetrics staging criteria
  2
  c0450454|figo stage (attribute)|t170
  c0243161|criteria|t170
colostomy
  3
  c0448971|colostomy stoma|t020
  c0546255|colostomy site|t020
  c0009410|colostomy procedure|t061
other variables
  2
  c0205394|other|t080
  c0439828|variable (qualifier value)|t080
univariate analysis
  1
  c0683962|univariate analysis|t062
radiation energy to
  3
  c0851346|radiation|t070
  c0542479|energy, physics|t070
  c0424589|vitality|t033
utilizing single multidrug regimen
  2
  c0042153|utilization|t081
  c0677937|regimen|t061
pa
  1
  c0030125|p-aminosalicylic acid|t109
wilcoxon rank sum test
  2
  c0242928|rank-sum tests|t081
  c0242931|wilcoxon rank test|t081
clusters
  1
  c0009085|cluster analysis|t081
initial days
  2
  c0439228|day (qualifier value)|t079
  c0205265|initial (qualifier value)|t079
long-term administration
  3
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
  c0443252|long-term (qualifier value)|t079
bulky cervical cancer
  1
  c0007847|malignant neoplasm of cervix uteri|t191
vessels
  1
  c0005847|blood vessels|t023
twelve patients
  2
  c0030705|patients|t101
  c0205458|twelve (qualifier value)|t081
type
  1
  c0332307|with type (attribute)|t169
higher pelvic radiation doses
  2
  c0747411|pelvis radiation|t061
  c0444956|high dose (qualifier value)|t081
clear explanation
  2
  c0681841|explanation|t062
  c0205305|clear (qualifier value)|t080
treatment sequence
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
courses
  1
  c0750729|courses (qualifier value)|t079
intestinal fistula
  1
  c0021833|intestinal fistula|t190
low purine concentrations
  4
  c0034140|purines|t109
  c0086045|concentration|t041
  c0220903|purine|t109
  c0205251|low (qualifier value)|t080
potential effectiveness
  3
  c0205414|effective (qualifier value)|t080
  c1280519|effectiveness (qualifier value)|t170
  c0237399|potential|t080
palliative irradiation only
  4
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
  c1285530|palliative - procedure intent (qualifier value)|t080
cytology
  4
  c1305671|cytology procedure|t059
  c0010820|cellular aspects of|t033
  c0849088|test, cytology, digestive|t059
  c0010819|cytology|t091
abdominal computed tomography to
  1
  c0412620|ct of abdomen (procedure)|t060
same factors
  1
  c0445247|same (qualifier value)|t080
metastatic spread
  2
  c0332261|spreading (qualifier value)|t169
  c0036525|metastatic to|t169
presentation
  1
  c0449450|presentation (attribute)|t078
survival data
  2
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
regimen
  1
  c0677937|regimen|t061
proliferating
  1
  c0334094|proliferation (morphologic abnormality)|t169
other distant metastases
  2
  c0205394|other|t080
  c1269798|pm category (observable entity)|t201
staging method
  2
  c0332305|with staging (attribute)|t169
  c0025663|methods|t170
mild symptoms
  2
  c0683368|symptoms|t169
  c0205080|mild (qualifier value)|t080
further therapy
  2
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
different combination regimen
  3
  c0443199|differential (qualifier value)|t080
  c0677937|regimen|t061
  c0205195|combined (qualifier value)|t080
categorical variables
  2
  c0439828|variable (qualifier value)|t080
  c0683312|categories|t170
constant delivery
  3
  c0011209|obstetric delivery|t061
  c1135594|delivery|t061
  c0559563|delivery finding (finding)|t033
median overall survival
  5
  c0282416|overall [publication type]|t170
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
median survival time
  1
  c0591830|mst|t109
developed acute leukemia
  4
  c0020119|human development|t039
  c0180397|developers|t130
  c0085669|acute leukemia, morphology, including blast cell or undifferentiated leukemia (morphologic abnormality)|t191
  c0243107|development aspects|t039
intraoperative boost
  2
  c0456904|intraoperative (qualifier value)|t079
  c0857515|booster|t061
sequential administration
  2
  c0001554|administration|t057
  c1262471|administration (procedure)|t061
evaluable patients to
  3
  c1261322|assessment procedure (procedure)|t058
  c0030705|patients|t101
  c0220825|evaluation|t169
larger lumen
  4
  c0443228|greater (qualifier value)|t081
  c0524461|structure of lumen of body system|t030
  c1282864|entire lumen of body system|t030
  c1301906|lumen (qualifier value)|t080
roles
  1
  c0035820|role|t054
neoadjuvant ct
  1
  c0040405|x-ray computed tomography|t060
contraindications
  1
  c0079164|contraindications|t080
general misinterpretation
  1
  c0205246|generalized (qualifier value)|t082
oedema
  2
  c0013604|edema|t046
  c0333239|edematous|t033
greatly.23 second
  3
  c0443228|greater (qualifier value)|t081
  c0549177|large|t080
  c0205436|second (qualifier value)|t081
large tumor size
  4
  c0475278|large tumor (finding)|t080
  c0549177|large|t080
  c0475440|tumor size (observable entity)|t082
  c0702146|size (attribute)|t081
one person
  2
  c0205447|one (qualifier value)|t081
  c0027361|persons|t098
diagnosis
  2
  c0011900|diagnosis|t060
  c0348026|diagnostic|t169
time deaths
  2
  c0040223|time|t079
  c0011065|cessation of life|t040
suspected recurrence
  2
  c0034897|recurrence|t067
  c0332147|suspected diagnosis (contextual qualifier) (qualifier value)|t080
same molecular weight
  2
  c0026385|molecular weight|t081
  c0445247|same (qualifier value)|t080
other drugs
  2
  c0205394|other|t080
  c0013227|pharmaceutical preparations|t121
product limit method
  2
  c0025663|methods|t170
  c0449205|lim (body structure)|t029
neutrophils
  1
  c0027950|neutrophils|t025
increase survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0442805|increase (qualifier value)|t169
adenocarcinoma
  1
  c0001418|adenocarcinoma|t191
in vitro document
  3
  c0021135|in vitro|t080
  c1301746|documents (qualifier value)|t170
  c1301725|documented (qualifier value)|t058
expansile barrel shaped tumors
  2
  c0205229|expanding (qualifier value)|t082
  c0027651|neoplasms|t191
selective procedures
  3
  c0036576|selection (genetics)|t045
  c0025664|methodology|t170
  c0184661|procedures|t058
planned course
  2
  c0449922|course (attribute)|t079
  c1301732|planned (qualifier value)|t169
precisely questions
  1
  c0876928|questioning|t041
disease-free survival curves
  2
  c0205134|curved (qualifier value)|t082
  c0242793|disease-free survival|t081
impact radiation therapy
  3
  c0726639|impact|t168
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
appetite loss
  1
  c0003123|anorexia|t184
exception
  1
  c0750577|exceptionally|t078
randomised three arm study
  6
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0034656|random allocation|t062
  c0003792|arm|t029
  c0205449|three (qualifier value)|t081
  c0446516|upper arm|t029
most incidence
  3
  c0021149|incidence|t081
  c0220856|incidence of cases|t169
  c0205393|most (qualifier value)|t081
portals
  1
  c0205054|hepatic|t029
acute radiation morbidity scoring criteria
  6
  c0220880|morbidity aspects|t170
  c0449820|scores (qualifier value)|t081
  c0026538|morbidity - disease rate|t102
  c0851346|radiation|t070
  c0205178|acuteness (qualifier value)|t079
  c0243161|criteria|t170
seventy six percent
  2
  c0205452|six (qualifier value)|t081
  c0439165|percent (qualifier value)|t081
pelvic radiation therapy still
  4
  c0424228|stillness (finding)|t033
  c0030797|pelvis|t029
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
probability distribution
  3
  c0520511|distributing|t078
  c0033204|probability|t081
  c0037775|spatial distribution|t082
length
  1
  c0439537|lengths (qualifier value)|t081
epirubicin dose level
  3
  c0014582|epirubicin|t109
  c0456079|disease classification level|t185
  c0178602|dosages (qualifier value)|t081
organ involvement
  2
  c0392760|not free of (attribute)|t169
  c0178784|organ|t023
doubt
  1
  c0870444|doubt|t041
surviving
  1
  c0310255|survive (product)|t121
only danish study
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
5-year actuarial disease-free survival
  2
  c0439234|year (qualifier value)|t079
  c0242793|disease-free survival|t081
mitolactolor ifosfamide
  1
  c0020823|ifosfamide|t115
only 4% response rate
  2
  c0237629|frequency of responses|t079
  c0878525|cancer treatment response rate|t079
overall local relapse rate
  6
  c0282416|overall [publication type]|t170
  c0205336|relapsing course|t079
  c0580802|relapse phase|t079
  c0205276|local (qualifier value)|t082
  c0871208|rating|t062
  c0035020|relapse|t067
neutropenia
  1
  c0027947|neutropenia|t047
not myelosuppressiveequivalent doses
  1
  c0719635|dos|t109
stepwise regression method
  3
  c0025663|methods|t170
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
pearson’s x2 test
  1
  c0392366|tests (qualifier value)|t170
medial parametria
  3
  c0205098|medial (qualifier value)|t082
  c0227822|parametrium|t023
  c1281249|entire parametrium|t023
dissection
  3
  c1293093|dissection procedure (procedure)|t061
  c1306808|dissection - action (qualifier value)|t169
  c0012737|dissection|t059
developments
  2
  c0020119|human development|t039
  c0243107|development aspects|t039
cardiac toxicity patient
  5
  c0741926|cardiac patient|t101
  c0040539|toxicity aspects|t081
  c0030705|patients|t101
  c0600688|toxic effect|t037
  c0280951|cardiac toxicity|t037
recent report
  3
  c0700287|reporting|t058
  c0332185|recent episode (qualifier value)|t079
  c0684224|report (document)|t170
mtx mg
  3
  c0024467|magnesium|t123
  c0025677|methotrexate|t109
  c0439210|milligram|t081
5-fu dosage
  1
  c0366485|fluorouracil:mass:point in time:dose med or substance:quantitative|t201
several swedish studies
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0443302|several (qualifier value)|t081
ultimately required hospitalization
  1
  c0019993|hospitalization|t058
not part
  1
  c0449719|part (attribute)|t082
nonirradiated patients
  1
  c0030705|patients|t101
bilateral mammography
  1
  c0203027|bilateral mammography (procedure)|t060
only colon cancer patients
  2
  c0007102|malignant tumor of colon|t191
  c0030705|patients|t101
devices
  3
  c0699733|devices|t073
  c0220819|device aspects|t073
  c0884854|physical devices|t074
dexamethasone
  1
  c0011777|dexamethasone|t121
larger bites
  2
  c0443228|greater (qualifier value)|t081
  c0005658|bites|t037
treatment plan
  1
  c0599880|plan of treatment|t170
limited apical lung fibrosis
  3
  c0034069|pulmonary fibrosis|t047
  c0205111|apical (qualifier value)|t082
  c0439801|limited (qualifier value)|t169
absolute improvement
  4
  c0184511|improved (qualifier value)|t080
  c0205344|absolute (qualifier value)|t080
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
baseline demographic
  2
  c0168634|baseline|t122
  c0011298|demography|t090
equal doses
  2
  c0205163|equal (qualifier value)|t080
  c0719635|dos|t109
clinical behaviour
  2
  c0205210|clinical (qualifier value)|t080
  c0004927|behavior|t055
similar analysis
  3
  c0871364|simile|t170
  c0002778|analysis of substances|t059
  c0936012|analysis|t062
significant benefit
  2
  c0814225|benefits|t081
  c0750502|significant (qualifier value)|t078
antineoplastic activity
  4
  c0600075|endurance of activity|t033
  c0441655|activities|t052
  c0003392|antineoplastic agents|t121
  c0221187|physical activity|t056
good estimate
  2
  c0205170|good (qualifier value)|t080
  c0750572|estimated|t078
median wbc nadir
  3
  c0023516|leukocytes|t025
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
important source
  1
  c0449416|source (attribute)|t033
normal renal function
  1
  c0232805|normal renal function (finding)|t033
radia to follow-up
  1
  c0589120|follow-up status (finding)|t169
pretreatment stratification
  1
  c0205363|stratified (qualifier value)|t080
complication
  1
  c0009566|complication|t046
higher diarrhoea
  3
  c0011991|diarrhea|t184
  c0235146|euphoric mood|t041
  c0205250|high|t080
irinotecan group subseqently received irinotecan
  2
  c0544683|reception|t042
  c0123931|irinotecan|t109
multivariate regression
  2
  c0684320|disease regression|t046
  c0684321|regression - mental defense mechanism|t055
cancer recurrences
  1
  c0920420|cancer recurrence|t191
initial statistical prediction
  3
  c0681842|prediction|t170
  c0205265|initial (qualifier value)|t079
  c0220917|statistical|t170
severe toxic effects
  2
  c0205082|severe (severity modifier) (qualifier value)|t080
  c0600688|toxic effect|t037
four randomized trials
  2
  c0205450|four (qualifier value)|t081
  c0034656|random allocation|t062
males
  1
  c0086582|males|t098
low rate
  2
  c0205251|low (qualifier value)|t080
  c0871208|rating|t062
mev photon linear accelerator
  4
  c1318457|linear accelerator electrons (procedure)|t061
  c0086805|photons|t167
  c0023730|linear accelerators|t073
  c0556642|mev (qualifier value)|t081
not escalated therapy
  3
  c0087111|therapeutic procedure|t061
  c0014829|escalators|t073
  c0039798|therapeutic aspects|t169
first cycle
  2
  c0439596|cyclic (qualifier value)|t079
  c0205435|first (qualifier value)|t081
cisplatin
  1
  c0008838|cisplatin|t197
yet epi
  3
  c0221908|epithelial|t169
  c0014609|epithelium|t024
  c0014544|epilepsy|t047
two other patients
  3
  c0205394|other|t080
  c0030705|patients|t101
  c0205448|two (qualifier value)|t081
not high cr rate
  2
  c0151578|creatinine increased|t033
  c0871208|rating|t062
four additional deaths
  3
  c0205450|four (qualifier value)|t081
  c0442796|additive (qualifier value)|t080
  c0011065|cessation of life|t040
postoperative radiation therapy
  3
  c0032790|postoperative period|t079
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
limit
  1
  c0449205|lim (body structure)|t029
systemic adjuvant therapy
  4
  c0205373|systemic (qualifier value)|t169
  c0677850|adjuvant therapy|t061
  c0677959|systemic therapy|t061
  c0001551|adjuvants, immunologic|t129
manchester study groups
  3
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0441833|groups (qualifier value)|t170
median monthly dose
  4
  c0332177|monthly (qualifier value)|t079
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0178602|dosages (qualifier value)|t081
concurrent chemoradiotherapy
  1
  c0205420|concurrent (qualifier value)|t079
inclusion criteria
  2
  c0332257|including (qualifier value)|t169
  c0243161|criteria|t170
nine symptom scales
  4
  c0683368|symptoms|t169
  c0175659|weight measurement scales|t073
  c0222045|integumentary scale|t023
  c0205455|nine (qualifier value)|t081
menopausal groups
  2
  c0232967|menopausal|t169
  c0441833|groups (qualifier value)|t170
potential efficacy
  1
  c0237399|potential|t080
monitoring
  1
  c0150369|preventive monitoring|t058
dizziness
  1
  c0012833|dizziness|t184
registration forms
  2
  c0600375|registers (pt)|t170
  c0376315|manufactured form|t073
new prospective trials
  1
  c0205314|new (qualifier value)|t079
combination therapy
  2
  c0556895|combination electrotherapy|t061
  c0009429|combined modality therapy|t061
local relapses simultaneously
  3
  c0521115|simultaneous (qualifier value)|t079
  c0205276|local (qualifier value)|t082
  c0035020|relapse|t067
parametrial extensions
  3
  c0227822|parametrium|t023
  c0231448|extension (qualifier value)|t042
  c1281249|entire parametrium|t023
published trials
  1
  c0034037|publishing|t057
patient’s preference
  1
  c0558295|preferences (qualifier value)|t055
parasitic infections
  1
  c0030499|parasitic diseases|t047
posteroanterior opposed beams
  3
  c1253942|opposition|t169
  c0231519|gegenhalten|t184
  c0680238|discord|t054
seventy five patients
  2
  c0205451|five (qualifier value)|t081
  c0030705|patients|t101
epi doses
  4
  c0719635|dos|t109
  c0221908|epithelial|t169
  c0014609|epithelium|t024
  c0014544|epilepsy|t047
two trials
  1
  c0205448|two (qualifier value)|t081
previous experience
  2
  c0596545|experience|t041
  c0205156|previous (qualifier value)|t082
sec
  1
  c0457385|seconds|t079
incidence
  2
  c0021149|incidence|t081
  c0220856|incidence of cases|t169
pathology slides
  5
  c0332246|sliding|t169
  c0677042|pathology processes|t046
  c0205469|pathological aspects|t169
  c0444330|slide (specimen)|t075
  c0030664|pathology|t091
biopsy proven invasive carcinoma
  6
  c0456369|proven findings|t080
  c0220797|biopsy characteristics|t169
  c0007097|carcinoma|t191
  c0700164|proven venom|t123
  c0005558|biopsy|t060
  c0205281|invasive (qualifier value)|t080
ordered categorical data
  1
  c0683312|categories|t170
two layer technique
  3
  c0934502|layer|t023
  c0449851|techniques|t170
  c0205448|two (qualifier value)|t081
phase ii trial
  1
  c0278782|phase ii study|t062
doubts
  1
  c0870444|doubt|t041
hr
  1
  c0439227|hour|t079
exercise
  2
  c1306338|physical exercise (qualifier value)|t169
  c0015259|exercise|t056
significantly improved survival
  4
  c0184511|improved (qualifier value)|t080
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0750502|significant (qualifier value)|t078
additive hormonal therapy
  2
  c0278784|hormone therapy (procedure)|t061
  c0442796|additive (qualifier value)|t080
overall 5-year actuarial survival
  3
  c0282416|overall [publication type]|t170
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
possible interaction
  3
  c0037420|social interaction|t033
  c0687133|drug interactions|t044
  c0332149|possible|t080
control
  1
  c0243148|control|t169
routine use
  2
  c0042153|utilization|t081
  c0205547|routine (qualifier value)|t080
forms
  1
  c0376315|manufactured form|t073
most active anticancer drug
  2
  c0205393|most (qualifier value)|t081
  c0013227|pharmaceutical preparations|t121
alkylating agents
  1
  c0002073|alkylating agents|t131
local control
  2
  c0243148|control|t169
  c0205276|local (qualifier value)|t082
experience
  1
  c0596545|experience|t041
meta-analysis to
  1
  c0920317|meta-analysis|t170
internal radiotherapy
  1
  c0203608|radionuclide therapy|t061
resistant neoplastic cells overgrow
  2
  c0597032|neoplastic cell|t025
  c0332325|resistant (qualifier value)|t169
node-negative group
  3
  c0678034|node-negative|t033
  c0441833|groups (qualifier value)|t170
  c1300322|group (social concept)|t096
changed fractionation scheme
  4
  c0392747|changing|t169
  c0524811|dose fractionation|t061
  c0443172|changed status|t081
  c0016640|fractionation|t059
calculated recurrence rate
  3
  c0444686|calculated (qualifier value)|t169
  c0034897|recurrence|t067
  c0871208|rating|t062
carcinoma
  1
  c0007097|carcinoma|t191
better therapeutic index
  2
  c0678793|therapeutic index|t081
  c0332272|better (qualifier value)|t080
further dox
  3
  c0048808|5'-deoxy-5-fluorouridine|t114
  c0013090|doxycycline|t195
  c0013089|doxorubicin|t195
most significant risk factors
  2
  c1299394|most significant (qualifier value)|t080
  c0035648|risk factors|t081
historical control
  6
  c0243148|control|t169
  c0019664|recording of previous events|t090
  c0019665|history|t170
  c0262926|medical history|t033
  c1321503|history of (contextual qualifier) (qualifier value)|t033
  c0262512|history of (present illness) (contextual qualifier) (qualifier value)|t032
many patients
  2
  c0030705|patients|t101
  c0439064|numerous (qualifier value)|t081
iva
  1
  c1054142|iva|t002
aged years
  2
  c0439234|year (qualifier value)|t079
  c0001792|elderly|t100
statistically significant overall effect
  3
  c0282416|overall [publication type]|t170
  c1280500|effect (qualifier value)|t080
  c0237881|statistical significance|t081
european organization
  4
  c0239307|european|t098
  c0029246|organization administrative structures|t092
  c0029237|physiologic organization|t039
  c0220885|organizational|t080
cancer
  3
  c0998265|cancer genus|t009
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
50% decrease
  1
  c0547047|decrease (qualifier value)|t081
complete response
  1
  c0677874|in complete remission (qualifier value)|t033
random assignment
  1
  c0814868|random assignment|t062
standard criteria
  3
  c0038137|standards characteristics|t170
  c0175675|standards of weights and measures|t080
  c0243161|criteria|t170
life tables
  1
  c0023683|life tables|t170
previous chemotherapy
  4
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c0205156|previous (qualifier value)|t082
two tailed
  2
  c0039259|tail|t023
  c0205448|two (qualifier value)|t081
real recovery time
  3
  c0237820|recovery from disease|t040
  c0040223|time|t079
  c0871222|reality|t078
distance
  1
  c0012751|distance|t081
value
  1
  c0042295|valuing|t080
other efficacy endpoints
  2
  c0205394|other|t080
  c0150100|endpoint|t062
addition
  1
  c0442796|additive (qualifier value)|t080
analgesics
  1
  c0002771|analgesics|t121
especially neutropenia
  2
  c0205555|special (qualifier value)|t080
  c0027947|neutropenia|t047
loco regional lymph nodes
  4
  c0275191|astragalus species poisoning (disorder)|t037
  c1269047|entire lymph node|t023
  c0024204|lymph nodes|t023
  c0205147|regional (qualifier value)|t082
standard radiation
  3
  c0038137|standards characteristics|t170
  c0851346|radiation|t070
  c0175675|standards of weights and measures|t080
probability
  1
  c0033204|probability|t081
external irradiation
  4
  c1282930|irradiation (physical force)|t070
  c0205101|external (qualifier value)|t082
  c0851346|radiation|t070
  c0034618|radiation therapy|t061
analysis of variance
  1
  c0002780|analysis of variance|t081
serum electrolytes
  2
  c0587355|serum electrolytes nos (procedure)|t059
  c1287347|finding of serum electrolyte levels (finding)|t033
planned treatment course
  4
  c0449922|course (attribute)|t079
  c0087111|therapeutic procedure|t061
  c1301732|planned (qualifier value)|t169
  c0039798|therapeutic aspects|t169
maximum only
  1
  c0806909|maximum|t033
radiologic tests
  2
  c0392366|tests (qualifier value)|t170
  c0205483|radiologic (qualifier value)|t169
not protocol treatment
  3
  c0442711|protocols documentation|t170
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
preliminary 3-yr results
  2
  c1274040|result (navigational concept)|t169
  c0439611|preliminary (qualifier value)|t079
dosimetry curves
  2
  c0205134|curved (qualifier value)|t082
  c0599911|dosimetry|t081
not specific response
  3
  c0871261|responses|t054
  c0205369|specific (qualifier value)|t080
  c1263442|specific|t121
mucositis
  1
  c0236177|inflammatory disease of mucous membrane (disorder)|t046
preference
  1
  c0558295|preferences (qualifier value)|t055
interruption
  1
  c0443239|interrupted (qualifier value)|t080
equivalent degree
  3
  c0439185|eq (qualifier value)|t081
  c0542560|academic degree|t170
  c0449286|degree or extent|t080
questionnaires
  1
  c0034394|questionnaires|t170
first infusion
  2
  c0574032|infusion (procedure)|t061
  c0205435|first (qualifier value)|t081
excluding melanoma
  2
  c0025202|melanoma|t191
  c0332196|exclude (qualifier value)|t169
prognostic information
  2
  c0870705|information|t078
  c0220901|prognostic|t170
month
  1
  c0439231|month (qualifier value)|t079
one year
  2
  c0439234|year (qualifier value)|t079
  c0205447|one (qualifier value)|t081
m local recurrence rate
  3
  c0205276|local (qualifier value)|t082
  c0034897|recurrence|t067
  c0871208|rating|t062
complication rates
  2
  c0871208|rating|t062
  c0009566|complication|t046
knowledge
  1
  c0376554|knowledge|t170
4.6 v 3.2 months
  6
  c0042306|vanadium|t123
  c0449468|volume (property) (qualifier value)|t081
  c0439830|velocity (property) (qualifier value)|t169
  c0598352|v (voltage)|t081
  c0439502|v - volt (qualifier value)|t081
  c0439231|month (qualifier value)|t079
started chemotherapy
  4
  c1272689|started (qualifier value)|t080
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
pulmonary functions
  1
  c0231921|pulmonary function (observable entity)|t042
partial responses
  1
  c0677924|partial response|t080
higher dose
  1
  c0444956|high dose (qualifier value)|t081
actuarial 5-year disease-free survival
  2
  c0334965|actuary (occupation)|t097
  c0242793|disease-free survival|t081
potential risk
  2
  c0237399|potential|t080
  c0035647|risk|t080
toxicities
  1
  c0600688|toxic effect|t037
hydroxyurea therapy
  3
  c0087111|therapeutic procedure|t061
  c0020402|hydroxyurea|t109
  c0039798|therapeutic aspects|t169
irinotecan
  1
  c0123931|irinotecan|t109
identical postsurgery radiation therapy regimens
  4
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
  c0677937|regimen|t061
  c0205280|identical (qualifier value)|t080
standard external beam pelvic irradiation
  5
  c1282930|irradiation (physical force)|t070
  c0038137|standards characteristics|t170
  c0851346|radiation|t070
  c0175675|standards of weights and measures|t080
  c0034618|radiation therapy|t061
two factors
  1
  c0205448|two (qualifier value)|t081
routine chemistry
  3
  c0079107|chemical aspects|t185
  c0205547|routine (qualifier value)|t080
  c0007996|science of chemistry|t090
included patients
  2
  c0332257|including (qualifier value)|t169
  c0030705|patients|t101
dose prescription
  2
  c0033080|prescriptions|t058
  c0178602|dosages (qualifier value)|t081
primary tumour site
  1
  c0475447|site of primary tumor (attribute)|t201
overall disease-free survival
  2
  c0282416|overall [publication type]|t170
  c0242793|disease-free survival|t081
hair loss
  1
  c0002170|alopecia|t184
estrogen receptors
  1
  c0034804|estrogen receptors|t116
portal adjuvant chemotherapy
  2
  c0205054|hepatic|t029
  c0085533|chemotherapy, adjuvant|t061
aggressiveness
  1
  c0235099|aggression aggravated|t048
local events
  2
  c0441471|events (event)|t051
  c0205276|local (qualifier value)|t082
median platelet nadir
  3
  c0876920|median statistical measurement|t081
  c0549183|median (qualifier value)|t082
  c0005821|blood platelets|t025
demonstration
  2
  c0332265|demonstrable (qualifier value)|t169
  c0335296|demonstrator (occupation)|t097
european organization for research and treatment of cancer
  4
  c0998265|cancer genus|t009
  c0239307|european|t098
  c0936282|malignant neoplasm, primary (morphologic abnormality)|t191
  c0006826|malignant neoplasms|t191
group given radiotherapy
  6
  c1136188|gifts|t071
  c0441833|groups (qualifier value)|t170
  c0034618|radiation therapy|t061
  c0034619|radiotherapeutic|t170
  c0016999|gamete intrafallopian transfer|t061
  c1300322|group (social concept)|t096
5-yr total survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439234|year (qualifier value)|t079
supraclavicular node
  1
  c0229730|structure of supraclavicular lymph node|t023
hand-sewn anastomosis
  5
  c0677554|anastomosis - action|t061
  c0332853|anastomosis|t020
  c0500470|anatomical anastomosis|t030
  c1281583|entire hand|t023
  c0018563|hand|t023
cdr
  2
  c0011485|deoxycytidine|t123
  c0055351|chlordecone reductase|t116
previous surgery
  4
  c0543467|general operative procedures|t061
  c0038895|surgical aspects|t169
  c0205156|previous (qualifier value)|t082
  c0038894|surgery specialty|t091
verification
  1
  c0237944|verification of theories|t080
tumour stabilisation
  2
  c1293130|stabilization (procedure)|t061
  c0027651|neoplasms|t191
previously received radiotherapy
  4
  c0544683|reception|t042
  c0034618|radiation therapy|t061
  c0205156|previous (qualifier value)|t082
  c0034619|radiotherapeutic|t170
control group
  1
  c0009932|control groups|t096
three packets
  1
  c0205449|three (qualifier value)|t081
weekly regimen
  2
  c0332174|weekly (qualifier value)|t079
  c0677937|regimen|t061
statistical evidence
  1
  c0220917|statistical|t170
exploratory subset analysis
  4
  c0002778|analysis of substances|t059
  c1280903|exploration procedure (procedure)|t061
  c0581690|exploration - action (qualifier value)|t058
  c0936012|analysis|t062
and percent confidence intervals
  2
  c0009667|confidence intervals|t081
  c0439165|percent (qualifier value)|t081
prophylactic oral antibiotics
  2
  c0362063|other prophylactic chemotherapy|t033
  c0442027|oral (qualifier value)|t082
relative cardiotoxicity
  3
  c0080103|relative (related person)|t099
  c0205345|relative|t080
  c0876994|cardiotoxicity|t047
performance status
  1
  c0935728|performance status|t033
concept
  2
  c0178566|concept|t078
  c0308714|concept drug|t121
lesser degrees
  3
  c0542560|academic degree|t170
  c0449286|degree or extent|t080
  c0547044|lesser (qualifier value)|t080
spain
  1
  c0037747|spain|t083
nonhaematological toxic effect
  1
  c0600688|toxic effect|t037
patients rbcs
  2
  c0014792|erythrocytes|t025
  c0030705|patients|t101
disproportionately larger number
  3
  c0443228|greater (qualifier value)|t081
  c0205350|disproportionate (qualifier value)|t080
  c0449788|count of entities (property) (qualifier value)|t081
chronic adverse effects
  2
  c0001688|adverse effects|t037
  c0205191|chronic (qualifier value)|t079
most common toxicity
  4
  c0205393|most (qualifier value)|t081
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
  c0205214|common (qualifier value)|t081
bun mg
  2
  c0024467|magnesium|t123
  c0439210|milligram|t081
radical irradiation
  5
  c0302912|radicals (chemistry)|t104
  c1282930|irradiation (physical force)|t070
  c0851346|radiation|t070
  c0439807|radical (qualifier value)|t080
  c0034618|radiation therapy|t061
increased rates
  2
  c0205217|increased (qualifier value)|t169
  c0871208|rating|t062
72% 5-yr survival
  3
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
  c0439234|year (qualifier value)|t079
approximately mm
  2
  c0332232|approximate (qualifier value)|t169
  c0439200|millimeter|t081
complete disability
  3
  c0231170|disability nos (finding)|t046
  c0205197|complete (qualifier value)|t080
  c0725685|compleat|t168
then weeks
  1
  c0439230|week (qualifier value)|t079
hyperfractionated radiation
  2
  c0851346|radiation|t070
  c0796569|hyperfractionation|t061
improved survival
  3
  c0184511|improved (qualifier value)|t080
  c0220921|survival aspects|t081
  c0038952|continuance of life|t052
tumors
  1
  c0027651|neoplasms|t191
careful approximation
  1
  c0332232|approximate (qualifier value)|t169
radiation treatments
  2
  c0851346|radiation|t070
  c0087111|therapeutic procedure|t061
never started chemotherapy
  4
  c1272689|started (qualifier value)|t080
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
marrow reserve
  2
  c0376152|marrow|t023
  c0086590|vegetable marrow|t168
partial responders
  1
  c0677924|partial response|t080
serum creatinine level
  1
  c0600061|serum creatinine level|t034
prior history
  6
  c0019664|recording of previous events|t090
  c0019665|history|t170
  c0262926|medical history|t033
  c0750516|prior|t078
  c1321503|history of (contextual qualifier) (qualifier value)|t033
  c0262512|history of (present illness) (contextual qualifier) (qualifier value)|t032
cervical cancer disproportionately
  2
  c0007847|malignant neoplasm of cervix uteri|t191
  c0205350|disproportionate (qualifier value)|t080
local recurrence alone metastasis
  4
  c0205276|local (qualifier value)|t082
  c0027627|neoplasm metastasis|t191
  c0034897|recurrence|t067
  c0679994|alone|t102
small bowel follow-up
  2
  c0021852|intestines, small|t023
  c0589120|follow-up status (finding)|t169
patient pretreatment characteristics
  1
  c0815172|patient characteristics|t201
27 98 days
  1
  c0439228|day (qualifier value)|t079
total survival
  3
  c0220921|survival aspects|t081
  c0439810|total (qualifier value)|t080
  c0038952|continuance of life|t052
because less mesentery
  1
  c0025474|mesentery|t029
chest pain
  1
  c0008031|chest pain|t184
primary end points
  3
  c0439631|primary operation (qualifier value)|t061
  c0150100|endpoint|t062
  c0205225|primary|t080
ovariectomy
  1
  c0029936|ovariectomy|t061
protocol treatment
  3
  c0442711|protocols documentation|t170
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
toxic cumulative dose
  2
  c0600688|toxic effect|t037
  c0178602|dosages (qualifier value)|t081
c1
  2
  c1305856|c1 innervation|t029
  c0009499|complement component c1|t116
mucocutaneous reactions
  1
  c0443286|reaction (qualifier value)|t169
about weeks
  1
  c0439230|week (qualifier value)|t079
— percent
  1
  c0439165|percent (qualifier value)|t081
fluorouracil infusion study
  4
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0574032|infusion (procedure)|t061
  c0016360|fluorouracil|t114
absence
  1
  c0424530|absences (finding)|t033
peculiar immunogenicity
  1
  c0872192|immunogenic|t169
deep one third stromal invasion
  4
  c0927195|stroma|t023
  c0205125|depth (qualifier value)|t082
  c0205437|third (qualifier value)|t081
  c0205447|one (qualifier value)|t081
reduced survival rates
  2
  c0392756|reduced (qualifier value)|t080
  c0038954|survival rate|t081
continuous method
  2
  c0549178|continuous (qualifier value)|t079
  c0025663|methods|t170
randomized phase iii trial
  2
  c0278781|phase iii study|t062
  c0034656|random allocation|t062
power analysis
  3
  c0002778|analysis of substances|t059
  c0032863|power (psychology)|t068
  c0936012|analysis|t062
contemporary innovation first
  1
  c0205435|first (qualifier value)|t081
injection
  2
  c0021485|injections|t061
  c1272883|injection (product)|t073
tumors cm
  2
  c0027651|neoplasms|t191
  c0475210|cm (qualifier value)|t081
parametrium status
  3
  c0449438|status (attribute)|t080
  c0227822|parametrium|t023
  c1281249|entire parametrium|t023
set
  1
  c0036849|set (psychology)|t041
abnormal cea values
  3
  c0205161|abnormal (qualifier value)|t169
  c0007082|carcinoembryonic antigen|t116
  c0042295|valuing|t080
main cause
  4
  c0678227|causing (attribute)|t169
  c0015127|causality|t169
  c1314792|etiology|t169
  c0205225|primary|t080
apparent evidence
  1
  c0750489|apparent|t078
previously untreated colorectal cancer patients
  3
  c0030705|patients|t101
  c0205156|previous (qualifier value)|t082
  c0009402|colorectal cancer|t191
arbitrarily
  1
  c1264693|arbitrary (property) (qualifier value)|t081
subsequent anticancer chemotherapies
  3
  c0750530|subsequent|t078
  c0392920|chemotherapy-oncologic procedure|t061
  c0013216|pharmacotherapy|t061
intravenously wk
  2
  c0348016|intravenous|t082
  c0439230|week (qualifier value)|t079
limb sparing procedure
  3
  c0015385|limb structure|t023
  c0184661|procedures|t058
  c1280090|entire limb|t023
more restricted selection criteria
  3
  c0205172|more (qualifier value)|t081
  c0242801|selection criteria|t080
  c0443288|restricted (qualifier value)|t169
m0 primary rectal adenocarcinoma
  3
  c0439631|primary operation (qualifier value)|t061
  c0149978|adenocarcinoma of rectum (disorder)|t191
  c0205225|primary|t080
similar high doses
  2
  c0871364|simile|t170
  c0444956|high dose (qualifier value)|t081
same procedures
  3
  c0025664|methodology|t170
  c0445247|same (qualifier value)|t080
  c0184661|procedures|t058
external beam radiation
  1
  c0796629|external radiation|t061
50% dose reduction
  3
  c0301630|reduction (chemical)|t070
  c0178602|dosages (qualifier value)|t081
  c0441610|reduction - action|t061
polymorphous liposarcoma
  2
  c0023827|liposarcoma|t191
  c0027950|neutrophils|t025
still predominant site
  3
  c0332251|predominate (qualifier value)|t080
  c0424228|stillness (finding)|t033
  c0205145|associated topography (attribute)|t082
adjunctive radiotherapy significantly
  3
  c0034618|radiation therapy|t061
  c0750502|significant (qualifier value)|t078
  c0034619|radiotherapeutic|t170
bilateral pelvic lymphade center
  3
  c0281267|bilateral breast cancer|t191
  c0205099|central|t082
  c0238767|bilateral|t082
chemotherapy program
  4
  c0392920|chemotherapy-oncologic procedure|t061
  c0013217|pharmacotherapeutic|t169
  c0013216|pharmacotherapy|t061
  c0376691|programs [publication type]|t170
postoperative radiation
  2
  c0032790|postoperative period|t079
  c0851346|radiation|t070
2 test
  1
  c0392366|tests (qualifier value)|t170
because number
  1
  c0449788|count of entities (property) (qualifier value)|t081
multivariate analysis
  1
  c0026777|multivariate analysis|t081
radiation groups
  2
  c0851346|radiation|t070
  c0441833|groups (qualifier value)|t170
relatively low proportion
  2
  c0205351|proportional (qualifier value)|t080
  c0205251|low (qualifier value)|t080
40% relative reduction
  4
  c0080103|relative (related person)|t099
  c0205345|relative|t080
  c0301630|reduction (chemical)|t070
  c0441610|reduction - action|t061
high creatinine concentration
  2
  c0086045|concentration|t041
  c0151578|creatinine increased|t033
congestive heart failure
  1
  c0018802|heart failure, congestive|t047
95% confidence interval
  1
  c0009667|confidence intervals|t081
sq m intravenously
  4
  c0205120|square (qualifier value)|t082
  c0348016|intravenous|t082
  c1182670|squamous|t080
  c0038071|squalene|t123
anterior restorative resection
  4
  c0205094|anterior|t082
  c0015252|excision|t061
  c1306255|excision - action (qualifier value)|t169
  c0449982|type of restoration (attribute)|t170
american joint committee on cancer
  1
  c0441915|ajcc (tumor staging)|t170
maximal tumor cytoreduction
  2
  c0205289|maximal (qualifier value)|t080
  c0027651|neoplasms|t191
protocol management
  2
  c0442711|protocols documentation|t170
  c0870834|management|t057
main aim
  1
  c0205225|primary|t080
four field techniques
  4
  c0205450|four (qualifier value)|t081
  c0025664|methodology|t170
  c0449851|techniques|t170
  c0440042|field's stain|t130
student t tests
  1
  c0871453|students t test|t170
severe actinic cystitis
  3
  c0439681|actinic (qualifier value)|t080
  c0010692|cystitis|t047
  c0205082|severe (severity modifier) (qualifier value)|t080
worse stomatitis
  3
  c0332271|worsening (qualifier value)|t080
  c1279889|deterioration of status|t080
  c0038362|stomatitis|t047
variations
  1
  c0205419|variant|t080
second rationale
  1
  c0205436|second (qualifier value)|t081
substantial minority recur
  2
  c0812423|recur|t079
  c0680221|minority|t054
combination chemotherapy
  1
  c0013218|drug therapy, combination|t061
definitive statements
  2
  c1301808|state (environment)|t083
  c0443196|definitive (qualifier value)|t079
tolerance
  2
  c0231197|physiologic tolerance|t039
  c0220929|mental tolerance|t041
study treatment
  4
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
  c0087111|therapeutic procedure|t061
  c0039798|therapeutic aspects|t169
similar rates
  2
  c0871364|simile|t170
  c0871208|rating|t062
gog study
  2
  c0947630|scientific study|t059
  c0557651|room of building - study|t073
ovarian cancer
  2
  c0029925|ovarian carcinoma|t191
  c1140680|malignant neoplasm of ovary|t191
bilirubin level 2.5 mg
  4
  c0344395|bilirubin measurement (procedure)|t059
  c1287365|finding of bilirubin level (finding)|t034
  c0024467|magnesium|t123
  c0439210|milligram|t081
genitourinary toxicity
  3
  c0447566|urogenital structure|t023
  c0040539|toxicity aspects|t081
  c0600688|toxic effect|t037
only fictitious difference
  1
  c0443199|differential (qualifier value)|t080
life-threatening conditions
  3
  c0009647|conditioning (psychology)|t041
  c0376558|life|t078
  c0348080|condition (attribute)|t080
m cisplatin
  1
  c0008838|cisplatin|t197
long-term improvement
  4
  c0184511|improved (qualifier value)|t080
  c0443252|long-term (qualifier value)|t079
  c0332161|attenuated by (contextual qualifier) (qualifier value)|t080
  c1272745|improving (qualifier value)|t170
higher proportion
  3
  c0205351|proportional (qualifier value)|t080
  c0235146|euphoric mood|t041
  c0205250|high|t080
polymorphous sarcomas
  2
  c1261473|sarcoma|t191
  c0027950|neutrophils|t025
doses
  1
  c0719635|dos|t109
other nine
  2
  c0205394|other|t080
  c0205455|nine (qualifier value)|t081
extended follow-up period
  3
  c0231449|extended (qualifier value)|t082
  c0332182|periodic (qualifier value)|t079
  c0589120|follow-up status (finding)|t169
incorrect primary diagnosis
  4
  c0439631|primary operation (qualifier value)|t061
  c0011900|diagnosis|t060
  c0205225|primary|t080
  c0348026|diagnostic|t169
